Warner Chilcott 10-K 26 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2015	Feb. 15, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	AGN
Entity Registrant Name	Allergan plc
Entity Central Index Key	1,578,845
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		394,687,384
Entity Public Float			$ 119
Warner Chilcott Limited [Member]
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	WARNER CHILCOTT LIMITED
Entity Central Index Key	1,620,602
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,096	$ 250
Marketable securities	9.3	1
Accounts receivable, net	2,401.6	1,112.3
Inventories	1,009.7	984.6
Prepaid expenses and other current assets	558.5	478.8
Current assets held for sale	3,540.3	3,806.9
Deferred tax assets	500.3	477
Total current assets	8,615.4	7,110.6
Property, plant and equipment, net	1,573.9	283.4
Investments and other assets	577.4	153.3
Non current assets held for sale	10,541.3	8,187.7
Deferred tax assets	49.5	34.7
Product rights and other intangibles	67,931.7	16,090.7
Goodwill	46,551.5	20,897.6
Total assets	135,840.7	52,758
Current liabilities:
Accounts payable and accrued expenses	4,349.5	3,030.1
Income taxes payable	54.2	33.9
Current portion of long-term debt and capital leases	2,432.8	693.4
Current liabilities held for sale	1,491.8	1,449.1
Deferred tax liabilities	47.3	41
Total current liabilities	8,328.3	5,247.5
Long-term debt and capital leases	40,293.4	14,837.7
Other long-term liabilities	1,262	253.3
Long-term liabilities held for sale	580.1	540.7
Other taxes payable	801.9	789.5
Deferred tax liabilities	7,985.7	2,753.8
Total liabilities	$ 59,251.4	$ 24,422.5
Commitments and contingencies
Equity:
Preferred shares, $0.0001 par value per share, 5.1 million shares authorized, 5.1 million and zero shares issued and outstanding, respectively	$ 4,929.7
Additional paid-in capital	68,508.3	$ 28,994.7
Retained earnings / (accumulated deficit)	3,647.5	(198.2)
Accumulated other comprehensive (loss)	(494.1)	(465.4)
Total shareholders’ equity	76,591.4	28,331.1
Noncontrolling interest	(2.1)	4.4
Total equity	76,589.3	28,335.5
Total liabilities and equity	135,840.7	52,758
Warner Chilcott Limited [Member]
Current assets:
Cash and cash equivalents	1,036.2	244.3
Marketable securities	9.3	1
Accounts receivable, net	2,401.6	1,111.6
Receivable from Parents	457.3	269.8
Inventories	1,009.7	984.6
Prepaid expenses and other current assets	556	475.9
Current assets held for sale	3,540.3	3,806.9
Deferred tax assets		477
Total current assets	9,010.4	7,371.1
Property, plant and equipment, net	1,573.9	282.5
Investments and other assets	577.4	153.3
Non current assets held for sale	10,541.3	8,187.7
Deferred tax assets	49.5	34.7
Product rights and other intangibles	67,931.7	16,090.7
Goodwill	46,551.5	20,897.6
Total assets	136,235.7	53,017.6
Current liabilities:
Accounts payable and accrued expenses	4,295.4	3,027
Payables to Parents	1,466.8	521.1
Income taxes payable	54.2	33.9
Current portion of long-term debt and capital leases	2,432.8	693.4
Current liabilities held for sale	1,491.8	1,449.1
Deferred tax liabilities		41
Total current liabilities	9,741	5,765.5
Long-term debt and capital leases	40,293.4	14,837.7
Other long-term liabilities	1,262	253.4
Long-term liabilities held for sale	580.1	540.7
Other taxes payable	801.9	789.5
Deferred tax liabilities	7,985.7	2,753.8
Total liabilities	$ 60,664.1	$ 24,940.6
Commitments and contingencies
Equity:
Member's capital	$ 72,935.1	$ 29,455.9
Retained earnings / (accumulated deficit)	3,132.7	(917.9)
Accumulated other comprehensive (loss)	(494.1)	(465.4)
Noncontrolling interest	(2.1)	4.4
Total equity	75,571.6	28,077
Total members’ equity	75,573.7	28,072.6
Total liabilities and equity	$ 136,235.7	$ 53,017.6

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Preferred shares, par value	$ 0.0001	$ 0.0001
Preferred shares, shares authorized	5,100,000	5,100,000
Preferred shares, shares issued	5,100,000	0
Preferred shares, shares outstanding	5,100,000	0
Ordinary shares, par value	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	1,000,000,000	1,000,000,000
Ordinary shares, shares issued	394,500,000	265,900,000
Ordinary shares, shares outstanding	394,500,000	265,900,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net revenues	$ 15,071	$ 6,738.9	$ 2,602.5
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	4,810.4	3,453.6	1,644.7
Research and development	2,358.5	605.7	191.3
Selling and marketing	2,914	1,201	374.8
General and administrative	1,765.6	1,247	456.1
Amortization	5,453.4	1,945.5	303.8
In-process research and development impairments	511.6	424.3
Asset sales and impairments, net	272	305.7	1
Total operating expenses	18,085.5	9,182.8	2,971.7
Operating (loss)	(3,014.5)	(2,443.9)	(369.2)
Non-Operating income (expense):
Interest income	11.4	8.9	4.8
Interest expense	(1,193.3)	(411.8)	(239.8)
Other (expense) income, net	(233.8)	(27.3)	(18.6)
Total other income (expense), net	(1,415.7)	(430.2)	(253.6)
(Loss) before income taxes and noncontrolling interest	(4,430.2)	(2,874.1)	(622.8)
(Benefit) for income taxes	(1,561.9)	(467)	(155.3)
Net (loss) from continuing operations, net of tax	(2,868.3)	(2,407.1)	(467.5)
Income / (loss) from discontinued operations, net of tax	6,787.7	776.6	(282.9)
Net income / (loss)	3,919.4	(1,630.5)	(750.4)
(Income) attributable to noncontrolling interest	(4.2)
Net income / (loss) attributable to shareholders	3,915.2	(1,630.5)	(750.4)
Dividends on preferred shares	232
Net income / (loss) attributable to ordinary shareholders	$ 3,683.2	$ (1,630.5)	$ (750.4)
Income / (loss) per share attributable to ordinary shareholders - basic:
Continuing operations	$ (8.44)	$ (10.96)	$ (3.29)
Discontinued operations	18.45	3.54	(1.98)
Net income / (loss) per share - basic	10.01	(7.42)	(5.27)
Income / (loss) per share attributable to ordinary shareholders - diluted:
Continuing operations	(8.44)	(10.96)	(3.29)
Discontinued operations	18.45	3.54	(1.98)
Net income / (loss) per share - diluted	$ 10.01	$ (7.42)	$ (5.27)
Weighted average shares outstanding:
Basic	367.8	219.7	142.3
Diluted	367.8	219.7	142.3
Warner Chilcott Limited [Member]
Net revenues	$ 15,071	$ 6,738.9	$ 2,602.5
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	4,810.4	3,453.6	1,644.7
Research and development	2,358.5	605.7	191.3
Selling and marketing	2,914	1,201	374.8
General and administrative	1,630.2	1,177	431.7
Amortization	5,453.4	1,945.5	303.8
In-process research and development impairments	511.6	424.3
Asset sales and impairments, net	272	305.7	1
Total operating expenses	17,950.1	9,112.8	2,947.3
Operating (loss)	(2,879.1)	(2,373.9)	(344.8)
Non-Operating income (expense):
Interest income	11.4	8.9	4.8
Interest expense	(1,193.3)	(411.8)	(239.8)
Other (expense) income, net	(233.8)	(27.3)	(18.6)
Total other income (expense), net	(1,415.7)	(430.2)	(253.6)
(Loss) before income taxes and noncontrolling interest	(4,294.8)	(2,804.1)	(598.4)
(Benefit) for income taxes	(1,561.9)	(467)	(156.2)
Net (loss) from continuing operations, net of tax	(2,732.9)	(2,337.1)	(442.2)
Income / (loss) from discontinued operations, net of tax	6,787.7	776.6	(282.3)
Net income / (loss)	4,054.8	(1,560.5)	(724.5)
(Income) attributable to noncontrolling interest	(4.2)
Net income / (loss) attributable to shareholders	4,050.6	(1,560.5)	(724.5)
Weighted average shares outstanding:
Net income / (loss) attributable to members	$ 4,050.6	$ (1,560.5)	$ (724.5)

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income / (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net income / (loss)	$ 3,919.4	$ (1,630.5)	$ (750.4)
Other comprehensive (loss) / income
Foreign currency translation (losses) / gains	(129.9)	(519.5)	48.4
Unrealized gains / (losses), net of tax	101.2	(36.4)	5.3
Total other comprehensive (loss) / income, net of tax	(28.7)	(555.9)	53.7
Comprehensive income / (loss)	3,890.7	(2,186.4)	(696.7)
Comprehensive (income) attributable to noncontrolling interest	(4.2)
Comprehensive income / (loss) attributable to ordinary shareholders / members	3,886.5	(2,186.4)	(696.7)
Warner Chilcott Limited [Member]
Net income / (loss)	4,054.8	(1,560.5)	(724.5)
Other comprehensive (loss) / income
Foreign currency translation (losses) / gains	(129.9)	(519.5)	48.4
Unrealized gains / (losses), net of tax	101.2	(36.4)	5.3
Total other comprehensive (loss) / income, net of tax	(28.7)	(555.9)	53.7
Comprehensive income / (loss)	4,026.1	(2,116.4)	(670.8)
Comprehensive (income) attributable to noncontrolling interest	(4.2)
Comprehensive income / (loss) attributable to ordinary shareholders / members	$ 4,021.9	$ (2,116.4)	$ (670.8)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities:
Net income / (loss)	$ 3,919.4	$ (1,630.5)	$ (750.4)
Reconciliation to net cash provided by operating activities:
Depreciation	218.3	230.9	202
Amortization	5,777	2,597.5	842.7
Provision for inventory reserve	140.9	156.1	113.8
Share-based compensation	690.4	368	133.6
Deferred income tax benefit	(7,380.1)	(690.1)	(275)
In-process research and development impairments	511.6	424.3	4.9
Goodwill impairment		17.3	647.5
Loss / (gain) on asset sales and impairments, net	334.4	143.1	55.9
Amortization of inventory step-up	1,192.9	985.8	267
Amortization of deferred financing costs	298.3	87.2	10.3
Accretion and contingent consideration	108.8	(71.2)	160
Excess tax benefit from stock-based compensation	(76.1)	(51.1)	(69)
Non-cash impact of debt extinguishment		(91.7)
Impact of assets held for sale		190.8	42.7
Other, net	66.4	8.5	(8.9)
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net	(1,034.3)	(611.1)	19.1
Decrease / (increase) in inventories	(226.2)	(207.2)	(213.1)
Decrease / (increase) in prepaid expenses and other current assets	70.9	29.4	49.9
Increase / (decrease) in accounts payable and accrued expenses	142.5	394.6	7.8
Increase / (decrease) in income and other taxes payable	(87.8)	29.7	7.4
Increase / (decrease) in other assets and liabilities	(137.3)	(67.3)	(34.7)
Net cash provided by operating activities	4,530	2,243	1,213.5
Cash Flows From Investing Activities:
Additions to property, plant and equipment	(454.9)	(238.6)	(177.9)
Additions to product rights and other intangibles	(154.7)	(36.1)	(130)
Additions to investments	(24.3)	(1)	2.9
Proceeds from the sale of investments and other assets	883	453.7	37.7
Proceeds from sales of property, plant and equipment	140.1	13.7	7.1
Acquisitions of businesses, net of cash acquired	(37,510.1)	(5,562.3)	(15.1)
Net cash (used in) investing activities	(37,120.9)	(5,370.6)	(275.3)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness	26,455.7	8,076.2	1,882.3
Proceeds from borrowings on credit facility and other	3,682	1,280	555
Debt issuance and other financing costs	(310.8)	(224.3)	(7.4)
Payments on debt, including capital lease obligations	(5,134.2)	(6,127)	(3,229.5)
Proceeds from issuance of preferred shares	4,929.7
Proceeds from issuance of ordinary shares	4,071.1
Proceeds from stock plans	230	105.9	37.6
Payments of contingent consideration	(230.1)	(14.3)	(4.3)
Repurchase of ordinary shares	(118)	(130.1)	(170)
Dividends	(208.1)
Excess tax benefit from stock-based compensation	76.1	51.1	69
Net cash provided by/(used in) financing activities	33,443.4	3,017.5	(867.3)
Effect of currency exchange rate changes on cash and cash equivalents	(6.5)	(5.9)	(23.9)
Movement in cash held for sale		37	(37)
Net increase in cash and cash equivalents	846	(79)	10
Cash and cash equivalents at beginning of period	250	329	319
Cash and cash equivalents at end of period	1,096	250	329
Cash paid during the year for:
Income taxes, net of refunds	377.6	560.6	380.1
Interest	689.9	316.8	226.5
Schedule of Non-Cash Investing and Financing Activities:
Dividends accrued	24
Warner Chilcott Limited [Member]
Cash Flows From Operating Activities:
Net income / (loss)	4,054.8	(1,560.5)	(724.5)
Reconciliation to net cash provided by operating activities:
Depreciation	218.3	230.9	202
Amortization	5,777	2,597.5	842.7
Provision for inventory reserve	140.9	156.1	113.8
Share-based compensation	690.4	368	133.6
Deferred income tax benefit	(7,380.1)	(690.1)	(275)
In-process research and development impairments	511.6	424.3	4.9
Goodwill impairment		17.3	647.5
Loss / (gain) on asset sales and impairments, net	334.4	143.1	55.9
Amortization of inventory step-up	1,192.9	985.8	267
Amortization of deferred financing costs	298.3	87.2	10.3
Accretion and contingent consideration	108.8	(71.2)	160
Excess tax benefit from stock-based compensation			(69.1)
Non-cash impact of debt extinguishment		(91.7)
Impact of assets held for sale		190.8	42.7
Other, net	66.4	8.5	(9)
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net	(1,033.6)	(611.2)	19.3
Decrease / (increase) in inventories	(226.2)	(207.2)	(213.1)
Decrease / (increase) in prepaid expenses and other current assets	71.3	29.4	49.9
Increase / (decrease) in accounts payable and accrued expenses	193.5	387.6	3.9
Increase / (decrease) in income and other taxes payable	(87.8)	29.7	7.4
Increase / (decrease) in other assets and liabilities	(266.9)	(154.6)	(63)
Net cash provided by operating activities	4,664	2,269.7	1,207.2
Cash Flows From Investing Activities:
Additions to property, plant and equipment	(454.9)	(238.6)	(177.9)
Additions to product rights and other intangibles	(154.7)	(36.1)	(130)
Additions to investments	(24.3)	(1)
Proceeds from the sale of investments and other assets	883	453.7	40.6
Proceeds from sales of property, plant and equipment	140.1	13.7	7.1
Acquisitions of businesses, net of cash acquired	(37,510.1)	(5,562.3)	(15.1)
Net cash (used in) investing activities	(37,120.9)	(5,370.6)	(275.3)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness	26,455.7	8,076.2	1,882.3
Proceeds from borrowings on credit facility and other	3,682	1,280	555
Debt issuance and other financing costs	(310.8)	(224.3)	(7.4)
Payments on debt, including capital lease obligations	(5,134.2)	(6,127)	(3,229.5)
Proceeds from stock plans			44
Payments of contingent consideration	(230.1)	(14.3)	(4.3)
Repurchase of ordinary shares			(165.4)
Acquisition of noncontrolling interest			(10.4)
Excess tax benefit from stock-based compensation			69.2
Dividend to Parent	(208.1)
Contribution from Parent	9,000.8
Net cash provided by/(used in) financing activities	33,255.3	2,990.6	(866.5)
Effect of currency exchange rate changes on cash and cash equivalents	(6.5)	(5.9)	(23.9)
Movement in cash held for sale		37	(37)
Net increase in cash and cash equivalents	791.9	(79.2)	4.5
Cash and cash equivalents at beginning of period	244.3	323.5	319
Cash and cash equivalents at end of period	1,036.2	244.3	323.5
Allergan, Inc. [Member]
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance for the Acquisition of net assets	34,687.2
Kythera [Member]
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance for the Acquisition of net assets	$ 40
Forest Laboratories Inc. [Member]
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance for the Acquisition of net assets		$ 20,590.5
Warner Chilcott [Member]
Reconciliation to net cash provided by operating activities:
Share-based compensation			45.4
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance for the Acquisition of net assets			5,654.4
Actavis Group [Member]
Schedule of Non-Cash Investing and Financing Activities:
Non-cash equity issuance for the Acquisition of net assets			$ 486.3

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' and Member's Equity - USD ($) $ in Millions	Total	Warner Chilcott Limited [Member]	Actavis Plc [Member]	Actavis Plc [Member]Warner Chilcott Limited [Member]	Warner Chilcott [Member]	Warner Chilcott [Member]Warner Chilcott Limited [Member]	Forest Laboratories Inc. [Member]	Allergan, Inc. [Member]	Kythera [Member]	Mandatory Convertible Preferred Shares [Member]	Ordinary Shares [Member]	Ordinary Shares [Member]Actavis Plc [Member]	Ordinary Shares [Member]Warner Chilcott [Member]	Ordinary Shares [Member]Forest Laboratories Inc. [Member]	Ordinary Shares [Member]Allergan, Inc. [Member]	Preferred Shares [Member]	Preferred Shares [Member]Mandatory Convertible Preferred Shares [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Actavis Plc [Member]	Additional Paid-in Capital [Member]Warner Chilcott [Member]	Additional Paid-in Capital [Member]Forest Laboratories Inc. [Member]	Additional Paid-in Capital [Member]Allergan, Inc. [Member]	Additional Paid-in Capital [Member]Kythera [Member]	Retained Earnings/(Accumulated Deficit) [Member]	Retained Earnings/(Accumulated Deficit) [Member]Warner Chilcott Limited [Member]	Accumulated Other Comprehensive (Loss)/Income [Member]	Accumulated Other Comprehensive (Loss)/Income [Member]Warner Chilcott Limited [Member]	Treasury Shares [Member]	Member's Capital [Member]Warner Chilcott Limited [Member]	Member's Capital [Member]Actavis Plc [Member]Warner Chilcott Limited [Member]	Member's Capital [Member]Warner Chilcott [Member]Warner Chilcott Limited [Member]
Balance at Dec. 31, 2012	$ 3,833.8										$ 0.4							$ 1,956.7						$ 2,182.7		$ 36.8		$ (342.8)
Balance, shares at Dec. 31, 2012											138,000,000																	(10,300,000)
Comprehensive income:
Net income (loss) attributable to shareholders	(750.4)	$ (724.5)																						(750.4)	$ (724.5)
Other comprehensive income (loss), net of tax	53.7	53.7																								53.7	$ 53.7
Comprehensive income / (loss) attributable to ordinary shareholders / members	(696.7)	(670.8)
Ordinary shares issued in connection with acquisition			$ 486.3	$ 486.3		$ 5,833.9													$ 486.3											$ 486.3	$ 5,833.9
Ordinary shares issued in connection with acquisition, shares												5,500,000
Ordinary shares issued in connection with acquisition, non-cash issuance					$ 5,833.9															$ 5,833.9
Ordinary shares issued in connection with acquisition, non-cash issuance, shares													40,400,000
Result of contribution of Actavis, Inc. to Allergan plc											$ (0.4)							(509.1)										$ 509.5
Result of contribution of Actavis, Inc. to Allergan plc, shares											(11,500,000)																	11,500,000
Share-based compensation	132.1	119.6																132.1											$ 119.6
Ordinary shares issued under employee stock plans	48																	48
Ordinary shares issued under employee stock plans, shares											1,800,000
Tax benefits from exercise of options	69																	69
Acquisition of noncontrolling interest	(4.3)	(4.3)																(4.3)											(4.3)
Repurchase of ordinary shares	(170)																											$ (170)
Repurchase of ordinary shares, shares																												(1,200,000)
Balance at Dec. 31, 2013	9,532.1																	8,012.6						1,432.3		90.5		$ (3.3)
Balance, shares at Dec. 31, 2013											174,200,000
Balance at Dec. 31, 2012		3,833.8																							2,182.7		36.8		$ 1,614.3
Balance, shares at Dec. 31, 2012																													100
Balance at Dec. 31, 2013		9,598.5																							1,458.2		90.5		$ 8,049.8
Balance, shares at Dec. 31, 2013																													100
Comprehensive income:
Net income (loss) attributable to shareholders	(1,630.5)	(1,560.5)																						(1,630.5)	(1,560.5)
Other comprehensive income (loss), net of tax	(555.9)	(555.9)																								(555.9)	(555.9)
Comprehensive income / (loss) attributable to ordinary shareholders / members	(2,186.4)	(2,116.4)
Contribution from Parent		21,406.1																											$ 21,406.1
Dividend to Parent		(815.6)																							(815.6)
Ordinary shares issued in connection with acquisition							$ 20,590.5														$ 20,590.5
Ordinary shares issued in connection with acquisition, shares														90,900,000
Share-based compensation	368																	368
Ordinary shares issued under employee stock plans	105.9																	105.9
Ordinary shares issued under employee stock plans, shares											1,400,000
Tax benefits from exercise of options	51.1																	51.1
Repurchase of ordinary shares	(130.1)																	(133.4)										$ 3.3
Repurchase of ordinary shares, shares											(600,000)
Balance at Dec. 31, 2014	28,331.1																	28,994.7						(198.2)		(465.4)
Balance, shares at Dec. 31, 2014											265,900,000
Balance at Dec. 31, 2014		28,072.6																							(917.9)		(465.4)		$ 29,455.9
Balance, shares at Dec. 31, 2014																													100
Comprehensive income:
Net income (loss) attributable to shareholders	3,915.2	4,050.6																						3,915.2	4,050.6
Other comprehensive income (loss), net of tax	(28.7)	(28.7)																								(28.7)	(28.7)
Comprehensive income / (loss) attributable to ordinary shareholders / members	3,886.5	4,021.9
Contribution from Parent		43,687.3																											$ 43,687.3
Dividend to Parent		(208.1)																											(208.1)
Ordinary shares issued in connection with acquisition								$ 38,757.6	$ 40													$ 38,757.6	$ 40
Ordinary shares issued in connection with acquisition, shares															126,300,000
Share-based compensation	690.4																	690.4
Ordinary shares issued under employee stock plans	230																	230
Ordinary shares issued under employee stock plans, shares											2,700,000
Tax benefits from exercise of options	76.1																	76.1
Repurchase of ordinary shares	(118)																	(118)
Repurchase of ordinary shares, shares											(400,000)
Balance at Dec. 31, 2015	76,591.4															$ 4,929.7		68,508.3						3,647.5		$ (494.1)
Balance, shares at Dec. 31, 2015											394,500,000					5,100,000
Comprehensive income:
Issuance of Mandatory Convertible Preferred Shares										$ 4,929.7							$ 4,929.7
Issuance of Mandatory Convertible Preferred Shares, shares																	5,100,000
Dividends declared	$ (232)																	$ (162.5)						$ (69.5)
Balance at Dec. 31, 2015		$ 75,573.7																							$ 3,132.7		$ (494.1)		$ 72,935.1
Balance, shares at Dec. 31, 2015																													100

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Description of Business	NOTE 1 — Description of Business Allergan plc (formerly Actavis plc) is a global specialty pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of brand name pharmaceutical products (“brand”, “branded” or “specialty brand”), medical aesthetics, biosimilar and over-the-counter (“OTC”) pharmaceutical products. The Company has operations in more than 100 countries. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc and has the same principal business activities. As a result of the Allergan Acquisition (defined below) which closed on March 17, 2015, the Company expanded its franchises to include ophthalmology, neurosciences and medical aesthetics/dermatology/plastic surgery, which complements the Company’s existing central nervous system, gastroenterology, women’s health and urology franchises. The combined company benefits significantly from Allergan, Inc.’s (“Legacy Allergan”) global brand equity and consumer awareness of key products, including Botox ® ® The results of our discontinued operations includes the results of our generic product development, manufacturing and distribution of off-patent pharmaceutical products, established international brands marketed similar to generic products and out-license generic pharmaceutical products primarily in Europe through our Medis third-party business. On July 26, 2015 we entered into a master purchase agreement (the “Teva Agreement”), under which Teva Pharmaceutical Industries Ltd. (“Teva”) agreed to acquire our global generic pharmaceuticals business and certain other assets (the “Teva Transaction”). Under the Teva Agreement, upon the closing of the Teva Transaction, we will receive $33.75 billion in cash and 100.3 million Teva ordinary shares (or American Depository Shares with respect thereto), which approximates $6.75 billion in Teva stock using the then-current stock price at the time the Teva Transaction was announced, in exchange for which Teva will acquire our global generics business, including the United States (“U.S.”) and international generic commercial units, our third-party supplier Medis, our global generic manufacturing operations, our global generic research and development (“R&D”) unit, our international OTC commercial unit (excluding OTC eye care products) and some established international brands. The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2016; however , it is possible that closing could slip beyond the end of the first quarter . As a result of the transaction, and in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) number 2014-08 “Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity”, the Company is accounting for the assets and liabilities to be divested as held for sale. Further, the financial results of the business held for sale have been reclassified to discontinued operations for all periods presented in our consolidated financial statements. On November 23, 2015, the Company announced that it entered into a definitive merger agreement (the “Pfizer Agreement”) under which Pfizer, Inc. (“Pfizer”), a global innovative biopharmaceutical company, and Allergan plc will merge in a stock and cash transaction (the “Pfizer Transaction”), which attributes a $160.0 billion enterprise valuation using the then-current stock price at the time the Pfizer Transaction was announced. Company shareholders will receive 11.3 shares of the combined company for each of their existing Allergan shares and Pfizer stockholders will receive in respect of each share of Pfizer common stock held by them, at their election and subject to certain proration procedures described in the Pfizer Agreement, either one combined company ordinary share or an amount in cash equal to the volume weighted average price per share of Pfizer common stock on the New York Stock Exchange (“NYSE”) on the trading day immediately preceding the date of the consummation of the Pfizer Transaction. The Pfizer Transaction is anticipated to close in the second half of 2016.

Formation of the Company

Formation of the Company	12 Months Ended
	Dec. 31, 2015
Regulated Operations [Abstract]
Formation of the Company	NOTE 2 — Formation of the Company Allergan plc was incorporated in Ireland on May 16, 2013 as a private limited company and re-registered effective September 20, 2013 as a public limited company. It was established for the purpose of facilitating the business combination between Actavis, Inc. and Warner Chilcott plc (“Warner Chilcott”). On October 1, 2013, pursuant to the transaction agreement dated May 19, 2013 among Actavis, Inc., Warner Chilcott, the Company, Actavis Ireland Holding Limited, Actavis W.C. Holding LLC (now known as Actavis W.C. Holding Inc.) and Actavis W.C. Holding 2 LLC (now known as Actavis W.C. Holding 2 Inc.) (“MergerSub”), (i) the Company acquired Warner Chilcott (the “Warner Chilcott Acquisition”) pursuant to a scheme of arrangement under Section 201, and a capital reduction under Sections 72 and 74, of the Irish Companies Act of 1963 where each Warner Chilcott ordinary share was converted into 0.160 of an Allergan plc ordinary share (the “Company Ordinary Shares”), or $5,833.9 million in equity consideration, and (ii) MergerSub merged with and into Actavis, Inc., with Actavis, Inc. as the surviving corporation in the merger (the “Merger” and, together with the Warner Chilcott Acquisition, the “Transactions”). Following the consummation of the Transactions, Actavis, Inc. and Warner Chilcott became wholly-owned subsidiaries of Allergan plc. Each of Actavis, Inc.’s common shares was converted into one Company Ordinary Share. Effective October 1, 2013, through a series of related-party transactions, Allergan plc contributed its indirect subsidiaries, including Actavis, Inc. to Warner Chilcott Limited. On March 17, 2015, the Company acquired Legacy Allergan for approximately $77.0 billion including outstanding indebtedness assumed of $2.2 billion, cash consideration of $40.1 billion and equity consideration of $34.7 billion, which includes outstanding equity awards (the “Allergan Acquisition”). Under the terms of the agreement, Legacy Allergan shareholders received 111.2 million of the Company’s ordinary shares, 7.0 million of the Company’s non-qualified stock options and 0.5 million of the Company’s share units. In connection with the Allergan Acquisition, the Company changed its name from Actavis plc to Allergan plc. Actavis plc’s ordinary shares were traded on the NYSE under the symbol “ACT” until the opening of trading on June 15, 2015, at which time Actavis plc changed its corporate name to “Allergan plc” and changed its ticker symbol to “AGN.” Pursuant to Rule 12g-3(c) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Allergan plc is the successor issuer to Actavis plc’s ordinary shares which are deemed to be registered under Section 12(b) of the Exchange Act, and Allergan plc is subject to the informational requirements of the Exchange Act, and the rules and regulations promulgated thereunder. References throughout to “we,” “our,” “us,” the “Company” or “Allergan” refer to financial information and transactions of Watson Pharmaceuticals, Inc. prior to January 23, 2013, Actavis, Inc. from January 23, 2013 until October 1, 2013 and Allergan plc and Warner Chilcott Limited subsequent to October 1, 2013. References throughout to “Ordinary Shares” refer to Actavis, Inc.’s Class A common shares, par value $0.0033 per share, prior to the consummation of the Transactions and to Allergan plc’s ordinary shares, par value $0.0001 per share, since the consummation of the Transactions.

Reconciliation of Warner Chilco

Reconciliation of Warner Chilcott Limited Results to Allergan plc Results	12 Months Ended
	Dec. 31, 2015
Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]
Reconciliation of Warner Chilcott Limited Results to Allergan plc Results	NOTE 3 — Reconciliation of Warner Chilcott Limited results to Allergan plc results Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc (together with other Warner Chilcott Limited parents, the “Parent”), the ultimate parent of the group. The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the deminimis activity between Allergan plc and Warner Chilcott Limited, references throughout this filing relate to both Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited representations relate only to itself and not to any other company. Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, these notes relate to the consolidated financial statements for both separate registrants, Allergan plc and Warner Chilcott Limited. In addition to certain inter-company payable and receivable amounts between the entities, the following is a reconciliation of the results of Warner Chilcott Limited to Allergan plc ($ in millions): December 31, 2015 December 31, 2014 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Cash and cash equivalents $ 1,096.0 $ 1,036.2 $ 59.8 $ 250.0 $ 244.3 $ 5.7 Accounts receivable, net 2,401.6 2,401.6 - 1,112.3 1,111.6 0.7 Prepaid expenses and other current assets 558.5 556.0 2.5 478.8 475.9 2.9 Property, plant and equipment, net 1,573.9 1,573.9 - 283.4 282.5 0.9 Accounts payable and accrued liabilities 4,349.5 4,295.4 54.1 3,030.1 3,027.0 3.1 Year Ended December 31, 2015 Year Ended December 31, 2014 Year Ended December 31, 2013 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 1,765.6 $ 1,630.2 $ 135.4 $ 1,247.0 $ 1,177.0 $ 70.0 $ 456.1 $ 431.7 $ 24.4 Operating (loss) (3,014.5 ) (2,879.1 ) (135.4 ) (2,443.9 ) (2,373.9 ) (70.0 ) (369.2 ) (344.8 ) (24.4 ) (Loss) before income taxes and noncontrolling interest (4,430.2 ) (4,294.8 ) (135.4 ) (2,874.1 ) (2,804.1 ) (70.0 ) (622.8 ) (598.4 ) (24.4 ) (Benefit) for income taxes (1,561.9 ) (1,561.9 ) - (467.0 ) (467.0 ) - (155.3 ) (156.2 ) 0.9 Net (loss) from continuing operations, net of tax (2,868.3 ) (2,732.9 ) (135.4 ) (2,407.1 ) (2,337.1 ) (70.0 ) (467.5 ) (442.2 ) (25.3 ) Net income / (loss) 3,919.4 4,054.8 (135.4 ) (1,630.5 ) (1,560.5 ) (70.0 ) (750.4 ) (724.5 ) (25.9 ) Net income / (loss) attributable to ordinary shareholders/members 3,683.2 4,050.6 (367.4 ) (1,630.5 ) (1,560.5 ) (70.0 ) (750.4 ) (724.5 ) (25.9 ) Dividends on preferred stock 232.0 - 232.0 - - - - - - The difference between general and administrative expenses in the years ending December 31, 2015, 2014 and 2013 were due to corporate related expenses incurred at Allergan plc as well as non-recurring transaction costs incurred as part of the acquisitions of the Company, including Allergan, Forest (defined below) and Warner Chilcott. Movements in equity are due to historical differences in the results of operations of the companies and differences in equity awards.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 4 — Summary of Significant Accounting Policies Basis of Presentation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented. The Company’s consolidated financial statements include the financial results of all acquired companies subsequent to the acquisition date. Reclassifications The Company has made certain reclassifications to prior period information to conform to the current period presentation, including the impact of the Teva Transaction. Use of Estimates Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The Company’s most significant estimates relate to the determination of SRA’s (defined below) included within either accounts receivable or accrued liabilities, the valuation of inventory balances, the determination of useful lives for intangible assets, pension and other post-retirement benefit plan assumptions, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment and recognition and measurement of assets acquired and liabilities assumed in business combinations at fair value. The estimation process required to prepare the Company’s consolidated financial statements requires assumptions to be made about future events and conditions, and as such, is inherently subjective and uncertain. The Company’s actual results could differ materially from those estimates. Foreign Currency Translation For most of the Company’s international operations, the local currency has been determined to be the functional currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transaction. Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive (loss) / income. The effects of revaluing non-functional currency assets and liabilities into the functional currency are recorded as general and administrative expenses in the consolidated statements of operations. The Company realizes foreign currency gains / (losses) in the normal course of business based on movement in the applicable exchange rates. These gains / (losses) are included as a component of general and administrative expenses. Cash and Cash Equivalents The Company considers cash and cash equivalents to include cash in banks, commercial paper and deposits with financial institutions that can be liquidated without prior notice or penalty. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Fair Value of Other Financial Instruments The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, investments, trade accounts payable, and long-term debt, including the current portion. The carrying amounts of cash and cash equivalents, marketable securities, accounts and other receivables and trade accounts payable are representative of their respective fair values due to their relatively short maturities. The fair values of investments in companies that are publicly traded and not accounted for under the equity method are based on quoted market prices. The Company estimates the fair value of its fixed rate long-term obligations based on quoted market rates. The carrying amount reported for long-term debt, other than the Company’s indebtedness under senior notes, is considered to be representative of fair value as they are at variable rates and reprice frequently. Inventories Inventories consist of finished goods held for distribution, raw materials and work in process. Inventory includes brand pharmaceutical and medical aesthetic products which represent Food and Drug Administration (“FDA”) approved indications. Inventory valuation reserves are established based on a number of factors/situations including, but not limited to, raw materials, work in process or finished goods not meeting product specifications, product obsolescence, or application of the lower of cost (first-in, first-out method) or market (net realizable value) concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. Assumptions utilized in our quantification of inventory reserves include, but are not limited to, estimates of future product demand, consideration of current and future market conditions, product net selling price, anticipated product launch dates, potential product obsolescence and other events relating to special circumstances surrounding certain products. No material adjustments have been required to our inventory reserve estimates for the periods presented. Adverse changes in assumptions utilized in our inventory reserve calculations could result in an increase to our inventory valuation reserves and higher cost of sales. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Major renewals and improvements are capitalized, while routine maintenance and repairs are expensed as incurred. The Company capitalizes interest on qualified construction projects. At the time property, plant and equipment are retired from service, the cost and accumulated depreciation is removed from the respective accounts. Depreciation expense is computed principally on the straight-line method, over the estimated useful lives of the related assets. The following table provides the range of estimated useful lives used for each asset type: Computer software/hardware (including internally developed) 3-10 years Machinery and equipment 3-15 years Research and laboratory equipment 3-10 years Furniture and fixtures 3-10 years Buildings, improvements, leasehold improvements and other 4-50 years Transportation equipment 3-20 years The Company assesses property, plant and equipment for impairment whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Investments The Company’s equity investments are accounted for under the equity method of accounting when the Company can exert significant influence and the Company’s ownership interest does not exceed 50%. The Company records equity method investments at cost and adjusts for the appropriate share of investee net earnings or losses. Investments in which the Company owns less than a 20% interest and cannot exert significant influence are accounted for using the cost method if the fair value of such investments is not readily determinable. Marketable Securities The Company’s marketable securities consist of U.S. treasury and agency securities and equity securities of publicly-held companies. The Company’s marketable securities are classified as available-for-sale and are recorded at fair value, based upon quoted market prices. Unrealized temporary adjustments to fair value are included on the balance sheet in a separate component of stockholders’ equity as unrealized gains and losses and are reported as a component of accumulated other comprehensive income / (loss). No gains or losses on marketable securities are realized until shares are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. Product Rights and Other Definite-Lived Intangible Assets Our product rights and other definite-lived intangible assets are stated at cost, less accumulated amortization, and are amortized using the economic benefit model or the straight-line method, if results are materially aligned, over their estimated useful lives. We determine amortization periods for product rights and other definite-lived intangible assets based on our assessment of various factors impacting estimated useful lives and cash flows. Such factors include the product’s position in its life cycle, the existence or absence of like products in the market, various other competitive and regulatory issues, and contractual terms. Significant changes to any of these factors may result in a reduction in the intangibles useful life and an acceleration of related amortization expense, which could cause our net results to decline. Product rights and other definite-lived intangible assets are tested periodically for impairment when events or changes in circumstances indicate that an asset’s carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in net (loss) / income in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Our projections of discounted cash flows use a discount rate determined by our management to be commensurate with the risk inherent in our business model. Our estimates of future cash flows attributable to our other definite-lived intangible assets require significant judgment based on our historical and anticipated results and are subject to many factors. Different assumptions and judgments could materially affect the calculation of the fair value of the other definite-lived intangible assets which could trigger impairment. Goodwill and Intangible Assets with Indefinite Lives The Company tests goodwill and intangible assets with indefinite-lives for impairment annually in the second quarter by comparing the fair value of each of the Company’s reporting units to the respective carrying value of the reporting units. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount or when the Company has a change to reporting units. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Impairment, if any, would be recorded in operating income and this could result in a material impact to net (loss) / income and (loss) / earnings per share. Acquired IPR&D intangible assets represent the value assigned to acquired research and development projects that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that the Company has acquired with respect to products and/or processes that have not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, R&D costs, selling and marketing costs and other costs which may be allocated), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, and competitive trends impacting the asset and each cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of the IPR&D projects include legal risk, market risk and regulatory risk. Changes in these assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project to commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results. Upon successful completion of each project and approval of the product, we will make a separate determination of the useful life of the intangible, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life. Warranties As a result of the Allergan Acquisition, the Company provides warranty programs for breast implant sales primarily in the United States, Europe and certain other countries. Management estimates the amount of potential future claims from these warranty programs based on actuarial analyses. Expected future obligations are determined based on the history of product shipments and claims and are discounted to a current value. The provision for warranty expense in the year ended December 31, 2015 was $4.5 million. The liability is included in both current and long-term liabilities in the Company’s consolidated balance sheets and amounted to $7.6 million and $28.4 million, respectively, as of December 31, 2015. The U.S. programs include the ConfidencePlus ® ConfidencePlus ® ConfidencePlus ® ConfidencePlus ® Contingent Consideration Contingent consideration is recorded at the acquisition date estimated fair value of the contingent payment for all applicable acquisitions. The fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statement of operations. (Refer to “NOTE 24 — Fair Value Measurement” for additional details regarding the fair value of contingent consideration.) Revenue Recognition General Revenue from product sales is recognized when title and risk of loss to the product transfers to the customer, which is based on the transaction shipping terms. Recognition of revenue also requires reasonable assurance of collection of sales proceeds, the seller’s price to the buyer to be fixed or determinable and the completion of all performance obligations. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, billback adjustments, sales returns and allowances, commercial and government rebates, customer loyalty programs and fee-for-service arrangements with certain distributors, which we refer to in the aggregate as “SRA” allowances. Royalty and commission revenue is recognized as a component of net revenues in accordance with the terms of their respective contractual agreements when collectability is reasonably assured and when revenue can be reasonably measured. Provisions for SRAs As is customary in the pharmaceutical industry, our gross product sales are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes gross revenue from the sale of products, an estimate of SRA is recorded, which reduces the product revenues. Accounts receivable and/or accrued liabilities are also reduced and/or increased by the SRA amount depending on whether we have the right of offset with the customer. These provisions are estimated based on historical payment experience, historical relationship of the deductions to gross product revenues, government regulations, estimated utilization or redemption rates, estimated customer inventory levels and current contract sales terms. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material revenue adjustments have been necessary in prior periods to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company uses a variety of methods to assess the adequacy of the SRA reserves to ensure that our financial statements are fairly stated. Chargebacks — A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at certain contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the vast majority of the recipients of the Company’s chargeback payments. We continually monitor current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Rebates — Rebates include volume related incentives to direct and indirect customers, third-party managed care and Medicare Part D rebates, Medicaid rebates and other government rebates. Rebates are accrued based on an estimate of claims to be paid for product sold into trade by the Company. Volume rebates are generally offered to customers as an incentive to use the Company’s products and to encourage greater product sales. These rebate programs include contracted rebates based on customers’ purchases made during an applicable monthly, quarterly or annual period. The provision for third-party rebates is estimated based on our customers’ contracted rebate programs and the Company’s historical experience of rebates paid. Any significant changes to our customer rebate programs are considered in establishing the provision for rebates. The provisions for government rebates are based, in part, upon historical experience of claims submitted by the various states / authorities, contractual terms and government regulations. We monitor legislative changes to determine what impact such legislation may have on our provision. Cash Discounts — Cash discounts are provided to customers that pay within a specific period. The provision for cash discounts is estimated based upon invoice billings and historical customer payment experience. The Company’s experience of payment history is fairly consistent and most customer payments qualify for the cash discount. Returns and Other Allowances — The Company’s provision for returns and other allowances include returns, pricing adjustments, promotional allowances, loyalty cards and billback adjustments. Consistent with industry practice, the Company maintains a returns policy that allows customers to return product for a credit. In accordance with the Company’s policy, credits for customer returns of products are applied against outstanding account activity or are settled in cash. Product exchanges are not permitted. Customer returned products are generally not resalable. The Company’s estimate of the provision for returns is based upon historical experience and current trends of actual customer returns. Additionally, we consider other factors when estimating the current period returns provision, including levels of inventory in the distribution channel, as well as significant market changes that may impact future expected returns. Pricing adjustments, which includes shelf stock adjustments, (and which primarily relate to our held for sale generics business) are credits issued to reflect price decreases in selling prices charged to the Company’s direct customers. Shelf stock adjustments are based upon the amount of product our customers have in their inventory at the time of an agreed-upon price reduction. The provision for shelf stock adjustments is based upon specific terms with the Company’s customers and includes estimates of existing customer inventory levels based upon their historical purchasing patterns. We regularly monitor all price changes to evaluate the Company’s reserve balances. The adequacy of these reserves is readily determinable as pricing adjustments and shelf stock adjustments are negotiated and settled on a customer-by-customer basis. Promotional allowances are credits that are issued in connection with a product launch or as an incentive for customers to carry our product. The Company establishes a reserve for promotional allowances based upon contractual terms. Billback adjustments (and which primarily relate to our held for sale generics business), are credits that are issued to certain customers who purchase directly from us as well as indirectly through a wholesaler. These credits are issued in the event there is a difference between the customer’s direct and indirect contract price. The provision for billbacks is estimated based upon historical purchasing patterns of qualified customers who purchase product directly from us and supplement their purchases indirectly through our wholesale customers. Loyalty cards allow the end user patients a discount per prescription and are accrued based on historical experience, contract terms and the volume of product and cards in the distribution channel. The following table summarizes the activity from continuing operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Return and Other Allowances Cash Discounts Total Balance at December 31, 2012 $ 81.2 $ 30.8 $ 178.9 $ 9.3 $ 300.2 Add: Warner Chilcott Acquisition 5.6 255.5 121.3 5.5 387.9 Provision related to sales in 2013 214.5 330.2 86.5 42.9 674.1 Credits and payments (279.5 ) (326.6 ) (183.6 ) (48.5 ) (838.2 ) Balance at December 31, 2013 $ 21.8 $ 289.9 $ 203.1 $ 9.2 $ 524.0 Add: Forest Acquisition 27.9 425.0 94.3 9.8 557.0 Provision related to sales in 2014 442.9 1,562.8 154.4 155.7 2,315.8 Credits and payments (464.6 ) (1,268.9 ) (191.0 ) (155.0 ) (2,079.5 ) Balance at December 31, 2014 $ 28.0 $ 1,008.8 $ 260.8 $ 19.7 $ 1,317.3 Add: Allergan Acquisition 14.1 306.4 100.4 8.6 429.5 Provision related to sales in 2015 649.9 4,082.9 732.2 301.9 5,766.9 Credits and payments (613.8 ) (4,044.1 ) (720.3 ) (301.7 ) (5,679.9 ) Balance at December 31, 2015 $ 78.2 $ 1,354.0 $ 373.1 $ 28.5 $ 1,833.8 The following table summarizes the activity from discontinued operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Return and Other Allowances Cash Discounts Total Balance at December 31, 2012 $ 130.3 $ 820.0 $ 170.6 $ 27.6 $ 1,148.5 Provision related to sales in 2013 2,125.5 2,008.9 817.6 158.8 5,110.8 Credits and payments (2,031.2 ) (2,057.0 ) (573.4 ) (147.9 ) (4,809.5 ) Balance at December 31, 2013 $ 224.6 $ 771.9 $ 414.8 $ 38.5 $ 1,449.8 Provision related to sales in 2014 4,148.8 1,761.1 705.0 195.0 6,809.9 Credits and payments (3,836.5 ) (1,795.2 ) (768.5 ) (192.5 ) (6,592.7 ) Balance at December 31, 2014 $ 536.9 $ 737.8 $ 351.3 $ 41.0 $ 1,667.0 Provision related to sales in 2015 5,907.2 1,944.7 657.0 251.0 8,759.9 Credits and payments (5,825.1 ) (1,961.1 ) (685.2 ) (235.4 ) (8,706.8 ) Balance at December 31, 2015 $ 619.0 $ 721.4 $ 323.1 $ 56.6 $ 1,720.1 The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): As of December 31, 2015 2014 Accounts receivable $ 263.8 $ 162.4 Accounts payable and accrued expenses 1,570.0 1,154.9 $ 1,833.8 $ 1,317.3 The following table summarizes the balance sheet classification of our SRA reserves relating to the generics business being divested to Teva ($ in millions): As of December 31, 2015 2014 Current assets held for sale $ 1,306.6 $ 1,269.6 Current liabilities held for sale 413.5 397.4 $ 1,720.1 $ 1,667.0 During the year ended December 31, 2015, the Company lowered SRA balances relating to the valuation of assets and liabilities acquired as part of the Forest Acquisition measurement period adjustments by $53.2 million, with an offset to goodwill ($33.2 million) and deferred tax liabilities ($20.0 million). The provisions recorded to reduce gross product sales to net product sales were as follows ($ in millions): Years Ended December 31, Gross Product Sales Chargebacks Rebates Return and Other Allowances Cash Discounts Net Product Sales Gross-to-net Percentages 2013 $ 3,212.2 $ 214.5 $ 330.2 $ 86.5 $ 42.9 $ 2,538.1 79.0 % 2014 $ 8,987.3 $ 442.9 $ 1,562.8 $ 154.4 $ 155.7 $ 6,671.5 74.2 % 2015 $ 20,653.9 $ 649.9 $ 4,082.9 $ 732.2 $ 301.9 $ 14,887.0 72.1 % The movement in the percentage of provisions to gross sales is a result of changes in product mix, competition and channels of distribution. In the year ended December 31, 2015, the Company’s increased sales of acquired eye care products and acquired Forest products lowered the provision percentage. The Company does not expect future payments of SRA reserves to materially exceed our current estimates. However, if future SRA payments were to materially exceed our estimates, such adjustments may have a material adverse impact on our financial position, results of operations and cash flows. Branded Prescription Drug Fee On July 28, 2014, the Internal Revenue Service (“IRS”) issued revised final rules and regulations for the Branded Prescription Drug Fee, an annual fee payable to the federal government based on an allocation of the Company’s market share for branded prescription and authorized generic drugs sold to certain government programs compared to that of the industry. The final rules accelerated the expense recognition criteria for the fee obligation from the year in which the fee is paid, to the year in which the market share used to allocate the fee is determined. This change required Allergan (and other industry participants) to recognize an additional year of expense in the third quarter of 2014 of $105.1 million, which is reflected in our 2014 selling and marketing expense. Litigation and Contingencies The Company is involved in various legal proceedings in the normal course of its business, including product liability litigation, intellectual property litigation, employment litigation and other litigation. Additionally, the Company, in consultation with its counsel, assesses the need to record a liability for contingencies on a case-by-case basis in accordance with ASC Topic 450 “Contingencies” (“ASC 450”). Accruals are recorded when the Company determines that a loss related to a matter is both probable and reasonably estimable. These accruals are adjusted periodically as assessment efforts progress or as additional information becomes available. Acquired contingencies in business combinations are recorded at fair value to the extent determinable, otherwise in accordance ASC R&D Activities R&D activities are expensed as incurred and consist of self-funded R&D costs, the costs associated with work performed under collaborative R&D agreements, regulatory fees, and license and milestone payments, if any. As of December 31, 2015, the Company is developing a number of branded products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs including the following: Product Therapeutic Area Indication Expected Launch Year Phase Restasis MDPF Eye Care Dry Eye 2016 Registration XEN45 Eye Care Glaucoma 2017 III Sarecycline Dermatology Severe Acne 2018 III Esmya Woman's healthcare Uterine Fibroids 2018 III Bimatoprost SR Eye Care Glaucoma 2018 III Tavilermide Eye Care Dry Eye 2019 III Relamorelin** Gastrointestinal Gastroparesis 2020 II Ubrogepant Neurology Acute Migraine 2020 II Abicipar Eye Care Age Related Macular Degeneration 2020 III Rapastinel Psychiatry Depression 2021 II ** As part of our agreement with Rhythm Health, Inc. We also have a number of products in development as part of our life-cycle management strategy for our existing product portfolio. Allocation of Acquisition Fair Values to Assets Acquired and Liabilities Assumed We account for acquired businesses using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at the date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values as determined using a market participant concept. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. The most material line items impacted by the allocation of acquisition fair values are: · Intangible assets (including IPR&D assets upon successful completion of the project and approval of the product) which are amortized to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected future net cash flow streams, the timing of approvals for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the future useful lives. For these and other reasons, actual results may vary significantly from estimated results. · Fixed asset valuations which are depreciated over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates and intended uses of the assets. · Inventory is recorded at fair market value factoring in selling price and costs to dispose. Inventory acquired is typically valued higher than replacement cost. Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets by assessing its valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in applicable tax jurisdictions could affect the ultimate realization of deferred tax assets and could result in

Business Development

Business Development	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Development	NOTE 5 — Business Development During the years ended December 31, 2015, 2014 and 2013, the Company acquired material assets and businesses. The unaudited pro forma results of the businesses acquired that materially impacted the reported results of the Company are as follows ($ in millions except per share information): Year Ended December 31, 2015 (unaudited) As reported Allergan Acquisition Pro Forma Net Revenue $ 15,071.0 $ 1,523.0 $ 16,594.0 Net income attributable to ordinary shareholders $ 3,683.2 $ 377.7 $ 4,060.9 Net income per share Basic $ 10.01 $ 10.32 Diluted $ 10.01 $ 10.32 Year Ended December 31, 2014 (unaudited) As reported Allergan Acquisition Forest Acquisition Pro Forma Net Revenue $ 6,738.9 $ 7,225.4 $ 2,239.8 $ 16,204.1 Net (loss) / income attributable to ordinary shareholders $ (1,630.5 ) $ (3,067.8 ) $ 146.1 $ (4,552.2 ) Net (loss) per share Basic $ (7.42 ) $ (11.66 ) Diluted $ (7.42 ) $ (11.66 ) Year Ended December 31, 2013 (unaudited) As reported Forest Acquisition Warner Chilcott Acquisition Pro Forma Net Revenue $ 2,602.5 $ 3,876.8 $ 1,646.6 $ 8,125.9 Net (loss) / income attributable to ordinary shareholders $ (750.4 ) $ (2,261.4 ) $ 518.2 $ (2,493.6 ) Net (loss) per share Basic $ (5.27 ) $ (9.51 ) Diluted $ (5.27 ) $ (9.51 ) 2015 Significant Business Developments During 2015, the following business development transactions impacted our results of operations and will continue to have an impact on our future results of operations. Acquisitions AqueSys On October 16, 2015, the Company acquired AqueSys, Inc. (“AqueSys”), a private, clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (“IOP”) associated with glaucoma, in an all-cash transaction. Under the terms of the agreement, the Company acquired AqueSys for an acquisition accounting purchase price of $298.9 million, including $193.5 million for the estimated fair value of contingent consideration relating to the regulatory approval and commercialization milestone payments. The Company acquired AqueSys for the lead development program, including XEN45, a soft shunt that is implanted in the sub conjunctival space in the eye through a minimally invasive procedure with a single use, pre-loaded proprietary injector (the “AqueSys Acquisition”). Assets Acquired and Liabilities Assumed at Fair Value The transaction has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. As of December 31, 2015, certain amounts relating to the valuation of tax related matters, contingent consideration and intangible assets have not been finalized. The finalization of these matters may result in changes to goodwill. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 6.2 Current assets 1.2 IPR&D intangible assets 302.0 Intangible assets 221.0 Goodwill 138.5 Current liabilities (6.9 ) Contingent consideration (193.5 ) Deferred tax liabilities, net (169.6 ) Net assets acquired $ 298.9 IPR&D and Intangible Assets IPR&D intangible assets represent the value assigned to acquired R&D projects that, as of the acquisition date, had not established technological feasibility and had no alternative future use. The IPR&D intangible assets are capitalized and accounted for as indefinite-lived intangible assets and will be subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project and launch of the product, the Company will make a separate determination of the estimated useful life of the IPR&D intangible asset and the related amortization will be recorded as an expense over the estimated useful life (“IPR&D Acquisition Accounting”). The estimated fair value of the IPR&D and identifiable intangible assets was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of sales, R&D costs, selling and marketing costs and working capital/asset contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors (the “IPR&D and Intangible Asset Valuation Technique”). The fair value of the currently marketed product (“CMP”) and IPR&D intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for CMP and IPR&D intangible assets was 21.0% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. The discount rate of the acquisition was driven by the early stage of the product and the therapeutic indication. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. The CMP intangible asset will be amortized over a period of 12.2 years. Goodwill Goodwill from the AqueSys Acquisition of $138.5 million, of which $50.5 million was assigned to the US Brands segment and $88.0 million was assigned to the International Brands segment. The goodwill arose in part, due to anticipated efficiencies in marketing the CMP asset in our International Brands and US Brands segments where we have an established infrastructure. Contingent Consideration As part of the acquisition, the Company is required to pay the former shareholders of AqueSys amounts based on the launch, labeling, and sales of the product. The Company estimated the acquisition accounting fair value of the contingent consideration to be $193.5 million using a probability weighted approach that considered the possible outcomes of the scenarios relating to the specified product. Long-Term Deferred Tax Liabilities and Other Tax Liabilities Long-term deferred tax liabilities and other tax liabilities result from identifiable intangible assets fair value adjustments. These adjustments create excess book basis over the tax basis which is multiplied by the statutory tax rate for the jurisdiction in which the deferred taxes exist. Northwood Medical Innovation On October 1, 2015, the Company completed the Northwood Acquisition under which we acquired earFold™ which is a medical device for the correction of prominent ears, with or without asymmetry, in patients aged 7 years and older. earFold™ received a Conformité Européene (“CE”) mark in April 2015, and has been made available by Northwood Medical Innovation Ltd to trained and accredited plastic surgeons, otolaryngologists (Ear, Nose and Throat) and maxillo-facial surgeons, primarily in the United Kingdom (“UK”). The Company acquired Northwood Medical Innovation Ltd. for acquisition accounting purchase price consideration of $25.5 million (the “Northwood Acquisition”), including $15.0 million of contingent consideration. Assets Acquired and Liabilities Assumed at Fair Value The transaction has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. As of December 31, 2015, certain amounts relating to the valuation of tax related matters, contingent consideration and intangible assets have not been finalized. The finalization of these matters may result in changes to goodwill. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 0.5 IPR&D intangible assets 13.6 Intangible assets 19.5 Goodwill 13.6 Other assets and liabilities (0.1 ) Contingent consideration (15.0 ) Deferred tax liabilities, net (6.6 ) Net assets acquired $ 25.5 IPR&D and Intangible Assets The fair value of the CMP and IPR&D intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for CMP and IPR&D intangible assets was 15.0% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. Goodwill Goodwill from the acquisition of $13.6 million was assigned to the International Brands segment. The goodwill arose in part, due to anticipated efficiencies in marketing the CMP asset in our International Brands segment where we have an established infrastructure. Contingent Consideration As part of the acquisition, the Company is required to pay the former shareholders of Northwood Medical Innovation Ltd. amounts based on the sales of the product. The Company estimated the acquisition accounting fair value of the contingent consideration to be $15.0 million using a probability weighted approach that considered the possible outcomes of the scenarios relating to the specified product. Long-Term Deferred Tax Liabilities and Other Tax Liabilities Long-term deferred tax liabilities and other tax liabilities result from identifiable intangible assets fair value adjustments. These adjustments create excess book basis over the tax basis which is multiplied by the statutory tax rate for the jurisdiction in which the deferred taxes exist. Kythera On October 1, 2015, the Company acquired Kythera Biopharmaceuticals (“Kythera”), for $75 per share, or an acquisition accounting purchase price of $2,089.5 million (the “Kythera Acquisition”), which is being accounted for as a business acquisition. Kythera was focused on the discovery, development and commercialization of novel prescription aesthetic products. Kythera’s lead product, Kybella ® Assets Acquired and Liabilities Assumed at Fair Value The transaction has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. As of December 31, 2015, certain amounts relating to the valuation of tax related matters, and intangible assets have not been finalized. The finalization of these matters may result in changes to goodwill. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 78.1 Marketable securities 79.9 Inventories 18.2 Other current assets 14.5 IPR&D intangible assets 320.0 Intangible assets 2,120.0 Goodwill 328.7 Other current liabilities (48.6 ) Deferred tax, net (766.7 ) Outstanding indebtedness (54.6 ) Net assets acquired $ 2,089.5 IPR&D and Intangible Assets The fair value of the IPR&D intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for CMP was 8.5% and for IPR&D intangible assets was 9.5% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. The CMP intangible asset will be amortized over a period of 17.3 years. Goodwill Goodwill from the Kythera Acquisition of $208.7 million was assigned to the US Medical Aesthetics segment and $120.0 million assigned to International Brands segment. The goodwill arose in part, due to anticipated efficiencies in marketing the CMP asset where we have an established infrastructure and is not deductible for tax purposes. Long-Term Deferred Tax Liabilities and Other Tax Liabilities Long-term deferred tax liabilities and other tax liabilities result from identifiable intangible assets fair value adjustments. These adjustments create excess book basis over the tax basis which is multiplied by the statutory tax rate for the jurisdiction in which the deferred taxes exist. Oculeve On August 10, 2015, the Company acquired Oculeve, Inc. (“Oculeve”), a development-stage medical device company focused on developing novel treatments for dry eye disease. Under the terms of the agreement, Allergan acquired Oculeve for an acquisition accounting purchase price of $134.5 million (the “Oculeve Acquisition”), including $90.0 million for the estimated fair value of contingent consideration of which the Company may owe up to $300.0 million in future payments. The Company acquired Oculeve and its lead product candidate OD-01, an intranasal neurostimulation device, as well as other dry eye products in development. Assets Acquired and Liabilities Assumed at Fair Value The transaction has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 1.6 IPR&D intangible assets 286.0 Goodwill 33.3 Other assets and liabilities (1.9 ) Contingent consideration (90.0 ) Deferred tax liabilities, net (94.5 ) Net assets acquired $ 134.5 IPR&D and Intangible Assets The fair value of the IPR&D intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value for IPR&D intangible assets was 11.0% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. Goodwill Among the primary reasons the Company acquired Oculeve and factors that contributed to the preliminary recognition of goodwill were to expand the Company’s pipeline of eye care products. Goodwill from the Oculeve Acquisition of $33.3 millionwas assigned to the US Brands segment and is not deductible for tax purposes. Contingent Consideration As part of the acquisition, the Company is required to pay the former shareholders of Oculeve amounts based on the launch, labeling, and sales of the product. The Company estimated the acquisition accounting fair value of the contingent consideration to be $90.0 million using a probability weighted approach that considered the possible outcomes of the scenarios relating to the specified product. Long-Term Deferred Tax Liabilities and Other Tax Liabilities Long-term deferred tax liabilities and other tax liabilities result from identifiable intangible assets fair value adjustments. These adjustments create excess book basis over the tax basis which is multiplied by the statutory tax rate for the jurisdiction in which the deferred taxes exist. Auden Mckenzie On May 29, 2015, the Company acquired Auden Mckenzie Holdings Limited (“Auden”), a company specializing in the development, licensing and marketing of niche generic medicines and proprietary brands in the UK and across Europe for approximately 323.7 million British Pounds, or $495.9 million (the “Auden Acquisition”). The assets and liabilities acquired, as well as the results of operations for the acquired Auden business are part of the assets being divested in the Teva Transaction and are included as a component of income from discontinued operations. In addition the acquired financial position is included in assets and liabilities held for sale. Recognition and Measurement of Assets Acquired and Liabilities Assumed at Fair Value The Auden Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. As of December 31, 2015, certain amounts relating to the valuation of tax-related matters, intangible assets and inventory have not been finalized. The following table summarizes the preliminary fair values of the tangible and identifiable intangible assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 32.2 Inventory 49.1 IPR&D intangible assets 38.6 Intangible assets 342.4 Goodwill 123.3 Other assets and liabilities 7.2 Contingent consideration (17.3 ) Deferred tax liabilities, net (79.6 ) Net assets acquired $ 495.9 IPR&D and Intangible Assets The fair value of the IPR&D and CMP intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value of CMPs was 15.0% and for IPR&D intangible assets was 16.0% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. The acquired intangible assets represent generic products with multiple useful lives across multiple therapeutic areas. Goodwill Among the primary reasons the Company acquired Auden and factors that contributed to the preliminary recognition of goodwill were to expand the Company’s pipeline of generics products. Goodwill from the Auden Acquisition of $123.3 million is included as a component of assets held for sale. Contingent Consideration As part of the acquisition, the Company is required to pay royalties based on the sales of hydrocortisone. The Company estimated the acquisition accounting fair value of the contingent consideration to be $17.3 million using a probability weighted approach that considered the possible outcomes of the scenarios relating to the specified product. Allergan On March 17, 2015, the Company completed the Allergan Acquisition. The addition of Legacy Allergan’s therapeutic franchises in ophthalmology, neurosciences and medical aesthetics/dermatology/plastic surgery complements the Company’s existing central nervous system, gastroenterology, women’s health and urology franchises. The combined company benefited from Legacy Allergan’s global brand equity and consumer awareness of key products, including Botox ® ® Assets Acquired and Liabilities Assumed at Fair Value The transaction has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Preliminary Amount as of March 31, 2015 Measurement Period Adjustments Final Amount as of December 31, 2015 Cash and cash equivalents $ 5,424.5 $ - $ 5,424.5 Accounts receivable 962.7 (14.0 ) 948.7 Inventories 1,223.2 (4.6 ) 1,218.6 Other current assets 318.8 - 318.8 Property, plant and equipment, net 1,202.5 12.0 1,214.5 Other long-term assets 189.3 6.8 196.1 IPR&D intangible assets 11,010.0 (1,310.0 ) 9,700.0 Intangible assets 45,050.5 - 45,050.5 Goodwill 26,368.5 720.4 27,088.9 Current liabilities (1,212.2 ) (9.9 ) (1,222.1 ) Contingent consideration (379.1 ) (4.6 ) (383.7 ) Deferred tax liabilities, net (12,512.9 ) 632.8 (11,880.1 ) Other taxes payable (82.4 ) (28.9 ) (111.3 ) Other long-term liabilities (622.0 ) - (622.0 ) Outstanding indebtedness (2,183.5 ) - (2,183.5 ) Net assets acquired $ 74,757.9 $ - $ 74,757.9 The measurement period adjustments for IPR&D intangible assets relate to the Company’s review of patent lives, contract terms and revised cash flow assumptions. Consideration The total consideration for the Allergan Acquisition of $74.8 billion is comprised of the equity value of shares that were outstanding and vested prior to March 17, 2015 of $33.9 billion, the portion of outstanding equity awards deemed to have been earned as of March 17, 2015 of $0.8 billion and cash of $40.1 billion. The portion of outstanding equity awards deemed not to have been earned of $843.1 million as of March 17, 2015 will be expensed over the remaining future vesting period, including $516.2 million in the year ended December 31, 2015. Inventories The fair value of inventories acquired included an acquisition accounting fair market value step-up of $923.9 million. In the year ended December 31, 2015, the Company recognized $902.3 million as a component of cost of sales as the inventory acquired was sold to the Company’s customers. Included in finished goods inventory as of December 31, 2015, was $21.6 million, relating to the remaining fair value step-up associated with the Allergan Acquisition. IPR&D and Intangible Assets The fair value of the intangible assets was determined using the IPR&D and Intangible Asset Valuation Technique. The discount rate used to arrive at the present value at the acquisition date of CMPs was 10.0% and for IPR&D intangibles ranged from 10.0% to 11.0% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite-lived assets Restasis ® $ 3,970.0 4.0 Refresh ® ® 2,720.0 7.6 Other Eye Care Products 6,690.0 4.2 Botox ® 22,600.0 8.0 Aczone ® 160.0 1.3 Other Skin Products 820.0 5.0 Other Aesthetics 6,350.0 6.0 Total CMP 43,310.0 6.7 Trade name 690.0 4.5 Customer relationships 1,050.5 3.4 Total definite-lived assets 45,050.5 6.6 In-process research and development Eye Care 5,500.0 Botox ® 810.0 Aesthetics 2,270.0 Other 1,120.0 Total IPR&D 9,700.0 Total intangible assets $ 54,750.5 Goodwill Among the primary reasons the Company acquired Allergan and factors that contributed to the preliminary recognition of goodwill were to expand the Company’s product portfolio, and to acquire certain benefits from the Legacy Allergan pipeline and the expectation of certain synergies. The goodwill recognized from the Allergan Acquisition, which includes the increase in the purchase price resulting from the movement in Allergan plc’s share price from the date of announcing the deal, until the date of acquisition, is not deductible for tax purposes. Goodwill from the Allergan Acquisition of $15,352.0 million, $3,798.0 million, and $7,938.9 million was assigned to the US Brands, US Medical Aesthetics, and International Brands segments, respectively. Contingent Consideration The Company acquired certain contingent obligations classified as contingent consideration related to historical business combinations. Additional consideration is conditionally due upon the achievement of certain milestones in respect to the development and commercialization of the products as well as reaching certain sales targets. The Company estimated the fair value of the contingent consideration acquired to be $383.7 million using a probability weighting approach that considered the possible outcomes based on assumptions related to the timing and probability of the product launch date, discount rates matched to the timing of first payment, and probability of success rates and discount adjustments on the related cash flows. Retirement Plans The Company acquired post-retirement plans as part of the Allergan Acquisition including defined benefit pension plans in the United States and Europe which had a net liability balance of $302.6 million. As of March 17, 2015, the Allergan Inc. defined benefit pension plans had assets with a fair value of $1,042.0 million, which included cash and cash equivalents of $13.6 million, equity securities of $480.1 million, and fixed income securities of $548.3 million. The Company assumed other post-retirement benefit obligations with defined benefits of $60.2 million. In addition, the Company acquired other benefit obligations which had an acquisition date fair value of assets of $117.1 million and an acquisition date fair value of liabilities of $120.0 million. Prior to the Allergan Acquisition, Legacy Allergan froze most of their defined benefit plans. As a result, the company anticipates deminimis service costs in its statement of operations. Deferred Tax Liabilities, Net Deferred tax liabilities, net, include the impact resulting from identifiable intangible assets and inventory fair value adjustments. These adjustments create excess book basis over the tax basis which is multiplied by the statutory tax rate for the jurisdiction in which the deferred taxes exist. Acquisition-Related Expenses As a result of the acquisition, the Company incurred the following transaction and integration costs in the year ended December 31, 2015 ($ in millions): Year Ended December 31, 2015 Cost of sales Stock-based compensation acquired for Legacy Allergan employees $ 22.5 Acquisition, integration and restructuring related charges 14.9 Research and development Stock-based compensation acquired for Legacy Allergan employees 124.8 Acquisition, integration and restructuring related charges 83.5 Selling and marketing Stock-based compensation acquired for Legacy Allergan employees 110.0 Acquisition, integration and restructuring related charges 75.7 General and administrative Stock-based compensation acquired for Legacy Allergan employees 258.9 Acquisition-related expenditures 65.5 Acquisition, integration and restructuring related charges 298.6 Other (expense) income Bridge loan facilities expense (264.9 ) Interest rate lock 30.9 Total transaction and integration costs $ 1,288.4 Licenses and Asset Acquisitions Mimetogen On November 4, 2015, the Company entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals (“Mimetogen”), a clinical stage biotechnology company, to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease, in exchange for an upfront payment of $50.0 million to Mimetogen, which is included as a component of R&D expenses in the year ended December 31, 2015. Mimetogen will be entitled to receive potential commercial milestones based on the achieving regulatory approval and predefined product labeling of the product. In addition, Mimetogen is entitled to receive one-time annual sales based milestone payments based on multiple pre-defined annual net sales thresolds which may or may not be received, and tiered royalties based on net sales to third parties of the licensed products (the “Mimetogen Transaction”). The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing as well as certain other inputs and processes that the transaction did not qualify as a business. Almirall On October 27, 2015, the Company and Ironwood Pharmaceuticals, Inc. announced that Allergan has acquired rights to Constella ® ® Naurex On August 28, 2015, the Company acquired certain products in early stage development of Naurex, Inc. (“Naurex”) in an all-cash transaction of $571.7 million (the “Naurex Transaction”), plus future contingent payments up to $1,150.0 million, which was accounted for as an asset acquisition. The Company recognized the upfront consideration of $571.7 million as a component of R&D expenses in the year ended December 31, 2015. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing as well as certain other inputs and processes that the transaction did not qualify as a business. The Naurex Transaction expands our pipeline with Naurex’s two leading product candidates GLYX-13 and NRX-1074, two compounds that utilize NMDA modulation as a potential new approach to the treatment of Major Depressive Disorder (“MDD”), a disease that can lead to suicidality among the most severe patients. Migraine License On August 17, 2015, the Company entered into an agreement with Merck & Co. (“Merck”) under which the Company acquired the exclusive worldwide rights to Merck’s early development stage investigational small molecule oral calcitonin gene-related peptide receptor antagonists, which are being developed for the treatment and prevention of migraines (the “Merck Transaction”). The transaction is being accounted for as an asset acquisition. The Company acquired these rights for an upfront charge of $250.0 million which was recognized as a component of R&D expenses in the year ended December 31, 2015. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing as well as certain other inputs and processes that the transaction did not qualify as a business. The Company paid $125.0 million in the year ended December 31, 2015 and the remaining $125.0 million is payable on April 30, 2016. Additionally, Merck is owed contingent payments based on commercial and development milestones of up to $965.0 million as well as royalties. Divestitures Respiratory Business As part of the Forest Acquisition (defined below), we acquired certain assets that comprised Legacy Forest’s branded respiratory business in the U.S. and Canada (the “Respiratory Business”). During the year ended December 31, 2014, we held for sale respiratory assets of $734.0 million, including allocated goodwill to this unit of $309.1 million. On March 2, 2015, the Company sold the Respiratory Business to AstraZeneca plc (“AstraZeneca”) for consideration of $600.0 million upon closing, additional funds to be received for the sale of certain of our inventory to AstraZeneca and low single-digit royalties above a certain revenue threshold. AstraZeneca also paid Allergan an additional $100.0 million and Allergan has agreed to a number of contractual consents and approvals, including certain amendments to the ongoing collaboration agreements between AstraZeneca and Allergan (the “Respiratory Sale”). As a result of the final terms of the agreement, in the year ended December 31, 2015, the Company recognized an incremental charge in cost of sales (including the acquisition accounting fair value mark-up of inventory) relating to inventory that will not be sold to AstraZeneca of $35.3 million. The Company recognized a loss in other (expense) income, net for the sale of the business of $5.3 million in the year ended December 31, 2015. Pharmatech As part of the Forest Acquisition, the Company acquired certain manufacturing plants and contract manufacturing agreements within the business known as Aptalis Pharmaceutical Technologies (“Pharmatech”). In accordance with acquisition accounting, the assets were fair valued on July 1, 2014 as assets held in use, including market participant synergies anticipated under the concept of “highest and best use.” During the fourth quarter of 2014, the decision was made to hold these assets for sale as one complete unit, without integrating the unit and realizing anticipated synergies. During the year ended December 31, 2014, the Company recognized an impairment on assets held for sale of $189.9 million (the “Pharmatech Transaction”) which included a portion of goodwill allocated to this business unit. In the year ended 2015, the Company completed the divestiture of the Pharmatech business and there was no material impact to the Company’s results of operations. 2014 Transactions The following a

Collaborations

Collaborations	12 Months Ended
	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborations	NOTE 6 — Collaborations The Company has ongoing transactions with other entities through collaboration agreements. The following represent the material collaboration agreements impacting the years ended December 31, 2015, 2014 and 2013. Acquired agreements from the Allergan Acquisition Apollo EndoSurgery, Inc. On December 2, 2013, Legacy Allergan completed the sale of the obesity intervention business to Apollo Endosurgery, Inc. for cash consideration of $75.0 million, subject to certain adjustments, and certain additional consideration, including a minority equity interest in Apollo with an estimated fair value of $15.0 million as of December 31, 2015. The Company is accounting for this asset as a cost method investment and it is included as a component of “investments and other assets”. LiRIS On August 13, 2014, Legacy Allergan completed the acquisition of LiRIS Biomedical, Inc. (“LiRIS”), a clinical-stage specialty pharmaceutical company based in the United States focused on developing a pipeline of innovative treatments for bladder diseases, for an upfront payment of $67.5 million, plus up to an aggregate of $295.0 million in payments contingent upon achieving certain future development milestones and up to an aggregate of $225.0 million in payments contingent upon achieving certain commercial milestones. The Company accounted for the contingent consideration in the Allergan Acquisition with an acquisition date fair value of $169.6 million. Acquired agreements from the Forest Acquisition Trevena On May 9, 2013, Forest entered into a collaborative licensing option agreement with Trevena, Inc. (“Trevena”) for the development of TRV027, a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor for the treatment of acute decompensated heart failure. Pursuant to the agreement, the Company purchased $30.0 million of Trevena preferred stock in a round of private placement financing. Trevena filed an initial public offering (“IPO”), at which time the Company’s preferred stock was converted to common stock traded on the NASDAQ stock market. In conjunction with the IPO, the Company purchased an additional $3.0 million of common stock of Trevena. The investment was subsequently accounted for using the fair value method of accounting. At December 31, 2015 and 2014, the fair value of the Trevena common stock held by the Company was $35.6 million and $20.3 million, respectively and is included as a component of “investments and other assets”. Ironwood collaboration agreement In September 2007, Forest entered into a collaboration agreement with Ironwood Pharmaceuticals (“Ironwood”) to jointly develop and commercialize Linzess ® The agreement included contingent milestone payments as well as a contingent equity investment based on the achievement of specific clinical and commercial milestones. The Company may be obligated to pay up to an additional $100.0 million if certain sales milestones are achieved. Based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable guidance, the Company records receipts from and payments to Ironwood in two pools: the Development pool which consists of R&D expenses, and the Commercialization pool, which consists of revenue, cost of sales and other operating expenses. The net payment to or receipt from Ironwood for the Development pool is recorded in R&D expense and the net payment to or receipt from Ironwood for the Commercialization pool is recorded in cost of goods sold. As of December 31, 2015 and 2014, the fair value of the Ironwood collaboration was $24.1 million and $31.9 million, respectively and is included as a component of “investments and other assets.” Moksha8 On October 22, 2012, Forest announced an agreement with Moksha8 which includes an exclusive license from Forest to Moksha8 to commercialize Viibryd ® Amendment to Sanofi Collaboration Agreement On October 28, 2013, Warner Chilcott Company, LLC (“WCCL”), one of our indirect wholly-owned subsidiaries, and Sanofi-Aventis U.S. LLC (“Sanofi”) entered into an amendment (the “Sanofi Amendment”) to the global collaboration agreement as amended (the “Collaboration Agreement”) to which WCCL and Sanofi are parties. WCCL and Sanofi co-develop and market Actonel ® ® Pursuant to the Sanofi Amendment, the parties amended the Collaboration Agreement with respect to Actonel ® ® In accordance with the terms of the Collaboration Agreement, the Company regained world-wide rights to promote Actonel ® ® Amgen Collaboration In December 2011, we entered into a collaboration agreement with Amgen Inc. (“Amgen”) to develop and commercialize, on a worldwide basis, biosimilar versions of Herceptin ® ® ® ®

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2015
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Discontinued Operations	NOTE 8 — Assets Held For Sale The following represents the global net assets held for sale ($ in millions): December 31, 2015 December 31, 2014 Accounts receivable, net $ - $ 17.7 Inventories - 161.5 Prepaid expenses and other assets 9.3 161.3 Intangible assets - 453.0 Goodwill - 309.1 Impairment on assets held for sale - (189.6 ) Total assets held for sale $ 9.3 $ 913.0 Accounts payable and accrued expenses $ - $ 25.9 Total liabilities held for sale $ - $ 25.9 Assets from the Teva Transaction 14,072.3 11,081.6 Liabilities from the Teva Transaction 2,071.9 1,963.9 Net assets held for sale $ 12,009.7 $ 10,004.8 As of December 31, 2015, the Company had the followings assets held for sale: · Total assets of $14,072.3 million and total liabilities of $2,071.9 million relating to the Teva Transaction. For further details refer to Note 7 – Discontinued Operations. · Properties acquired in the Forest Acquisition. · Facilities in Irvine, California. As of December 31, 2014, the Company included the following assets held for sale: · Total assets of $11,081.6 million and total liabilities of $1,963.9 million relating to the Teva Transaction. For further details refer to Note 7 – Discontinued Operations. · Certain intangible assets and related inventory for products sold in the Respiratory Sale. The book value of the respiratory assets held for sale was $734.0 million as of December 31, 2014, including allocated goodwill to this unit included within US Brands segment of $309.1 million. The transaction closed on March 2, 2015. · Assets in connection with the Pharmatech Transaction, which included assets held for sale of $97.2 million and liabilities held for sale of $25.9 million. The transaction closed in the second quarter of 2015. · Properties acquired in the Forest Acquisition including: · Commack, Long Island - $46.4 million · St. Louis, Missouri - $20.4 million · Hauppauge, New York - $14.8 million
Global Generics [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Discontinued Operations	NOTE 7 — Discontinued Operations Global Generics Business On July 26, 2015, the Company entered into the Teva Transaction. Under the Teva Agreement, Teva will acquire Allergan's global generics business, including the U.S. and international generic commercial units, our third-party supplier Medis, our global generic manufacturing operations, our global generic R&D unit, our international OTC commercial unit (excluding OTC eye care products) and some established international brands. Allergan will retain its global branded pharmaceutical and medical aesthetics businesses, as well as its biosimilars development programs, certain over the counter products, and the Anda Distribution business. The Company will also have continuing involvement with Teva after the close of the transaction. As a result of the Teva Transaction, the Company will hold equity in Teva, continue to distribute Teva products through our Anda Distribution segment as well as purchase product manufactured by Teva for sale in our US Brands segment as part of ongoing transitional service and contract manufacturing agreements. Financial results of the global generics business are presented as "Income from discontinued operations" on the Consolidated Statements of Operations for the years ended December 31, 2015, 2014 and 2013; and assets and liabilities of the global generics business to be disposed of are presented as a component of "Current assets held for sale", "Non current assets held for sale", “Current liabilities held for sale” and “Long term liabilities held for sale” on the Consolidated Balance Sheet as of December 31, 2015 and 2014. Financial results for discontinued operations were based on the terms and conditions of the agreements with Teva as of the date of this filing. Subsequent changes in terms and products transferring may impact results presented. The following table presents key financial results of the global generics business included in "Income from discontinued operations" for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, 2015 2014 2013 Third party revenues $ 6,116.1 $ 6,323.4 $ 6,075.1 Related party sales 259.2 255.4 273.1 Net revenues 6,375.3 6,578.8 6,348.2 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) 3,048.1 3,105.6 3,319.1 Research and development 422.2 480.2 425.6 Selling and marketing 557.7 649.0 645.5 General and administrative 653.0 496.2 571.4 Amortization 323.6 652.0 538.9 In-process research and development impairments - - 4.9 Asset sales and impairments, net 62.4 19.6 896.8 Total operating expenses 5,067.0 5,402.6 6,402.2 Operating income 1,308.3 1,176.2 (54.0 ) Other (expense) income, net (7.9 ) (14.5 ) 39.1 (Benefit) / provision for income taxes (5,487.3 ) 385.1 268.0 Net income / (loss) from discontinued operations $ 6,787.7 $ 776.6 $ (282.9 ) Related party revenues represent the sale of products to the Company’s Anda Distribution segment. For the year ended December 31, 2015, the company recorded a deferred tax benefit of $5,738.8 million related to investments in certain U.S. subsidiaries as this tax benefit will reverse in the foreseeable future. The recognition of this benefit has been reflected in income from discontinued operations, net of tax with the deferred tax asset reflected in non-current deferred tax assets on the balance sheet. The following table presents the aggregate carrying amounts of the major classes of assets and liabilities related to the global generics business to be disposed of ($ in millions): December 31, 2015 December 31, 2014 Assets: Accounts receivable, net $ 2,089.7 $ 1,488.9 Inventories 1,138.5 1,090.9 Prepaid expenses and other current assets 302.8 254.6 Current deferred tax assets - 23.3 Property, plant and equipment, net 1,355.6 1,347.5 Investments and other assets 33.0 82.1 Non-current deferred tax assets 223.7 72.7 Product rights and other intangibles 2,919.3 3,097.7 Goodwill 6,009.7 3,623.9 Total assets $ 14,072.3 $ 11,081.6 Liabilities: Accounts payable and accrued expenses $ 1,455.8 $ 1,396.4 Income taxes payable 33.9 16.5 Current deferred tax liabilities - 6.3 Debt and capital leases 5.8 12.6 Other long-term liabilities 92.0 121.3 Other taxes payable 69.0 102.7 Long-term deferred tax liabilities 415.4 308.1 Total liabilities $ 2,071.9 $ 1,963.9 Depreciation and amortization was ceased upon the determination that the held for sale criteria were met, which was the announcement date of the Teva Transaction. The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows ($ in millions): Years Ended December 31, 2015 2014 2013 Depreciation from discontinued operations $ 89.7 $ 159.6 $ 166.9 Amortization from discontinued operations 323.6 652.0 538.9 Capital expenditures 234.5 184.5 168.0 Deferred taxes (5,568.8 ) (259.5 ) (242.4 )

Assets Held For Sale

Assets Held For Sale	12 Months Ended
	Dec. 31, 2015
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	NOTE 8 — Assets Held For Sale The following represents the global net assets held for sale ($ in millions): December 31, 2015 December 31, 2014 Accounts receivable, net $ - $ 17.7 Inventories - 161.5 Prepaid expenses and other assets 9.3 161.3 Intangible assets - 453.0 Goodwill - 309.1 Impairment on assets held for sale - (189.6 ) Total assets held for sale $ 9.3 $ 913.0 Accounts payable and accrued expenses $ - $ 25.9 Total liabilities held for sale $ - $ 25.9 Assets from the Teva Transaction 14,072.3 11,081.6 Liabilities from the Teva Transaction 2,071.9 1,963.9 Net assets held for sale $ 12,009.7 $ 10,004.8 As of December 31, 2015, the Company had the followings assets held for sale: · Total assets of $14,072.3 million and total liabilities of $2,071.9 million relating to the Teva Transaction. For further details refer to Note 7 – Discontinued Operations. · Properties acquired in the Forest Acquisition. · Facilities in Irvine, California. As of December 31, 2014, the Company included the following assets held for sale: · Total assets of $11,081.6 million and total liabilities of $1,963.9 million relating to the Teva Transaction. For further details refer to Note 7 – Discontinued Operations. · Certain intangible assets and related inventory for products sold in the Respiratory Sale. The book value of the respiratory assets held for sale was $734.0 million as of December 31, 2014, including allocated goodwill to this unit included within US Brands segment of $309.1 million. The transaction closed on March 2, 2015. · Assets in connection with the Pharmatech Transaction, which included assets held for sale of $97.2 million and liabilities held for sale of $25.9 million. The transaction closed in the second quarter of 2015. · Properties acquired in the Forest Acquisition including: · Commack, Long Island - $46.4 million · St. Louis, Missouri - $20.4 million · Hauppauge, New York - $14.8 million

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	NOTE 9 — Share-Based Compensation The Company recognizes compensation expense for all share-based compensation awards made to employees and directors based on the fair value of the awards on the date of grant. A summary of the Company’s share-based compensation plans is presented below. Equity Award Plans The Company has adopted several equity award plans which authorize the granting of options, restricted shares, restricted stock units and other forms of equity awards of the Company’s ordinary shares, subject to certain conditions. The Company grants awards with the following features: · Time-based vesting restricted stock awards; · Performance-based restricted stock awards measured to the EBITDA, as defined, of the Company or other performance-based targets defined by the Company; · Performance-based restricted stock awards measured to the Total Stockholders Return, compared to pre-defined metrics; · Non-qualified options to purchase outstanding shares; and · Cash-settled awards recorded as a liability. These cash settled awards are based on pre-established earnings per share, total shareholder returns and cost savings targets and the fair value is marked to market each reporting unit. Option awards require options to be granted at the fair value of the shares underlying the options at the date of the grant and generally become exercisable over periods ranging from three to five years. Each option granted expires ten years from the date of the grant. Restricted stock awards are grants that entitle the holder to ordinary shares, subject to certain terms. Restricted stock unit awards are grants that entitle the holder the right to receive an ordinary share, subject to certain terms. Restricted stock and restricted stock unit awards (both time-based vesting and performance-based vesting) generally have restrictions eliminated over a one to four year vesting period. Restrictions generally lapse for non-employee directors after one year. Certain restricted stock units are performance-based awards issued at a target number with the actual number of restricted shares issued ranging based on achievement of the performance criteria. The Company’s equity awards include the acquired awards from the Allergan Acquisition and the Kythera Acquisition (“2015 Acquired Awards”) and the acquired awards from the Forest Acquisition (“2014 Acquired Awards”). Fair Value Assumptions All restricted stock and restricted stock units (whether time-based vesting or performance-based vesting), are granted and expensed, using the fair value per share on the applicable grant date, over the applicable vesting period. Non-qualified options to purchase ordinary shares are granted to employees at exercise prices per share equal to the closing market price per share on the date of grant. The fair value of non-qualified options is determined on the applicable grant dates using the Black-Scholes method of valuation and that amount is recognized as an expense over the vesting period. Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions: 2015 Grants 2015 Acquired Awards 2014 Grants 2014 Acquired Awards Dividend yield 0 % 0 % 0 % 0 % Expected volatility 26.0 - 29.0% 26.0 - 27.0% 29.0 % 28.0 % Risk-free interest rate 1.9-2.1% 0.1-2.1% 1.9 - 2.2% 0 - 2.1 % Expected term (years) 7.0 - 7.5 up to 6.9 7.5 up to 6.4 Share-Based Compensation Expense Share-based compensation expense recognized in the Company’s results of operations, including discontinued operations, for the years ended December 31, 2015, 2014 and 2013 was as follows ($ in millions): Year Ended December 31, 2015 2014 2013 Equity-based compensation awards $ 690.4 $ 368.0 $ 132.1 Cash-settled equity awards in connection with the Allergan Acquisition 127.1 - - Cash-settled equity awards in connection with the Kythera Acquisition 9.6 - - Cash-settled equity awards in connection with the Durata Acquisition - 16.6 - Cash-settled equity awards in connection with the Furiex Acquisition - 16.6 - Non equity-settled awards other 98.6 - 1.5 Total stock-based compensation expense $ 925.7 $ 401.2 $ 133.6 In the years ended December 31, 2015, 2014, and 2013, share-based compensation expense included as discontinued operations was $31.5 million, $18.8 million, and $22.1 million, respectively. In the years ended December 31, 2015, 2014 and 2013 the related tax benefits were $285.9 million, $145.7 million and $44.4 million, respectively relating to stock-based compensation. Included in the equity-based compensation awards for the year ended December 31, 2015 is the impact of accelerations and step-ups relating to the acquisition accounting treatment of outstanding awards acquired in the Allergan, Kythera and Forest Acquisitions of $314.8 million, $64.4 million and $109.7 million, respectively. Included in the year ended December 31, 2014, was $287.5 million of stock-based compensation inclusive of a $249.1 million of a step-up relating to the acquisition accounting treatment of outstanding awards acquired in the Forest Acquisition. Included in the year ended December 31, 2013, was higher stock-based compensation and related employer payroll taxes resulting from acceleration of directors and named executive officers unvested equity-based awards immediately prior to, but in connection with, the Warner Chilcott Acquisition, as provided by the transaction agreement, of $41.3 million. Also included in the year-ended December 31, 2013, was $45.4 million of stock-based compensation relating to the Warner Chilcott Acquisition. These costs included the immediate vesting of outstanding equity for certain employees on October 1, 2013, as well as the recognition of compensation over the remaining vesting period for severed employees. Unrecognized future stock-based compensation expense was $672.0 million as of December 31, 2015, including $319.8 million from the Allergan Acquisition and $115.4 million from the Forest Acquisition. This amount will be recognized as an expense over a remaining weighted average period of 1.7 years. Stock-based compensation is being amortized and charged to operations over the same period as the restrictions are eliminated for the participants, which is generally on a straight-line basis. Share Activity The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, 2014 through December 31, 2015: (in millions, except per share data) Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Aggregate Grant Date Fair Value Restricted shares / units outstanding at December 31, 2014 2.1 $ 148.79 1.3 $ 312.5 Granted 0.5 304.94 152.5 Vested (1.0 ) (127.15 ) (128.1 ) Assumed as part of the Allergan Acquisition ** 0.5 218.47 102.8 Forfeited (0.1 ) (152.63 ) (19.9 ) Restricted shares / units outstanding at December 31, 2015 2.0 $ 209.90 1.7 $ 419.8 ** Assumed as part of the Allergan Acquisition for the pro rata portion representing future compensation as of March 17, 2015. The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, 2014 through December 31, 2015: (in millions, except per share data) Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, December 31, 2014 5.4 $ 93.96 7.3 $ 858.9 Granted 0.2 300.29 Exercised (2.4 ) (134.54 ) Assumed as part of the Allergan Acquisition** 7.0 103.63 Assumed as part of the Kythera Acquisition*** 0.7 127.02 Cancelled (0.4 ) (135.92 ) Outstanding, December 31, 2015 10.5 $ 149.11 6.7 $ 1,707.8 Vested and expected to vest at December 31, 2015 9.9 $ 148.14 6.7 $ 1,620.5 ** Assumed as part of the Allergan Acquisition for the pro rata portion representing future compensation as of March 17, 2015. *** Assumed as part of the Kythera Acquisition for the pro rata portion representing future compensation as of October 1, 2015.

Pension and Other Postretiremen

Pension and Other Postretirement Benefit Plans	12 Months Ended
	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefit Plans	NOTE 10 — Pension and Other Postretirement Benefit Plans Defined Benefit Plan Obligations The Company has numerous defined benefit plans offered to employees around the world. For these plans, retirement benefits are generally based on an employee’s years of service and compensation. Funding requirements are determined on an individual country and plan basis and are subject to local country practices and market circumstances. Prior to the Warner Chilcott Acquisition, which occurred on October 1, 2013, there were no material continuing operations defined benefit plans. As such, activity within the year ended December 31, 2013 was immaterial. The net periodic benefit cost of the defined benefit plans was de minimis for the year ended December 31, 2013. The net periodic benefit cost of the defined benefit plans for continuing operations for the years ended December 31, 2015 and 2014 was as follows ($ in millions): Defined Benefit Year Ended December 31, 2015 2014 Service cost $ 5.0 $ 2.0 Interest cost 35.0 3.3 Expected Return on plan assets (46.4 ) (3.5 ) Settlement (4.3 ) - Net periodic benefit (income) cost $ (10.7 ) $ 1.8 Obligations and Funded Status Employee benefit plans are an exception to the recognition and fair value measurement principles in business combinations. Employee benefit plan obligations are recognized and measured in accordance with the existing authoritative literature for accounting for benefit plans rather than at fair value. Accordingly, the Company remeasured the benefit plans acquired as part of its acquisitions and recognized an asset or liability for the funded status of these plans as of the respective acquisition dates. Benefit obligation and asset data for the defined benefit plans for continuing operations, were as follows ($ in millions): Year Ended December 31, 2015 (1) 2014 Change in Plan Assets Fair value of plan assets at beginning of year $ 83.6 $ 79.9 Fair value of plan assets assumed in the Allergan Acquisition 1,042.0 - Employer contribution 107.6 3.2 Return on plan assets (60.3 ) 13.9 Benefits paid (21.5 ) (2.9 ) Settlements (100.0 ) - Effects of exchange rate changes (0.3 ) (10.5 ) Fair value of plan assets at end of year $ 1,051.1 $ 83.6 Year Ended December 31, 2015 (1) 2014 Change in Benefit Obligation Benefit obligation at beginning of the year $ 111.6 $ 96.5 Benefit obligation assumed in the Allergan Acquisition 1,344.6 - Service cost 5.0 2.0 Interest cost 35.0 3.3 Actuarial loss/(gain) (191.2 ) 27.0 Curtailments - (0.7 ) Settlements and other (101.1 ) - Benefits paid (21.5 ) (2.8 ) Effects of exchange rate changes 6.1 (13.7 ) Benefit obligation at end of year $ 1,188.5 $ 111.6 Funded status at end of year $ (137.4 ) $ (28.0 ) (1) The year ended December 31, 2015 includes benefit obligation and asset data from the Allergan Plans following the Allergan Acquisition on March 17, 2015. The following table outlines the funded actuarial amounts recognized ($ in millions): As of December 31, 2015 2014 Current liabilities $ (29.3 ) $ (2.7 ) Noncurrent liabilities (108.1 ) (25.3 ) $ (137.4 ) $ (28.0 ) The underfunding of pension benefits is primarily a function of the different funding incentives that exist outside of the United States. In certain countries, there are no legal requirements or financial incentives provided to companies to pre-fund pension obligations. In these instances, benefit payments are typically paid directly by the Company as they become due. Discontinued Operations As of December 31, 2015 and 2014, the following is the plan assets and liabilities included in assets and liabilities held for sale as part of the Teva Transaction ($ in millions): Year Ended December 31, 2015 (1) 2014 Fair value of plan assets at end of year $ 111.9 $ 112.5 Benefit obligation at end of year $ 161.8 $ 174.5 Funded status at end of year $ (49.9 ) $ (62.0 ) For the years ended December 31, 2015, 2014 and 2013, the Company recognized $6.8 million, $4.7 million and $7.1 million, respectively, as a component of income from discontinued operations related to the Teva Transaction. Plan Assets Companies are required to use a fair value hierarchy as defined in ASC Topic 820 “Fair Value Measurement,” (“ASC 820”) which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The fair values of the Company’s pension plan assets for continuing operations at December 31, 2015 by asset category are as follows ($ in millions): Quoted Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds U.S. equities $ 114.6 $ - $ - $ 114.6 International equities 151.3 - - 151.3 Other equity securities 99.1 - - 99.1 Equity securities $ 365.0 $ - $ - $ 365.0 U.S. Treasury bonds $ - $ 120.6 $ - $ 120.6 Bonds and bond funds - 490.7 - 490.7 Other debt securities - 60.0 - 60.0 Debt securities $ - $ 671.3 $ - $ 671.3 Other investments Other - 14.8 - 14.8 Total assets $ 365.0 $ 686.1 $ - $ 1,051.1 The fair values of the Company’s pension plan assets for continuing operations at December 31, 2014 by asset category are as follows ($ in millions): Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds Equity securities $ 24.9 $ - $ - $ 24.9 Debt securities - 56.5 - 56.5 Other investments Other - 2.2 - 2.2 Total assets $ 24.9 $ 58.7 $ - $ 83.6 The assets of the pension plan are held in separately administered trusts. The investment guidelines for the Company’s pension plans is to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of the plan, given an acceptable level of risk. The target investment portfolio of the Company’s continuing operations pension plans is allocated as follows: Target Allocation as of December 31, 2015 (1) 2014 Bonds 35.0 % 30.0 % Equity securities 62.5 % 67.5 % Other investments 2.5 % 2.5 % (1) Includes the asset allocation of the Allergan Plans following the Allergan Acquisition on March 17, 2015. Expected Contributions Employer contributions to the pension plan during the year ending December 31, 2016 are expected to be $29.3 million for continuing operations and $6.0 million for discontinued operations. Expected Benefit Payments Total expected benefit payments for the Company’s continuing operations pension plans are as follows ($ in millions): 2016 $ 29.3 2017 31.7 2018 34.6 2019 37.6 2020 40.5 Thereafter 1,014.8 Total liability $ 1,188.5 Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service. The majority of the payments will be paid from plan assets and not Company assets. Information for continuing operations defined benefit plans with an accumulated benefit obligation in excess of plan assets is presented below ($ in millions): Defined Benefit as of December 31, 2015 2014 Projected benefit obligations $ 1,188.5 $ 111.6 Accumulated benefit obligations $ 1,054.6 $ 100.8 Plan assets $ 904.3 $ 83.6 Amounts Recognized in Other Comprehensive Income / (Loss) Net loss / gain amounts reflect experience differentials primarily relating to differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net loss amounts in excess of certain thresholds are amortized into net pension cost over the average remaining service life of employees. Balances recognized within accumulated other comprehensive income/(loss) that have not been recognized as components of net periodic benefit costs are as follows ($ in millions): Defined Benefit Balance as of December 31, 2013 $ 5.6 Net actuarial loss (36.4 ) Balance as of December 31, 2014 (30.8 ) Net actuarial gain 101.2 Balance as of December 31, 2015 $ 70.4 Actuarial Assumptions The weighted average assumptions used to calculate the projected benefit obligations of the Company’s defined benefit plans, including assets and liabilities held for sale, are as follows: As of December 31, 2015 2014 Discount rate 3.8 % 2.9 % Salary growth rate 3.7 % 3.7 % The weighted average assumptions used to calculate the net periodic benefit cost of the Company’s defined benefit plans, including assets and liabilities held for sale, are as follows: As of December 31, 2015 2014 Discount rate 3.5 % 3.9 % Expected rate of return on plan assets 4.6 % 4.9 % Salary growth rate 3.5 % 3.7 % In order to select a discount rate for purposes of valuing the plan obligations the Company uses market returns and adjusts them as needed to fit the estimated duration of the plan liabilities. The expected rate of return represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rate of return, long-term historical returns data are considered as well as actual returns on the plan assets and other capital markets experience. Using this reference information, the long-term return expectations for each asset category and a weighted average expected return was developed, according to the allocation among those investment categories. Other Post-Employment Benefit Plans As a result of the Allergan and Forest acquisitions, the Company assumed post-retirement benefit plans. Accumulated benefit obligation and asset data for the defined benefit plans, were as follows ($ in millions): Accumulated benefit obligation as of December 31, 2013 $ - Accumulated benefit obligation assumed as part of the Forest Acquisition 14.0 Interest cost 0.4 Actuarial loss 6.4 Benefits paid (0.3 ) Accumulated benefit obligation as of December 31, 2014 $ 20.5 Accumulated benefit obligation assumed as part of the Allergan Acquisition 60.2 Interest cost (2.3 ) Actuarial gain (26.3 ) Benefits paid (2.0 ) Accumulated benefit obligation as of December 31, 2015 $ 50.1 Savings Plans The Company also maintains certain defined contribution savings plans covering substantially all U.S.-based employees. The Company contributes to the plans based upon the employee contributions. The Company’s contributions to these retirement plans for amounts included in continuing operations were $26.6 million, $35.0 million and $24.9 million in the years ended December 31, 2015, 2014 and 2013, respectively. The Company’s contributions to these retirement plans for amounts included in income from discontinued operations were $23.6 million, $31.0 million and $22.0 million in the years ended December 31, 2015, 2014 and 2013, respectively.

Other Income (Expense)

Other Income (Expense)	12 Months Ended
	Dec. 31, 2015
Other Income And Expenses [Abstract]
Other Income (Expense)	NOTE 11 — Other Income (Expense) Other income (expense) consisted of the following ($ in millions): Years Ended December 31, 2015 2014 2013 Bridge loan commitment fee $ (264.9 ) $ (73.6 ) $ - Interest rate lock 31.0 - - Extinguishment of debt - 29.9 (18.5 ) Other (expense) income 0.1 16.4 (0.1 ) Other (expense) income, net $ (233.8 ) $ (27.3 ) $ (18.6 ) Bridge Loan Commitment Fee During the year ended December 31, 2015, in connection with the Allergan Acquisition, we incurred costs associated with bridge loan commitments of $264.9 million. During the year ended December 31, 2014, the Company recognized an expense of $47.8 million associated with the Allergan Acquisition bridge and term loan financing commitment fees. In connection with the Forest Acquisition, we secured a bridge loan commitment of up to $7.0 billion and incurred associated commitment costs of $25.8 million, which have been expensed in full. Interest rate lock During the year ended December 31, 2015, the Company entered into interest rate locks on a portion of the $21.0 billion of debt issued as part of the Allergan Acquisition. As a result of the interest rate locks, the Company recorded income of $31.0 million. Extinguishment of Debt On July 21, 2014, the Company redeemed the WC Notes (defined below) for $1,311.8 million, which included a make-whole premium of $61.8 million and the principal amount of the WC Notes of $1,250.0 million. As a result of the transaction, the Company recognized a gain of $29.9 million, which includes the write-off of the then outstanding unamortized premium. As a result of the extinguishment of our $450.0 million 5.000% senior notes due 2014, the Company recorded a loss of $17.1 million in the year ended December 31, 2013. In addition, the Company incurred a $1.4 million non-cash write-off of deferred loan costs in connection with the optional prepayment of term loan indebtedness.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	NOTE 12 — Inventories Inventories consist of finished goods held for sale and distribution, raw materials and work-in-process. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors, which may differ from actual results. Inventories consisted of the following as of December 31, 2015 and 2014 ($ in millions): December 31, December 31, 2015 2014 Raw materials $ 242.3 $ 203.5 Work-in-process 149.7 80.9 Finished goods 706.3 763.6 1,098.3 1,048.0 Less: inventory reserves 88.6 63.4 Total Inventories $ 1,009.7 $ 984.6 Included in finished goods were the following amounts related to the fair-value step-up of acquired inventory ($ in millions): Allergan Forest Durata Warner Chilcott Acquisition Acquisition Acquisition Acquisition Total December 31, 2015 $ 21.6 $ 20.1 $ 4.4 $ - $ 46.1 December 31, 2014 $ - $ 244.7 $ 16.3 $ 1.9 $ 262.9

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Payables And Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 13 — Accounts payable and accrued expenses Accounts payable and accrued expenses consisted of the following ($ in millions): December 31, 2015 December 31, 2014 Accrued expenses: Accrued third-party rebates $ 1,281.6 $ 904.6 Accrued payroll and related benefits 409.7 198.7 Accrued R&D expenditures 384.1 169.9 Interest payable 312.0 82.7 Accrued returns 288.4 250.3 Litigation-related reserves and legal fees 213.5 300.9 Accrued non-provision taxes 100.3 3.3 Accrued pharmaceutical fees 162.2 118.7 Accrued selling and marketing expenditures 127.2 9.6 Royalties payable 126.9 128.9 Accrued severance, retention and other shutdown costs 110.4 107.2 Current portion of contingent consideration obligations 79.9 233.9 Accrued professional fees 25.4 39.3 Dividends payable 23.9 - Manufacturing related 14.9 11.2 Accrued warranties 7.6 - Other accrued expenses 312.1 147.6 Total accrued expenses $ 3,980.1 $ 2,706.8 Accounts payable 369.4 323.3 Total Accounts Payable and Accrued Expenses $ 4,349.5 $ 3,030.1

Property, plant and equipment,

Property, plant and equipment, net	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Property, plant and equipment, net	NOTE 14 — Property, plant and equipment, net Property, plant and equipment, net consisted of the following, as well as the net book value of continuing operations and discontinued operations as of December 31, 2015 and 2014 ($ in millions): Machinery and Equipment Research and Laboratory Equipment Other Transportation Land, Buildings and Leasehold Improvements Construction in Progress Total At December 31, 2014 $ 950.3 $ 155.5 $ 365.4 $ 85.7 $ 907.1 $ 150.7 $ 2,614.7 Additions 79.8 4.1 40.0 77.5 10.8 236.2 448.4 Additions due to acquisitions 224.4 19.1 72.3 1.0 585.2 312.5 1,214.5 Disposals/transfers/impairments 19.9 (6.3 ) (23.3 ) (9.4 ) (20.3 ) (118.1 ) (157.5 ) Transfer to assets held for sale - - - - (4.5 ) - (4.5 ) Currency translation (42.7 ) (0.5 ) (8.9 ) (4.3 ) (38.4 ) (2.9 ) (97.7 ) At December 31, 2015 $ 1,231.7 $ 171.9 $ 445.5 $ 150.5 $ 1,439.9 $ 578.4 $ 4,017.9 Accumulated depreciation At December 31, 2014 $ 415.3 $ 130.8 $ 249.4 $ 11.4 $ 213.1 $ - $ 1,020.0 Additions 65.7 8.3 78.7 12.3 53.3 - 218.3 Disposals/transfers/impairments (22.6 ) (8.3 ) (23.3 ) (6.0 ) (60.5 ) - (120.7 ) Transfer to assets held for sale - - - - - - - Currency translation (16.2 ) (0.7 ) (4.6 ) (1.4 ) (6.3 ) - (29.2 ) At December 31, 2015 $ 442.2 $ 130.1 $ 300.2 $ 16.3 $ 199.6 $ - $ 1,088.4 Machinery and Equipment Research and Laboratory Equipment Other Transportation Land, Buildings and Leasehold Improvements Construction in Progress Total At December 31, 2014 $ 535.0 $ 24.7 $ 116.0 $ 74.3 $ 694.0 $ 150.7 $ 1,594.7 Continuing Operations $ 30.9 $ 2.4 $ 51.0 $ 53.4 $ 109.1 $ 36.6 $ 283.4 Discontinued Operations $ 504.1 $ 22.3 $ 65.0 $ 20.9 $ 584.9 $ 114.1 $ 1,311.3 At December 31, 2015 $ 789.5 $ 41.8 $ 145.3 $ 134.2 $ 1,240.3 $ 578.4 $ 2,929.5 Continuing Operations $ 269.2 $ 17.8 $ 90.9 $ 117.5 $ 654.6 $ 423.9 $ 1,573.9 Discontinued Operations $ 520.3 $ 24.0 $ 54.4 $ 16.7 $ 585.7 $ 154.5 $ 1,355.6 Depreciation expense for continuing operations was $128.6 million, $71.3 million and $35.1 million in the years ended December 31, 2015, 2014 and 2013, respectively.

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2015
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Other Assets	NOTE 15 — Other assets Prepaid expenses and other current assets consisted of the following ($ in millions): December 31, 2015 December 31, 2014 Prepaid taxes $ 240.5 $ 207.7 Current portion of deferred loan costs 36.3 124.9 Prepaid insurance 24.1 14.0 Other 257.6 132.2 Total prepaid expenses and other current assets $ 558.5 $ 478.8 Investments in marketable securities and other investments consisted of the following ($ in millions): December 31, 2015 December 31, 2014 Marketable securities: U.S. Treasury and agency securities — maturing within one year $ 9.3 $ 1.0 Total marketable securities $ 9.3 $ 1.0 Investments and other assets: Deferred loan costs $ 159.5 $ 58.9 Legacy Allergan Deferred executive compensation investments 118.1 - Equity method investments 17.3 0.1 Cost method investments 16.7 0.3 Other long-term investments 78.2 53.9 Taxes receivable 39.6 - Other assets 148.0 40.1 Total investments and other assets $ 577.4 $ 153.3 The Company’s marketable securities and other long-term investments are classified as available-for-sale and are recorded at fair value based on quoted market prices using the specific identification method. These investments are classified as either current or non-current, as appropriate, in the Company’s consolidated balance sheets. The following table provides a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities ($ in millions): At December 31, 2015 Amortized Cost Gross Gains Gross Unrealized Losses Fair Value Available-for-sale: U.S. treasury and agency securities $ 29.9 $ - $ - $ 29.9 Total $ 29.9 $ - $ - $ 29.9 At December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale: U.S. treasury and agency securities $ 1.0 $ - $ - $ 1.0 Total $ 1.0 $ - $ - $ 1.0 Current Investments The Company invests in U.S. treasury and agency securities. These investments are included in marketable securities on the Company’s consolidated balance sheets at December 31, 2015 and 2014. Current investments are classified as available-for-sale and are recorded at fair value based on quoted market prices. Investment in Equity Method Investments The Company’s equity method investments at December 31, 2015 and 2014 consist of various equity method investments in privately held companies. Cost Method Investments The Company’s cost method investments consist primarily of investments in common shares of a number of private and public companies where its ownership interest is less than 20% or where it does not have the ability to exercise significant influence. The movements in long-term investments were as follows ($ in millions): Equity Method Investments Cost Method and Other Long-term Investments Balance at December 31, 2014 $ 0.1 $ 54.2 Additions - 20.0 Acquired from the Allergan Acquisition 17.3 15.0 Other (0.1 ) 5.7 Balance at December 31, 2015 $ 17.3 $ 94.9 Deferred Loan Costs Expenses associated with the issuance of indebtedness are capitalized and amortized as a component of interest expense over the term of the respective financing arrangements using the effective interest method. In the event that long-term debt is prepaid, the deferred loan costs associated with such indebtedness are expensed as a component of interest expense in the period in which such prepayment is made. Other Assets Other assets include security and equipment deposits and long-term receivables.

Goodwill, Product Rights and Ot

Goodwill, Product Rights and Other Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, Product Rights and Other Intangible Assets	NOTE 16 — Goodwill, Product Rights and Other Intangible Assets Goodwill Goodwill for the Company’s reporting segments consisted of the following ($ in millions): US Brands US Aesthetics International Brands Anda Distribution Total Balance as of December 31, 2014 $ 20,603.7 $ - $ 207.6 $ 86.3 $ 20,897.6 Additions through acquisitions 15,435.8 4,006.7 8,283.8 - 27,726.3 Measurement period adjustments and other 68.0 - - - 68.0 Held for sale - - (2,385.8 ) - (2,385.8 ) Foreign exchange and other adjustments - - 245.4 - 245.4 Balance as of December 31, 2015 $ 36,107.5 $ 4,006.7 $ 6,351.0 $ 86.3 $ 46,551.5 As of December 31, 2015 and 2014, the gross balance of goodwill, pre-impairments, was $46,568.8 million and $20,914.9 million, respectively. The following items had a significant impact on goodwill in the year ended December 31, 2015: · An increase in goodwill of $27,088.9 million resulting from the Allergan Acquisition; · A decrease in goodwill due to classification of goodwill held for sale in connection with the Teva Transaction of $2,385.8 million. Goodwill was allocated based on the relative fair value of the former International Brands and Global Generics segments respective reporting units between the assets remaining with Allergan versus those held for sale based upon the expected price to be received upon disposition of the assets. Included within this total is goodwill acquired in the Auden Acquisition of $123.3 million. The balance of goodwill which was held for sale as of December 31, 2014 was $3,623.9 million; · An increase in goodwill of $33.3 million resulting from the Oculeve Acquisition; · An increase in goodwill of $328.7 million resulting from the Kythera Acquisition; · An increase in goodwill of $138.5 million resulting from the AqueSys Acqusition; · An increase in goodwill of $13.6 million resulting from the Northwood Acquisition; and · Measurement period adjustments decreasing goodwill of $21.3 million resulting from the Forest and Durata Acquisitions and an out-of-period adjustment in goodwill of $83.6 million relating to the Forest Acquisition. During the second quarter of 2013, concurrent with the availability of discrete financial information for our discontinued operations’ new reporting units, the Company completed an extensive review of its operating businesses, including exploring options for addressing overall profitability of seven Western European commercial operations consisting of, among other things, restructuring their operations, refocusing their activities on specific sub-markets, as well as potential divestitures of such businesses to other third parties. The potential impact of these conditions were considered in the Company’s projections when determining the indicated fair value of its then current reporting units for the impairment tests that were performed during the second quarter of 2013. Upon completion of step one of the impairment analysis for each of the Company’s reporting units, it was concluded the fair value of the then current Actavis Pharma — Europe reporting unit was below its carrying value including goodwill. As a result of completing step two of the Company’s impairment analysis, the Company recorded an impairment of the then current Actavis Pharma — Europe reporting unit of $647.5 million, representing primarily all the goodwill allocated to this reporting unit, in the year ended December 31, 2013, which is included as a component of income from discontinued operations. Product Rights and Other Intangible Assets Product rights and other intangible assets consisted of the following for the years ended December 31, 2015 and 2014 ($ in millions): Cost Basis Balance as of December 31, 2014 Acquisitions Impairments IPR&D to CMP Transfers Disposals/ Held Sale/ Other Foreign Currency Translation Balance as of December 31, 2015 Intangibles with definite lives: Product rights and other related intangibles $ 15,305.7 $ 47,163.8 $ (242.2 ) $ 3,128.5 $ (975.5 ) $ 163.9 $ 64,544.2 Trade name - 690.0 - - - - 690.0 Total definite-lived intangible assets $ 15,305.7 $ 47,853.8 $ (242.2 ) $ 3,128.5 $ (975.5 ) $ 163.9 $ 65,234.2 Intangibles with indefinite lives: IPR&D $ 4,116.4 $ 10,714.4 $ (511.6 ) $ (3,128.5 ) $ (38.8 ) $ (23.7 ) $ 11,128.2 Trade name 76.2 - - - - - 76.2 Total indefinite- lived intangible assets $ 4,192.6 $ 10,714.4 $ (511.6 ) $ (3,128.5 ) $ (38.8 ) $ (23.7 ) $ 11,204.4 Total product rights and related intangibles $ 19,498.3 $ 58,568.2 $ (753.8 ) $ - $ (1,014.3 ) $ 140.2 $ 76,438.6 Accumulated Amortization Balance as of December 31, 2014 Amortization Impairments Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2015 Intangibles with definite lives: Product rights and other related intangibles $ (3,407.6 ) $ (5,393.9 ) $ (7.5 ) $ 361.7 $ (0.1 ) $ (8,447.4 ) Trade name - (59.5 ) - - - (59.5 ) Total definite-lived intangible assets $ (3,407.6 ) $ (5,453.4 ) $ (7.5 ) $ 361.7 $ (0.1 ) $ (8,506.9 ) Total product rights and related intangibles $ (3,407.6 ) $ (5,453.4 ) $ (7.5 ) $ 361.7 $ (0.1 ) $ (8,506.9 ) Net Product Rights and Other Intangibles $ 16,090.7 $ 67,931.7 The following items had a significant impact on net product rights and other intangibles in the year ended December 31, 2015: · The Company acquired intangible assets in connection with the Allergan Acquisition of $54,750.5 million, including product rights and other related intangibles, trade name and IPR&D assets of $44,360.5 million, $690.0 million, and $9,700.0 million, respectively; · The Company acquired IPR&D assets of $286.0 million in connection with the Oculeve Acquisition; · The Company acquired CMP and IPR&D assets of $2,120.0 million and $320.0 million, respectively, in connection with the Kythera Acquisition; · The Company acquired CMP and IPR&D assets of $221.0 million and $302.0 million, respectively, in connection with the AqueSys Acquisition; · The Company acquired CMP and IPR&D assets of $19.5 million and $13.6 million, respectively, in connection with Northwood Acquisition; · In the year ended December 31, 2015 , · In the year ended December 31, 2015, the Company recognized $511.6 million in IPR&D impairments which reduced product rights and other intangibles. As part of IPR&D impairments, the Company made the decision to abandon a select IPR&D asset (acquired in connection with the Allergan Acquisition) based on the review of research studies, resulting in an impairment of the full asset value of $300.0 million. The Company recorded an impairment of $192.1 million related to a reduction in cash flows for women’s healthcare portfolio products acquired in the Warner Chilcott Acquisition as planned promotional initiatives on these future products has been reduced. The Company also recorded an impairment of $14.0 million due to the expected delay in the launch of a product acquired as part of the Allergan Acquisition; · In the year ended December 31, 2015, the Company recorded an impairment to CMP $206.1 million related to the abandonment of an surgical product line; · In the year ended December 31, 2015, the Company wrote off the value of royalty rights that expired in connection with the Respiratory Sale of $38.8 million; and · In the year ended December 31, 2015, the Company recognized an out-of-period adjustment in intangible assets relating to the Forest Acquisition of $135.0 million relating to a contract termination. Product rights and other intangible assets consisted of the following for the years ended December 31, 2014 and 2013 ($ in millions): Cost Basis Balance as of December 31, 2013 Acquisitions Impairments IPR&D Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2014 Intangibles with definite lives: Product rights and other related intangibles $ 4,006.6 $ 11,850.8 $ - $ 140.0 $ (685.5 ) $ (6.2 ) $ 15,305.7 Trade name - - - - - - - Total definite-lived intangible assets $ 4,006.6 $ 11,850.8 $ - $ 140.0 $ (685.5 ) $ (6.2 ) $ 15,305.7 Intangibles with indefinite lives: IPR&D $ 2,116.0 $ 2,675.8 $ (424.3 ) $ (140.0 ) $ (36.3 ) $ (74.8 ) $ 4,116.4 Trade name 76.2 - - - - - 76.2 Total indefinite-lived intangible assets $ 2,192.2 $ 2,675.8 $ (424.3 ) $ (140.0 ) $ (36.3 ) $ (74.8 ) $ 4,192.6 Total product rights and related intangibles $ 6,198.8 $ 14,526.6 $ (424.3 ) $ - $ (721.8 ) $ (81.0 ) $ 19,498.3 Accumulated Amortization Balance as of December 31, 2013 Amortization Impairments Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2014 Intangibles with definite lives: Product rights and other related intangibles $ (1,160.8 ) $ (1,945.5 ) $ (289.7 ) $ 8.5 $ (20.1 ) $ (3,407.6 ) Trade name - - - - - - Total definite-lived intangible assets $ (1,160.8 ) $ (1,945.5 ) $ (289.7 ) $ 8.5 $ (20.1 ) $ (3,407.6 ) Total product rights and related intangibles $ (1,160.8 ) $ (1,945.5 ) $ (289.7 ) $ 8.5 $ (20.1 ) $ (3,407.6 ) Net Product Rights and Other Intangibles $ 5,038.0 $ 16,090.7 The following items had a significant impact on net product rights and other intangibles in the year ended December 31, 2014: · On July 1, 2014, the Company acquired intangible assets in connection with the Forest Acquisition of $12,256.5 million, including IPR&D assets of $1,362.0 million, primarily related to continuing operations. On July 1, 2014, the Company divested certain products resulting in a reduction of intangible assets of approximately $13.5 million. · On July 2, 2014, the Company acquired intangible assets in connection with the Furiex Acquisition of $1,411.6 million, including $408.6 million related to product rights and other intangibles and $1,003.0 million of acquired IPR&D. On July 2, 2014, the Company sold the product rights and other intangibles related to the royalty rights for Alogliptin and Priligy of $408.6 million to Royalty Pharm, Inc. · In connection with the Forest Acquisition, the Company reviewed all ongoing R&D projects of both legacy Forest and Allergan plc. As a result of that review, the Company aligned future R&D expenditures with revised strategic priorities. As a result of this review, the Company abandoned certain ongoing R&D projects resulting in an impairment charge of $165.0 million in the year ended December 31, 2014. · During the third quarter of 2014, the FDA’s Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis’ NDA for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. As a result of the announcement, the Company recorded an impairment charge of $140.0 million for its asset in the quarter ended September 30, 2014. During the fourth quarter of 2014, the Company abandoned the IPR&D project based on FDA correspondence. As a result, the Company impaired the remaining $53.0 million related to the asset. · On November 17, 2014, the Company acquired intangible assets in connection with the Durata Acquisition of $729.0 million, including $480.0 million related to product rights and other intangibles and $249.0 million of acquired IPR&D. · During the fourth quarter of 2014, the Company held for sale intangible assets in connection with the Pharmatech Transaction and its respiratory franchise. · During the fourth quarter of 2014, the Company recorded an impairment related to Doryx of $89.0 million. The impairment was caused by a shortening of the products life cycle for which to recover the value of the asset. Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, continuing operations related to annual amortization expense on product rights and other related intangibles as of December 31, 2015 over each of the next five years is estimated to be as follows ($ in millions): Amortization Expense 2016 $ 6,349.0 2017 $ 6,286.8 2018 $ 5,799.1 2019 $ 5,717.3 2020 $ 5,470.8 The above amortization expense is an estimate. Actual amounts may change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions, finalization of preliminary fair value estimate, potential impairments, accelerated amortization or other events.

Long-Term Debt and Leases

Long-Term Debt and Leases	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Long-Term Debt and Leases	NOTE 17 — Long-Term Debt and Leases Debt consisted of the following ($ in millions): Balance As of Fair Market Value As of December 31, 2015 December 31, 2014 December 31, 2015 December 31, 2014 Senior Notes: Floating Rate Notes $500.0 million floating rate notes due September 1, 2016 $ 500.0 $ - $ 500.5 $ - $500.0 million floating rate notes due March 12, 2018 500.0 - 499.6 - $500.0 million floating rate notes due March 12, 2020 500.0 - 496.2 - 1,500.0 - 1,496.3 - Fixed Rate Notes $800.0 million 5.750% notes due April 1, 2016 800.0 - 808.4 - $1,000.0 million 1.850% notes due March 1, 2017 1,000.0 - 1,001.5 - $500.0 million 1.300% notes due June 15, 2017 500.0 500.0 496.3 489.0 $1,200.0 million 1.875% notes due October 1, 2017 1,200.0 1,200.0 1,196.0 1,187.3 $3,000.0 million 2.350% notes due March 12, 2018 3,000.0 - 3,004.6 - $250.0 million 1.350% notes due March 15, 2018 250.0 - 244.9 - $1,050.0 million 4.375% notes due February 1, 2019 1,050.0 1,050.0 1,099.5 1,111.4 $500.0 million 2.450% notes due June 15, 2019 500.0 500.0 494.4 498.2 $400.0 million 6.125% notes due August 15, 2019 400.0 400.0 444.2 457.9 $3,500.0 million 3.000% notes due March 12, 2020 3,500.0 - 3,505.1 - $650.0 million 3.375% notes due September 15, 2020 650.0 - 656.6 - $750.0 million 4.875% notes due February 15, 2021 750.0 750.0 807.4 808.9 $1,200.0 million 5.000% notes due December 15, 2021 1,200.0 1,200.0 1,299.4 1,301.0 $3,000.0 million 3.450% notes due March 15, 2022 3,000.0 - 3,006.8 - $1,700.0 million 3.250% notes due October 1, 2022 1,700.0 1,700.0 1,669.6 1,647.5 $350.0 million 2.800% notes due March 15, 2023 350.0 - 327.7 - $1,200.0 million 3.850% notes due June 15, 2024 1,200.0 1,200.0 1,202.6 1,215.5 $4,000.0 million 3.800% notes due March 15, 2025 4,000.0 - 3,984.6 - $2,500.0 million 4.550% notes due March 15, 2035 2,500.0 - 2,462.2 - $1,000.0 million 4.625% notes due October 1, 2042 1,000.0 1,000.0 956.1 980.1 $1,500.0 million 4.850% notes due June 15, 2044 1,500.0 1,500.0 1,483.6 1,539.9 $2,500.0 million 4.750% notes due March 15, 2045 2,500.0 - 2,452.7 - 32,550.0 11,000.0 32,604.2 11,236.7 Total Senior Notes Gross 34,050.0 11,000.0 34,100.5 11,236.7 Unamortized premium 225.9 239.9 - - Unamortized discount (107.4 ) (52.1 ) - - Total Senior Notes Net 34,168.5 11,187.8 34,100.5 11,236.7 Term Loan Indebtedness: WC Term Loan WC 191.5 506.9 WC Five Year Tranche variable rate debt maturing October 1, 2018** 498.8 744.7 690.3 1,251.6 ACT Term Loan 2017 Term Loan variable rate debt maturing October 31, 2017** 572.1 932.6 2019 Term Loan variable rate debt maturing July 1, 2019** 1,700.0 1,900.0 2,272.1 2,832.6 AGN Term Loan AGN Three Year Tranche variable rate debt maturing March 17, 2018 2,750.0 - AGN Five Year Tranche variable rate debt maturing March 17, 2020** 2,543.8 - 5,293.8 - Total Term Loan Indebtedness 8,256.2 4,084.2 Other Indebtedness Revolver Borrowings 200.0 255.0 Other 97.4 - Total Other Borrowings 297.4 255.0 Capital Leases 4.1 4.1 Total Indebtedness $ 42,726.2 $ 15,531.1 ** Fair market value in the table above is determined in accordance with ASC Topic 820 “Fair Value Measurement” (“ASC 820”) under Level 2 based upon quoted prices for similar items in active markets. The book value of the outstanding term loan indebtedness approximates fair value as the debt is at variable interest rates and re-prices frequently. Unless otherwise indicated, the remaining loan balances after the quarterly required payments are due upon maturity. Floating Rate Notes On March 4, 2015, Actavis Funding SCS, a limited partnership (société en commandite simple) organized under the laws of the Grand Duchy of Luxembourg and an indirect wholly-owned subsidiary of Allergan plc, issued floating rate notes due 2016 (the “2016 Floating Rate Notes”), floating rate notes due 2018 (the “2018 Floating Rate Notes”), floating rate notes due 2020 (the “2020 Floating Rate Notes”), 1.850% notes due 2017 (the “1.850% 2017 Notes”), 2.350% notes due 2018 (the “2.350% 2018 Notes”), 3.000% notes due 2020 (the “3.000% 2020 Notes”), 3.450% notes due 2022 (the “3.450% 2022 Notes”), 3.800% notes due 2025 (the “3.800% 2025 Notes”), 4.550% notes due 2035 (the “4.550% 2035 Notes”) and 4.750% notes due 2045 (the “4.750% 2045 Notes”). The notes are fully and unconditionally guaranteed by Actavis Funding SCS’s indirect parents, Warner Chilcott Limited and Actavis Capital S.a.r.l. (“Actavis Capital”), and by Actavis, Inc., a subsidiary of Actavis Capital, on an unsecured and unsubordinated basis. Allergan plc has not guaranteed the notes. The 2016 Floating Rate Notes, the 2018 Floating Rate Notes and the 2020 Floating Rate Notes bear interest at a floating rate equal to three-month LIBOR plus 0.875%, 1.080% and 1.255% per annum, respectively. Interest on the 2016 Floating Rate Notes is payable quarterly on March 1, June 1, September 1 and December 1 of each year, and began on June 1, 2015. Interest on the 2018 Floating Rate Notes and the 2020 Floating Rate Notes is payable quarterly on March 12, June 12, September 12 and December 12 of each year, and began on June 12, 2015. Fixed Rate Notes Acquired Allergan Notes On March 17, 2015 in connection with the Allergan Acquisition, the Company acquired, and subsequently guaranteed, along with Warner Chilcott Limited, the indebtedness of Allergan, Inc. comprised of the $350.0 million 2.800% senior notes due 2023, the $650.0 million 3.375% senior notes due 2020, the $250.0 million 1.350% senior notes due 2018 and the $800.0 million 5.750% senior notes due 2016. Interest payments are due on the $350.0 million senior notes semi-annually on the principal amount of the notes at a rate of 2.80% per annum, and are redeemable at any time at the Company’s option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption, if the redemption occurs prior to December 15, 2022 (three months prior to the maturity of the 2023 senior notes). If the redemption occurs on or after December 15, 2022, then such redemption is not subject to the make-whole provision. Interest payments are due on the $650.0 million senior notes semi-annually on the principal amount of the notes at a rate of 3.375% per annum, and are redeemable at any time at the Company’s option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. Interest payments are due on the $250.0 million senior notes semi-annually on the principal amount of the notes at a rate of 1.350% per annum, and are redeemable at any time at the Company’s option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. Interest payments are due on the $800.0 million senior notes semi-annually on the principal amount of the notes at a rate of 5.750% per annum, and are redeemable at any time at the Company’s option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. The fair value of the acquired senior notes was determined to be $2,087.5 million as of March 17, 2015. As such, as part of acquisition accounting, the company recorded a premium of $37.5 million to be amortized as contra interest over the life of the notes. Acquired Forest Notes On July 1, 2014 in connection with the Forest Acquisition, the Company acquired the indebtedness of Forest comprised of the $1,050.0 million 4.375% senior notes due 2019, the $750.0 million 4.875% senior notes due 2021 and the $1,200.0 million 5.000% senior notes due 2021 (together the “Acquired Forest Notes”). Interest payments are due on the $1,050.0 million senior notes semi-annually in arrears on February 1 and August 1 beginning August 1, 2014. Interest payments are due on the $750.0 million senior notes due 2021 semi-annually in arrears on February 15 and August 15 beginning August 15, 2014. Interest payments are due on the $1,200.0 million senior note due 2021 semi-annually in arrears on June 15 and December 15, beginning December 15, 2014. As a result of acquisition accounting, the notes were fair valued with a premium of $260.3 million as of July 1, 2014, which will be amortized as contra-interest over the life of the notes. 2014 Notes Issuance On June 10, 2014, Actavis Funding SCS, a limited partnership ( societe en commandite simple Actavis, Inc. Supplemental Indenture On October 1, 2013, the Company, Actavis, Inc., a wholly owned subsidiary of the Company, and Wells Fargo Bank, National Association, as trustee, entered into a fourth supplemental indenture (the “Fourth Supplemental Indenture”) to the indenture, dated as of August 24, 2009 (the “Base Indenture” and, together with the First Supplemental Indenture, the Second Supplemental Indenture and the Third Supplemental Indenture (each as defined below), the “Indenture”), as supplemented by the first supplemental indenture, dated as of August 24, 2009 (the “First Supplemental Indenture”), the second supplemental indenture, dated as of May 7, 2010 (the “Second Supplemental Indenture”), and the third supplemental indenture, dated as of October 2, 2012 (the “Third Supplemental Indenture”). Pursuant to the Fourth Supplemental Indenture, the Company has provided a full and unconditional guarantee of Actavis, Inc.’s obligations under its then outstanding $450.0 million 5.000% senior notes due August 15, 2014, (the “2014 Notes”), its $400.0 million 6.125% senior notes due August 15, 2019 (the “2019 Notes”), its $1,200.0 million 1.875% senior notes due October 1, 2017 (the “2017 Notes”), its $1,700.0 million 3.250% senior notes due October 1, 2022 (the “2022 Notes”) and its $1,000.0 million 4.625% Senior Notes due October 1, 2042 (the “2042 Notes”). WC Supplemental Indenture On October 1, 2013, the Company, WCCL (defined below), Warner Chilcott Finance LLC (the “Co-Issuer” and together with WC Company, the “Issuers”) and Wells Fargo Bank, National Association, as trustee (the “WC Trustee”), entered into a third supplemental indenture (the “Supplemental Indenture”) to the indenture, dated as of August 20, 2010 (the “WC Indenture”), among the Issuers, the guarantors party thereto and the WC Trustee, with respect to the Issuers’ WC Notes. Pursuant to the Supplemental Indenture, the Company had provided a full and unconditional guarantee of the Issuers’ obligations under the WC Notes and the WC Indenture. On July 21, 2014, the Company redeemed the WC Notes for $1,311.8 million, which includes a make-whole premium of $61.8 million and the principal amount of the WC Notes of $1,250.0 million. As a result of the transaction, the Company recognized a gain in July of 2014 of $29.9 million, which includes the write-off of the then outstanding unamortized premium. 2012 Notes Issuance On October 2, 2012, Actavis, Inc. issued the 2017 Notes, the 2022 Notes, and the 2042 Notes (collectively the “2012 Senior Notes”). Interest payments are due on the 2012 Senior Notes semi-annually in arrears on April 1 and October 1 beginning April 1, 2013. Net proceeds from the offering of the 2012 Senior Notes were used for the Actavis Group acquisition. 2009 Notes Issuance On August 24, 2009, Actavis, Inc. issued the 2014 Notes and the 2019 Notes (collectively the “2009 Senior Notes”). Interest payments are due on the 2009 Senior Notes semi-annually in arrears on February 15 and August 15, respectively, beginning February 15, 2010. Net proceeds from the offering of 2009 Senior Notes were used to repay certain debt with the remaining net proceeds being used to fund a portion of the cash consideration for the Arrow Group acquisition. The 2014 Notes, which had an outstanding principal balance of $450.0 million and which were fully and unconditionally guaranteed by us, were redeemed on November 5, 2013 at a redemption price equal to $465.6 million, which resulted in a cash expense of $15.6 million in the fourth quarter of 2013. Credit Facility Indebtedness WC Term Loan Agreement On December 17, 2014, Allergan plc and certain of its subsidiaries entered into a second amendment agreement (the “WC Term Loan Amendment”) among Allergan plc, Warner Chilcott Limited, Warner Chilcott Finance, LLC, Actavis WC 2 S.à r.l. (“Actavis WC 2”), Warner Chilcott Company, LLC (“WCCL”), Warner Chilcott Corporation (“WC Corporation” and together with Actavis WC 2 and WCCL, the “WC Borrowers”), Bank of America, N.A. (“BofA”), as administrative agent, and the lenders party thereto. The WC Term Loan Amendment amends and restates Allergan plc’s existing amended and restated WC term loan credit and guaranty agreement, dated as of June 9, 2014 (such agreement, prior to its amendment and restatement pursuant to the WC Term Loan Amendment, the “2014 WC Term Loan Agreement” and the 2014 WC Term Loan Agreement as amended and restated by the WC Term Loan Amendment, the “WC Term Loan Agreement”), among the WC Borrowers, Allergan plc, Warner Chilcott Limited, Warner Chilcott Finance, LLC, the lenders from time to time party thereto and BofA, as administrative agent, which amended and restated Allergan plc’s existing WC term loan credit and guaranty agreement, dated as of August 1, 2013 (such agreement, prior to its amendment and restatement, the “Existing WC Term Loan Agreement”) among the WC Borrowers, Warner Chilcott Finance, LLC, Actavis Limited, BofA, as administrative agent and a syndicate of banks participating as lenders. Pursuant to the Existing WC Term Loan Agreement, on October 1, 2013 (the “WC Closing Date”), the lenders party thereto provided term loans in a total aggregate principal amount of $2.0 billion, comprised of (i) a $1.0 billion tranche that will mature on October 1, 2016 (the “WC Three Year Tranche”) and (ii) a $1.0 billion tranche that will mature on October 1, 2018 (the “WC Five Year Tranche”). The proceeds of borrowings under the Existing WC Term Loan Agreement, together with $41.0 million of cash on hand, were used to finance the repayment in full of all amounts outstanding under Warner Chilcott’s then-existing Credit Agreement, dated as of March 17, 2011, as amended by Amendment No. 1 on August 20, 2012, among the WC Borrowers, Warner Chilcott Holdings Company III, Limited, BofA, as administrative agent and a syndicate of banks participating as lenders. Borrowings under the WC Term Loan Agreement bear interest at the applicable borrower’s choice of a per annum rate equal to either (a) a base rate plus an applicable margin per annum varying from (x) 0.00% per annum to 0.75% per annum under the WC Three Year Tranche and (y) 0.125% per annum to 0.875% per annum under the WC Five Year Tranche, depending on the publicly announced debt ratings for non-credit-enhanced, senior unsecured long-term indebtedness of Allergan plc (such applicable debt rating the “Debt Rating”) or (b) a Eurodollar rate, plus an applicable margin varying from (x) 1.00% per annum to 1.75% per annum under the WC Three Year Tranche and (y) 1.125% per annum to 1.875% per annum under the WC Five Year Tranche, depending on the Debt Rating. The outstanding principal amount of loans under the WC Three Year Tranche is not subject to quarterly amortization and shall be payable in full on the three year anniversary of the WC Closing Date. The outstanding principal amount of loans under the WC Five Year Tranche is payable in equal quarterly amounts of 2.50% per quarter prior to the fifth anniversary of the WC Closing Date, with the remaining balance payable on the fifth year anniversary of the WC Closing Date. The Company is subject to, and, at December 31, 2015, was in compliance with, all financial and operational covenants under the terms of the WC Term Loan Agreement. In February 2016, the Company prepaid approximately $310.0 million of indebtedness under the outstanding WC Five Year Tranche. ACT Term Loan On December 17, 2014, Allergan plc and certain of its subsidiaries entered into a third amendment agreement (the “ACT Term Loan Amendment”) among Allergan plc, Warner Chilcott Limited, Actavis Capital, Actavis, Inc., Actavis Funding SCS, BofA, as administrative agent, and the lenders party thereto. The ACT Term Loan Amendment amends and restates Allergan plc’s existing second amended and restated Allergan term loan credit and guaranty agreement, dated as of March 31, 2014 (such agreement, prior to its amendment and restatement pursuant to the ACT Term Loan Amendment, the “2014 ACT Term Loan Agreement” and the 2014 ACT Term Loan Agreement as amended and restated by the ACT Term Loan Amendment, the “ACT Term Loan”) among Actavis Capital, Allergan plc, Warner Chilcott Limited, Actavis, Inc., Actavis Funding SCS, BofA, as administrative agent, and the lenders from time to time party thereto, which amended and restated Allergan plc’s existing amended and restated Allergan term loan credit and guaranty agreement, dated as of October 1, 2013 (such agreement, prior to its amendment and restatement, the “Existing ACT Term Loan Agreement”) among Actavis Capital, Allergan plc, Actavis, Inc., BofA, as administrative agent, and the lenders from time to time party thereto. The Existing ACT Term Loan Agreement amended and restated Actavis, Inc.’s $1,800.0 million senior unsecured term loan credit facility, dated as of June 22, 2012. At the closing of the Existing ACT Term Loan Agreement, an aggregate principal amount of $1,572.5 million was outstanding (the “2017 term-loan”). The 2017 term-loan matures on October 31, 2017. The outstanding principal amount is payable in equal quarterly installments of 2.50% per quarter, with the remaining balance payable on the maturity date. On March 31, 2014, Allergan plc, Actavis Capital, Actavis, Inc., BofA, as Administrative Agent, and a syndicate of banks participating as lenders entered into the 2014 ACT Term Loan Agreement to amend and restate the Existing ACT Term Loan Agreement. On July 1, 2014, in connection with the Forest Acquisition, the Company borrowed $2.0 billion of term loan indebtedness under tranche A-2 of the 2014 ACT Term Loan Agreement, which is due July 1, 2019 (the “2019 term-loan”). The outstanding principal amount is payable in equal quarterly installments of 2.50% per quarter, with the remaining balance payable on the maturity date. The ACT Term Loan Agreement provides that loans thereunder will bear interest, at the Company’s choice, of a per annum rate equal to either (a) a base rate, plus an applicable margin per annum varying from (x) 0.00% per annum to 1.00% per annum with respect to the 2017 term-loan and (y) 0.125% per annum to 0.875% per annum with respect to the 2019 term-loan, depending on the Debt Rating or (b) a Eurodollar rate, plus an applicable margin varying from (x) 1.00% per annum to 2.00% per annum with respect to the 2017 term-loan and (y) 1.125% per annum to 1.875% per annum with respect to the 2019 term-loan, depending on the Debt Rating. The Company is subject to, and at December 31, 2015 was in compliance with, all financial and operational covenants under the terms of the ACT Term Loan Agreement. In February 2016, the Company prepaid approximately $200.0 million of indebtedness under the outstanding 2017 Term Loan. AGN Term Loan On December 17, 2014, Allergan, Inc. and certain of its subsidiaries entered into a senior unsecured term loan credit agreement (the “AGN Term Loan”), among Actavis Capital, as borrower, Allergan plc, Warner Chilcott Limited, Actavis, Inc., Actavis Funding SCS, the lenders from time to time party thereto (the “Term Lenders”), JPMorgan Chase Bank, N.A. (“JPMCB”), as administrative agent and the other financial institutions party thereto. Under the AGN Term Loan, the Term Lenders provided (i) a $2.75 billion tranche maturing on March 17, 2018 (the “AGN Three Year Tranche”) and (ii) a $2.75 billion tranche and maturing on March 17, 2020 (the “AGN Five Year Tranche”). The proceeds of borrowings under the AGN Term Loan were used to finance, in part, the cash component of the Allergan Acquisition consideration and certain fees and expenses incurred in connection with the Allergan Acquisition. Borrowings under the AGN Term Loan bear interest at our choice of a per annum rate equal to either (a) a base rate plus an applicable margin per annum varying from (x) 0.00% per annum to 1.00% per annum under the AGN Three Year Tranche and (y) 0.125% per annum to 1.250%% per annum under the AGN Five Year Tranche, depending on the Debt Rating or (b) a Eurodollar rate, plus an applicable margin varying from (x) 1.00% per annum to 2.00% per annum under the AGN Three Year Tranche and (y) 1.125% per annum to 2.250% per annum under the AGN Five Year Tranche, depending on the Debt Rating. The outstanding principal amount of loans under the AGN Three Year Tranche is not subject to quarterly amortization and shall be payable in full on the maturity date. The outstanding principal amount of loans under the AGN Five Year Tranche is payable in equal quarterly amounts of 2.50% per quarter prior to March 17, 2020, with the remaining balance payable on March 17, 2020. The obligations of Actavis Capital under the Term Loan Credit Agreement are guaranteed by Warner Chilcott Limited, Actavis, Inc. and Actavis Funding SCS and will be guaranteed by any subsidiary of Allergan plc (other than Actavis Capital or a direct subsidiary of Allergan plc) that becomes a guarantor of third party indebtedness in an aggregate principal amount exceeding $350.0 million (unless, in the case of a foreign subsidiary, such guarantee would give rise to adverse tax consequences as reasonably determined by Allergan plc). The Company is subject to, and at December 31, 2015 was in compliance with, all financial and operational covenants under the terms of the AGN Term Loan. Bridge Loan Facility On December 17, 2014, Allergan and certain of its subsidiaries entered into a 364-day senior unsecured bridge credit agreement (the “Bridge Loan Facility”), among Actavis Capital, as borrower, Allergan plc, Warner Chilcott Limited, Actavis, Inc., Actavis Funding SCS, the lenders from time to time party thereto, JPMCB, as administrative agent and the other financial institutions party thereto. No amounts were borrowed under the Bridge Loan Facility and the commitments under the Bridge Loan Facility expired on March 17, 2015 upon the closing of the Allergan Acquisition. Cash Bridge Loan Facility On March 11, 2015, Allergan and certain of its subsidiaries entered into a 60-day senior unsecured bridge credit agreement (the “Cash Bridge Loan Facility”), among Actavis Capital, as borrower, Allergan plc, Warner Chilcott Limited, Actavis, Inc., Actavis Funding SCS, the lenders from time to time party thereto (the “Cash Bridge Lenders”), JPMCB, as administrative agent and the other financial institutions party thereto. Under the Cash Bridge Loan Facility, the Cash Bridge Lenders committed to provide, subject to certain conditions, unsecured bridge financing, of which $2.8 billion was drawn to finance the Allergan Acquisition on March 17, 2015. The outstanding balance of the Cash Bridge Loan Facility was repaid on April 9, 2015. Borrowings under the Cash Bridge Loan Facility bore interest at our choice of a per annum rate equal to either (a) a base rate plus an applicable margin per annum varying from 0.00% per annum to 1.00% per annum, depending on the Debt Rating or (b) a Eurodollar rate, plus an applicable margin varying from 1.00% per annum to 2.00% per annum, depending on the Debt Rating. Revolving Credit Facility On December 17, 2014, Allergan plc and certain of its subsidiaries entered into a revolving credit loan and guaranty agreement (the “Revolver Agreement”) among Actavis Capital, as borrower, Allergan plc, Warner Chilcott Limited, Actavis, Inc., Actavis Funding SCS, the lenders from time to time party thereto (the “Revolving Lenders”), JPMCB as administrative agent, J.P. Morgan Europe Limited, as London agent, and the other financial institutions party thereto. Under the Revolver Agreement, the Revolving Lenders have committed to provide an unsecured revolving credit facility in an aggregate principal amount of up to $1.0 billion. The Revolver Agreement replaces Allergan plc’s existing $750 million second amended and restated Actavis revolving credit and guaranty agreement dated as of June 30, 2014 (the “Existing Revolver”) among Actavis Capital, Allergan plc, Warner Chilcott Limited, Actavis, Inc., Actavis Funding SCS, BofA, as administrative agent and the lenders from time to time party thereto. At closing, $600.0 million of loans were borrowed under the Revolver Agreement. The Revolver Agreement provides that loans thereunder will bear interest, at Actavis Capital’s choice, of a per annum rate equal to either (a) a base rate, plus an applicable margin per annum varying from 0.00% per annum to 1.00% per annum depending on the Debt Rating or (b) a Eurodollar rate, plus an applicable margin varying from 0.875% per annum to 2.00% per annum depending on the Debt Rating. Additionally, to maintain availability of funds, the Company pays an unused commitment fee, which according to the pricing grid is set at 0.075% to 0.250% per annum, depending on the Debt Rating, of the unused portion of the revolver. The Revolving Credit Agreement will mature on December 17, 2019. The obligations of Actavis Capital under the Revolver Agreement are guaranteed by Allergan plc, Warner Chilcott Limited, Actavis, Inc. and Actavis Funding SCS and will be guaranteed by any subsidiary of Allergan (other than Actavis Capital) that becomes a guarantor of third party indebtedness in an aggregate principal amount exceeding $350 million (unless, in the case of a foreign subsidiary, such guarantee would give rise to adverse tax consequences as reasonably determined by Allergan plc). The Company is subject to, and as of December 31, 2015 was in compliance with, all financial and operational covenants under the terms of the Revolving Credit Facility. In the fourth quarter of 2015, the Company borrowed $800.0 million under the revolving credit facility to fund, in part, the Kythera Acquisition. At December 31, 2015, $200.0 million was outstanding and was paid in full in January 2016. As of December 31, 2015, letters of credit outstanding were $28.8 million. The net availability under the Revolving Credit Facility was $771.2 million. Annual Debt Maturities As of December 31, 2015, annual debt maturities were as follows ($ in millions): Total Payments 2016 $ 2,175.5 2017 3,999.8 2018 7,095.1 2019 3,325.0 2020 6,093.8 2021 and after 19,617.0 $ 42,306.2 Capital leases 4.1 Other borrowings 297.4 Unamortized premium 225.9 Unamortized discount (107.4 ) Total Indebtedness $ 42,726.2 Amounts represent total anticipated cash payments assuming scheduled repayments. Lease Commitments The Company has operating leases for certain facilities and equipment. The terms of the operating leases for the Company’s facility leases require the Company to pay property taxes, normal maintenance expense and maintain minimum insurance coverage. Total rental expense for operating leases for December 31, 2015, 2014, and 2013 was $49.9 million, $69.7 million, and $12.3 million, respectively. The Company also has capital leases for certain facilities and equipment, as addressed below. The future minimum lease payments under both capital and operating leases that have remaining terms in excess of one year are ($ in millions): Capital Operating 2016 $ 0.3 $ 29.9 2017 0.3 27.7 2018 0.3 23.6 2019 0.3 21.6 2020 0.3 17.0 Thereafter 2.6 70.8 Total minimum lease payments $ 4.1 $ 190.6 Less: amount representing interest - Present value of net minimum lease payments $ 4.1

Other Long-Term Liabilities

Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	NOTE 18 — Other Long-Term Liabilities Other long-term liabilities consisted of the following ($ in millions): December 31, December 31, 2015 2014 Acquisition related contingent consideration liabilities $ 788.1 $ 139.9 Long-term pension and post retirement liability 222.1 48.1 Legacy Allergan deferred executive compensation 117.9 - Long-term severance and restructuring liabilities 34.9 3.9 Product warranties 28.4 - Long-term contractual obligations 26.4 29.7 Litigation-related reserves - 4.9 Deferred Revenue 18.2 26.3 Other long-term liabilities 26.0 0.5 Total other long-term liabilities $ 1,262.0 $ 253.3 The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The resultant probability-weighted cash flows are discounted using an appropriate effective annual interest rate to reflect the internal rate of return and incremental commercial uncertainty, major risks and uncertainties associated with the successful completion of the projects triggering the contingent obligation. At each reporting date, the Company revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. Accretion expense related to the increase in the net present value of the contingent liability is included in operating income for the period.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 19 — Income Taxes For the years ended December 31, 2015, 2014 and 2013, foreign losses before taxes were $4,174.4 million, $2,841.8 million and $604.7 million, respectively. The Company’s (benefit)/provision for income taxes consisted of the following ($ in millions): Years Ended December 31, 2015 2014 2013 Current (benefit) provision: U.S. federal $ 14.4 $ (62.0 ) $ (105.1 ) U.S. state 9.7 12.9 (3.6 ) Non-U.S. 225.6 17.2 (14.1 ) Total current (benefit) provision 249.7 (31.9 ) (122.8 ) Deferred (benefit) provision: U.S. federal (1,326.2 ) (304.3 ) (2.0 ) U.S. state (58.7 ) (5.1 ) 0.8 Non-U.S. (426.7 ) (125.7 ) (31.3 ) Total deferred (benefit) provision (1,811.6 ) (435.1 ) (32.5 ) Total provision for income taxes $ (1,561.9 ) $ (467.0 ) $ (155.3 ) The exercise of certain equity based awards resulted in a tax benefit that has been reflected as an increase to additional paid-in capital. Such benefits recorded were $76.1 million, $51.1 million and $69.0 million for the years ended December 31, 2015, 2014 and 2013, respectively. The reconciliations for the years ended December 31, 2015, 2014 and 2013 between the statutory Irish and Bermuda income tax rates for Allergan plc and Warner Chilcott Limited, respectively, and the effective income tax rates were as follows: Allergan plc Years Ended December 31, 2015 2014 2013 Statutory rate (12.5 %) (12.5 %) (12.5 %) Earnings subject to the U.S. federal and state tax rates (18.5 %) (11.3 %) (13.9 %) Earnings subject to rates different than the statutory rate (2.3 %) 1.1 % (2.5 %) Tax reserves and audit outcomes 0.3 % 1.3 % 4.8 % Non-deductible expenses 5.4 % 5.0 % 0.1 % R&D credits and U.S. manufacturing deduction (0.5 %) (1.2 %) (0.4 %) Rate changes 0.0 % 1.5 % (0.1 %) Valuation allowances (6.7 %) 0.0 % (0.8 %) Other (0.5 %) (0.1 %) 0.4 % Effective income tax rate (35.3 %) (16.2 %) (24.9 %) Warner Chilcott Limited Years Ended December 31, 2015 2014 2013 Statutory rate 0.0 % 0.0 % 0.0 % Earnings subject to the U.S. federal and state tax rates (29.6 %) (18.1 %) (22.3 %) Earnings subject to rates different than the statutory rate (4.8 %) (5.1 %) (7.7 %) Tax reserves and audit outcomes 0.3 % 1.3 % 5.0 % Non-deductible expenses 5.6 % 5.2 % 0.1 % R&D credits and U.S. manufacturing deduction (0.6 %) (1.2 %) (0.5 %) Rate changes 0.0 % 1.5 % (0.1 %) Valuation allowances (6.9 %) 0.0 % (0.8 %) Other (0.4 %) (0.3 %) 0.2 % Effective income tax rate (36.4 %) (16.7 %) (26.1 %) In December 2009, the Commonwealth of Puerto Rico Department of Economic Development and Commerce granted a tax ruling to the Company on behalf of its Puerto Rican subsidiary for industrial development income derived from its manufacturing, servicing and licensing activities subject to a reduced 2% income tax rate. This tax ruling resulted in a tax benefit of $97.5 million for the year ended December 31, 2015. For the years ended December 31, 2014 and 2013, the tax ruling did not result in an income tax benefit. Continued qualification for the tax ruling is subject to certain requirements. The tax ruling is effective through 2024. The Company’s Puerto Rican subsidiary is one of the entities included in the Teva Transaction. Deferred tax assets and liabilities are measured based on the difference between the financial statement and tax basis of assets and liabilities at the applicable tax rates. The significant components of the Company’s net deferred tax assets and liabilities consisted of the following (in millions): Years Ended December 31, 2015 2014 Benefits from net operating and capital losses and tax credit carryforwards $ 1,305.8 $ 709.9 Differences in financial statement and tax accounting for: Inventories, receivables and accruals 1,023.8 404.5 Outside basis differences 5,738.8 - Share-based compensation 596.6 235.9 Basis difference in debt 82.2 89.9 Other 15.7 41.9 Total deferred tax asset, gross $ 8,762.9 $ 1,482.1 Less: Valuation allowance (196.2 ) (474.0 ) Total deferred tax asset, net $ 8,566.7 $ 1,008.1 Differences in financial statement and tax accounting for: Property, equipment and intangible assets (14,080.7 ) (2,346.7 ) Outside basis differences (2,422.2 ) (944.5 ) Total deferred tax liabilities $ (16,502.9 ) $ (3,291.2 ) Total deferred taxes $ (7,936.2 ) $ (2,283.1 ) During the years ended December 31, 2015 and 2014, respectively, the Company recorded deferred tax liabilities of approximately $12.9 billion and $2.6 billion related to acquired entities. The Company had the following carryforward tax attributes at December 31, 2015: • $866.6 million U.S. capital loss which expires in 2018; • $1,961.6 million U.S. federal net operating losses (“NOL”) and other tax attributes which begin to expire in 2016; • $289.2 million of U.S. tax credits which begin to expire in 2018; • $367.7 million U.S. state tax NOLs which begin to expire in 2016; • $46.7 million non-U.S. tax NOLs which begin to expire in 2016 and $354.2 million non-U.S. NOLs which are not subject to expiration. Net operating loss and tax credit carryforwards of $1,931.7 million and $191.7 million, respectively, are subject to an annual limitation under Internal Revenue Code Section 382. During the year ended December 31, 2015, the Company recorded a benefit of $296.2 million for the reversal of a valuation allowance on a portion of U.S. capital loss carryforwards resulting from restructuring associated with the sale of the generics business. As of December 31, 2015, a valuation allowance of $196.2 million has been maintained due to the uncertainty of realizing net operating losses ($88.2 million), tax credits ($101.8 million), a capital loss carryforward ($5.8 million) and other deferred tax assets ($0.4 million). In the third quarter of 2015, the Company reported its global generics business as a discontinued operation and its assets and liabilities as part of assets held for sale. For provision for income taxes, the Company calculated its total provision and its provision for taxes from continuing operations as well as discontinued operations consistent with the accounting standard. As part of recording assets held for sale, the Company also recorded the tax provision or benefit on certain differences between book and tax on its outside basis of both domestic and foreign subsidiaries. The most significant of these is a $5.7 billion deferred tax asset related to investments in certain domestic subsidiaries. This asset was recorded in Q3 since the benefit is expected to be realized in the foreseeable future. Specifically, the deferred tax asset will reverse upon the sale of these subsidiaries to Teva. Refer to “NOTE 7 — Discontinued Operations” for more information. As of December 31, 2015, deferred income taxes have not been provided on $2,087.6 million of undistributed earnings of certain non-Irish subsidiaries as these amounts are intended to be indefinitely reinvested in non-Irish operations. It is not practicable to calculate the deferred taxes associated with these earnings because of the variability of multiple factors that would need to be assessed at the time of any assumed repatriation. In making this assertion, the Company evaluates, among other factors, the profitability of its Irish and non-Irish operations and the need for cash within and outside Ireland, including cash requirements for capital improvement, acquisitions and market expansion. Additionally, the Company has accrued income taxes, including withholding taxes, of $2,165.6 million for certain pre-acquisition earnings primarily related to the Forest and Allergan acquisitions. The Company expects that future subsidiary earnings will be indefinitely reinvested. Accounting for Uncertainty in Income Taxes A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in millions): Years Ended December 31, 2015 2014 2013 Balance at the beginning of the year $ 712.2 $ 119.3 $ 5.7 Increases for current year tax positions 41.2 51.3 29.4 Increases for prior year tax positions 19.7 4.2 0.1 Increases due to acquisitions 115.5 567.0 83.7 Decreases for prior year tax positions (41.4 ) (26.6 ) 0.1 Settlements (60.6 ) (0.4 ) (0.6 ) Lapse of applicable statute of limitations (3.2 ) (0.5 ) 0.0 Foreign exchange (1.7 ) (2.1 ) 0.9 Balance at the end of the year $ 781.7 $ 712.2 $ 119.3 If these benefits were subsequently recognized, $749.1 million would favorably impact the Company’s effective tax rate. The Company's continuing policy is to recognize interest and penalties related to uncertain tax positions in tax expense. During the years ended December 31, 2015, 2014 and 2013, the company recognized approximately $(0.5) million, $5.1 million and $0.2 million in interest and penalties, respectively. At December 31, 2015, 2014 and 2013, the Company had accrued $63.3 million (net of tax benefit of $34.2 million), $65.6 million (net of tax benefit of $25.3 million) and $5.2 million (net of tax benefit of $2.2 million) of interest and penalties related to uncertain tax positions, respectively. Although the company cannot determine the impact with certainty based on specific factors, it is reasonably possible that the unrecognized tax benefits may change by up to approximately $200.0 million within the next twelve months. The Company conducts business globally and, as a result, it files federal, state and foreign tax returns. The Company strives to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While the Company has accrued for amounts it believes are in accordance with the accounting standard, the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in the condensed consolidated financial statements. Furthermore, the Company may later decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations with tax authorities, identification of new issues and issuance of new legislation, regulations or case law. Due to our numerous acquisitions, the Company has several concurrent audits still pending with the IRS as set forth below: IRS Audits Taxable Years Actavis, Inc. (f/k/a Watson Pharmaceuticals, Inc.) 2008, 2009, 2010 and 2011 Actavis Inc. 2009, 2010, 2011 and 2012 Warner Chilcott Corporation 2010, 2011 and 2012 Forest Laboratories, Inc. 2007, 2008 and 2009 Aptalis Holdings, Inc. 2013 Durata Therapeutics Inc. 2012 Allergan, Inc. 2009 and 2010 The Warner Chilcott U.S. operating entities entered into an Advanced Pricing Agreement (“APA”) with the IRS that specified the agreed upon terms under which the Warner Chilcott U.S. entities are compensated for distribution and service transactions between the Warner Chilcott U.S. entities and the Warner Chilcott non-U.S. entities, effective for 2011 through 2017. On December 29, 2015, the IRS and Warner Chilcott U.S. agreed to amend the term of the APA to 2011 through 2015. The Company believes that its transfer pricing arrangements comply with existing U.S. and non-U.S. tax rules.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Stockholders' Equity	NOTE 20 — Stockholders’ Equity Preferred Shares On February 24, 2015, the Company completed an offering of 5,060,000 of our 5.500% mandatorily convertible preferred shares, Series A, par value $0.0001 per share (the “Mandatory Convertible Preferred Shares”). Dividends on the Mandatory Convertible Preferred Shares will be payable on a cumulative basis when, as and if declared by our board of directors, or an authorized committee thereof, at an annual rate of 5.500% on the liquidation preference of $1,000.00 per Mandatory Convertible Preferred Share. The Company may pay declared dividends in cash, by delivery of our ordinary shares or by delivery of any combination of cash and our ordinary shares, as determined by us in our sole discretion, subject to certain limitations, on March 1, June 1, September 1 and December 1 of each year commencing June 1, 2015, to and including March 1, 2018. The net proceeds from the Mandatory Convertible Preferred Share issuance of $4,929.7 million were used to fund the Allergan Acquisition. Each Mandatory Convertible Preferred Share will automatically convert on March 1, 2018, into between 2.8345 and 3.4722 ordinary shares, subject to anti-dilution adjustments. The number of our ordinary shares issuable on conversion of the Mandatory Convertible Preferred Shares will be determined based on the volume weighted average price per ordinary share over the 20 consecutive trading day period beginning on and including the 22nd scheduled trading day immediately preceding March 1, 2018, the mandatory conversion date. At any time prior to March 1, 2018, other than during a fundamental change conversion period as defined, holders of the Mandatory Convertible Preferred Shares may elect to convert each Mandatory Convertible Preferred Share into our ordinary shares at the minimum conversion rate of 2.8345 ordinary shares per Mandatory Convertible Preferred Share, subject to anti-dilution adjustments. In addition, holders may elect to convert any Mandatory Convertible Preferred Shares during a specified period beginning on the fundamental change effective date, in which case such Mandatory Convertible Preferred Shares will be converted into our ordinary shares at the fundamental change conversion rate and converting holders will also be entitled to receive a fundamental change dividend make-whole amount and accumulated dividend amount. In the year ended December 31, 2015, the Company paid $208.1 million of dividends on preferred shares. 2015 Ordinary Shares Offering On March 2, 2015, in connection with the Allergan Acquisition, the Company issued 14,513,889 of its ordinary shares for an actual public offering price of $288.00 per share. The net proceeds of $4,071.1 million were used, in part, to finance the Allergan Acquisition. Share Repurchases During the year ended December 31, 2014, the Company approved the cancellation of its then outstanding treasury shares. The Company has approved the cancellation of future shares repurchased and currently does not intend to hold shares repurchased by the Company in treasury shares. The financial statement impact resulting from this transaction was a reclassification from treasury stock to additional paid-in-capital. Accumulated Other Comprehensive Income / (Loss) For most of the Company’s international operations, the local currency has been determined to be the functional currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transaction. Translation adjustments are reflected in shareholders’ equity and are included as a component of other comprehensive (loss). The effects of evaluating non-functional currency assets and liabilities into the functional currency are recorded as transaction gains/losses in general and administrative expenses in the consolidated statements of operations. Unrealized gain / (losses) net of tax primarily represent experience differentials and other actuarial charges related to the Company’s defined benefit plans. The movements in accumulated other comprehensive (loss) for the years ended December, 2015 and 2014 were as follows ($ in millions): Foreign Currency Translation Items Unrealized gain / (loss) net of tax Total Accumulated Other Comprehensive Income / (Loss) Balance as of December 31, 2013 $ 85.1 $ 5.4 $ 90.5 Other comprehensive (loss) before reclassifications into general and administrative (519.5 ) (36.4 ) (555.9 ) Total other comprehensive (loss) (519.5 ) (36.4 ) (555.9 ) Balance as of December 31, 2014 $ (434.4 ) $ (31.0 ) $ (465.4 ) Other comprehensive gain / (loss) before reclassifications into general and administrative (129.9 ) 101.2 (28.7 ) Total other comprehensive income (129.9 ) 101.2 (28.7 ) Balance as of December 31, 2015 $ (564.3 ) $ 70.2 $ (494.1 )

Segments

Segments	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segments	NOTE 21 — Segments In the third quarter of 2015, there was a strategic shift in the business as a result of the Teva Transaction. As a result, the Company realigned its continuing operations into the following segments: US Brands, US Medical Aesthetics, International Brands and Anda Distribution. Prior to the realignment, the Company operated and managed its business as five distinct operating segments: US Brands, US Medical Aesthetics, International Brands, Global Generics, and Anda Distribution. In addition, certain revenues and shared costs and the results of corporate initiatives are managed outside of the four segments. The new operating segments are organized as follows: · The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox ® · The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox ® · The International Brands segment includes sales and expenses relating to products sold outside of the United States. · The Anda Distribution segment includes distribution of generic and branded pharmaceutical products manufactured by third parties, as well as by the Company, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians’ offices. The Anda Distribution segment operating results exclude sales of products developed, acquired, or licensed by the US Brands, US Medical Aesthetics and International Brands segments. As the generics business is now reported within Discontinued Operations, the Anda Distribution segment includes revenues and expenses related to Company manufactured generics products sold through Anda. The Company evaluates segment performance based on segment contribution. Segment contribution for segments represents net revenues less cost of sales (excluding amortization and impairment of acquired intangibles including product rights), selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items at the segment level: · Revenues and operating expenses within cost of sales (excluding amortization and impairment of acquired intangibles including product rights), selling and marketing expenses, and general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs. · General and administrative expenses that result from shared infrastructure, including certain expenses located within the United States. · Total assets including capital expenditures. · Other select revenues and operating expenses including R&D expenses, amortization, IPR&D impairments and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments. The Company defines segment net sales as product sales and other revenue derived from branded products or licensing agreements. In March 2015, as a result of the Allergan Acquisition, we began to promote Restasis®, Lumigan ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® Cost of sales within segment contribution includes production and packaging costs for the products we manufacture, third party acquisition costs for products manufactured by others, profit-sharing or royalty payments for products sold pursuant to licensing agreements, inventory reserve charges and excess capacity utilization charges, where applicable. Cost of sales does not include amortization or impairment costs for acquired product rights or other acquired intangibles. Selling and marketing expenses consist mainly of personnel-related costs, product promotion costs, distribution costs, professional service costs, insurance, depreciation and travel costs. General and administrative expenses consist mainly of personnel-related costs, facilities costs, transaction costs, insurance, depreciation, litigation and settlement costs and professional services costs which are general in nature and attributable to the segment. Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Year Ended December 31, 2015 US US International Anda Brands Aesthetics Brands Distribution Total Net revenues $ 9,134.3 $ 1,513.9 $ 2,187.3 $ 2,225.4 $ 15,060.9 Operating expenses: Cost of sales (1) 1,131.9 99.0 376.4 1,905.3 3,512.6 Selling and marketing 1,664.6 302.9 569.2 146.9 2,683.6 General and administrative 139.6 34.0 125.5 44.2 343.3 Segment Contribution $ 6,198.2 $ 1,078.0 $ 1,116.2 $ 129.0 $ 8,521.4 Contribution margin 67.9 % 71.2 % 51.0 % 5.8 % 56.6 % Corporate 2,940.4 Research and development 2,358.5 Amortization 5,453.4 In-process research and development impairments 511.6 Asset sales and impairments, net 272.0 Operating (loss) (3,014.5 ) Operating margin (20.0 )% (1) Excludes amortization and impairment of acquired intangibles including product rights. Year Ended December 31, 2014 US US Medical International Anda Brands Aesthetics Brands Distribution Total Net revenues $ 4,511.2 $ - $ 203.5 $ 2,024.2 $ 6,738.9 Operating expenses: Cost of sales (1) 736.7 - 48.2 1,711.6 2,496.5 Selling and marketing 806.4 - 48.2 135.6 990.2 General and administrative 119.5 - 12.0 36.4 167.9 Segment Contribution $ 2,848.6 $ - $ 95.1 $ 140.6 $ 3,084.3 Contribution margin 63.1 % 46.7 % 6.9 % 45.8 % Corporate 2,247.0 Research and development 605.7 Amortization 1,945.5 In-process research and development impairments 424.3 Asset sales and impairments, net 305.7 Operating (loss) (2,443.9 ) Operating margin (36.3 )% (1) Excludes amortization and impairment of acquired intangibles including product rights. Year Ended December 31, 2013 US US Medical International Anda Brands Aesthetics Brands Distribution Total Net revenues $ 1,001.2 $ - $ 40.2 $ 1,561.1 $ 2,602.5 Operating expenses: Cost of sales (1) 153.8 - 15.8 1,297.6 1,467.2 Selling and marketing 240.7 - 21.6 112.5 374.8 General and administrative 39.4 - 1.4 32.7 73.5 Segment Contribution $ 567.3 $ - $ 1.4 $ 118.3 $ 687.0 Contribution margin 56.7 % 3.5 % 7.6 % 26.4 % Corporate 560.1 Research and development 191.3 Amortization 303.8 In-process research and development impairments - Asset sales and impairments, net 1.0 Operating (loss) (369.2 ) Operating margin (14.2 )% (1) Excludes amortization and impairment of acquired intangibles including product rights. The following is a reconciliation of net revenues for the operating segments to the Company’s net revenues for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, 2015 2014 2013 Segment net revenues $ 15,060.9 $ 6,738.9 $ 2,602.5 Corporate revenues 10.1 - - Net revenues $ 15,071.0 $ 6,738.9 $ 2,602.5 No country represents ten percent or more of net revenues outside of the United States. The US Brands, US Medical Aesthetics, and Anda Distribution segments are comprised solely of sales within the United States. The following tables present global net revenues for the top products of the Company for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, Global U.S. International 2015 2014 2013 2015 2014 2013 2015 2014 2013 Botox® $ 1,975.7 $ - $ - $ 1,386.6 $ - $ - $ 589.1 $ - $ - Restasis® 1,047.8 - - 999.6 - - 48.2 - - Namenda XR® 759.3 269.5 - 759.3 269.5 - - - - Bystolic® 646.1 292.6 - 644.8 291.6 - 1.3 1.0 - Asacol®/Delzicol® 618.5 614.1 164.2 552.9 541.0 145.2 65.6 73.1 19.0 Fillers 573.9 - - 304.3 - - 269.6 - - Namenda® IR 556.3 629.7 - 556.3 629.7 - - - - Lumigan®/Ganfort® 547.3 - - 260.7 - - 286.6 - - Linzess®/Constella® 459.3 174.4 - 454.8 173.2 - 4.5 1.2 - Alphagan®/Combigan® 411.1 - - 285.0 - - 126.1 - - Lo Loestrin® 349.6 277.1 63.3 346.5 275.7 63.3 3.1 1.4 - Viibryd®/Fetzima® 327.6 140.3 - 327.6 140.3 - - - - Estrace® Cream 326.2 258.2 60.7 326.2 258.2 60.7 - - - Minastrin® 24 273.0 217.9 53.7 272.4 217.9 53.7 0.6 - - Silicone Implants 229.7 - - 113.3 - - 116.4 - - Carafate® / Sulcrate® 213.1 90.9 - 213.1 90.9 - - - - Aczone® 170.8 - - 170.8 - - - - - Other Products Revenues 3,360.3 1,750.0 699.5 2,684.1 1,623.2 678.3 676.2 126.8 21.2 Total Products Revenues 12,845.6 4,714.7 1,041.4 10,658.3 4,511.2 1,001.2 2,187.3 203.5 40.2 ANDA Revenues 2,225.4 2,024.2 1,561.1 2,225.4 2,024.2 1,561.1 - - - Total Net Revenues $ 15,071.0 $ 6,738.9 $ 2,602.5 $ 12,883.7 $ 6,535.4 $ 2,562.3 $ 2,187.3 $ 203.5 $ 40.2 No other product represents ten percent or more of total net revenues. The following table presents net revenues for the US Brands segment for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, 2015 2014 2013 Central Nervous System (CNS) $ 2,541.2 $ 1,109.4 $ - Eye Care 1,831.3 - - Gastroenterology (GI) 1,575.3 966.8 145.2 Women's Health 998.0 791.7 290.8 Cardiovascular 644.8 291.6 - Urology 238.8 111.9 - Infectious Disease 188.8 62.7 - Other 1,116.1 1,177.1 565.2 Total US Brands Net Revenues $ 9,134.3 $ 4,511.2 $ 1,001.2 The following table presents revenues for the US Medical Aesthetics segment for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, 2015 2014 2013 Facial Aesthetics Total $ 817.8 $ - $ - Medical Dermatology Total 493.5 - - Plastic Surgery Total 202.6 - - Total US Medical Aesthetic Net Revenues $ 1,513.9 $ - $ - The following table presents net revenues for the International Brands segment for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, 2015 2014 2013 Eye Care $ 924.0 $ - $ - Facial Aesthetics 620.0 - - Other Therapeutics 517.8 203.5 40.2 Plastic Surgery 125.5 - - Total International Brands Net Revenues $ 2,187.3 $ 203.5 $ 40.2

Business Restructuring Charges

Business Restructuring Charges	12 Months Ended
	Dec. 31, 2015
Restructuring And Related Activities [Abstract]
Business Restructuring Charges	NOTE 22 — Business Restructuring Charges During 2015, activity related to our business restructuring and facility rationalization activities primarily related to the cost optimization initiatives in conjunction with the Allergan and Forest acquisitions. Restructuring activities for the year ended December 31, 2015 as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2014 $ 111.1 $ - $ - $ 111.1 Acquired liability 27.9 - 29.2 57.1 Charged to expense: Cost of sales 9.3 19.8 23.4 52.5 Research and development 77.7 104.6 - 182.3 Selling and marketing 71.5 47.0 - 118.5 General and administrative 130.5 293.3 42.4 466.2 Total expense 289.0 464.7 65.8 819.5 Cash payments (312.3 ) (127.1 ) (59.1 ) (498.5 ) Other reserve impact (19.0 ) (337.6 ) 12.7 (343.9 ) Reserve balance at December 31, 2015 $ 96.7 $ - $ 48.6 $ 145.3 During 2014, activity related to our business restructuring and facility rationalization activities primarily related to the cost optimization initiatives in conjunction with the Forest and Warner Chilcott acquisitions. Restructuring activities for the year ended December 31, 2014 as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2013 $ 67.5 $ - $ - $ 67.5 Acquired liability 12.2 - - 12.2 Charged to expense: Cost of sales 7.0 3.4 - 10.4 Research and development 22.8 - - 22.8 Selling and marketing 40.9 - - 40.9 General and administrative 71.8 183.2 1.8 256.8 Total expense 142.5 186.6 1.8 330.9 Cash payments (111.1 ) - - (111.1 ) Other reserve impact - (186.6 ) (1.8 ) (188.4 ) Reserve balance at December 31, 2014 $ 111.1 $ - $ - $ 111.1 During the years ended December 31, 2015, 2014 and 2013, the Company recognized restructuring charges related to continuing operations of $819.5 million, $330.9 million and $147.8 million, respectively.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Dec. 31, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	NOTE 23 — Derivative Instruments and Hedging Activities The Company’s revenue, earnings, cash flows and fair value of its assets and liabilities can be impacted by fluctuations in foreign exchange risks and interest rates, as applicable. The Company manages the impact of foreign exchange risk and interest rate movements through operational means and through the use of various financial instruments, including derivative instruments such as foreign currency derivatives. Foreign Currency Derivatives Overall, the Company is a net recipient of currencies other than the U.S. dollar and, as such, benefits from a weaker dollar and is adversely affected by a stronger dollar relative to major currencies worldwide. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may negatively affect the Company’s consolidated revenues and favorably impact operating expenses in U.S. dollars. Primarily as a result of the Allergan Acquisition and from time to time, the Company enters into foreign currency derivatives to reduce current and future earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on its core business issues. Accordingly, the Company enters into various contracts which change in value as foreign exchange rates change to economically offset the effect of changes in the value of foreign currency assets and liabilities, commitments and anticipated foreign currency denominated sales and operating expenses. The Company enters into foreign currency derivatives in amounts between minimum and maximum anticipated foreign exchange exposures. The Company does not designate the current derivative instruments as accounting hedges. The Company uses foreign currency derivatives, which provide for the sale or purchase or the option for sale or purchase of foreign currencies to economically hedge the currency exchange risks associated with probable but not firmly committed transactions that arise in the normal course of the Company’s business. Probable but not firmly committed transactions are comprised primarily of sales of products and purchases of raw material in currencies other than the U.S. dollar. The foreign currency derivatives are entered into to reduce the volatility of earnings generated in currencies other than the U.S. dollar. While these instruments are subject to fluctuations in value, such fluctuations are anticipated to offset changes in the value of the underlying exposures. The Company recognized realized and unrealized (gains) / losses on such contracts of $(1.4) million, $(2.3) million and $0.3 million, respectively, during the years ended December 31, 2015, 2014 and 2013. The fair value of outstanding foreign currency derivatives are recorded in “Prepaid expenses and other current assets,” “investments and other assets” or “Accounts payable and accrued expenses.” At December 31, 2015 and 2014, foreign currency derivative assets associated with the foreign exchange option contracts of $73.5 million and $2.3 million, respectively, were included in “Prepaid expenses and other current assets” and “investments and other assets,” At December 31, 2015, net foreign currency derivative liabilities associated with the foreign exchange forward contracts of $(0.3) million were included in “Accounts payable and accrued expenses.”

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurement	NOTE 24 — Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Fair values determined based on Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. Assets and liabilities measured at fair value or disclosed at fair value on a recurring basis as of December 31, 2015 and 2014 consisted of the following ($ in millions): Fair Value Measurements as of December 31, 2015 Using: Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 29.9 $ 29.9 $ - $ - Deferred executive compensation investments 118.1 102.3 15.8 - Foreign currency derivatives 73.5 - 73.5 - Marketable equity securities 32.3 32.3 - - Total assets $ 253.8 $ 164.5 $ 89.3 $ - Liabilities: Deferred executive compensation liabilities 117.9 102.1 15.8 - Contingent consideration obligations 868.0 - - 868.0 Total liabilities $ 985.9 $ 102.1 $ 15.8 $ 868.0 Fair Value Measurements as of December 31, 2014 Using: Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 1.0 $ 1.0 $ - $ - Foreign currency derivatives 2.3 - 2.3 - Total assets $ 3.3 $ 1.0 $ 2.3 $ - Liabilities: Contingent consideration obligations 373.8 - - 373.8 Total liabilities $ 373.8 $ - $ - $ 373.8 Marketable securities and investments consist of available-for-sale investments in U.S. treasury and agency securities and publicly traded equity securities for which market prices are readily available. Unrealized gains or losses on marketable securities and investments are recorded in accumulated other comprehensive (loss). Foreign Currency Contracts At December 31, 2015 and 2014, the notional principal and fair value of the Company’s outstanding foreign currency derivative financial instruments were as follows ($ in millions, except average contract rate or strike amount): Year Ended December 31, 2015 Year Ended December 31, 2014 Notional Principal Average Contract Rate or Strike Amount Notional Principal Average Contract Rate or Strike Amount Foreign currency forward contracts: (Receive U.S. dollar/pay foreign currecy) Russian ruble $ 18.8 1.41 $ 10.3 1.05 $ 18.8 $ 10.3 Estimated fair value $ (0.3 ) $ 2.3 Foreign currency sold - put options: Euro 340.5 1.41 - $ 340.5 $ - Estimated fair value $ 73.5 $ - The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2015 and 2014, and do not represent the amount of the Company’s exposure to market loss. The estimates of fair value are based on applicable and commonly used pricing models using prevailing financial market information as of December 31, 2015 and 2014. The amounts ultimately realized upon settlement of these financial instruments, together with the gains and losses on the underlying exposures, will depend on actual market conditions during the remaining life of the instruments. Contingent Consideration Obligations The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions. Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions): Years Ended December 31, Expense / (income) 2015 2014 2013 Cost of sales $ 58.5 $ (9.9 ) $ 5.8 Research and development 37.7 (69.3 ) 1.1 General and administrative - 0.4 3.2 Total $ 96.2 $ (78.8 ) $ 10.1 During the year ended December 31, 2015, the Company recorded additional contingent consideration of $29.8 million in connection with the approval of Viberzi™, $81.4 million in connection with the approval of Liletta ® ® During the year ended December 31, 2014, the Company recorded additional contingent consideration of $50.3 million in connection with the acquisition of metronidazole 1.3% vaginal gel antibiotic from Valeant Pharmaceuticals, Inc. In the year ended December 31, 2014, the Company evaluated future projections of metronidazole 1.3% vaginal gel antibiotic. As a result of this review, the Company noted the intangible asset was not fully recoverable. As such, the Company impaired the asset by $25.0 million. At the same time, the Company reversed contingent consideration (through cost of sales) of $21.0 million, for a net loss of $4.0 million. During the second quarter of 2014, the Company recorded fair value adjustments of contingent consideration of $22.8 million related specifically to IPR&D related to a project named Estelle and $1.5 million related to IPR&D for Colvir. Estelle is a novel natural estrogen-based 28 day cycle oral contraceptive for the prevention of pregnancy. At June 30, 2014, the acquired IPR&D intangible asset of $13.1 million was deemed to be fully impaired. Consequently the $22.8 million contingent liability was written off; resulting in a net gain of $9.7 million in the year ended December 31, 2014. Colvir is a treatment of premalignant Human Papilloma Virus (HPV) lesions of the uterine cervix. At June 30, 2014, the acquired IPR&D intangible asset of $2.0 million was deemed to be fully impaired. Consequently the $1.5 million contingent liability was written off; resulting in a net loss of $0.5 million in the year ended December 31, 2014. During the fourth quarter of 2014, the Company sold its rights in Aeroquin. As a result, the Company wrote-off $16.0 million in contingent consideration in the year ended December 31, 2014. In addition, the Company wrote-off IPR&D of $18.0 million, resulting in a net loss of $2.0 million. The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and 2014 ($ in millions): Balance as of December 31, 2014 Net transfers in to (out of) Level 3 Purchases and settlements, net Net accretion and fair value adjustments Foreign currency translation Balance as of December 31, 2015 Liabilities: Contingent consideration obligations $ 373.8 $ - $ 405.1 $ 96.2 $ (7.1 ) $ 868.0 Balance at December 31, 2013 Net transfers in to (out of) Level 3 Purchases and settlements, net Net accretion and fair value adjustments Foreign currency translation Balance at December 2014 Liabilities: Contingent consideration obligations $ 203.8 $ - $ 251.9 $ (78.8 ) $ (3.1 ) $ 373.8 During the year ended December 31, 2015, the following activity in contingent consideration obligations by acquisition was incurred ($ in millions): Balance as of December 31, 2014 Acquisitions Fair Value Adjustments Payments and Other Balance as of December 31, 2015 Medicines 360 acquisition $ 126.6 $ - $ 93.6 $ (76.1 ) $ 144.1 Furiex Acquisition 88.4 - 30.2 (118.6 ) - Forest Acquisition 52.4 - (29.8 ) (2.2 ) 20.4 Durata Acquisition 49.0 - 6.4 (30.9 ) 24.5 Metrogel acquisition 31.2 - (0.4 ) 0.1 30.9 Uteron acquisition 10.4 - (2.1 ) (0.1 ) 8.2 Allergan Acquisition - 383.7 3.1 (57.1 ) 329.7 Oculeve Acquisition - 90.0 - - 90.0 AqueSys Acquisition - 193.5 - - 193.5 Other 15.8 15.8 (4.8 ) (0.1 ) 26.7 Total $ 373.8 $ 683.0 $ 96.2 $ (285.0 ) $ 868.0

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 25 — Commitments and Contingencies The Company and its affiliates are involved in various disputes, governmental and/or regulatory inspections, inquires, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that is accrued. As of December 31, 2015, the Company’s consolidated balance sheet includes accrued loss contingencies of approximately $340.0 million, which includes the amount relating to the resolution with the federal government, as well as 50 states and the District of Columbia, concluding the previously disclosed federal investigation into certain sales and marketing practices involving several Warner Chilcott products during the time period January 2009 through March 2013. The Company’s legal proceedings range from cases brought by a single plaintiff to mass tort actions and class actions with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims (including, but not limited to, qui tam actions, antitrust, product liability, breach of contract, securities, patent infringement and trade practices), some of which present novel factual allegations and/or unique legal theories. In addition, a number of the matters pending against us are at very early stages of the legal process (which in complex proceedings of the sort faced by us often extend for several years). As a result, some matters have not yet progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to estimate a range of possible loss. In those proceedings in which plaintiffs do request publicly quantified amounts of relief, the Company does not believe that the quantified amounts are meaningful because they are merely stated jurisdictional limits, exaggerated and/or unsupported by the evidence or applicable burdens of proof. Antitrust Litigation Actos ® . On December 31, 2013 two putative class actions, on behalf of putative classes of indirect purchaser plaintiffs, were filed in the federal court for the Southern District of New York against Actavis plc and certain of its affiliates alleging that Watson Pharmaceuticals, Inc.’s (“Watson” now known as Actavis, Inc.) 2010 patent lawsuit settlement with Takeda Pharmaceutical, Co. Ltd. related to Actos ® (pioglitazone hydrochloride and metformin “Actos ® ”) is unlawful. Several additional complaints have also been filed. Plaintiffs then filed a consolidated, amended complaint on May 20, 2014. The amended complaint generally alleges an overall scheme that included Watson improperly delaying the launch of its generic version of Actos ® in exchange for substantial payments from Takeda in violation of federal and state antitrust and consumer protection laws. The complaint seeks declaratory and injunctive relief and unspecified damages. Defendants have moved to dismiss the amended complaint. On September 23, 2015, the court granted the motion to dismiss the indirect purchasers’ complaint in its entirety. In May 2015, two additional putative class action complaints, each of which makes similar allegations against the Company and Takeda, were filed by plaintiffs on behalf of a putative class of direct purchasers. Defendants have moved to dismiss the direct purchasers’ complaint. The Company believes that it has substantial meritorious defenses to the claims alleged. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. AndroGel ® On January 29, 2009, the U.S. Federal Trade Commission and the State of California filed a lawsuit in federal district court in California alleging that the September 2006 patent lawsuit settlement between Watson and Solvay Pharmaceuticals, Inc. (“Solvay”), related to AndroGel ® 1% (testosterone gel) CIII is unlawful. The complaint generally alleged that Watson improperly delayed its launch of a generic version of AndroGel ® in exchange for Solvay’s agreement to permit Watson to co-promote AndroGel ® for consideration in excess of the fair value of the services provided by Watson, in violation of federal and state antitrust and consumer protection laws. The complaint sought equitable relief and civil penalties. On February 2 and 3, 2009, three separate lawsuits alleging similar claims were filed in federal district court in California by various private plaintiffs purporting to represent certain classes of similarly situated claimants. On April 8, 2009, the Court transferred the government and private cases to the United States District Court for the Northern District of Georgia. The FTC and the private plaintiffs filed amended complaints on May 28, 2009. The private plaintiffs amended their complaints to include allegations concerning conduct before the U.S. Patent and Trademark Office (the “USPTO”), conduct in connection with the listing of Solvay’s patent in the FDA “Orange Book,” and sham litigation. Additional actions alleging similar claims have been filed in various courts by other private plaintiffs purporting to represent certain classes of similarly situated direct or indirect purchasers of AndroGel ® . The Judicial Panel on Multidistrict Litigation (“JPML”) transferred all federal court actions then pending outside of Georgia to that district. The district court then granted the Company’s motion to dismiss all claims except the private plaintiffs’ sham litigation claims. After the dismissal was upheld by the Eleventh Circuit Court of Appeals, the FTC petitioned the United States Supreme Court to hear the case. On June 17, 2013, the Supreme Court issued a decision, holding that the settlements between brand and generic drug companies which include a payment from the brand company to the generic competitor must be evaluated under a “rule of reason” standard of review and ordered the case remanded (the “Supreme Court AndroGel Decision”). The case is now back in the district court in Georgia. On August 5, 2014 the indirect purchaser plaintiffs filed an amended complaint which the Company answered on September 15, 2014. The Company believes it has substantial meritorious defenses and intends to defend itself vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Asacol ® On June 22, 2015, two class action complaints were filed in federal court in Massachusetts on behalf of a putative class of indirect purchasers. In each complaint plaintiffs allege that they paid higher prices for Warner Chilcott’s Asacol ® HD and Delzicol ® products as a result of Warner Chilcott’s alleged actions preventing or delaying generic competition in the market for Warner Chilcott’s older Asacol ® product in violation of U.S. federal antitrust laws and/or state laws. Plaintiffs seek unspecified injunctive relief, treble damages and/or attorneys’ fees. All of the actions were consolidated in the federal district court. On September 21, 2015, three additional complaints were filed on behalf of putative classes of indirect purchasers, each raising similar allegations to the complaints filed in June 2015. The Company believes it has substantial meritorious defenses and intends to defend itself vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Botox ® . On February 24, 2015, a class action complaint was filed in federal court in California. The complaint alleges unlawful market allocation in violation of Section 1 of the Sherman Act, 15 U.S.C. §1, agreement in restraint of trade in violation of 15 U.S.C. §1 of the Sherman Act, unlawful maintenance of monopoly market power in violation of Section 2 of the Sherman Act, 15 U.S.C. §2 of the Sherman Act, violations of California’s Cartwright Act, Section 16700 et seq. of Calif. Bus. and Prof. Code., and violations of California’s unfair competition law, Section 17200 et seq. of Calif. Bus. and Prof. Code. Plaintiffs filed an amended complaint on May 29, 2015. On June 29, 2015, the Company filed a motion to dismiss the complaint. On October 20, 2015, the Court denied the Company’s motion to dismiss the complaint. On December 18, 2015, plaintiffs filed a motion for partial judgment on the pleadings or, in the alternative, for partial summary judgment or adjudication. The Company filed a response to the motion for judgment on the pleadings on February 11, 2016. The court has not yet scheduled oral argument on plaintiff’s motion. The Company believes it has substantial meritorious defenses and intends to defend itself vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Cipro ® . Beginning in July 2000, a number of suits were filed against Watson and certain Company affiliates including The Rugby Group, Inc. (“Rugby”) in various state and federal courts alleging claims under various federal and state competition and consumer protection laws. The actions generally allege that the defendants engaged in unlawful, anticompetitive conduct in connection with alleged agreements, entered into prior to Watson’s acquisition of Rugby from Sanofi Aventis (“Sanofi”), related to the development, manufacture and sale of the drug substance ciprofloxacin hydrochloride, the generic version of Bayer’s brand drug, Cipro ® . The actions generally seek declaratory judgment, damages, injunctive relief, restitution and other relief on behalf of certain purported classes of individuals and other entities. While many of these actions have been dismissed, actions remain pending in various state courts, including California, Kansas, Tennessee, and Florida. There has been activity in Tennessee and Florida since 2003. In the action pending in Kansas, plaintiffs’ motion for class certification has been fully briefed. In the action pending in the California state court, following the decision from the United States Supreme Court in the matter involving AndroGel ® , described above, Plaintiffs and Bayer announced that they reached an agreement to settle the claims pending against Bayer and Bayer has now been dismissed from the action. Plaintiffs are continuing to pursue claims against the generic defendants, including Watson and Rugby. The remaining parties submitted letter briefs to the court regarding the impact of the Supreme Court AndroGel Decision and on May 7, 2015, the California Supreme Court issued a ruling, consistent with the Supreme Court AndroGel Decision discussed above, that the settlements between brand and generic drug companies which include a payment from the brand company to the generic competitor must be evaluated under a “rule of reason” standard of review. In addition to the pending actions, the Company understands that various state and federal agencies are investigating the allegations made in these actions. Sanofi has agreed to defend and indemnify Watson and its affiliates in connection with the claims and investigations arising from the conduct and agreements allegedly undertaken by Rugby and its affiliates prior to Watson’s acquisition of Rugby, and is currently controlling the defense of these actions. Doryx ® . In July 2012, Mylan Pharmaceuticals Inc. (“Mylan”) filed a complaint against Warner Chilcott and Mayne Pharma International Pty. Ltd. (“Mayne”) in federal court in Pennsylvania alleging that Warner Chilcott and Mayne prevented or delayed Mylan’s generic competition to Warner Chilcott’s Doryx ® products in violation of U.S. federal antitrust laws and tortiously interfered with Mylan’s prospective economic relationships under Pennsylvania state law. In the complaint, Mylan seeks unspecified treble and punitive damages and attorneys’ fees. Following the filing of Mylan’s complaint, three putative class actions were filed against Warner Chilcott and Mayne by purported direct purchasers, and one putative class action was filed against by purported indirect purchasers. In addition, four retailers filed in the same court a civil antitrust complaint in their individual capacities against Warner Chilcott and Mayne regarding Doryx ® . In each of the class and individual cases the plaintiffs allege that they paid higher prices for Warner Chilcott’s Doryx ® products as a result of Warner Chilcott’s and Mayne’s alleged actions preventing or delaying generic competition in violation of U.S. federal antitrust laws and/or state laws. Plaintiffs seek unspecified injunctive relief, treble damages and/or attorneys’ fees. All of the actions were consolidated in the federal district court. Warner Chilcott and Mayne’s motion to dismiss was denied without prejudice by the court in June 2013. Thereafter, Warner Chilcott and Mayne reached agreements to settle the claims of the Direct Purchaser Plaintiff class representatives, the Indirect Purchaser Plaintiff class representatives and each of the individual retailer plaintiffs. Warner Chilcott and Mylan filed motions for summary judgment on March 10, 2014. On April 16, 2015, the court issued an order granting Warner Chilcott and Mayne’s motion for summary judgment, denying Mylan’s summary judgment motion and entering judgment in favor of Warner Chilcott and Mayne on all counts. Mylan is appealing the district court’s decision to the Third Circuit Court of Appeals and the appeal is fully briefed. The date for oral argument on the appeal has not yet been set. The Company intends to vigorously defend its rights in the litigations. However, it is impossible to predict with certainty the outcome of any litigation and whether any additional similar suits will be filed. Lidoderm ® . On November 8, 2013, a putative class action was filed in the federal district court against Actavis, Inc. and certain of its affiliates alleging that Watson’s 2012 patent lawsuit settlement with Endo Pharmaceuticals, Inc. related to Lidoderm ® (lidocaine transdermal patches, “Lidoderm ® ”) is unlawful. The complaint, asserted on behalf of putative classes of direct purchaser plaintiffs, generally alleges that Watson improperly delayed launching generic versions of Lidoderm ® in exchange for substantial payments from Endo in violation of federal and state antitrust and consumer protection laws. The complaint seeks declaratory and injunctive relief and damages. Additional lawsuits containing similar allegations have followed on behalf of other classes of putative direct purchasers and suits have been filed on behalf of putative classes of end-payer plaintiffs. The Company anticipates additional claims or lawsuits based on the same or similar allegations may be filed. On April 3, 2014 the JPML consolidated the cases in federal district court in California. Defendants filed motions to dismiss each of the plaintiff classes’ claims. On November 17, 2014, the court issued an order granting the motion in part but denying it with respect to the claims under Section 1 of the Sherman Act. Plaintiffs then filed an amended, consolidated complaint on December 19, 2014. Defendants have responded to the amended consolidated complaint. On March 5, 2015, a group of five retailers filed a civil antitrust complaint in their individual capacities regarding Lidoderm ® in the same court where it was consolidated with the direct and indirect purchaser class complaints. The retailer complaint recites similar facts and asserts similar legal claims for relief to those asserted in the related cases described above. The five retailers amended their complaint on July 27, 2015. The Company believes it has substantial meritorious defenses and intends to defend itself vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Loestrin ® On April 5, 2013, two putative class actions were filed in the federal district court against Actavis, Inc. and certain affiliates alleging that Watson’s 2009 patent lawsuit settlement with Warner Chilcott related to Loestrin ® 24 Fe (norethindrone acetate/ethinyl estradiol tablets and ferrous fumarate tablets, “Loestrin ® 24”) is unlawful. The complaints, both asserted on behalf of putative classes of end-payors, generally allege that Watson and another generic manufacturer improperly delayed launching generic versions of Loestrin ® 24 in exchange for substantial payments from Warner Chilcott, which at the time was an unrelated company, in violation of federal and state antitrust and consumer protection laws. The complaints each seek declaratory and injunctive relief and damages. Additional complaints have been filed by different plaintiffs seeking to represent the same putative class of end-payors. In addition to the end-payor suits, two lawsuits have been filed on behalf of a class of direct payors. The Company anticipates additional claims or lawsuits based on the same or similar allegations. After a hearing on September 26, 2013, the JPML issued an order transferring all related Loestrin ® 24 cases to the federal court for the District of Rhode Island. On September 4, 2014, the court granted the defendants’ motion to dismiss the complaint. The plaintiffs appealed the district court’s decision to the First Circuit Court of Appeals and oral argument was held on December 7, 2015. On February 22, 2016 the First Circuit issued its decision vacating the decision of, and remanding the matter to, the district court. The Company believes it has substantial meritorious defenses and intends to defend itself vigorously including in the appeal of the district court’s decision granting the Company’s motion to dismiss. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Namenda ® . On September 15, 2014, the State of New York, through the Office of the Attorney General of the State of New York, filed a lawsuit in the United States District Court for the Southern District of New York alleging that Forest is acting to prevent or delay generic competition to Forest’s immediate-release product Namenda ® in violation of federal and New York antitrust laws and committed other fraudulent acts in connection with its commercial plans for Namenda ® XR. In the complaint, the state seeks unspecified monetary damages and injunctive relief. On September 24, 2014, the state filed a motion for a preliminary injunction prohibiting Forest from discontinuing or otherwise limiting the availability of immediate-release Namenda ® until the conclusion of the litigation. A hearing was held in November 2014 on the state’s preliminary injunction motion. On December 11, 2014, the district court issued a ruling granting the state’s injunction motion and issued an injunction on December 15, 2014. On May 22, 2015, the Court of Appeals for the Second Circuit affirmed the preliminary injunction. On June 5, 2015, Forest filed a petition with the Second Circuit for rehearing en banc which was denied. Forest and the New York Attorney General reached a settlement on November 24, 2015. On May 29, 2015, a putative class action was filed on behalf of a class of direct purchasers and on June 8, 2015 a similar putative class action was filed on behalf of a class of indirect purchasers. Since that time, additional complaints have been filed on behalf of putative classes of direct and indirect purchasers. The class action complaints make claims similar to those asserted by the New York Attorney General and also include claims that Namenda ® patent litigation settlements between Forest and generic companies also violated the antitrust laws. On December 22, 2015, Forest and its co-defendants filed motions to dismiss the pending complaints of the putative classes of direct and indirect purchasers. These motions remain pending. The Company believes it has substantial meritorious defenses and intends to defend both its brand and generic defendant entities vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Zymar ® ® . On February 16, 2012, Apotex Inc. and Apotex Corp. filed a complaint in the federal district court in Delaware against Senju Pharmaceuticals Co., Ltd. (“Senju”), Kyorin Pharmaceutical Co., Ltd. (“Kyorin”), and Allergan, Inc. (“Allergan”) alleging monopolization in violation of Section 2 of the Sherman Act, conspiracy to monopolize, and unreasonable restraint of trade in the market for gatifloxacin ophthalmic formulations, which includes Allergan’s ZYMAR ® gatifloxacin ophthalmic solution 0.3% and ZYMAXID ® gatifloxacin ophthalmic solution 0.5% products. On May 24, 2012, Allergan filed a motion to dismiss the complaint to the extent it seeks to impose liability for alleged injuries occurring prior to August 19, 2011, which is the date Apotex obtained final approval of its proposed generic product. Allergan and the other defendants also moved to dismiss. Defendants also filed a motion to stay the action pending resolution of related patent actions in the federal court in Delaware and in the U.S. Court of Appeals for the Federal Circuit. On February 7, 2013, the court granted defendants’ motion to stay the proceedings pending resolution of the appeal in the patent dispute and denied the motion to dismiss without prejudice to renew. On September 18, 2014, defendants filed a new motion to dismiss the Apotex plaintiffs’ complaint. The court dismissed Allergan’s motion on May 2, 2015. Thereafter, Allergan filed an answer to Apotex’s complaint on June 1, 2015. On June 6, 2014, a separate antitrust class action complaint was filed in the federal district court in Delaware against the same defendants as in the Apotex case. The complaint alleges that defendants unlawfully excluded or delayed generic competition in the gatifloxacin ophthalmic formulations market (generic versions of ZYMAR ® and ZYMAXID ® ). On September 18, 2014, Allergan filed a motion to dismiss for lack of subject matter jurisdiction and joined in co-defendants’ motion to dismiss for failure to state a claim. On August 19, 2015, the court granted Allergan’s motion to dismiss. On September 18, 2015, plaintiff filed a notice of appeal with the U.S. Court of Appeals for the Third Circuit. The Company believes it has substantial meritorious defenses and intends to defend itself vigorously. However, these actions, if successful, could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Commercial Litigation Celexa ® ® . Forest and certain of its affiliates are defendants in three federal court actions filed on behalf of individuals who purchased Celexa ® and/or Lexapro ® for pediatric use, all of which have been consolidated for pretrial purposes in an MDL proceeding in the federal district court Massachusetts (the “Celexa ® /Lexapro ® MDL”). These actions, two of which were originally filed as putative nationwide class actions, and one of which is a putative California-wide class action, allege that Forest marketed Celexa ® and/or Lexapro ® for off-label pediatric use and paid illegal kickbacks to physicians to induce prescriptions of Celexa ® and Lexapro ® . The complaints assert various similar claims, including claims under the state consumer protection statutes and state common laws. Plaintiffs in the various actions sought to have certified California, Missouri, Illinois and New York state-wide classes. However, only the Missouri state class was certified. Forest subsequently reached an agreement with the MDL plaintiffs to settle the Missouri class claims, including claims by both individuals and third party payors that purchased Celexa ® or Lexapro ® for use by a minor from 1998 to December 31, 2013, for $7.65 million with a potential to increase the amount to $10.35 million if settling plaintiffs meet certain thresholds. On September 8, 2014 the court granted final approval for the settlement. Additional actions relating to the promotion of Celexa ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® ® Forest and certain of its affiliates are also named as defendants in two actions filed on behalf of entities or individuals who purchased or reimbursed certain purchases of Celexa ® ® ® ® ® ® The Company intends to continue to vigorously defend against these actions. At this time, the Company does not believe losses, if any, would have a material effect on the results of operations or financial position taken as a whole. Telephone Consumer Protection Act Litigation. A putative class action complaint against Anda, Inc. (“Anda”), a subsidiary of the Company, was filed in Missouri state court alleging claims for conversion and alleged violations of the Telephone Consumer Protection Act (“TCPA”) and Missouri Consumer Fraud and Deceptive Business Practices Act. An amended complaint alleges that by sending unsolicited facsimile advertisements, Anda misappropriated the class members’ paper, toner, ink and employee time when they received the alleged unsolicited faxes, and that the alleged unsolicited facsimile advertisements were sent to the plaintiff in violation of the TCPA and Missouri Consumer Fraud and Deceptive Business Practices Act. The complaint seeks to assert class action claims on behalf of the plaintiff and other similarly situated third parties. On May 19, 2011, the plaintiff’s filed a motion seeking certification of a class of entities with Missouri telephone numbers who were sent Anda faxes for the period January 2004 through January 2008 but the court vacated the class certification hearing until the FCC Petition, described in more detail below, was addressed. On May 1, 2012, a separate action was filed in federal court in Florida, purportedly on behalf of the “end users of the fax numbers in the United States but outside Missouri to which faxes advertising pharmaceutical products for sale by Anda were sent.” On July 10, 2012, Anda filed its answer and affirmative defenses. The parties filed a joint motion to stay the action pending the resolution of the FCC Petition which the court granted. In addition, in October 2012, Forest and certain of its affiliates were named as defendants, in a putative class action in federal court in Missouri. This suit alleges that Forest and another defendant violated the TCPA and was filed on behalf of a proposed class that includes all persons who, from four years prior to the filing of the action, were sent telephone facsimile messages of material advertising the commercial availability of any property, goods, or services by or on behalf of defendants, which did not display an opt-out notice compliant with a certain regulation promulgated by the FCC. On July 17, 2013, the district court granted Forest’s motion to stay the action pending the administrative proceeding initiated by the pending FCC Petition and a separate petition Forest filed. On October 31, 2015, another class action complaint was filed in Missouri state court against Allergan USA, Inc., Warner Chilcott Corporation and Actavis, Inc. alleging violations of the Telephone Consumer Protection Act, the Missouri Consumer Fraud and Protection Act and conversion on behalf of a putative nationwide class of plaintiffs to who defendant Warner Chilcott Corporation sent unsolicited facsimile advertisements. Defendants removed this action to the federal district court for the Western District of Missouri on December 10, 2015 and responded to the complaint on February 8, 2016. On February 17, 2016, plaintiffs voluntarily dismissed defendants Allergan USA, Inc. and Actavis, Inc. from the litigation. In a related matter, in November 2010 Anda filed a petition with the FCC, asking the FCC to clarify the statutory basis for its regulation requiring “opt-out” language on faxes sent with express permission of the recipient (the “FCC Petition”). On May 2, 2012, the Consumer & Governmental Affairs Bureau of the FCC dismissed the FCC Petition. On May 14, 2012, Anda filed an application for review of the Bureau’s dismissal by the full Commission, requesting the FCC to vacate the dismissal and grant the relief sought in the FCC Petition. The FCC did not rule on the application for review. On June 27, 2013, Forest filed a Petition for Declaratory Ruling with the FCC requesting that the FCC find that (1) the faxes at issue in the action complied, or substantially complied with the FCC regulation, and thus did not violate it, or (2) the FCC regulation was not properly promulgated under the TCPA. On January 31, 2014, the FCC issued a Public Notice seeking comment on several other recently-filed petitions, all similar to the one Anda filed in 2010. On October 30, 2014, the FCC issued a final order on the FCC Petition granting Anda, Forest and several other petitioners a retroactive waiver of the opt-out notice requirement for all faxes sent with express consent. The litigation plaintiffs, who had filed comments on the January 2014 Public Notice, have appealed the final order to the Court of Appeals for the District of Columbia. Anda, Forest and other petitioners have moved to intervene in the appeal seeking review of that portion of the FCC final order addressing the statutory basis for the opt out/express consent portion of the regulation. Anda and Forest believe they have substantial meritorious defenses to the putative class actions brought under the TCPA, and intend to defend the actions vigorously. However, these actions, if successful, could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Prescription Drug Abuse Litigation . On May 21, 2014, the California counties Santa Clara and Orange filed a lawsuit in California state court on behalf of the State of California against several pharmaceutical manufacturers. Plaintiffs named Actavis plc in the suit. The California plaintiffs filed an amended complaint on June 9, 2014. On June 2, 2014, the City of Chicago also filed a complaint in Illinois state court against the same set of defendants, including Actavis plc, that were sued in the California Action. Co-defendants in the action removed the matter to the federal court in Illinois. Both the California and Chicago complaints allege that the manufacturer defendants engaged in a deceptive campaign to promote their products in violation of state and local laws. Each of the complaints seeks unspecified monetary damages, penalties and injunctive relief. Defendants have moved to dismiss the complaints in each action. On May 8, 2015, the court in the Chicago litigation granted the Company’s motion to dismiss the complaint. On August 26, 2015, the City of Chicago filed a second amended complaint. In the California action, on August 27, 2015, the court stayed the action based on primary jurisdiction arguments raised in the motions to dismiss. The Company anticipates that additional suits will be filed. The Company believes it has several meritorious defenses to the claims alleged. However, an adverse determination in these actions could have an adverse effect on the Company’s business, results of operations, financial condition and cash flows. Testosterone Replacement Therapy Class Action . On November 24, 2014, the Company was served with a putative class action complaint filed on behalf a class of third party payers in federal court in Illinois. The suit alleges that the Company and other named pharmaceutical defendants violated

Warner Chilcott Limited ("WCL")

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information	12 Months Ended
	Dec. 31, 2015
Warner Chilcott Acquisition [Member]
Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information	NOTE 26 — Warner Chilcott Limited (“WCL”) Guarantor and Non-Guarantor Condensed Consolidating Financial Information The following financial information is presented to segregate the financial results of WCL, Actavis Funding SCS, and Actavis, Inc. (the issuers of the long-term notes), the guarantor subsidiaries for the long-term notes and the non-guarantor subsidiaries. The guarantors jointly and severally, and fully and unconditionally, guarantee the Company’s obligation under the long-term notes. The information includes elimination entries necessary to consolidate the guarantor and the non-guarantor subsidiaries. Investments in subsidiaries are accounted for using the equity method of accounting. The principal elimination entries eliminate investments in subsidiaries, equity and intercompany balances and transactions. WCL, Actavis Capital S.a.r.l. and Actavis, Inc. are guarantors of the long-term notes. Warner Chilcott Limited has revised its consolidating financial statements as previously presented in Footnote 25 of the 2014 Annual Report on Form 10-K due to a change in the Company’s legal entity structure that occurred during the year ended December 31, 2015. As a result, prior period information has been recast to conform to the current period presentation. The following financial information presents the consolidating balance sheets as of December 31, 2015 and 2014, the related statement of operations for the years ended December 31, 2015, 2014 and 2013 and the statement of cash flows for the years ended December 31, 2015, 2014 and 2013. Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2015 ($ in millions) Current assets: Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash and cash equivalents $ - $ 13.5 $ - $ 2.0 $ 1,020.7 $ - $ 1,036.2 Marketable securities - - - - 9.3 - 9.3 Accounts receivable, net - - - - 2,401.6 - 2,401.6 Receivable from Parents - - - - 457.3 - 457.3 Inventories, net - - - - 1,009.7 - 1,009.7 Intercompany receivables - 94,999.2 25,225.6 302.4 101,864.8 (222,392.0 ) - Prepaid expenses and other current assets - 12.6 24.5 6.1 512.8 - 556.0 Current assets held for sale - - - - 3,540.3 - 3,540.3 Deferred tax assets - - - - - - - Total current assets - 95,025.3 25,250.1 310.5 110,816.5 (222,392.0 ) 9,010.4 Property, plant and equipment, net - - - 34.3 1,539.6 - 1,573.9 Investments and other assets - 14.1 124.6 37.7 401.0 - 577.4 Investment in subsidiaries 75,571.6 79,597.3 - 6,742.7 - (161,911.6 ) - Non current assets held for sale - - - 45.8 10,495.5 - 10,541.3 Deferred tax assets - - - - 49.5 - 49.5 Product rights and other intangibles - - - - 67,931.7 - 67,931.7 Goodwill - - - - 46,551.5 - 46,551.5 Total assets $ 75,571.6 $ 174,636.7 $ 25,374.7 $ 7,171.0 $ 237,785.3 $ (384,303.6 ) $ 136,235.7 Current liabilities: Accounts payable and accrued expenses - 3.9 210.5 171.5 3,909.5 - 4,295.4 Intercompany payables - 92,093.5 526.3 9,245.0 120,527.2 (222,392.0 ) - Payable to Parents - - - - 1,466.8 - 1,466.8 Income taxes payable - - - 44.1 10.1 - 54.2 Current portion of long-term debt and capital leases - 756.7 - - 1,676.1 - 2,432.8 Current liabilities held for sale - - - 23.3 1,468.5 - 1,491.8 Deferred tax liabilities - - - - - - - Total current liabilities - 92,854.1 736.8 9,483.9 129,058.2 (222,392.0 ) 9,741.0 Long-term debt and capital leases - 7,009.1 24,637.6 4,273.5 4,373.2 - 40,293.4 Other long-term liabilities - - - - 1,262.0 - 1,262.0 Non current liabilities held for sale - - - - 580.1 - 580.1 Other taxes payable - - - 72.1 729.8 - 801.9 Deferred tax liabilities - - - - 7,985.7 - 7,985.7 Total liabilities - 99,863.2 25,374.4 13,829.5 143,989.0 (222,392.0 ) 60,664.1 Total equity 75,571.6 74,773.5 0.3 (6,658.5 ) 93,796.3 (161,911.6 ) 75,571.6 Total liabilities and equity $ 75,571.6 $ 174,636.7 $ 25,374.7 $ 7,171.0 $ 237,785.3 $ (384,303.6 ) $ 136,235.7 Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2014 ($ in millions) Current assets: Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash and cash equivalents $ 0.1 $ 5.5 $ - $ 1.5 $ 237.2 $ - $ 244.3 Marketable securities - - - - 1.0 - 1.0 Accounts receivable, net - - - - 1,111.6 - 1,111.6 Receivable from Parents - - - - 269.8 - 269.8 Inventories - - - - 984.6 - 984.6 Intercompany receivables - 22,987.9 3,659.0 18,720.9 52,730.5 (98,098.3 ) - Prepaid expenses and other current assets - 123.1 2.7 - 350.1 - 475.9 Current assets held for sale - - - - 3,806.9 - 3,806.9 Deferred tax assets - - - - 477.0 - 477.0 Total current assets 0.1 23,116.5 3,661.7 18,722.4 59,968.7 (98,098.3 ) 7,371.1 Property, plant and equipment, net - - - 8.2 274.3 - 282.5 Investments and other assets - 9.0 23.6 82.0 38.7 - 153.3 Investment in subsidiaries 28,076.9 31,549.0 - 4,761.1 - (64,387.0 ) - Non current assets held for sale - - - 43.4 8,144.3 - 8,187.7 Deferred tax assets - - - - 34.7 - 34.7 Product rights and other intangibles - - - - 16,090.7 - 16,090.7 Goodwill - - - - 20,897.6 - 20,897.6 Total assets $ 28,077.0 $ 54,674.5 $ 3,685.3 $ 23,617.1 $ 105,449.0 $ (162,485.3 ) $ 53,017.6 Current liabilities: Accounts payable and accrued expenses - 2.8 6.1 112.7 2,905.4 - 3,027.0 Intercompany payables - 25,953.8 2.0 26,774.7 45,367.8 (98,098.3 ) - Payable to Parents - - - - 521.1 - 521.1 Income taxes payable - - - 33.9 - - 33.9 Current portion of long-term debt and capital leases - 571.6 - - 121.8 - 693.4 Current liabilities held for sale - - - 62.8 1,386.3 - 1,449.1 Deferred tax liabilities - - - - 41.0 - 41.0 Total current liabilities - 26,528.2 8.1 26,984.1 50,343.4 (98,098.3 ) 5,765.5 Long-term debt and capital leases - 2,516.0 3,677.2 4,270.7 4,373.8 - 14,837.7 Other long-term liabilities - - - - 253.4 - 253.4 Non current liabilities for sale 102.7 438.0 540.7 Other taxes payable - - - 789.5 - - 789.5 Deferred tax liabilities - - - - 2,753.8 - 2,753.8 Total liabilities - 29,044.2 3,685.3 32,147.0 58,162.4 (98,098.3 ) 24,940.6 Total equity 28,077.0 25,630.3 - (8,529.9 ) 47,286.6 (64,387.0 ) 28,077.0 Total liabilities and equity $ 28,077.0 $ 54,674.5 $ 3,685.3 $ 23,617.1 $ 105,449.0 $ (162,485.3 ) $ 53,017.6 Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2015 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 15,071.0 $ - $ 15,071.0 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 4,810.4 - 4,810.4 Research and development - - - - 2,358.5 - 2,358.5 Selling and marketing - - - - 2,914.0 - 2,914.0 General and administrative - 212.1 16.1 - 1,402.0 - 1,630.2 Amortization - - - - 5,453.4 - 5,453.4 In-process research and development impairments - - - - 511.6 - 511.6 Asset sales and impairments, net - - - - 272.0 - 272.0 Total operating expenses - 212.1 16.1 - 17,721.9 - 17,950.1 Operating income / (loss) - (212.1 ) (16.1 ) - (2,650.9 ) - (2,879.1 ) Non-operating income (expense): Interest income / (expense), net - 1,572.4 (14.6 ) (168.5 ) (2,571.2 ) - (1,181.9 ) Other income (expense), net - (265.4 ) 31.0 - 0.6 - (233.8 ) Total other income (expense), net - 1,307.0 16.4 (168.5 ) (2,570.6 ) - (1,415.7 ) Income / (loss) before income taxes and noncontrolling interest - 1,094.9 0.3 (168.5 ) (5,221.5 ) - (4,294.8 ) Provision for income taxes - - - (58.3 ) (1,503.6 ) - (1,561.9 ) (Earnings) / losses of equity interest subsidiaries (4,050.6 ) (4,336.5 ) - (1,981.6 ) - 10,368.7 - Net income / (loss) from continuing operations, net of tax $ 4,050.6 $ 5,431.4 $ 0.3 $ 1,871.4 $ (3,717.9 ) $ (10,368.7 ) $ (2,732.9 ) Income from discontinued operations - - - - 6,787.7 - 6,787.7 Net income / (loss) $ 4,050.6 $ 5,431.4 $ 0.3 $ 1,871.4 $ 3,069.8 $ (10,368.7 ) $ 4,054.8 (Income) attributable to noncontrolling interest - - - - (4.2 ) - (4.2 ) Net income / (loss) attributable to ordinary shareholders $ 4,050.6 $ 5,431.4 $ 0.3 $ 1,871.4 $ 3,065.6 $ (10,368.7 ) $ 4,050.6 Other comprehensive (loss) / income (28.7 ) 24.5 - - (28.7 ) 4.2 (28.7 ) Comprehensive income / (loss) $ 4,021.9 $ 5,455.9 $ 0.3 $ 1,871.4 $ 3,036.9 $ (10,364.5 ) $ 4,021.9 Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2014 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues - - - - 6,738.9 - 6,738.9 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 3,453.6 - 3,453.6 Research and development - - - - 605.7 - 605.7 Selling and marketing - - - - 1,201.0 - 1,201.0 General and administrative - - - 9.9 1,167.1 - 1,177.0 Amortization - - - - 1,945.5 - 1,945.5 In process research and development impairments - - - - 424.3 - 424.3 Asset sales and impairments, net - - - (0.1 ) 305.8 - 305.7 Total operating expenses - - - 9.8 9,103.0 - 9,112.8 Operating income / (loss) - - - (9.8 ) (2,364.1 ) - (2,373.9 ) Non-operating income (expense): Interest income / (expense), net - (740.0 ) - (182.0 ) 519.1 - (402.9 ) Other income (expense), net - (74.5 ) - - 47.2 - (27.3 ) Total other income (expense), net - (814.5 ) - (182.0 ) 566.3 - (430.2 ) Income / (loss) before income taxes and noncontrolling interest - (814.5 ) - (191.8 ) (1,797.8 ) - (2,804.1 ) Provision for income taxes - - - (108.6 ) (358.4 ) - (467.0 ) Losses / (earnings) of equity interest subsidiaries 1,560.5 539.7 - (886.2 ) - (1,214.0 ) - Net (loss) / income from continuing operations, net of tax $ (1,560.5 ) $ (1,354.2 ) $ - $ 803.0 $ (1,439.4 ) $ 1,214.0 $ (2,337.1 ) (Loss) / income from discontinued operations - - - (70.0 ) 846.6 - 776.6 Net (loss) / income $ (1,560.5 ) $ (1,354.2 ) $ - $ 733.0 $ (592.8 ) $ 1,214.0 $ (1,560.5 ) (Income) / loss attributable to noncontrolling interest - - - - - - - Net (loss) / income attributable to ordinary shareholders $ (1,560.5 ) $ (1,354.2 ) $ - $ 733.0 $ (592.8 ) $ 1,214.0 $ (1,560.5 ) Other comprehensive (loss) / income (555.9 ) (505.9 ) - - (555.9 ) 1,061.8 (555.9 ) Comprehensive (loss) / income $ (2,116.4 ) $ (1,860.1 ) $ - $ 733.0 $ (1,148.7 ) $ 2,275.8 $ (2,116.4 ) Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2013 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 2,602.5 $ - $ 2,602.5 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 1,644.7 - 1,644.7 Research and development - - - - 191.3 - 191.3 Selling and marketing - - - - 374.8 - 374.8 General and administrative - 0.3 - 75.0 356.4 - 431.7 Amortization - - - - 303.8 - 303.8 In process research and development impairments - - - - - - - Asset sales and impairments, net - - - (0.3 ) 1.3 - 1.0 Total operating expenses - 0.3 - 74.7 2,872.3 - 2,947.3 Operating income / (loss) - (0.3 ) - (74.7 ) (269.8 ) - (344.8 ) Non-operating income (expense): Interest income / (expense), net - 87.5 - 264.5 (587.0 ) - (235.0 ) Other income (expense), net - (1.1 ) - (6.4 ) (11.1 ) - (18.6 ) Total other income (expense), net - 86.4 - 258.1 (598.1 ) - (253.6 ) Income / (loss) before income taxes and noncontrolling interest - 86.1 - 183.4 (867.9 ) - (598.4 ) Provision for income taxes - - - 19.1 (175.3 ) - (156.2 ) (Earnings) / losses of equity interest subsidiaries 724.5 162.2 - 498.8 - (1,385.5 ) - Net (loss) / income from continuing operations, net of tax $ (724.5 ) $ (76.1 ) $ - $ (334.5 ) $ (692.6 ) $ 1,385.5 $ (442.2 ) Income / (loss) from discontinued operations - - - - (282.3 ) - (282.3 ) Net (loss) /income $ (724.5 ) $ (76.1 ) $ - $ (334.5 ) $ (974.9 ) $ 1,385.5 $ (724.5 ) (Income) / loss attributable to noncontrolling interest - - - - - - - Net income / (loss) attributable to ordinary shareholders $ (724.5 ) $ (76.1 ) $ - $ (334.5 ) $ (974.9 ) $ 1,385.5 $ (724.5 ) Other comprehensive income / (loss) 53.7 48.2 - 6.7 53.7 (108.6 ) 53.7 Comprehensive (loss) / income $ (670.8 ) $ (27.9 ) $ - $ (327.8 ) $ (921.2 ) $ 1,276.9 $ (670.8 ) Warner Chilcott Limited Consolidating Statement of Cash Flows For the Year Ended December 31, 2015 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ 4,050.6 $ 5,431.4 $ 0.3 $ 1,871.4 $ 3,069.8 $ (10,368.7 ) $ 4,054.8 Reconciliation to net cash provided by operating activities: (Earnings) / losses of equity interest subsidiaries (4,050.6 ) (4,336.5 ) - (1,981.6 ) - 10,368.7 - Depreciation - - - 0.2 218.1 - 218.3 Amortization - - - - 5,777.0 - 5,777.0 Provision for inventory reserve - - - - 140.9 - 140.9 Share-based compensation - - - 51.6 638.8 - 690.4 Deferred income tax benefit - - - - (7,380.1 ) - (7,380.1 ) In-process research and development impairments - - - - 511.6 - 511.6 Loss / (gain) on asset sales and impairments, net - - - - 334.4 - 334.4 Amortization of inventory step-up - - - - 1,192.9 - 1,192.9 Amortization of deferred financing costs - 272.5 20.9 4.1 0.8 - 298.3 Accretion and contingent consideration - - - - 108.8 - 108.8 Dividends from subsidiaries 208.1 208.1 - - - (416.2 ) - Other, net - - - - 66.4 - 66.4 Changes in assets and liabilities (net of effects of acquisitions) (0.1 ) (370.6 ) 122.5 97.7 (1,199.2 ) - (1,349.7 ) Net cash provided by / (used in) operating activities 208.0 1,204.9 143.7 43.4 3,480.2 (416.2 ) 4,664.0 Cash Flows From Investing Activities: Additions to property plant and equipment - - - (42.9 ) (412.0 ) - (454.9 ) Additions to product rights and other intangibles - - - - (154.7 ) - (154.7 ) Additions to investments (9,000.8 ) (9,000.8 ) - - (24.3 ) 18,001.6 (24.3 ) Proceeds from sale of investments and other assets - - - - 883.0 - 883.0 Proceeds from sales of property, plant and equipment - - - - 140.1 - 140.1 Acquisitions of business, net of cash acquired - - - - (37,510.1 ) - (37,510.1 ) Net cash (used in) investing activities (9,000.8 ) (9,000.8 ) - (42.9 ) (37,078.0 ) 18,001.6 (37,120.9 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness - 5,500.0 20,955.6 - 0.1 - 26,455.7 Financing structure and other activity with affiliates - (5,500.0 ) (20,955.6 ) - 26,455.6 - - Proceeds from borrowings on credit facility and other - 3,610.0 - - 72.0 - 3,682.0 Debt issuance and other financing costs - (167.1 ) (143.7 ) - - - (310.8 ) Payments on debt, including capital lease obligations - (4,431.7 ) - - (702.5 ) - (5,134.2 ) Payments of contingent consideration - - - - (230.1 ) - (230.1 ) Dividends to Parent (208.1 ) (208.1 ) - - (208.1 ) 416.2 (208.1 ) Contribution from Parent 9,000.8 9,000.8 - - 9,000.8 (18,001.6 ) 9,000.8 Net cash provided by / (used in) financing activities 8,792.7 7,803.9 (143.7 ) - 34,387.8 (17,585.4 ) 33,255.3 Effect of currency exchange rate changes on cash and cash equivalents - - - - (6.5 ) - (6.5 ) Movement in cash held for sale - - - - - - - Net increase / (decrease) in cash and cash equivalents (0.1 ) 8.0 - 0.5 783.5 - 791.9 Cash and cash equivalents at beginning of period 0.1 5.5 - 1.5 237.2 - 244.3 Cash and cash equivalents at end of period $ - $ 13.5 $ - $ 2.0 $ 1,020.7 $ - $ 1,036.2 Warner Chilcott Limited Consolidating Statement of Cash Flows For the Year Ended December 31, 2014 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (1,560.5 ) $ (1,354.2 ) $ - $ 733.0 $ (592.8 ) $ 1,214.0 $ (1,560.5 ) Reconciliation to net cash provided by operating activities: Losses / (earnings) of equity interest subsidiaries 1,560.5 539.7 - (886.2 ) - (1,214.0 ) - Depreciation - - - 0.2 230.7 - 230.9 Amortization - - - - 2,597.5 - 2,597.5 Provision for inventory reserve - - - - 156.1 - 156.1 Share-based compensation - - - 1.4 366.6 - 368.0 Deferred income tax benefit - - - - (690.1 ) - (690.1 ) In-process research and development impairments - - - - 424.3 - 424.3 Goodwill Impairment - - - - 17.3 - 17.3 Loss / (gain) on asset sales and impairments, net - - - - 143.1 - 143.1 Amortization of inventory step-up - - - - 985.8 - 985.8 Amortization of deferred financing costs - 1.0 22.9 2.4 60.9 - 87.2 Accretion and contingent consideration - - - - (71.2 ) - (71.2 ) Non-cash impact of debt extinguishment - - - - (91.7 ) - (91.7 ) Impact of assets held for sale - - - - 190.8 - 190.8 Other, net - - - - 8.5 - 8.5 Changes in assets and liabilities (net of effects of acquisitions) - 1,156.5 (3,647.2 ) 159.2 1,805.2 - (526.3 ) Net cash provided by / (used in) operating activities - 343.0 (3,624.3 ) 10.0 5,541.0 - 2,269.7 Cash Flows From Investing Activities: Additions to property plant and equipment - - - (9.9 ) (228.7 ) - (238.6 ) Additions to product rights and other intangibles - - - - (36.1 ) - (36.1 ) Additions to investments - - - - (1.0 ) - (1.0 ) Proceeds from sale of investments and other assets - - - - 453.7 - 453.7 Proceeds from sales of property, plant and equipment - - - - 13.7 - 13.7 Acquisitions of business, net of cash acquired - - - - (5,562.3 ) - (5,562.3 ) Net cash (used in) investing activities - - - (9.9 ) (5,360.7 ) - (5,370.6 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness - - 6,076.2 - 2,000.0 - 8,076.2 Proceeds from borrowings on credit facility and other - 80.0 - - 1,200.0 - 1,280.0 Debt issuance and other financing costs - - (51.9 ) - (172.4 ) - (224.3 ) Payments on debt, including capital lease obligations - (417.8 ) (2,400.0 ) - (3,309.2 ) - (6,127.0 ) Payments of contingent consideration - - - - (14.3 ) - (14.3 ) Dividends to Parent - - - - - - - Contribution from Parent - - - - - - - Net cash provided by / (used in) financing activities - (337.8 ) 3,624.3 - (295.9 ) - 2,990.6 Effect of currency exchange rate changes on cash and cash equivalents - - - - (5.9 ) - (5.9 ) Movement in cash held for sale - - - - 37.0 - 37.0 Net increase / (decrease) in cash and cash equivalents - 5.2 - 0.1 (84.5 ) - (79.2 ) Cash and cash equivalents at beginning of period 0.1 0.3 - 1.4 321.7 - 323.5 Cash and cash equivalents at end of period $ 0.1 $ 5.5 $ - $ 1.5 $ 237.2 $ - $ 244.3 Warner Chilcott Limited Consolidating Statement of Cash Flows For the Year Ended December 31, 2013 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (724.5 ) $ (76.1 ) $ - $ (334.5 ) $ (974.9 ) $ 1,385.5 $ (724.5 ) Reconciliation to net cash provided by operating activities: Losses / (earnings) of equity interest subsidiaries 724.5 162.2 - 498.8 - (1,385.5 ) - Depreciation - - - 1.0 201.0 - 202.0 Amortization - - - - 842.7 - 842.7 Provision for inventory reserve - - - - 113.8 - 113.8 Share-based compensation - - - 48.2 85.4 - 133.6 Deferred income tax benefit - - - - (275.0 ) - (275.0 ) In-process research and development impairments - - - - 4.9 - 4.9 Goodwill Impairment - - - - 647.5 - 647.5 Loss / (gain) on asset sales and impairments, net - - - - 55.9 - 55.9 Amortization of inventory step-up - - - - 267.0 - 267.0 Amortization of deferred financing costs - - - - 10.3 - 10.3 Accretion and contingent consideration - - - - 160.0 - 160.0 Excess tax benefit from stock-based compensation - - - (69.2 ) 0.1 - (69.1 ) Non-cash impact of debt extinguishment - - - - - - - Impact of assets held for sale - - - - 42.7 - 42.7 Other, net - - - - (9.0 ) - (9.0 ) Changes in assets and liabilities (net of effects of acquisitions) 0.1 (86.1 ) - 503.8 (613.4 ) - (195.6 ) Net cash provided by operating activities 0.1 - - 648.1 559.0 - 1,207.2 Cash Flows From Investing Activities: Additions to property plant and equipment - - - (17.6 ) (160.3 ) - (177.9 ) Additions to product rights and other intangibles - - - - (130.0 ) - (130.0 ) Additions to investments - - - - - - - Proceeds from sale of investments and other assets - - - - 40.6 - 40.6 Proceeds from sales of property, plant and equipment - - - - 7.1 - 7.1 Acquisitions of business, net of cash acquired - - - - (15.1 ) - (15.1 ) Net cash (used in) investing activities - - - (17.6 ) (257.7 ) - (275.3 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness - - - - 1,882.3 - 1,882.3 Proceeds from borrowings on credit facility and other - 430.0 - 125.0 - - 555.0 Debt issuance and other financing costs - (2.2 ) - (0.5 ) (4.7 ) - (7.4 ) Payments on debt, including capital lease obligations - (427.5 ) - (702.5 ) (2,099.5 ) - (3,229.5 ) Proceeds from stock plans - - - 44.0 - - 44.0 Payments of contingent consideration - - - - (4.3 ) - (4.3 ) Repurchase of ordinary shares - - - (165.4 ) - - (165.4 ) Acquisition of noncontrolling interest - - - - (10.4 ) - (10.4 ) Excess tax benefit from stock-based compensation - - - 69.2 - - 69.2 Net cash provided by / (used in) financing activities - 0.3 - (630.2 ) (236.6 ) - (866.5 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - (23.9 ) - (23.9 ) Movement in cash held for sale - - - - (37.0 ) - (37.0 ) Net increase / (decrease) in cash and cash equivalents 0.1 0.3 - 0.3 3.8 - 4.5 Cash and cash equivalents at beginning of period - - - 1.1 317.9 - 319.0 Cash and cash equivalents at end of period $ 0.1 $ 0.3 $ - $ 1.4 $ 321.7 $ - $ 323.5

Compensation

Compensation	12 Months Ended
	Dec. 31, 2015
Compensation Related Costs [Abstract]
Compensation	NOTE 27 — Compensation The following table represents compensation costs for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Year Ended December 31, 2015 2014 2013 Wages and salaries $ 2,252.3 $ 1,557.9 $ 887.2 Stock-based compensation 925.7 401.2 133.6 Pensions 99.9 89.0 53.9 Social welfare 185.1 97.1 62.4 Other benefits 271.6 231.8 287.7 Total $ 3,734.6 $ 2,377.0 $ 1,424.8 Amount included in continuing operations $ 2,681.0 $ 1,332.9 $ 558.2 Amount included in discontinued operations $ 1,053.6 $ 1,044.1 $ 866.6

Concentration

Concentration	12 Months Ended
	Dec. 31, 2015
Risks And Uncertainties [Abstract]
Concentration	NOTE 28 — Concentration The Company considers there to be a concentration risk for customers that account for 10% of more of their third party revenues. The following table illustrates any customer, on a global basis, which accounted for 10% or more of our annual revenues in any of the past three fiscal years and the respective percentage of our revenues for which they account for each of the last three years: Customer 2015 2014 2013 McKesson Corporation 24 % 22 % 11 % Cardinal Health, Inc. 18 % 16 % 10 % AmerisourceBergen Corporation 17 % 17 % 6 % Changes in the mix of concentration amongst the Company’s largest customers are due, in part, to the impact of acquisitions as well as changes in the supply chain of our indirect customers. The Company’s accounts receivable primarily arise from product sales in North America and Europe and primarily represent amounts due from wholesalers, distributors, drug store chains and service providers in the health care and pharmaceutical industries, public hospitals and other government entities. Approximately 65% and 70% of the gross accounts receivable balance are concentrated among the Company’s three largest customers as of December 31, 2015 and 2014, respectively. The Company performs ongoing credit evaluations of its customers and maintains an allowance for potential uncollectible accounts. Actual losses from uncollectible accounts have been minimal. Outside of the U.S., concentrations of credit risk with respect to accounts receivable are limited due to the wide variety of customers and markets using the Company’s products, as well as their dispersion across many different geographic areas. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The Company does not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on its financial position, liquidity or results of operations. Certain of the Company’s finished products and raw materials are obtained from single source suppliers. Although the Company seeks to identify more than one source for its various finished products and raw materials, loss of a single source supplier could have an adverse effect on the Company’s results of operations, financial condition and cash flows. Further, a second source supplier may not be able to produce the same volumes of inventory as the Company’s primary supplier. No third party manufacturer accounted for 10% or more of the Company’s products sold based on third-party revenues for the year ended December 31, 2015.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 29 — Subsequent Events On January 7, 2016, the Company

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation And Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	Schedule II Allergan plc Valuation and Qualifying Accounts Years Ended December 31, 2015, 2014 and 2013 ($ in millions) Balance at Beginning of Period Charged to Costs and Expenses Deductions/ Write-offs Other* Balance at End of Period Allowance for doubtful accounts: Year ended December 31, 2015 $ 4.8 $ 8.4 $ (7.3 ) $ 74.7 $ 80.6 Year ended December 31, 2014 $ 2.7 $ 3.9 $ (4.2 ) $ 2.4 $ 4.8 Year ended December 31, 2013 $ 5.2 $ 1.6 $ (4.9 ) $ 0.8 $ 2.7 Tax valuation allowance: Year ended December 31, 2015 $ 474.0 $ (335.6 ) $ - $ 57.8 $ 196.2 Year ended December 31, 2014 $ 319.1 $ 112.7 $ - $ 42.2 $ 474.0 Year ended December 31, 2013 $ 7.2 $ 310.6 $ - $ 1.3 $ 319.1 * Includes opening balances of businesses acquired in the period.

Supplementary Data

Supplementary Data	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Supplementary Data	SUPPLEMENTARY DATA (UNAUDITED) Selected unaudited quarterly consolidated financial data and market price information are shown below ($ in millions except per share data): For Three Month Periods Ended Year Ended 12/31/2015 Dec. 31, 2015 Sept. 30, 2015 June 30, 2015 Mar. 31, 2015 Net revenues $ 15,071.0 $ 4,197.5 $ 4,088.9 $ 4,222.0 $ 2,562.6 Net income/(loss) $ 3,919.4 $ (629.3 ) $ 5,302.6 $ (241.6 ) $ (512.3 ) Basic earnings per share 10.01 (1.78 ) 13.29 (0.80 ) (1.85 ) Diluted earnings per share 10.01 (1.78 ) 13.29 (0.80 ) (1.85 ) Market price per share: High $ 322.68 $ 340.34 $ 315.00 $ 317.72 Low $ 237.50 $ 245.32 $ 279.74 $ 253.00 For Three Month Periods Ended Year Ended 12/31/2014 Dec. 31, 2014 Sept. 30, 2014 June 30, 2014 Mar. 31, 2014 Net revenues $ 6,738.9 $ 2,415.6 $ 2,150.8 $ 1,087.2 $ 1,085.3 Net income/(loss) $ (1,630.5 ) $ (733.2 ) $ (1,042.8 ) $ 48.8 $ 96.7 Basic earnings per share (7.42 ) (3.34 ) (3.95 ) 0.28 0.56 Diluted earnings per share (7.42 ) (3.34 ) (3.95 ) 0.28 0.55 Market price per share: High $ 272.75 $ 249.94 $ 226.23 $ 230.77 Low $ 208.64 $ 201.91 $ 184.71 $ 166.38 In the quarter ended September 30, 2015, the company recorded a deferred tax benefit of $5,985.4 million related to the outside basis difference since the benefit is expected to be realized in the foreseeable future. The recognition of this benefit was reflected in income from discontinued operations, net of tax with the deferred tax asset reflected in our consolidated balance sheet. The Company notes that the tax benefit recognized was overstated by $145.0 million. As a result, the Company is revising its net income for the quarter ended September 30, 2015 as previously reported of $5,231.6 million to $5,086.6 million. Management believes this error is not material to the quarter ended September 30, 2015. F-1

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented. The Company’s consolidated financial statements include the financial results of all acquired companies subsequent to the acquisition date.
Reclassifications	Reclassifications The Company has made certain reclassifications to prior period information to conform to the current period presentation, including the impact of the Teva Transaction.
Use of Estimates	Use of Estimates Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The Company’s most significant estimates relate to the determination of SRA’s (defined below) included within either accounts receivable or accrued liabilities, the valuation of inventory balances, the determination of useful lives for intangible assets, pension and other post-retirement benefit plan assumptions, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment and recognition and measurement of assets acquired and liabilities assumed in business combinations at fair value. The estimation process required to prepare the Company’s consolidated financial statements requires assumptions to be made about future events and conditions, and as such, is inherently subjective and uncertain. The Company’s actual results could differ materially from those estimates.
Foreign Currency Translation	Foreign Currency Translation For most of the Company’s international operations, the local currency has been determined to be the functional currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transaction. Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive (loss) / income. The effects of revaluing non-functional currency assets and liabilities into the functional currency are recorded as general and administrative expenses in the consolidated statements of operations. The Company realizes foreign currency gains / (losses) in the normal course of business based on movement in the applicable exchange rates. These gains / (losses) are included as a component of general and administrative expenses.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash and cash equivalents to include cash in banks, commercial paper and deposits with financial institutions that can be liquidated without prior notice or penalty. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Fair Value of Other Financial Instruments	Fair Value of Other Financial Instruments The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, investments, trade accounts payable, and long-term debt, including the current portion. The carrying amounts of cash and cash equivalents, marketable securities, accounts and other receivables and trade accounts payable are representative of their respective fair values due to their relatively short maturities. The fair values of investments in companies that are publicly traded and not accounted for under the equity method are based on quoted market prices. The Company estimates the fair value of its fixed rate long-term obligations based on quoted market rates. The carrying amount reported for long-term debt, other than the Company’s indebtedness under senior notes, is considered to be representative of fair value as they are at variable rates and reprice frequently.
Inventories	Inventories Inventories consist of finished goods held for distribution, raw materials and work in process. Inventory includes brand pharmaceutical and medical aesthetic products which represent Food and Drug Administration (“FDA”) approved indications. Inventory valuation reserves are established based on a number of factors/situations including, but not limited to, raw materials, work in process or finished goods not meeting product specifications, product obsolescence, or application of the lower of cost (first-in, first-out method) or market (net realizable value) concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. Assumptions utilized in our quantification of inventory reserves include, but are not limited to, estimates of future product demand, consideration of current and future market conditions, product net selling price, anticipated product launch dates, potential product obsolescence and other events relating to special circumstances surrounding certain products. No material adjustments have been required to our inventory reserve estimates for the periods presented. Adverse changes in assumptions utilized in our inventory reserve calculations could result in an increase to our inventory valuation reserves and higher cost of sales.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Major renewals and improvements are capitalized, while routine maintenance and repairs are expensed as incurred. The Company capitalizes interest on qualified construction projects. At the time property, plant and equipment are retired from service, the cost and accumulated depreciation is removed from the respective accounts. Depreciation expense is computed principally on the straight-line method, over the estimated useful lives of the related assets. The following table provides the range of estimated useful lives used for each asset type: Computer software/hardware (including internally developed) 3-10 years Machinery and equipment 3-15 years Research and laboratory equipment 3-10 years Furniture and fixtures 3-10 years Buildings, improvements, leasehold improvements and other 4-50 years Transportation equipment 3-20 years The Company assesses property, plant and equipment for impairment whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable.
Investments	Investments The Company’s equity investments are accounted for under the equity method of accounting when the Company can exert significant influence and the Company’s ownership interest does not exceed 50%. The Company records equity method investments at cost and adjusts for the appropriate share of investee net earnings or losses. Investments in which the Company owns less than a 20% interest and cannot exert significant influence are accounted for using the cost method if the fair value of such investments is not readily determinable.
Marketable Securities	Marketable Securities The Company’s marketable securities consist of U.S. treasury and agency securities and equity securities of publicly-held companies. The Company’s marketable securities are classified as available-for-sale and are recorded at fair value, based upon quoted market prices. Unrealized temporary adjustments to fair value are included on the balance sheet in a separate component of stockholders’ equity as unrealized gains and losses and are reported as a component of accumulated other comprehensive income / (loss). No gains or losses on marketable securities are realized until shares are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Product Rights and Other Definite-Lived Intangible Assets	Product Rights and Other Definite-Lived Intangible Assets Our product rights and other definite-lived intangible assets are stated at cost, less accumulated amortization, and are amortized using the economic benefit model or the straight-line method, if results are materially aligned, over their estimated useful lives. We determine amortization periods for product rights and other definite-lived intangible assets based on our assessment of various factors impacting estimated useful lives and cash flows. Such factors include the product’s position in its life cycle, the existence or absence of like products in the market, various other competitive and regulatory issues, and contractual terms. Significant changes to any of these factors may result in a reduction in the intangibles useful life and an acceleration of related amortization expense, which could cause our net results to decline. Product rights and other definite-lived intangible assets are tested periodically for impairment when events or changes in circumstances indicate that an asset’s carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in net (loss) / income in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Our projections of discounted cash flows use a discount rate determined by our management to be commensurate with the risk inherent in our business model. Our estimates of future cash flows attributable to our other definite-lived intangible assets require significant judgment based on our historical and anticipated results and are subject to many factors. Different assumptions and judgments could materially affect the calculation of the fair value of the other definite-lived intangible assets which could trigger impairment.
Goodwill and Intangible Assets with Indefinite Lives	Goodwill and Intangible Assets with Indefinite Lives The Company tests goodwill and intangible assets with indefinite-lives for impairment annually in the second quarter by comparing the fair value of each of the Company’s reporting units to the respective carrying value of the reporting units. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount or when the Company has a change to reporting units. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Impairment, if any, would be recorded in operating income and this could result in a material impact to net (loss) / income and (loss) / earnings per share. Acquired IPR&D intangible assets represent the value assigned to acquired research and development projects that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that the Company has acquired with respect to products and/or processes that have not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, R&D costs, selling and marketing costs and other costs which may be allocated), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, and competitive trends impacting the asset and each cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of the IPR&D projects include legal risk, market risk and regulatory risk. Changes in these assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project to commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results. Upon successful completion of each project and approval of the product, we will make a separate determination of the useful life of the intangible, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life.
Warranties	Warranties As a result of the Allergan Acquisition, the Company provides warranty programs for breast implant sales primarily in the United States, Europe and certain other countries. Management estimates the amount of potential future claims from these warranty programs based on actuarial analyses. Expected future obligations are determined based on the history of product shipments and claims and are discounted to a current value. The provision for warranty expense in the year ended December 31, 2015 was $4.5 million. The liability is included in both current and long-term liabilities in the Company’s consolidated balance sheets and amounted to $7.6 million and $28.4 million, respectively, as of December 31, 2015. The U.S. programs include the ConfidencePlus ® ConfidencePlus ® ConfidencePlus ® ConfidencePlus ®
Contingent Consideration	Contingent Consideration Contingent consideration is recorded at the acquisition date estimated fair value of the contingent payment for all applicable acquisitions. The fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statement of operations. (Refer to “NOTE 24 — Fair Value Measurement” for additional details regarding the fair value of contingent consideration.)
Revenue Recognition	Revenue Recognition General Revenue from product sales is recognized when title and risk of loss to the product transfers to the customer, which is based on the transaction shipping terms. Recognition of revenue also requires reasonable assurance of collection of sales proceeds, the seller’s price to the buyer to be fixed or determinable and the completion of all performance obligations. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, billback adjustments, sales returns and allowances, commercial and government rebates, customer loyalty programs and fee-for-service arrangements with certain distributors, which we refer to in the aggregate as “SRA” allowances. Royalty and commission revenue is recognized as a component of net revenues in accordance with the terms of their respective contractual agreements when collectability is reasonably assured and when revenue can be reasonably measured.
Provisions for SRAs	Provisions for SRAs As is customary in the pharmaceutical industry, our gross product sales are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes gross revenue from the sale of products, an estimate of SRA is recorded, which reduces the product revenues. Accounts receivable and/or accrued liabilities are also reduced and/or increased by the SRA amount depending on whether we have the right of offset with the customer. These provisions are estimated based on historical payment experience, historical relationship of the deductions to gross product revenues, government regulations, estimated utilization or redemption rates, estimated customer inventory levels and current contract sales terms. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material revenue adjustments have been necessary in prior periods to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company uses a variety of methods to assess the adequacy of the SRA reserves to ensure that our financial statements are fairly stated. Chargebacks — A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at certain contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the vast majority of the recipients of the Company’s chargeback payments. We continually monitor current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Rebates — Rebates include volume related incentives to direct and indirect customers, third-party managed care and Medicare Part D rebates, Medicaid rebates and other government rebates. Rebates are accrued based on an estimate of claims to be paid for product sold into trade by the Company. Volume rebates are generally offered to customers as an incentive to use the Company’s products and to encourage greater product sales. These rebate programs include contracted rebates based on customers’ purchases made during an applicable monthly, quarterly or annual period. The provision for third-party rebates is estimated based on our customers’ contracted rebate programs and the Company’s historical experience of rebates paid. Any significant changes to our customer rebate programs are considered in establishing the provision for rebates. The provisions for government rebates are based, in part, upon historical experience of claims submitted by the various states / authorities, contractual terms and government regulations. We monitor legislative changes to determine what impact such legislation may have on our provision. Cash Discounts — Cash discounts are provided to customers that pay within a specific period. The provision for cash discounts is estimated based upon invoice billings and historical customer payment experience. The Company’s experience of payment history is fairly consistent and most customer payments qualify for the cash discount. Returns and Other Allowances — The Company’s provision for returns and other allowances include returns, pricing adjustments, promotional allowances, loyalty cards and billback adjustments. Consistent with industry practice, the Company maintains a returns policy that allows customers to return product for a credit. In accordance with the Company’s policy, credits for customer returns of products are applied against outstanding account activity or are settled in cash. Product exchanges are not permitted. Customer returned products are generally not resalable. The Company’s estimate of the provision for returns is based upon historical experience and current trends of actual customer returns. Additionally, we consider other factors when estimating the current period returns provision, including levels of inventory in the distribution channel, as well as significant market changes that may impact future expected returns. Pricing adjustments, which includes shelf stock adjustments, (and which primarily relate to our held for sale generics business) are credits issued to reflect price decreases in selling prices charged to the Company’s direct customers. Shelf stock adjustments are based upon the amount of product our customers have in their inventory at the time of an agreed-upon price reduction. The provision for shelf stock adjustments is based upon specific terms with the Company’s customers and includes estimates of existing customer inventory levels based upon their historical purchasing patterns. We regularly monitor all price changes to evaluate the Company’s reserve balances. The adequacy of these reserves is readily determinable as pricing adjustments and shelf stock adjustments are negotiated and settled on a customer-by-customer basis. Promotional allowances are credits that are issued in connection with a product launch or as an incentive for customers to carry our product. The Company establishes a reserve for promotional allowances based upon contractual terms. Billback adjustments (and which primarily relate to our held for sale generics business), are credits that are issued to certain customers who purchase directly from us as well as indirectly through a wholesaler. These credits are issued in the event there is a difference between the customer’s direct and indirect contract price. The provision for billbacks is estimated based upon historical purchasing patterns of qualified customers who purchase product directly from us and supplement their purchases indirectly through our wholesale customers. Loyalty cards allow the end user patients a discount per prescription and are accrued based on historical experience, contract terms and the volume of product and cards in the distribution channel. The following table summarizes the activity from continuing operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Return and Other Allowances Cash Discounts Total Balance at December 31, 2012 $ 81.2 $ 30.8 $ 178.9 $ 9.3 $ 300.2 Add: Warner Chilcott Acquisition 5.6 255.5 121.3 5.5 387.9 Provision related to sales in 2013 214.5 330.2 86.5 42.9 674.1 Credits and payments (279.5 ) (326.6 ) (183.6 ) (48.5 ) (838.2 ) Balance at December 31, 2013 $ 21.8 $ 289.9 $ 203.1 $ 9.2 $ 524.0 Add: Forest Acquisition 27.9 425.0 94.3 9.8 557.0 Provision related to sales in 2014 442.9 1,562.8 154.4 155.7 2,315.8 Credits and payments (464.6 ) (1,268.9 ) (191.0 ) (155.0 ) (2,079.5 ) Balance at December 31, 2014 $ 28.0 $ 1,008.8 $ 260.8 $ 19.7 $ 1,317.3 Add: Allergan Acquisition 14.1 306.4 100.4 8.6 429.5 Provision related to sales in 2015 649.9 4,082.9 732.2 301.9 5,766.9 Credits and payments (613.8 ) (4,044.1 ) (720.3 ) (301.7 ) (5,679.9 ) Balance at December 31, 2015 $ 78.2 $ 1,354.0 $ 373.1 $ 28.5 $ 1,833.8 The following table summarizes the activity from discontinued operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Return and Other Allowances Cash Discounts Total Balance at December 31, 2012 $ 130.3 $ 820.0 $ 170.6 $ 27.6 $ 1,148.5 Provision related to sales in 2013 2,125.5 2,008.9 817.6 158.8 5,110.8 Credits and payments (2,031.2 ) (2,057.0 ) (573.4 ) (147.9 ) (4,809.5 ) Balance at December 31, 2013 $ 224.6 $ 771.9 $ 414.8 $ 38.5 $ 1,449.8 Provision related to sales in 2014 4,148.8 1,761.1 705.0 195.0 6,809.9 Credits and payments (3,836.5 ) (1,795.2 ) (768.5 ) (192.5 ) (6,592.7 ) Balance at December 31, 2014 $ 536.9 $ 737.8 $ 351.3 $ 41.0 $ 1,667.0 Provision related to sales in 2015 5,907.2 1,944.7 657.0 251.0 8,759.9 Credits and payments (5,825.1 ) (1,961.1 ) (685.2 ) (235.4 ) (8,706.8 ) Balance at December 31, 2015 $ 619.0 $ 721.4 $ 323.1 $ 56.6 $ 1,720.1 The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): As of December 31, 2015 2014 Accounts receivable $ 263.8 $ 162.4 Accounts payable and accrued expenses 1,570.0 1,154.9 $ 1,833.8 $ 1,317.3 The following table summarizes the balance sheet classification of our SRA reserves relating to the generics business being divested to Teva ($ in millions): As of December 31, 2015 2014 Current assets held for sale $ 1,306.6 $ 1,269.6 Current liabilities held for sale 413.5 397.4 $ 1,720.1 $ 1,667.0 During the year ended December 31, 2015, the Company lowered SRA balances relating to the valuation of assets and liabilities acquired as part of the Forest Acquisition measurement period adjustments by $53.2 million, with an offset to goodwill ($33.2 million) and deferred tax liabilities ($20.0 million). The provisions recorded to reduce gross product sales to net product sales were as follows ($ in millions): Years Ended December 31, Gross Product Sales Chargebacks Rebates Return and Other Allowances Cash Discounts Net Product Sales Gross-to-net Percentages 2013 $ 3,212.2 $ 214.5 $ 330.2 $ 86.5 $ 42.9 $ 2,538.1 79.0 % 2014 $ 8,987.3 $ 442.9 $ 1,562.8 $ 154.4 $ 155.7 $ 6,671.5 74.2 % 2015 $ 20,653.9 $ 649.9 $ 4,082.9 $ 732.2 $ 301.9 $ 14,887.0 72.1 % The movement in the percentage of provisions to gross sales is a result of changes in product mix, competition and channels of distribution. In the year ended December 31, 2015, the Company’s increased sales of acquired eye care products and acquired Forest products lowered the provision percentage. The Company does not expect future payments of SRA reserves to materially exceed our current estimates. However, if future SRA payments were to materially exceed our estimates, such adjustments may have a material adverse impact on our financial position, results of operations and cash flows.
Branded Prescription Drug Fee	Branded Prescription Drug Fee On July 28, 2014, the Internal Revenue Service (“IRS”) issued revised final rules and regulations for the Branded Prescription Drug Fee, an annual fee payable to the federal government based on an allocation of the Company’s market share for branded prescription and authorized generic drugs sold to certain government programs compared to that of the industry. The final rules accelerated the expense recognition criteria for the fee obligation from the year in which the fee is paid, to the year in which the market share used to allocate the fee is determined. This change required Allergan (and other industry participants) to recognize an additional year of expense in the third quarter of 2014 of $105.1 million, which is reflected in our 2014 selling and marketing expense.
Litigation and Contingencies	Litigation and Contingencies The Company is involved in various legal proceedings in the normal course of its business, including product liability litigation, intellectual property litigation, employment litigation and other litigation. Additionally, the Company, in consultation with its counsel, assesses the need to record a liability for contingencies on a case-by-case basis in accordance with ASC Topic 450 “Contingencies” (“ASC 450”). Accruals are recorded when the Company determines that a loss related to a matter is both probable and reasonably estimable. These accruals are adjusted periodically as assessment efforts progress or as additional information becomes available. Acquired contingencies in business combinations are recorded at fair value to the extent determinable, otherwise in accordance ASC
R&D Activities	R&D Activities R&D activities are expensed as incurred and consist of self-funded R&D costs, the costs associated with work performed under collaborative R&D agreements, regulatory fees, and license and milestone payments, if any. As of December 31, 2015, the Company is developing a number of branded products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs including the following: Product Therapeutic Area Indication Expected Launch Year Phase Restasis MDPF Eye Care Dry Eye 2016 Registration XEN45 Eye Care Glaucoma 2017 III Sarecycline Dermatology Severe Acne 2018 III Esmya Woman's healthcare Uterine Fibroids 2018 III Bimatoprost SR Eye Care Glaucoma 2018 III Tavilermide Eye Care Dry Eye 2019 III Relamorelin** Gastrointestinal Gastroparesis 2020 II Ubrogepant Neurology Acute Migraine 2020 II Abicipar Eye Care Age Related Macular Degeneration 2020 III Rapastinel Psychiatry Depression 2021 II ** As part of our agreement with Rhythm Health, Inc. We also have a number of products in development as part of our life-cycle management strategy for our existing product portfolio.
Allocation of Acquisition Fair Values to Assets Acquired and Liabilities Assumed	Allocation of Acquisition Fair Values to Assets Acquired and Liabilities Assumed We account for acquired businesses using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at the date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values as determined using a market participant concept. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. The most material line items impacted by the allocation of acquisition fair values are: · Intangible assets (including IPR&D assets upon successful completion of the project and approval of the product) which are amortized to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected future net cash flow streams, the timing of approvals for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the future useful lives. For these and other reasons, actual results may vary significantly from estimated results. · Fixed asset valuations which are depreciated over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates and intended uses of the assets. · Inventory is recorded at fair market value factoring in selling price and costs to dispose. Inventory acquired is typically valued higher than replacement cost.
Income Taxes	Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets by assessing its valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in applicable tax jurisdictions could affect the ultimate realization of deferred tax assets and could result in an increase in the Company’s effective tax rate on future earnings. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. Income tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold are derecognized in the first financial reporting period in which that threshold is no longer met. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within the consolidated statements of operations as income tax expense.
Comprehensive Income / (Loss)	Comprehensive Income / (Loss) Comprehensive income / (loss) includes all changes in equity during a period except those that resulted from investments by or distributions to the Company’s stockholders. Other comprehensive income / (loss) refers to revenues, expenses, gains and losses that are included in comprehensive income / (loss), but excluded from net income / (loss) as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company’s other comprehensive income / (loss) is comprised of unrealized gains / (losses) on certain holdings of publicly traded equity securities, investments in U.S. treasury and agency securities and actuarial gains/(losses), net of realized gains / (losses) included in net income / (loss), net of tax and foreign currency translation adjustments.
Earnings Per Share ("EPS")	Earnings Per Share (“EPS”) The Company accounts for EPS in accordance with ASC Topic 260, “Earnings Per Share” (“ASC 260”) and related guidance, which requires two calculations of EPS to be disclosed: basic and diluted. Basic EPS is computed by dividing net (loss) / income by the weighted average ordinary shares outstanding during a period. Diluted EPS is based on the treasury stock method and includes the effect from potential issuance of Ordinary Shares, such as shares issuable pursuant to the exercise of stock options and restricted stock units. Ordinary share equivalents have been excluded where their inclusion would be anti-dilutive. The calculation for diluted EPS for discontinued operations is computed using the basis of continuing operations. A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following ($ in millions, except per share amounts): Years Ended December 31, 2015 2014 2013 Net income: Net income/(loss) attributable to ordinary shareholders excluding income/(loss) from discontinued operations, net of tax $ (3,104.5 ) $ (2,407.1 ) $ (467.5 ) Income / (loss) from discontinued operations, net of tax 6,787.7 776.6 (282.9 ) Net income/(loss) attributable to ordinary shareholders $ 3,683.2 $ (1,630.5 ) $ (750.4 ) Basic weighted average ordinary shares outstanding 367.8 219.7 142.3 Basic EPS: Continuing operations $ (8.44 ) $ (10.96 ) $ (3.29 ) Discontinued operations $ 18.45 $ 3.54 $ (1.98 ) Net income / (loss) per share $ 10.01 $ (7.42 ) $ (5.27 ) Diluted weighted average ordinary shares outstanding 367.8 219.7 142.3 Diluted EPS: Continuing operations $ (8.44 ) $ (10.96 ) $ (3.29 ) Discontinued operations $ 18.45 $ 3.54 $ (1.98 ) Net income / (loss) per share $ 10.01 $ (7.42 ) $ (5.27 ) Stock awards to purchase 5.2 million ordinary shares for the year ended December 31, 2015 were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive for continuing operations and as such the treatment for discontinued operations is also anti-dilutive. The weighted average impact of ordinary share equivalents of 13.6 million for the year ended December 31, 2015, which are anticipated to result from the mandatory conversion of the Company’s preferred shares were not included in the calculation of diluted EPS as their impact would be anti-dilutive. Stock awards to purchase/acquire 3.0 million and 2.1 million ordinary shares for the year ended December 31, 2014 and 2013, respectively, were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive for continuing operations and as such the treatment for discontinued operations is also anti-dilutive.
Employee Benefits	Employee Benefits Defined Contribution Plans The Company has defined contribution plans that are post-employment benefit plans under which the Company pays fixed contributions to a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to the defined contribution plans are recognized as an employee benefit expense in the consolidated statement of operations in the periods during which the related services were rendered. Defined Benefit Plans The Company recognizes the overfunded or underfunded status of each of its defined benefit plans as an asset or liability on its consolidated balance sheets. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. The estimates of the obligation and related expense of these plans recorded in the financial statements are based on certain assumptions. The most significant assumptions relate to discount rate and expected return on plan assets. Other assumptions used may include employee demographic factors such as compensation rate increases, retirement patterns, expected employee turnover and participant mortality rates. The difference between these assumptions and actual experience results in the recognition of an asset or liability based upon a net actuarial (gain) / loss. If the total net actuarial (gain) / loss included in accumulated other comprehensive (loss) / income exceeds a threshold of 10% of the greater of the projected benefit obligation or the market related value of plan assets, it is subject to amortization and recorded as a component of net periodic pension cost over the average remaining service lives of the employees participating in the pension plan. Net periodic benefit costs are recognized in the consolidated statement of operations.
Share-based Compensation	Share-based Compensation The Company has adopted several equity award plans which authorize the granting of options, restricted shares, restricted stock units and other forms of equity awards of the Company’s ordinary shares, subject to certain conditions. The Company grants awards with the following features: · Time-based vesting restricted stock awards; · Performance-based restricted stock awards measured to the EBITDA, as defined, of the Company or other performance-based targets defined by the Company; · Performance-based restricted stock awards measured to the Total Stockholders Return, compared to pre-defined metrics; · Non-qualified options to purchase outstanding shares; and · Cash-settled awards recorded as a liability. These cash settled awards are based on pre-established earnings per share, total shareholder returns and cost savings targets and the fair value is marked-to-market each reporting period. The Company recognizes share-based compensation expense for the granted awards over the applicable vesting period, net of estimated forfeitures. Estimates of anticipated vesting of awards are revised in future periods based on actual forfeiture rates and targets achieved. Such revisions may have a material impact on the results of operations.
Restructuring Costs	Restructuring Costs The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee severance costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also incurs costs with contract terminations and costs of transferring products as part of restructuring activities. Refer to “NOTE 22 — Business Restructuring Charges” for more information.
Recent Accounting Pronouncements	Recent Accounting Pronouncements On May 28, 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), with an effective date for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, for public business entities, certain not-for-profit entities, and certain employee benefit plans. The effective date for ASU 2014-09 was deferred by one year through the issuance of ASU 2015-14, Revenue from Contracts with Customers – Deferral of the Effective Date, to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company is evaluating the impact, if any, the pronouncement will have on both historical and future financial positions and results of operations. In January 2015, the FASB issued ASU No. 2015-01 “Income Statement – Extraordinary and Unusual Items (Subtopic 225-20). ” In April 2015, the FASB issued guidance which changes the classification of debt issuance costs from being an asset on the balance sheet to netting the costs against the carrying value of the debt. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The impact of the adoption of this guidance will decrease “prepaid expenses and other current assets” and “current portion of long-term debt and capital leases” by $36.3 million as well as “investments and other assets” and “long-term debt and capital leases” by $159.5 million. In May 2015, the FASB issued ASU No. 2015-07, “Fair Value Measurement: Topic 820 Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or its Equivalent).” The amendments remove the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The amendments also remove the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The amendments are effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The adoption of this guidance is not anticipated to have a material impact on the Company’s financial position or results of operations. In July 2015, the FASB issued ASU No. 2015-12 “Plan Accounting: Defined Benefit Pension Plans (Topic 960), Defined Contribution Pensions Plans (Topic 962) and Health and Welfare Benefit Plans (Topic 965).” GAAP requires plans to disclose (i) individual investments that represent five percent or more of net assets available for benefits and (ii) the net appreciation or depreciation for investments by general type. Stakeholders said that while less costly to prepare, those disclosures do not provide decision-useful information. The amendments in this update will eliminate those requirements for both participant-directed investments and nonparticipant-directed investments. Plan investments need to be disaggregated only by general type within the statement of net assets available for benefits or within the footnotes and no longer required to provide the disclosures by investment class. The net appreciation or depreciation in investments for the period still will be required to be presented in the aggregate, but will no longer be required to be disaggregated and disclosed by general type. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The adoption of this guidance is not anticipated to have a material impact on the Company’s financial position or results of operations. On September 25, 2015, the FASB issued Accounting Standards Update 2015-16 (ASU 2015-16), which changes the requirement to restate prior period financial statements for measurement period adjustments. The new guidance requires that measurement period adjustments be recognized in the reporting period in which the adjustment amount is determined. This includes the cumulative impact of measurement period adjustments on current and prior periods. The cumulative adjustment would be reflected within the respective financial statement line items affected. The adoption of this guidance is not anticipated to have a material impact on the Company’s financial position or results of operations. In November 2015, the FASB ASU No. 2015-17 “Income Taxes (Topic 704): Balance Sheet Classification of Deferred Taxes.” The amendments require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this update. The Company has elected to adopt this guidance in the year ended December 31, 2015 and prior balance sheets were not retrospectively adjusted. The total current deferred tax assets of $500.3 million included in current deferred tax assets and assets held for sale and current deferred tax liabilities of $47.3 million included in deferred tax liabilities and current liabilities held for sale were not reclassified in 2014.

Reconciliation of Warner Chil40

Reconciliation of Warner Chilcott Limited Results to Allergan plc Results (Tables)	12 Months Ended
	Dec. 31, 2015
Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]
Summary of Assets Reconciliation Results of Warner Chilcott Limited to Allergan Plc	December 31, 2015 December 31, 2014 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Cash and cash equivalents $ 1,096.0 $ 1,036.2 $ 59.8 $ 250.0 $ 244.3 $ 5.7 Accounts receivable, net 2,401.6 2,401.6 - 1,112.3 1,111.6 0.7 Prepaid expenses and other current assets 558.5 556.0 2.5 478.8 475.9 2.9 Property, plant and equipment, net 1,573.9 1,573.9 - 283.4 282.5 0.9 Accounts payable and accrued liabilities 4,349.5 4,295.4 54.1 3,030.1 3,027.0 3.1
Summary of Operating Profit Loss Reconciliation Results of Warner Chilcott Limited to Allergan Plc	Year Ended December 31, 2015 Year Ended December 31, 2014 Year Ended December 31, 2013 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 1,765.6 $ 1,630.2 $ 135.4 $ 1,247.0 $ 1,177.0 $ 70.0 $ 456.1 $ 431.7 $ 24.4 Operating (loss) (3,014.5 ) (2,879.1 ) (135.4 ) (2,443.9 ) (2,373.9 ) (70.0 ) (369.2 ) (344.8 ) (24.4 ) (Loss) before income taxes and noncontrolling interest (4,430.2 ) (4,294.8 ) (135.4 ) (2,874.1 ) (2,804.1 ) (70.0 ) (622.8 ) (598.4 ) (24.4 ) (Benefit) for income taxes (1,561.9 ) (1,561.9 ) - (467.0 ) (467.0 ) - (155.3 ) (156.2 ) 0.9 Net (loss) from continuing operations, net of tax (2,868.3 ) (2,732.9 ) (135.4 ) (2,407.1 ) (2,337.1 ) (70.0 ) (467.5 ) (442.2 ) (25.3 ) Net income / (loss) 3,919.4 4,054.8 (135.4 ) (1,630.5 ) (1,560.5 ) (70.0 ) (750.4 ) (724.5 ) (25.9 ) Net income / (loss) attributable to ordinary shareholders/members 3,683.2 4,050.6 (367.4 ) (1,630.5 ) (1,560.5 ) (70.0 ) (750.4 ) (724.5 ) (25.9 ) Dividends on preferred stock 232.0 - 232.0 - - - - - -

Summary of Significant Accoun41

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Property and Equipment	The following table provides the range of estimated useful lives used for each asset type: Computer software/hardware (including internally developed) 3-10 years Machinery and equipment 3-15 years Research and laboratory equipment 3-10 years Furniture and fixtures 3-10 years Buildings, improvements, leasehold improvements and other 4-50 years Transportation equipment 3-20 years
Schedule of Balance Sheet Classification of SRA Reserves	The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): As of December 31, 2015 2014 Accounts receivable $ 263.8 $ 162.4 Accounts payable and accrued expenses 1,570.0 1,154.9 $ 1,833.8 $ 1,317.3
Summary of Activity in Gross-to-Net Revenue	The provisions recorded to reduce gross product sales to net product sales were as follows ($ in millions): Years Ended December 31, Gross Product Sales Chargebacks Rebates Return and Other Allowances Cash Discounts Net Product Sales Gross-to-net Percentages 2013 $ 3,212.2 $ 214.5 $ 330.2 $ 86.5 $ 42.9 $ 2,538.1 79.0 % 2014 $ 8,987.3 $ 442.9 $ 1,562.8 $ 154.4 $ 155.7 $ 6,671.5 74.2 % 2015 $ 20,653.9 $ 649.9 $ 4,082.9 $ 732.2 $ 301.9 $ 14,887.0 72.1 %
Summary of Branded Products Which Utilize Novel Drug Delivery Systems through Combination of Internal and Collaborative Programs	As of December 31, 2015, the Company is developing a number of branded products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs including the following: Product Therapeutic Area Indication Expected Launch Year Phase Restasis MDPF Eye Care Dry Eye 2016 Registration XEN45 Eye Care Glaucoma 2017 III Sarecycline Dermatology Severe Acne 2018 III Esmya Woman's healthcare Uterine Fibroids 2018 III Bimatoprost SR Eye Care Glaucoma 2018 III Tavilermide Eye Care Dry Eye 2019 III Relamorelin** Gastrointestinal Gastroparesis 2020 II Ubrogepant Neurology Acute Migraine 2020 II Abicipar Eye Care Age Related Macular Degeneration 2020 III Rapastinel Psychiatry Depression 2021 II ** As part of our agreement with Rhythm Health, Inc.
Earnings Per Share	A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following ($ in millions, except per share amounts): Years Ended December 31, 2015 2014 2013 Net income: Net income/(loss) attributable to ordinary shareholders excluding income/(loss) from discontinued operations, net of tax $ (3,104.5 ) $ (2,407.1 ) $ (467.5 ) Income / (loss) from discontinued operations, net of tax 6,787.7 776.6 (282.9 ) Net income/(loss) attributable to ordinary shareholders $ 3,683.2 $ (1,630.5 ) $ (750.4 ) Basic weighted average ordinary shares outstanding 367.8 219.7 142.3 Basic EPS: Continuing operations $ (8.44 ) $ (10.96 ) $ (3.29 ) Discontinued operations $ 18.45 $ 3.54 $ (1.98 ) Net income / (loss) per share $ 10.01 $ (7.42 ) $ (5.27 ) Diluted weighted average ordinary shares outstanding 367.8 219.7 142.3 Diluted EPS: Continuing operations $ (8.44 ) $ (10.96 ) $ (3.29 ) Discontinued operations $ 18.45 $ 3.54 $ (1.98 ) Net income / (loss) per share $ 10.01 $ (7.42 ) $ (5.27 )
Teva Pharmaceutical Industries Ltd [Member]
Schedule of Balance Sheet Classification of SRA Reserves	The following table summarizes the balance sheet classification of our SRA reserves relating to the generics business being divested to Teva ($ in millions): As of December 31, 2015 2014 Current assets held for sale $ 1,306.6 $ 1,269.6 Current liabilities held for sale 413.5 397.4 $ 1,720.1 $ 1,667.0
Continuing Operations [Member]
Provisions for Sales Returns and Allowances from Continuing Operations Activity	The following table summarizes the activity from continuing operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Return and Other Allowances Cash Discounts Total Balance at December 31, 2012 $ 81.2 $ 30.8 $ 178.9 $ 9.3 $ 300.2 Add: Warner Chilcott Acquisition 5.6 255.5 121.3 5.5 387.9 Provision related to sales in 2013 214.5 330.2 86.5 42.9 674.1 Credits and payments (279.5 ) (326.6 ) (183.6 ) (48.5 ) (838.2 ) Balance at December 31, 2013 $ 21.8 $ 289.9 $ 203.1 $ 9.2 $ 524.0 Add: Forest Acquisition 27.9 425.0 94.3 9.8 557.0 Provision related to sales in 2014 442.9 1,562.8 154.4 155.7 2,315.8 Credits and payments (464.6 ) (1,268.9 ) (191.0 ) (155.0 ) (2,079.5 ) Balance at December 31, 2014 $ 28.0 $ 1,008.8 $ 260.8 $ 19.7 $ 1,317.3 Add: Allergan Acquisition 14.1 306.4 100.4 8.6 429.5 Provision related to sales in 2015 649.9 4,082.9 732.2 301.9 5,766.9 Credits and payments (613.8 ) (4,044.1 ) (720.3 ) (301.7 ) (5,679.9 ) Balance at December 31, 2015 $ 78.2 $ 1,354.0 $ 373.1 $ 28.5 $ 1,833.8
Discontinued Operations [Member]
Provisions for Sales Returns and Allowances from Continuing Operations Activity	The following table summarizes the activity from discontinued operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Return and Other Allowances Cash Discounts Total Balance at December 31, 2012 $ 130.3 $ 820.0 $ 170.6 $ 27.6 $ 1,148.5 Provision related to sales in 2013 2,125.5 2,008.9 817.6 158.8 5,110.8 Credits and payments (2,031.2 ) (2,057.0 ) (573.4 ) (147.9 ) (4,809.5 ) Balance at December 31, 2013 $ 224.6 $ 771.9 $ 414.8 $ 38.5 $ 1,449.8 Provision related to sales in 2014 4,148.8 1,761.1 705.0 195.0 6,809.9 Credits and payments (3,836.5 ) (1,795.2 ) (768.5 ) (192.5 ) (6,592.7 ) Balance at December 31, 2014 $ 536.9 $ 737.8 $ 351.3 $ 41.0 $ 1,667.0 Provision related to sales in 2015 5,907.2 1,944.7 657.0 251.0 8,759.9 Credits and payments (5,825.1 ) (1,961.1 ) (685.2 ) (235.4 ) (8,706.8 ) Balance at December 31, 2015 $ 619.0 $ 721.4 $ 323.1 $ 56.6 $ 1,720.1

Business Development (Tables)

Business Development (Tables)	12 Months Ended
	Dec. 31, 2015
Unaudited Pro Forma Results of Businesses Acquired	The unaudited pro forma results of the businesses acquired that materially impacted the reported results of the Company are as follows ($ in millions except per share information): Year Ended December 31, 2015 (unaudited) As reported Allergan Acquisition Pro Forma Net Revenue $ 15,071.0 $ 1,523.0 $ 16,594.0 Net income attributable to ordinary shareholders $ 3,683.2 $ 377.7 $ 4,060.9 Net income per share Basic $ 10.01 $ 10.32 Diluted $ 10.01 $ 10.32 Year Ended December 31, 2014 (unaudited) As reported Allergan Acquisition Forest Acquisition Pro Forma Net Revenue $ 6,738.9 $ 7,225.4 $ 2,239.8 $ 16,204.1 Net (loss) / income attributable to ordinary shareholders $ (1,630.5 ) $ (3,067.8 ) $ 146.1 $ (4,552.2 ) Net (loss) per share Basic $ (7.42 ) $ (11.66 ) Diluted $ (7.42 ) $ (11.66 ) Year Ended December 31, 2013 (unaudited) As reported Forest Acquisition Warner Chilcott Acquisition Pro Forma Net Revenue $ 2,602.5 $ 3,876.8 $ 1,646.6 $ 8,125.9 Net (loss) / income attributable to ordinary shareholders $ (750.4 ) $ (2,261.4 ) $ 518.2 $ (2,493.6 ) Net (loss) per share Basic $ (5.27 ) $ (9.51 ) Diluted $ (5.27 ) $ (9.51 )
AqueSys [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 6.2 Current assets 1.2 IPR&D intangible assets 302.0 Intangible assets 221.0 Goodwill 138.5 Current liabilities (6.9 ) Contingent consideration (193.5 ) Deferred tax liabilities, net (169.6 ) Net assets acquired $ 298.9
Northwood Medical Innovation Ltd [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 0.5 IPR&D intangible assets 13.6 Intangible assets 19.5 Goodwill 13.6 Other assets and liabilities (0.1 ) Contingent consideration (15.0 ) Deferred tax liabilities, net (6.6 ) Net assets acquired $ 25.5
Kythera [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 78.1 Marketable securities 79.9 Inventories 18.2 Other current assets 14.5 IPR&D intangible assets 320.0 Intangible assets 2,120.0 Goodwill 328.7 Other current liabilities (48.6 ) Deferred tax, net (766.7 ) Outstanding indebtedness (54.6 ) Net assets acquired $ 2,089.5
Oculeve, Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 1.6 IPR&D intangible assets 286.0 Goodwill 33.3 Other assets and liabilities (1.9 ) Contingent consideration (90.0 ) Deferred tax liabilities, net (94.5 ) Net assets acquired $ 134.5
Auden Mckenzie [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the preliminary fair values of the tangible and identifiable intangible assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 32.2 Inventory 49.1 IPR&D intangible assets 38.6 Intangible assets 342.4 Goodwill 123.3 Other assets and liabilities 7.2 Contingent consideration (17.3 ) Deferred tax liabilities, net (79.6 ) Net assets acquired $ 495.9
Allergan, Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date and reflects purchase accounting adjustments subsequent to the acquisition date ($ in millions): Preliminary Amount as of March 31, 2015 Measurement Period Adjustments Final Amount as of December 31, 2015 Cash and cash equivalents $ 5,424.5 $ - $ 5,424.5 Accounts receivable 962.7 (14.0 ) 948.7 Inventories 1,223.2 (4.6 ) 1,218.6 Other current assets 318.8 - 318.8 Property, plant and equipment, net 1,202.5 12.0 1,214.5 Other long-term assets 189.3 6.8 196.1 IPR&D intangible assets 11,010.0 (1,310.0 ) 9,700.0 Intangible assets 45,050.5 - 45,050.5 Goodwill 26,368.5 720.4 27,088.9 Current liabilities (1,212.2 ) (9.9 ) (1,222.1 ) Contingent consideration (379.1 ) (4.6 ) (383.7 ) Deferred tax liabilities, net (12,512.9 ) 632.8 (11,880.1 ) Other taxes payable (82.4 ) (28.9 ) (111.3 ) Other long-term liabilities (622.0 ) - (622.0 ) Outstanding indebtedness (2,183.5 ) - (2,183.5 ) Net assets acquired $ 74,757.9 $ - $ 74,757.9
Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets	The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amount recognized as of the acquisition date Weighted average useful lives (years) Definite-lived assets Restasis ® $ 3,970.0 4.0 Refresh ® ® 2,720.0 7.6 Other Eye Care Products 6,690.0 4.2 Botox ® 22,600.0 8.0 Aczone ® 160.0 1.3 Other Skin Products 820.0 5.0 Other Aesthetics 6,350.0 6.0 Total CMP 43,310.0 6.7 Trade name 690.0 4.5 Customer relationships 1,050.5 3.4 Total definite-lived assets 45,050.5 6.6 In-process research and development Eye Care 5,500.0 Botox ® 810.0 Aesthetics 2,270.0 Other 1,120.0 Total IPR&D 9,700.0 Total intangible assets $ 54,750.5
Summary of Transaction and Integration Costs	As a result of the acquisition, the Company incurred the following transaction and integration costs in the year ended December 31, 2015 ($ in millions): Year Ended December 31, 2015 Cost of sales Stock-based compensation acquired for Legacy Allergan employees $ 22.5 Acquisition, integration and restructuring related charges 14.9 Research and development Stock-based compensation acquired for Legacy Allergan employees 124.8 Acquisition, integration and restructuring related charges 83.5 Selling and marketing Stock-based compensation acquired for Legacy Allergan employees 110.0 Acquisition, integration and restructuring related charges 75.7 General and administrative Stock-based compensation acquired for Legacy Allergan employees 258.9 Acquisition-related expenditures 65.5 Acquisition, integration and restructuring related charges 298.6 Other (expense) income Bridge loan facilities expense (264.9 ) Interest rate lock 30.9 Total transaction and integration costs $ 1,288.4
Durata Acquisition [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the fair values of the tangible and identifiable intangible assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 17.8 Inventory 21.0 IPR&D intangible assets 249.0 Intangible assets 480.0 Goodwill 75.8 Other assets and liabilities (30.2 ) Contingent consideration (49.0 ) Deferred tax liabilities, net (39.9 ) Outstanding indebtedness (67.0 ) Net assets acquired $ 657.5
Furiex Pharmaceuticals, Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the final fair values of the tangible and identifiable intangible assets acquired and liabilities assumed at the acquisition date ($ in millions): Amount Cash and cash equivalents $ 14.9 IPR&D intangible assets 1,003.0 Intangible assets 408.6 Goodwill 251.9 Other assets and liabilities (30.1 ) Contingent consideration (88.0 ) Deferred tax liabilities, net (404.1 ) Outstanding indebtedness (55.3 ) Net assets acquired $ 1,100.9
Forest Laboratories Inc. [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date, of which the majority of the assets and liabilities relate to continuing operations. ($ in millions): Amount Cash and cash equivalents $ 3,424.2 Accounts receivable 496.2 Inventories 1,455.8 Other current assets 261.2 Current assets held for sale 87.1 Property, plant and equipment, net 221.1 Other long-term assets 84.1 IPR&D intangible assets 1,362.0 Intangible assets 11,515.5 Goodwill 16,403.6 Current liabilities (1,372.1 ) Deferred tax liabilities, net (2,277.3 ) Other taxes payable (618.4 ) Other long-term liabilities (120.0 ) Outstanding indebtedness (3,261.9 ) Net assets acquired $ 27,661.1
Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets	The following table identifies the summarized amounts recognized and the weighted average useful lives using the economic benefit of intangible assets ($ in millions): Amounts Recognized as of the Acquisition Date Weighted Average Useful Lives (Years) CMP: Namenda Franchise $ 2,125.0 1.7 Bystolic Franchise 1,810.0 3.3 Linzess ® 1,052.0 5.0 Zenpep ® 978.0 6.8 Carafate ® 915.0 6.2 Armour Thyroid ® 747.0 5.9 Viibryd ® 413.0 4.5 Fetzima ® 392.0 5.0 Teflaro ® 343.0 3.0 Canasa ® 327.0 2.6 Daliresp ® 269.0 3.5 Other CMP Products 1,904.0 5.7 Total CMP 11,275.0 4.3 IPR&D: Gastroenterology 791.0 Central nervous system 304.0 Cardiovascular 193.0 Other 74.0 Total IPR&D 1,362.0 Customer relationships 67.0 4.5 Other 173.5 4.2 Total identifiable intangible assets $ 12,877.5
Summary of Transaction and Integration Costs	As a result of the Forest Acquisition, the Company incurred the following transaction and integration costs in the years ended December 31, 2015 and 2014($ in millions): Years Ended December 31, 2015 2014 Cost of sales Stock-based compensation acquired for Forest employees $ 4.7 $ 9.5 Severance-related charges 1.1 11.3 Research and development Stock-based compensation acquired for Forest employees 36.3 66.7 Severance-related charges 9.2 24.5 Selling and marketing Stock-based compensation acquired for Forest employees 47.9 58.7 Severance-related charges 17.4 45.3 Other integration costs - 3.8 General and administrative Stock-based compensation acquired for Forest employees 53.9 152.6 Severance-related charges 17.1 71.5 Other integration costs 58.4 92.9 Financing related charges - 9.3 Other income (expense) Bridge loan facilities - (25.8 ) Total transaction and integration costs $ 246.0 $ 571.9
Silom Medical Company [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The Silom Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date as follows ($ in millions): Amount Cash and cash equivalents $ 3.0 Inventories, net 4.0 Property, plant and equipment, net 16.0 Product rights and other intangibles 64.0 Goodwill 20.0 Other assets and liabilities (4.0 ) Net assets acquired $ 103.0
Warner Chilcott [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date, of which the majority of the assets and liabilities relate to continuing operations ($ in millions): Amount Cash and cash equivalents $ 179.5 Accounts receivable 306.1 Inventories 532.5 Other current assets 83.4 Property, plant and equipment, net 220.0 Other long-term assets 1.2 IPR&D intangible assets 1,708.0 Intangible assets 3,021.0 Goodwill 3,956.1 Current liabilities (613.5 ) Deferred tax liabilities, net (60.4 ) Other long-term liabilities (99.6 ) Outstanding indebtedness (3,400.4 ) Net assets acquired $ 5,833.9
Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets	The following table identifies the summarized amounts recognized and the weighted average useful lives of intangible assets ($ in millions): Amounts Recognized as of the Acquisition Date Weighted Average Useful Lives (Years) CMP: Oral contraceptive franchise $ 1,181.0 3.2 Mesalamine franchise 589.0 1.8 Estrace® Cream 397.0 2.1 Risedronate franchise 311.0 3.6 Doryx® 237.0 2.4 Enablex® 107.0 2.1 Other CMP products 199.0 3.9 Total CMP 3,021.0 2.7 IPR&D: Mesalamine franchise 809.0 Oral Contraceptive franchise 321.0 Estradiol 278.0 Urology 165.0 Other 135.0 Total IPR&D 1,708.0 Total identifiable intangible assets $ 4,729.0
Uteron Pharma, SA [Member]
Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date	The transaction has been accounted for using the acquisition method of accounting. The following table summarizes the fair values of the tangible and identifiable intangible assets acquired and liabilities assumed at the acquisition date ($ in millions): Final Values Accounts receivable $ 1.6 Other current assets 1.2 Property, plant & equipment 5.7 Other long-term assets 0.5 IPR&D intangible assets 250.0 Goodwill 26.4 Current liabilities, excluding current portion of debt (8.0 ) Long-term deferred tax and other tax liabilities (82.5 ) Contingent consideration (43.4 ) Debt (5.2 ) Other long-term liabilities (4.3 ) Net assets acquired $ 142.0

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued Operations And Disposal Groups [Abstract]
Summary of Key Financial Results of Global Generics Business from Discontinued Operations	Financial results for discontinued operations were based on the terms and conditions of the agreements with Teva as of the date of this filing. Subsequent changes in terms and products transferring may impact results presented. The following table presents key financial results of the global generics business included in "Income from discontinued operations" for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, 2015 2014 2013 Third party revenues $ 6,116.1 $ 6,323.4 $ 6,075.1 Related party sales 259.2 255.4 273.1 Net revenues 6,375.3 6,578.8 6,348.2 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) 3,048.1 3,105.6 3,319.1 Research and development 422.2 480.2 425.6 Selling and marketing 557.7 649.0 645.5 General and administrative 653.0 496.2 571.4 Amortization 323.6 652.0 538.9 In-process research and development impairments - - 4.9 Asset sales and impairments, net 62.4 19.6 896.8 Total operating expenses 5,067.0 5,402.6 6,402.2 Operating income 1,308.3 1,176.2 (54.0 ) Other (expense) income, net (7.9 ) (14.5 ) 39.1 (Benefit) / provision for income taxes (5,487.3 ) 385.1 268.0 Net income / (loss) from discontinued operations $ 6,787.7 $ 776.6 $ (282.9 )
Schedule of Aggregate Carrying Amounts of Major Classes of Assets and Liabilities	The following table presents the aggregate carrying amounts of the major classes of assets and liabilities related to the global generics business to be disposed of ($ in millions): December 31, 2015 December 31, 2014 Assets: Accounts receivable, net $ 2,089.7 $ 1,488.9 Inventories 1,138.5 1,090.9 Prepaid expenses and other current assets 302.8 254.6 Current deferred tax assets - 23.3 Property, plant and equipment, net 1,355.6 1,347.5 Investments and other assets 33.0 82.1 Non-current deferred tax assets 223.7 72.7 Product rights and other intangibles 2,919.3 3,097.7 Goodwill 6,009.7 3,623.9 Total assets $ 14,072.3 $ 11,081.6 Liabilities: Accounts payable and accrued expenses $ 1,455.8 $ 1,396.4 Income taxes payable 33.9 16.5 Current deferred tax liabilities - 6.3 Debt and capital leases 5.8 12.6 Other long-term liabilities 92.0 121.3 Other taxes payable 69.0 102.7 Long-term deferred tax liabilities 415.4 308.1 Total liabilities $ 2,071.9 $ 1,963.9
Schedule of Depreciation Amortization and Significant Operating and Investing Noncash Items of Discontinued Operations	The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows ($ in millions): Years Ended December 31, 2015 2014 2013 Depreciation from discontinued operations $ 89.7 $ 159.6 $ 166.9 Amortization from discontinued operations 323.6 652.0 538.9 Capital expenditures 234.5 184.5 168.0 Deferred taxes (5,568.8 ) (259.5 ) (242.4 )

Assets Held For Sale (Tables)

Assets Held For Sale (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued Operations And Disposal Groups [Abstract]
Net Assets Held for Sale	The following represents the global net assets held for sale ($ in millions): December 31, 2015 December 31, 2014 Accounts receivable, net $ - $ 17.7 Inventories - 161.5 Prepaid expenses and other assets 9.3 161.3 Intangible assets - 453.0 Goodwill - 309.1 Impairment on assets held for sale - (189.6 ) Total assets held for sale $ 9.3 $ 913.0 Accounts payable and accrued expenses $ - $ 25.9 Total liabilities held for sale $ - $ 25.9 Assets from the Teva Transaction 14,072.3 11,081.6 Liabilities from the Teva Transaction 2,071.9 1,963.9 Net assets held for sale $ 12,009.7 $ 10,004.8

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Fair Value Assumptions of Options based on Black-Scholes Valuation Model	Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions: 2015 Grants 2015 Acquired Awards 2014 Grants 2014 Acquired Awards Dividend yield 0 % 0 % 0 % 0 % Expected volatility 26.0 - 29.0% 26.0 - 27.0% 29.0 % 28.0 % Risk-free interest rate 1.9-2.1% 0.1-2.1% 1.9 - 2.2% 0 - 2.1 % Expected term (years) 7.0 - 7.5 up to 6.9 7.5 up to 6.4
Share-Based Compensation Expense Recognized in Company's Results of Operations	Share-based compensation expense recognized in the Company’s results of operations, including discontinued operations, for the years ended December 31, 2015, 2014 and 2013 was as follows ($ in millions): Year Ended December 31, 2015 2014 2013 Equity-based compensation awards $ 690.4 $ 368.0 $ 132.1 Cash-settled equity awards in connection with the Allergan Acquisition 127.1 - - Cash-settled equity awards in connection with the Kythera Acquisition 9.6 - - Cash-settled equity awards in connection with the Durata Acquisition - 16.6 - Cash-settled equity awards in connection with the Furiex Acquisition - 16.6 - Non equity-settled awards other 98.6 - 1.5 Total stock-based compensation expense $ 925.7 $ 401.2 $ 133.6
Summary of Equity Award Activity for Unvested Restricted Stock and Stock Units	The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, 2014 through December 31, 2015: (in millions, except per share data) Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Aggregate Grant Date Fair Value Restricted shares / units outstanding at December 31, 2014 2.1 $ 148.79 1.3 $ 312.5 Granted 0.5 304.94 152.5 Vested (1.0 ) (127.15 ) (128.1 ) Assumed as part of the Allergan Acquisition ** 0.5 218.47 102.8 Forfeited (0.1 ) (152.63 ) (19.9 ) Restricted shares / units outstanding at December 31, 2015 2.0 $ 209.90 1.7 $ 419.8 ** Assumed as part of the Allergan Acquisition for the pro rata portion representing future compensation as of March 17, 2015.
Summary of Equity Award Activity for Non-Qualified Options to Purchase Ordinary Shares	The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, 2014 through December 31, 2015: (in millions, except per share data) Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, December 31, 2014 5.4 $ 93.96 7.3 $ 858.9 Granted 0.2 300.29 Exercised (2.4 ) (134.54 ) Assumed as part of the Allergan Acquisition** 7.0 103.63 Assumed as part of the Kythera Acquisition*** 0.7 127.02 Cancelled (0.4 ) (135.92 ) Outstanding, December 31, 2015 10.5 $ 149.11 6.7 $ 1,707.8 Vested and expected to vest at December 31, 2015 9.9 $ 148.14 6.7 $ 1,620.5 ** Assumed as part of the Allergan Acquisition for the pro rata portion representing future compensation as of March 17, 2015. *** Assumed as part of the Kythera Acquisition for the pro rata portion representing future compensation as of October 1, 2015.

Pension and Other Postretirem46

Pension and Other Postretirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2015
Summary of Net Periodic Benefit Cost of Defined Benefit Plans for Continuing Operations	The net periodic benefit cost of the defined benefit plans was de minimis for the year ended December 31, 2013. The net periodic benefit cost of the defined benefit plans for continuing operations for the years ended December 31, 2015 and 2014 was as follows ($ in millions): Defined Benefit Year Ended December 31, 2015 2014 Service cost $ 5.0 $ 2.0 Interest cost 35.0 3.3 Expected Return on plan assets (46.4 ) (3.5 ) Settlement (4.3 ) - Net periodic benefit (income) cost $ (10.7 ) $ 1.8
Schedule of Benefit Obligation and Asset Data for Defined Benefit Plans for Continuing Operations	Benefit obligation and asset data for the defined benefit plans for continuing operations, were as follows ($ in millions): Year Ended December 31, 2015 (1) 2014 Change in Plan Assets Fair value of plan assets at beginning of year $ 83.6 $ 79.9 Fair value of plan assets assumed in the Allergan Acquisition 1,042.0 - Employer contribution 107.6 3.2 Return on plan assets (60.3 ) 13.9 Benefits paid (21.5 ) (2.9 ) Settlements (100.0 ) - Effects of exchange rate changes (0.3 ) (10.5 ) Fair value of plan assets at end of year $ 1,051.1 $ 83.6 Year Ended December 31, 2015 (1) 2014 Change in Benefit Obligation Benefit obligation at beginning of the year $ 111.6 $ 96.5 Benefit obligation assumed in the Allergan Acquisition 1,344.6 - Service cost 5.0 2.0 Interest cost 35.0 3.3 Actuarial loss/(gain) (191.2 ) 27.0 Curtailments - (0.7 ) Settlements and other (101.1 ) - Benefits paid (21.5 ) (2.8 ) Effects of exchange rate changes 6.1 (13.7 ) Benefit obligation at end of year $ 1,188.5 $ 111.6 Funded status at end of year $ (137.4 ) $ (28.0 ) (1) The year ended December 31, 2015 includes benefit obligation and asset data from the Allergan Plans following the Allergan Acquisition on March 17, 2015.
Schedule of Funded Status Amount Recognized in Consolidated Balance Sheet	The following table outlines the funded actuarial amounts recognized ($ in millions): As of December 31, 2015 2014 Current liabilities $ (29.3 ) $ (2.7 ) Noncurrent liabilities (108.1 ) (25.3 ) $ (137.4 ) $ (28.0 )
Schedule of Fair Values of Pension Plan Assets by Asset Category for Continuing Operations	The fair values of the Company’s pension plan assets for continuing operations at December 31, 2015 by asset category are as follows ($ in millions): Quoted Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds U.S. equities $ 114.6 $ - $ - $ 114.6 International equities 151.3 - - 151.3 Other equity securities 99.1 - - 99.1 Equity securities $ 365.0 $ - $ - $ 365.0 U.S. Treasury bonds $ - $ 120.6 $ - $ 120.6 Bonds and bond funds - 490.7 - 490.7 Other debt securities - 60.0 - 60.0 Debt securities $ - $ 671.3 $ - $ 671.3 Other investments Other - 14.8 - 14.8 Total assets $ 365.0 $ 686.1 $ - $ 1,051.1 The fair values of the Company’s pension plan assets for continuing operations at December 31, 2014 by asset category are as follows ($ in millions): Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Investment funds Equity securities $ 24.9 $ - $ - $ 24.9 Debt securities - 56.5 - 56.5 Other investments Other - 2.2 - 2.2 Total assets $ 24.9 $ 58.7 $ - $ 83.6
Schedule of Allocated Target Investment Portfolio of Pension Plans for Continuing Operations	The target investment portfolio of the Company’s continuing operations pension plans is allocated as follows: Target Allocation as of December 31, 2015 (1) 2014 Bonds 35.0 % 30.0 % Equity securities 62.5 % 67.5 % Other investments 2.5 % 2.5 % (1) Includes the asset allocation of the Allergan Plans following the Allergan Acquisition on March 17, 2015.
Schedule of Expected Benefit Payments of Pension Plans for Continuing Operations	Total expected benefit payments for the Company’s continuing operations pension plans are as follows ($ in millions): 2016 $ 29.3 2017 31.7 2018 34.6 2019 37.6 2020 40.5 Thereafter 1,014.8 Total liability $ 1,188.5
Schedule of Defined Benefit Plans with Accumulated Benefit Obligation in Excess of Plan Assets for Continuing Operations	Information for continuing operations defined benefit plans with an accumulated benefit obligation in excess of plan assets is presented below ($ in millions): Defined Benefit as of December 31, 2015 2014 Projected benefit obligations $ 1,188.5 $ 111.6 Accumulated benefit obligations $ 1,054.6 $ 100.8 Plan assets $ 904.3 $ 83.6
Schedule of Balances Recognized within Accumulated Other Comprehensive Income / (Loss)	Balances recognized within accumulated other comprehensive income/(loss) that have not been recognized as components of net periodic benefit costs are as follows ($ in millions): Defined Benefit Balance as of December 31, 2013 $ 5.6 Net actuarial loss (36.4 ) Balance as of December 31, 2014 (30.8 ) Net actuarial gain 101.2 Balance as of December 31, 2015 $ 70.4
Weighted Average Assumptions Used to Calculate Projected Benefit Obligations and Net Periodic Benefit Cost	The weighted average assumptions used to calculate the projected benefit obligations of the Company’s defined benefit plans, including assets and liabilities held for sale, are as follows: As of December 31, 2015 2014 Discount rate 3.8 % 2.9 % Salary growth rate 3.7 % 3.7 % The weighted average assumptions used to calculate the net periodic benefit cost of the Company’s defined benefit plans, including assets and liabilities held for sale, are as follows: As of December 31, 2015 2014 Discount rate 3.5 % 3.9 % Expected rate of return on plan assets 4.6 % 4.9 % Salary growth rate 3.5 % 3.7 %
Schedule of Accumulated Benefit Obligation and Asset Data for Defined Benefit Plans	Accumulated benefit obligation and asset data for the defined benefit plans, were as follows ($ in millions): Accumulated benefit obligation as of December 31, 2013 $ - Accumulated benefit obligation assumed as part of the Forest Acquisition 14.0 Interest cost 0.4 Actuarial loss 6.4 Benefits paid (0.3 ) Accumulated benefit obligation as of December 31, 2014 $ 20.5 Accumulated benefit obligation assumed as part of the Allergan Acquisition 60.2 Interest cost (2.3 ) Actuarial gain (26.3 ) Benefits paid (2.0 ) Accumulated benefit obligation as of December 31, 2015 $ 50.1
Teva Pharmaceutical Industries Ltd [Member]
Schedule of Benefit Obligation and Asset Data for Defined Benefit Plans for Continuing Operations	As of December 31, 2015 and 2014, the following is the plan assets and liabilities included in assets and liabilities held for sale as part of the Teva Transaction ($ in millions): Year Ended December 31, 2015 (1) 2014 Fair value of plan assets at end of year $ 111.9 $ 112.5 Benefit obligation at end of year $ 161.8 $ 174.5 Funded status at end of year $ (49.9 ) $ (62.0 )

Other Income (Expense) (Tables)

Other Income (Expense) (Tables)	12 Months Ended
	Dec. 31, 2015
Other Income And Expenses [Abstract]
Components of Other Income (Expense)	Other income (expense) consisted of the following ($ in millions): Years Ended December 31, 2015 2014 2013 Bridge loan commitment fee $ (264.9 ) $ (73.6 ) $ - Interest rate lock 31.0 - - Extinguishment of debt - 29.9 (18.5 ) Other (expense) income 0.1 16.4 (0.1 ) Other (expense) income, net $ (233.8 ) $ (27.3 ) $ (18.6 )

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following as of December 31, 2015 and 2014 ($ in millions): December 31, December 31, 2015 2014 Raw materials $ 242.3 $ 203.5 Work-in-process 149.7 80.9 Finished goods 706.3 763.6 1,098.3 1,048.0 Less: inventory reserves 88.6 63.4 Total Inventories $ 1,009.7 $ 984.6
Schedule of Amounts Related to Fair Value Step-up of Acquired Inventory	Included in finished goods were the following amounts related to the fair-value step-up of acquired inventory ($ in millions): Allergan Forest Durata Warner Chilcott Acquisition Acquisition Acquisition Acquisition Total December 31, 2015 $ 21.6 $ 20.1 $ 4.4 $ - $ 46.1 December 31, 2014 $ - $ 244.7 $ 16.3 $ 1.9 $ 262.9

Accounts Payable and Accrued 49

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Payables And Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following ($ in millions): December 31, 2015 December 31, 2014 Accrued expenses: Accrued third-party rebates $ 1,281.6 $ 904.6 Accrued payroll and related benefits 409.7 198.7 Accrued R&D expenditures 384.1 169.9 Interest payable 312.0 82.7 Accrued returns 288.4 250.3 Litigation-related reserves and legal fees 213.5 300.9 Accrued non-provision taxes 100.3 3.3 Accrued pharmaceutical fees 162.2 118.7 Accrued selling and marketing expenditures 127.2 9.6 Royalties payable 126.9 128.9 Accrued severance, retention and other shutdown costs 110.4 107.2 Current portion of contingent consideration obligations 79.9 233.9 Accrued professional fees 25.4 39.3 Dividends payable 23.9 - Manufacturing related 14.9 11.2 Accrued warranties 7.6 - Other accrued expenses 312.1 147.6 Total accrued expenses $ 3,980.1 $ 2,706.8 Accounts payable 369.4 323.3 Total Accounts Payable and Accrued Expenses $ 4,349.5 $ 3,030.1

Property, plant and equipment50

Property, plant and equipment, net (Tables)	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	Property, plant and equipment, net consisted of the following, as well as the net book value of continuing operations and discontinued operations as of December 31, 2015 and 2014 ($ in millions): Machinery and Equipment Research and Laboratory Equipment Other Transportation Land, Buildings and Leasehold Improvements Construction in Progress Total At December 31, 2014 $ 950.3 $ 155.5 $ 365.4 $ 85.7 $ 907.1 $ 150.7 $ 2,614.7 Additions 79.8 4.1 40.0 77.5 10.8 236.2 448.4 Additions due to acquisitions 224.4 19.1 72.3 1.0 585.2 312.5 1,214.5 Disposals/transfers/impairments 19.9 (6.3 ) (23.3 ) (9.4 ) (20.3 ) (118.1 ) (157.5 ) Transfer to assets held for sale - - - - (4.5 ) - (4.5 ) Currency translation (42.7 ) (0.5 ) (8.9 ) (4.3 ) (38.4 ) (2.9 ) (97.7 ) At December 31, 2015 $ 1,231.7 $ 171.9 $ 445.5 $ 150.5 $ 1,439.9 $ 578.4 $ 4,017.9 Accumulated depreciation At December 31, 2014 $ 415.3 $ 130.8 $ 249.4 $ 11.4 $ 213.1 $ - $ 1,020.0 Additions 65.7 8.3 78.7 12.3 53.3 - 218.3 Disposals/transfers/impairments (22.6 ) (8.3 ) (23.3 ) (6.0 ) (60.5 ) - (120.7 ) Transfer to assets held for sale - - - - - - - Currency translation (16.2 ) (0.7 ) (4.6 ) (1.4 ) (6.3 ) - (29.2 ) At December 31, 2015 $ 442.2 $ 130.1 $ 300.2 $ 16.3 $ 199.6 $ - $ 1,088.4 Machinery and Equipment Research and Laboratory Equipment Other Transportation Land, Buildings and Leasehold Improvements Construction in Progress Total At December 31, 2014 $ 535.0 $ 24.7 $ 116.0 $ 74.3 $ 694.0 $ 150.7 $ 1,594.7 Continuing Operations $ 30.9 $ 2.4 $ 51.0 $ 53.4 $ 109.1 $ 36.6 $ 283.4 Discontinued Operations $ 504.1 $ 22.3 $ 65.0 $ 20.9 $ 584.9 $ 114.1 $ 1,311.3 At December 31, 2015 $ 789.5 $ 41.8 $ 145.3 $ 134.2 $ 1,240.3 $ 578.4 $ 2,929.5 Continuing Operations $ 269.2 $ 17.8 $ 90.9 $ 117.5 $ 654.6 $ 423.9 $ 1,573.9 Discontinued Operations $ 520.3 $ 24.0 $ 54.4 $ 16.7 $ 585.7 $ 154.5 $ 1,355.6

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following ($ in millions): December 31, 2015 December 31, 2014 Prepaid taxes $ 240.5 $ 207.7 Current portion of deferred loan costs 36.3 124.9 Prepaid insurance 24.1 14.0 Other 257.6 132.2 Total prepaid expenses and other current assets $ 558.5 $ 478.8
Marketable Securities and Other Investments	Investments in marketable securities and other investments consisted of the following ($ in millions): December 31, 2015 December 31, 2014 Marketable securities: U.S. Treasury and agency securities — maturing within one year $ 9.3 $ 1.0 Total marketable securities $ 9.3 $ 1.0 Investments and other assets: Deferred loan costs $ 159.5 $ 58.9 Legacy Allergan Deferred executive compensation investments 118.1 - Equity method investments 17.3 0.1 Cost method investments 16.7 0.3 Other long-term investments 78.2 53.9 Taxes receivable 39.6 - Other assets 148.0 40.1 Total investments and other assets $ 577.4 $ 153.3
Summary of Fair Value and Unrealized Gains (Losses) Related to Available-for-Sale Securities	The following table provides a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities ($ in millions): At December 31, 2015 Amortized Cost Gross Gains Gross Unrealized Losses Fair Value Available-for-sale: U.S. treasury and agency securities $ 29.9 $ - $ - $ 29.9 Total $ 29.9 $ - $ - $ 29.9 At December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Available-for-sale: U.S. treasury and agency securities $ 1.0 $ - $ - $ 1.0 Total $ 1.0 $ - $ - $ 1.0
Summary of Long-term Investments	The movements in long-term investments were as follows ($ in millions): Equity Method Investments Cost Method and Other Long-term Investments Balance at December 31, 2014 $ 0.1 $ 54.2 Additions - 20.0 Acquired from the Allergan Acquisition 17.3 15.0 Other (0.1 ) 5.7 Balance at December 31, 2015 $ 17.3 $ 94.9

Goodwill, Product Rights and 52

Goodwill, Product Rights and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill for the Company’s reporting segments consisted of the following ($ in millions): US Brands US Aesthetics International Brands Anda Distribution Total Balance as of December 31, 2014 $ 20,603.7 $ - $ 207.6 $ 86.3 $ 20,897.6 Additions through acquisitions 15,435.8 4,006.7 8,283.8 - 27,726.3 Measurement period adjustments and other 68.0 - - - 68.0 Held for sale - - (2,385.8 ) - (2,385.8 ) Foreign exchange and other adjustments - - 245.4 - 245.4 Balance as of December 31, 2015 $ 36,107.5 $ 4,006.7 $ 6,351.0 $ 86.3 $ 46,551.5
Schedule of Cost Basis on Product Rights and Other Intangible Assets	Product rights and other intangible assets consisted of the following for the years ended December 31, 2015 and 2014 ($ in millions): Cost Basis Balance as of December 31, 2014 Acquisitions Impairments IPR&D to CMP Transfers Disposals/ Held Sale/ Other Foreign Currency Translation Balance as of December 31, 2015 Intangibles with definite lives: Product rights and other related intangibles $ 15,305.7 $ 47,163.8 $ (242.2 ) $ 3,128.5 $ (975.5 ) $ 163.9 $ 64,544.2 Trade name - 690.0 - - - - 690.0 Total definite-lived intangible assets $ 15,305.7 $ 47,853.8 $ (242.2 ) $ 3,128.5 $ (975.5 ) $ 163.9 $ 65,234.2 Intangibles with indefinite lives: IPR&D $ 4,116.4 $ 10,714.4 $ (511.6 ) $ (3,128.5 ) $ (38.8 ) $ (23.7 ) $ 11,128.2 Trade name 76.2 - - - - - 76.2 Total indefinite- lived intangible assets $ 4,192.6 $ 10,714.4 $ (511.6 ) $ (3,128.5 ) $ (38.8 ) $ (23.7 ) $ 11,204.4 Total product rights and related intangibles $ 19,498.3 $ 58,568.2 $ (753.8 ) $ - $ (1,014.3 ) $ 140.2 $ 76,438.6 Accumulated Amortization Balance as of December 31, 2014 Amortization Impairments Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2015 Intangibles with definite lives: Product rights and other related intangibles $ (3,407.6 ) $ (5,393.9 ) $ (7.5 ) $ 361.7 $ (0.1 ) $ (8,447.4 ) Trade name - (59.5 ) - - - (59.5 ) Total definite-lived intangible assets $ (3,407.6 ) $ (5,453.4 ) $ (7.5 ) $ 361.7 $ (0.1 ) $ (8,506.9 ) Total product rights and related intangibles $ (3,407.6 ) $ (5,453.4 ) $ (7.5 ) $ 361.7 $ (0.1 ) $ (8,506.9 ) Net Product Rights and Other Intangibles $ 16,090.7 $ 67,931.7 Product rights and other intangible assets consisted of the following for the years ended December 31, 2014 and 2013 ($ in millions): Cost Basis Balance as of December 31, 2013 Acquisitions Impairments IPR&D Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2014 Intangibles with definite lives: Product rights and other related intangibles $ 4,006.6 $ 11,850.8 $ - $ 140.0 $ (685.5 ) $ (6.2 ) $ 15,305.7 Trade name - - - - - - - Total definite-lived intangible assets $ 4,006.6 $ 11,850.8 $ - $ 140.0 $ (685.5 ) $ (6.2 ) $ 15,305.7 Intangibles with indefinite lives: IPR&D $ 2,116.0 $ 2,675.8 $ (424.3 ) $ (140.0 ) $ (36.3 ) $ (74.8 ) $ 4,116.4 Trade name 76.2 - - - - - 76.2 Total indefinite-lived intangible assets $ 2,192.2 $ 2,675.8 $ (424.3 ) $ (140.0 ) $ (36.3 ) $ (74.8 ) $ 4,192.6 Total product rights and related intangibles $ 6,198.8 $ 14,526.6 $ (424.3 ) $ - $ (721.8 ) $ (81.0 ) $ 19,498.3 Accumulated Amortization Balance as of December 31, 2013 Amortization Impairments Disposals/ Held for Sale/ Other Foreign Currency Translation Balance as of December 31, 2014 Intangibles with definite lives: Product rights and other related intangibles $ (1,160.8 ) $ (1,945.5 ) $ (289.7 ) $ 8.5 $ (20.1 ) $ (3,407.6 ) Trade name - - - - - - Total definite-lived intangible assets $ (1,160.8 ) $ (1,945.5 ) $ (289.7 ) $ 8.5 $ (20.1 ) $ (3,407.6 ) Total product rights and related intangibles $ (1,160.8 ) $ (1,945.5 ) $ (289.7 ) $ 8.5 $ (20.1 ) $ (3,407.6 ) Net Product Rights and Other Intangibles $ 5,038.0 $ 16,090.7
Schedule of Annual Amortization Expense on Product Rights and Other Related Intangibles	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, continuing operations related to annual amortization expense on product rights and other related intangibles as of December 31, 2015 over each of the next five years is estimated to be as follows ($ in millions): Amortization Expense 2016 $ 6,349.0 2017 $ 6,286.8 2018 $ 5,799.1 2019 $ 5,717.3 2020 $ 5,470.8

Long-Term Debt and Leases (Tabl

Long-Term Debt and Leases (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Long-Term Debt and Capital Leases	Debt consisted of the following ($ in millions): Balance As of Fair Market Value As of December 31, 2015 December 31, 2014 December 31, 2015 December 31, 2014 Senior Notes: Floating Rate Notes $500.0 million floating rate notes due September 1, 2016 $ 500.0 $ - $ 500.5 $ - $500.0 million floating rate notes due March 12, 2018 500.0 - 499.6 - $500.0 million floating rate notes due March 12, 2020 500.0 - 496.2 - 1,500.0 - 1,496.3 - Fixed Rate Notes $800.0 million 5.750% notes due April 1, 2016 800.0 - 808.4 - $1,000.0 million 1.850% notes due March 1, 2017 1,000.0 - 1,001.5 - $500.0 million 1.300% notes due June 15, 2017 500.0 500.0 496.3 489.0 $1,200.0 million 1.875% notes due October 1, 2017 1,200.0 1,200.0 1,196.0 1,187.3 $3,000.0 million 2.350% notes due March 12, 2018 3,000.0 - 3,004.6 - $250.0 million 1.350% notes due March 15, 2018 250.0 - 244.9 - $1,050.0 million 4.375% notes due February 1, 2019 1,050.0 1,050.0 1,099.5 1,111.4 $500.0 million 2.450% notes due June 15, 2019 500.0 500.0 494.4 498.2 $400.0 million 6.125% notes due August 15, 2019 400.0 400.0 444.2 457.9 $3,500.0 million 3.000% notes due March 12, 2020 3,500.0 - 3,505.1 - $650.0 million 3.375% notes due September 15, 2020 650.0 - 656.6 - $750.0 million 4.875% notes due February 15, 2021 750.0 750.0 807.4 808.9 $1,200.0 million 5.000% notes due December 15, 2021 1,200.0 1,200.0 1,299.4 1,301.0 $3,000.0 million 3.450% notes due March 15, 2022 3,000.0 - 3,006.8 - $1,700.0 million 3.250% notes due October 1, 2022 1,700.0 1,700.0 1,669.6 1,647.5 $350.0 million 2.800% notes due March 15, 2023 350.0 - 327.7 - $1,200.0 million 3.850% notes due June 15, 2024 1,200.0 1,200.0 1,202.6 1,215.5 $4,000.0 million 3.800% notes due March 15, 2025 4,000.0 - 3,984.6 - $2,500.0 million 4.550% notes due March 15, 2035 2,500.0 - 2,462.2 - $1,000.0 million 4.625% notes due October 1, 2042 1,000.0 1,000.0 956.1 980.1 $1,500.0 million 4.850% notes due June 15, 2044 1,500.0 1,500.0 1,483.6 1,539.9 $2,500.0 million 4.750% notes due March 15, 2045 2,500.0 - 2,452.7 - 32,550.0 11,000.0 32,604.2 11,236.7 Total Senior Notes Gross 34,050.0 11,000.0 34,100.5 11,236.7 Unamortized premium 225.9 239.9 - - Unamortized discount (107.4 ) (52.1 ) - - Total Senior Notes Net 34,168.5 11,187.8 34,100.5 11,236.7 Term Loan Indebtedness: WC Term Loan WC 191.5 506.9 WC Five Year Tranche variable rate debt maturing October 1, 2018** 498.8 744.7 690.3 1,251.6 ACT Term Loan 2017 Term Loan variable rate debt maturing October 31, 2017** 572.1 932.6 2019 Term Loan variable rate debt maturing July 1, 2019** 1,700.0 1,900.0 2,272.1 2,832.6 AGN Term Loan AGN Three Year Tranche variable rate debt maturing March 17, 2018 2,750.0 - AGN Five Year Tranche variable rate debt maturing March 17, 2020** 2,543.8 - 5,293.8 - Total Term Loan Indebtedness 8,256.2 4,084.2 Other Indebtedness Revolver Borrowings 200.0 255.0 Other 97.4 - Total Other Borrowings 297.4 255.0 Capital Leases 4.1 4.1 Total Indebtedness $ 42,726.2 $ 15,531.1 **
Schedule of Annual Debt Maturities	As of December 31, 2015, annual debt maturities were as follows ($ in millions): Total Payments 2016 $ 2,175.5 2017 3,999.8 2018 7,095.1 2019 3,325.0 2020 6,093.8 2021 and after 19,617.0 $ 42,306.2 Capital leases 4.1 Other borrowings 297.4 Unamortized premium 225.9 Unamortized discount (107.4 ) Total Indebtedness $ 42,726.2
Schedule of Future Minimum Lease Payments under Capital and Operating Leases	The future minimum lease payments under both capital and operating leases that have remaining terms in excess of one year are ($ in millions): Capital Operating 2016 $ 0.3 $ 29.9 2017 0.3 27.7 2018 0.3 23.6 2019 0.3 21.6 2020 0.3 17.0 Thereafter 2.6 70.8 Total minimum lease payments $ 4.1 $ 190.6 Less: amount representing interest - Present value of net minimum lease payments $ 4.1

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Summary of Other Long-Term Liabilities	Other long-term liabilities consisted of the following ($ in millions): December 31, December 31, 2015 2014 Acquisition related contingent consideration liabilities $ 788.1 $ 139.9 Long-term pension and post retirement liability 222.1 48.1 Legacy Allergan deferred executive compensation 117.9 - Long-term severance and restructuring liabilities 34.9 3.9 Product warranties 28.4 - Long-term contractual obligations 26.4 29.7 Litigation-related reserves - 4.9 Deferred Revenue 18.2 26.3 Other long-term liabilities 26.0 0.5 Total other long-term liabilities $ 1,262.0 $ 253.3

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of (Benefit)/Provision for Income Taxes	The Company’s (benefit)/provision for income taxes consisted of the following ($ in millions): Years Ended December 31, 2015 2014 2013 Current (benefit) provision: U.S. federal $ 14.4 $ (62.0 ) $ (105.1 ) U.S. state 9.7 12.9 (3.6 ) Non-U.S. 225.6 17.2 (14.1 ) Total current (benefit) provision 249.7 (31.9 ) (122.8 ) Deferred (benefit) provision: U.S. federal (1,326.2 ) (304.3 ) (2.0 ) U.S. state (58.7 ) (5.1 ) 0.8 Non-U.S. (426.7 ) (125.7 ) (31.3 ) Total deferred (benefit) provision (1,811.6 ) (435.1 ) (32.5 ) Total provision for income taxes $ (1,561.9 ) $ (467.0 ) $ (155.3 )
Schedule of Components Company's Net Deferred Tax Assets and Liabilities	The significant components of the Company’s net deferred tax assets and liabilities consisted of the following (in millions): Years Ended December 31, 2015 2014 Benefits from net operating and capital losses and tax credit carryforwards $ 1,305.8 $ 709.9 Differences in financial statement and tax accounting for: Inventories, receivables and accruals 1,023.8 404.5 Outside basis differences 5,738.8 - Share-based compensation 596.6 235.9 Basis difference in debt 82.2 89.9 Other 15.7 41.9 Total deferred tax asset, gross $ 8,762.9 $ 1,482.1 Less: Valuation allowance (196.2 ) (474.0 ) Total deferred tax asset, net $ 8,566.7 $ 1,008.1 Differences in financial statement and tax accounting for: Property, equipment and intangible assets (14,080.7 ) (2,346.7 ) Outside basis differences (2,422.2 ) (944.5 ) Total deferred tax liabilities $ (16,502.9 ) $ (3,291.2 ) Total deferred taxes $ (7,936.2 ) $ (2,283.1 )
Schedule of Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in millions): Years Ended December 31, 2015 2014 2013 Balance at the beginning of the year $ 712.2 $ 119.3 $ 5.7 Increases for current year tax positions 41.2 51.3 29.4 Increases for prior year tax positions 19.7 4.2 0.1 Increases due to acquisitions 115.5 567.0 83.7 Decreases for prior year tax positions (41.4 ) (26.6 ) 0.1 Settlements (60.6 ) (0.4 ) (0.6 ) Lapse of applicable statute of limitations (3.2 ) (0.5 ) 0.0 Foreign exchange (1.7 ) (2.1 ) 0.9 Balance at the end of the year $ 781.7 $ 712.2 $ 119.3
Summary of Acquired U.S. Entities and Taxable Years that are Currently under Audit by IRS	Due to our numerous acquisitions, the Company has several concurrent audits still pending with the IRS as set forth below: IRS Audits Taxable Years Actavis, Inc. (f/k/a Watson Pharmaceuticals, Inc.) 2008, 2009, 2010 and 2011 Actavis Inc. 2009, 2010, 2011 and 2012 Warner Chilcott Corporation 2010, 2011 and 2012 Forest Laboratories, Inc. 2007, 2008 and 2009 Aptalis Holdings, Inc. 2013 Durata Therapeutics Inc. 2012 Allergan, Inc. 2009 and 2010
Irish And Bermuda Income Tax Authority [Member]
Schedule of Reconciliations between Statutory Income Tax Rate and Company's Effective Income Tax Rate	The reconciliations for the years ended December 31, 2015, 2014 and 2013 between the statutory Irish and Bermuda income tax rates for Allergan plc and Warner Chilcott Limited, respectively, and the effective income tax rates were as follows: Allergan plc Years Ended December 31, 2015 2014 2013 Statutory rate (12.5 %) (12.5 %) (12.5 %) Earnings subject to the U.S. federal and state tax rates (18.5 %) (11.3 %) (13.9 %) Earnings subject to rates different than the statutory rate (2.3 %) 1.1 % (2.5 %) Tax reserves and audit outcomes 0.3 % 1.3 % 4.8 % Non-deductible expenses 5.4 % 5.0 % 0.1 % R&D credits and U.S. manufacturing deduction (0.5 %) (1.2 %) (0.4 %) Rate changes 0.0 % 1.5 % (0.1 %) Valuation allowances (6.7 %) 0.0 % (0.8 %) Other (0.5 %) (0.1 %) 0.4 % Effective income tax rate (35.3 %) (16.2 %) (24.9 %) Warner Chilcott Limited Years Ended December 31, 2015 2014 2013 Statutory rate 0.0 % 0.0 % 0.0 % Earnings subject to the U.S. federal and state tax rates (29.6 %) (18.1 %) (22.3 %) Earnings subject to rates different than the statutory rate (4.8 %) (5.1 %) (7.7 %) Tax reserves and audit outcomes 0.3 % 1.3 % 5.0 % Non-deductible expenses 5.6 % 5.2 % 0.1 % R&D credits and U.S. manufacturing deduction (0.6 %) (1.2 %) (0.5 %) Rate changes 0.0 % 1.5 % (0.1 %) Valuation allowances (6.9 %) 0.0 % (0.8 %) Other (0.4 %) (0.3 %) 0.2 % Effective income tax rate (36.4 %) (16.7 %) (26.1 %)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Summary of Movements in Accumulated Other Comprehensive (Loss)	Unrealized gain / (losses) net of tax primarily represent experience differentials and other actuarial charges related to the Company’s defined benefit plans. The movements in accumulated other comprehensive (loss) for the years ended December, 2015 and 2014 were as follows ($ in millions): Foreign Currency Translation Items Unrealized gain / (loss) net of tax Total Accumulated Other Comprehensive Income / (Loss) Balance as of December 31, 2013 $ 85.1 $ 5.4 $ 90.5 Other comprehensive (loss) before reclassifications into general and administrative (519.5 ) (36.4 ) (555.9 ) Total other comprehensive (loss) (519.5 ) (36.4 ) (555.9 ) Balance as of December 31, 2014 $ (434.4 ) $ (31.0 ) $ (465.4 ) Other comprehensive gain / (loss) before reclassifications into general and administrative (129.9 ) 101.2 (28.7 ) Total other comprehensive income (129.9 ) 101.2 (28.7 ) Balance as of December 31, 2015 $ (564.3 ) $ 70.2 $ (494.1 )

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment	Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Year Ended December 31, 2015 US US International Anda Brands Aesthetics Brands Distribution Total Net revenues $ 9,134.3 $ 1,513.9 $ 2,187.3 $ 2,225.4 $ 15,060.9 Operating expenses: Cost of sales (1) 1,131.9 99.0 376.4 1,905.3 3,512.6 Selling and marketing 1,664.6 302.9 569.2 146.9 2,683.6 General and administrative 139.6 34.0 125.5 44.2 343.3 Segment Contribution $ 6,198.2 $ 1,078.0 $ 1,116.2 $ 129.0 $ 8,521.4 Contribution margin 67.9 % 71.2 % 51.0 % 5.8 % 56.6 % Corporate 2,940.4 Research and development 2,358.5 Amortization 5,453.4 In-process research and development impairments 511.6 Asset sales and impairments, net 272.0 Operating (loss) (3,014.5 ) Operating margin (20.0 )% (1) Excludes amortization and impairment of acquired intangibles including product rights. Year Ended December 31, 2014 US US Medical International Anda Brands Aesthetics Brands Distribution Total Net revenues $ 4,511.2 $ - $ 203.5 $ 2,024.2 $ 6,738.9 Operating expenses: Cost of sales (1) 736.7 - 48.2 1,711.6 2,496.5 Selling and marketing 806.4 - 48.2 135.6 990.2 General and administrative 119.5 - 12.0 36.4 167.9 Segment Contribution $ 2,848.6 $ - $ 95.1 $ 140.6 $ 3,084.3 Contribution margin 63.1 % 46.7 % 6.9 % 45.8 % Corporate 2,247.0 Research and development 605.7 Amortization 1,945.5 In-process research and development impairments 424.3 Asset sales and impairments, net 305.7 Operating (loss) (2,443.9 ) Operating margin (36.3 )% (1) Excludes amortization and impairment of acquired intangibles including product rights. Year Ended December 31, 2013 US US Medical International Anda Brands Aesthetics Brands Distribution Total Net revenues $ 1,001.2 $ - $ 40.2 $ 1,561.1 $ 2,602.5 Operating expenses: Cost of sales (1) 153.8 - 15.8 1,297.6 1,467.2 Selling and marketing 240.7 - 21.6 112.5 374.8 General and administrative 39.4 - 1.4 32.7 73.5 Segment Contribution $ 567.3 $ - $ 1.4 $ 118.3 $ 687.0 Contribution margin 56.7 % 3.5 % 7.6 % 26.4 % Corporate 560.1 Research and development 191.3 Amortization 303.8 In-process research and development impairments - Asset sales and impairments, net 1.0 Operating (loss) (369.2 ) Operating margin (14.2 )% (1) Excludes amortization and impairment of acquired intangibles including product rights.
Schedule of Reconciliation of Net Revenues for Operating Segments	The following is a reconciliation of net revenues for the operating segments to the Company’s net revenues for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, 2015 2014 2013 Segment net revenues $ 15,060.9 $ 6,738.9 $ 2,602.5 Corporate revenues 10.1 - - Net revenues $ 15,071.0 $ 6,738.9 $ 2,602.5
Schedule Of Revenue Classified By Products	The following tables present global net revenues for the top products of the Company for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, Global U.S. International 2015 2014 2013 2015 2014 2013 2015 2014 2013 Botox® $ 1,975.7 $ - $ - $ 1,386.6 $ - $ - $ 589.1 $ - $ - Restasis® 1,047.8 - - 999.6 - - 48.2 - - Namenda XR® 759.3 269.5 - 759.3 269.5 - - - - Bystolic® 646.1 292.6 - 644.8 291.6 - 1.3 1.0 - Asacol®/Delzicol® 618.5 614.1 164.2 552.9 541.0 145.2 65.6 73.1 19.0 Fillers 573.9 - - 304.3 - - 269.6 - - Namenda® IR 556.3 629.7 - 556.3 629.7 - - - - Lumigan®/Ganfort® 547.3 - - 260.7 - - 286.6 - - Linzess®/Constella® 459.3 174.4 - 454.8 173.2 - 4.5 1.2 - Alphagan®/Combigan® 411.1 - - 285.0 - - 126.1 - - Lo Loestrin® 349.6 277.1 63.3 346.5 275.7 63.3 3.1 1.4 - Viibryd®/Fetzima® 327.6 140.3 - 327.6 140.3 - - - - Estrace® Cream 326.2 258.2 60.7 326.2 258.2 60.7 - - - Minastrin® 24 273.0 217.9 53.7 272.4 217.9 53.7 0.6 - - Silicone Implants 229.7 - - 113.3 - - 116.4 - - Carafate® / Sulcrate® 213.1 90.9 - 213.1 90.9 - - - - Aczone® 170.8 - - 170.8 - - - - - Other Products Revenues 3,360.3 1,750.0 699.5 2,684.1 1,623.2 678.3 676.2 126.8 21.2 Total Products Revenues 12,845.6 4,714.7 1,041.4 10,658.3 4,511.2 1,001.2 2,187.3 203.5 40.2 ANDA Revenues 2,225.4 2,024.2 1,561.1 2,225.4 2,024.2 1,561.1 - - - Total Net Revenues $ 15,071.0 $ 6,738.9 $ 2,602.5 $ 12,883.7 $ 6,535.4 $ 2,562.3 $ 2,187.3 $ 203.5 $ 40.2
US Brands [Member]
Schedule Of Net Revenues by Segment	The following table presents net revenues for the US Brands segment for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, 2015 2014 2013 Central Nervous System (CNS) $ 2,541.2 $ 1,109.4 $ - Eye Care 1,831.3 - - Gastroenterology (GI) 1,575.3 966.8 145.2 Women's Health 998.0 791.7 290.8 Cardiovascular 644.8 291.6 - Urology 238.8 111.9 - Infectious Disease 188.8 62.7 - Other 1,116.1 1,177.1 565.2 Total US Brands Net Revenues $ 9,134.3 $ 4,511.2 $ 1,001.2
US Medical Aesthetics [Member]
Schedule Of Net Revenues by Segment	The following table presents revenues for the US Medical Aesthetics segment for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, 2015 2014 2013 Facial Aesthetics Total $ 817.8 $ - $ - Medical Dermatology Total 493.5 - - Plastic Surgery Total 202.6 - - Total US Medical Aesthetic Net Revenues $ 1,513.9 $ - $ -
International Brands [Member]
Schedule Of Net Revenues by Segment	The following table presents net revenues for the International Brands segment for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Years Ended December 31, 2015 2014 2013 Eye Care $ 924.0 $ - $ - Facial Aesthetics 620.0 - - Other Therapeutics 517.8 203.5 40.2 Plastic Surgery 125.5 - - Total International Brands Net Revenues $ 2,187.3 $ 203.5 $ 40.2

Business Restructuring Charges

Business Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2015
Restructuring And Related Activities [Abstract]
Schedule of Activity Related to Business Restructuring and Facility Rationalization Activities	During 2015, activity related to our business restructuring and facility rationalization activities primarily related to the cost optimization initiatives in conjunction with the Allergan and Forest acquisitions. Restructuring activities for the year ended December 31, 2015 as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2014 $ 111.1 $ - $ - $ 111.1 Acquired liability 27.9 - 29.2 57.1 Charged to expense: Cost of sales 9.3 19.8 23.4 52.5 Research and development 77.7 104.6 - 182.3 Selling and marketing 71.5 47.0 - 118.5 General and administrative 130.5 293.3 42.4 466.2 Total expense 289.0 464.7 65.8 819.5 Cash payments (312.3 ) (127.1 ) (59.1 ) (498.5 ) Other reserve impact (19.0 ) (337.6 ) 12.7 (343.9 ) Reserve balance at December 31, 2015 $ 96.7 $ - $ 48.6 $ 145.3 During 2014, activity related to our business restructuring and facility rationalization activities primarily related to the cost optimization initiatives in conjunction with the Forest and Warner Chilcott acquisitions. Restructuring activities for the year ended December 31, 2014 as follows ($ in millions): Severance Retention Share-Based Compensation Other Total Reserve balance at December 31, 2013 $ 67.5 $ - $ - $ 67.5 Acquired liability 12.2 - - 12.2 Charged to expense: Cost of sales 7.0 3.4 - 10.4 Research and development 22.8 - - 22.8 Selling and marketing 40.9 - - 40.9 General and administrative 71.8 183.2 1.8 256.8 Total expense 142.5 186.6 1.8 330.9 Cash payments (111.1 ) - - (111.1 ) Other reserve impact - (186.6 ) (1.8 ) (188.4 ) Reserve balance at December 31, 2014 $ 111.1 $ - $ - $ 111.1

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value or disclosed at fair value on a recurring basis as of December 31, 2015 and 2014 consisted of the following ($ in millions): Fair Value Measurements as of December 31, 2015 Using: Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 29.9 $ 29.9 $ - $ - Deferred executive compensation investments 118.1 102.3 15.8 - Foreign currency derivatives 73.5 - 73.5 - Marketable equity securities 32.3 32.3 - - Total assets $ 253.8 $ 164.5 $ 89.3 $ - Liabilities: Deferred executive compensation liabilities 117.9 102.1 15.8 - Contingent consideration obligations 868.0 - - 868.0 Total liabilities $ 985.9 $ 102.1 $ 15.8 $ 868.0 Fair Value Measurements as of December 31, 2014 Using: Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 1.0 $ 1.0 $ - $ - Foreign currency derivatives 2.3 - 2.3 - Total assets $ 3.3 $ 1.0 $ 2.3 $ - Liabilities: Contingent consideration obligations 373.8 - - 373.8 Total liabilities $ 373.8 $ - $ - $ 373.8
Summary of Notional Principal and Fair Value of Company's Outstanding Foreign Currency Derivative Financial Instruments	At December 31, 2015 and 2014, the notional principal and fair value of the Company’s outstanding foreign currency derivative financial instruments were as follows ($ in millions, except average contract rate or strike amount): Year Ended December 31, 2015 Year Ended December 31, 2014 Notional Principal Average Contract Rate or Strike Amount Notional Principal Average Contract Rate or Strike Amount Foreign currency forward contracts: (Receive U.S. dollar/pay foreign currecy) Russian ruble $ 18.8 1.41 $ 10.3 1.05 $ 18.8 $ 10.3 Estimated fair value $ (0.3 ) $ 2.3 Foreign currency sold - put options: Euro 340.5 1.41 - $ 340.5 $ - Estimated fair value $ 73.5 $ -
Change in Fair Value of Contingent Consideration Obligations	Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions): Years Ended December 31, Expense / (income) 2015 2014 2013 Cost of sales $ 58.5 $ (9.9 ) $ 5.8 Research and development 37.7 (69.3 ) 1.1 General and administrative - 0.4 3.2 Total $ 96.2 $ (78.8 ) $ 10.1
Summary of Changes in Fair Value of all Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs	The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and 2014 ($ in millions): Balance as of December 31, 2014 Net transfers in to (out of) Level 3 Purchases and settlements, net Net accretion and fair value adjustments Foreign currency translation Balance as of December 31, 2015 Liabilities: Contingent consideration obligations $ 373.8 $ - $ 405.1 $ 96.2 $ (7.1 ) $ 868.0 Balance at December 31, 2013 Net transfers in to (out of) Level 3 Purchases and settlements, net Net accretion and fair value adjustments Foreign currency translation Balance at December 2014 Liabilities: Contingent consideration obligations $ 203.8 $ - $ 251.9 $ (78.8 ) $ (3.1 ) $ 373.8
Schedule of Contingent Consideration Obligations	During the year ended December 31, 2015, the following activity in contingent consideration obligations by acquisition was incurred ($ in millions): Balance as of December 31, 2014 Acquisitions Fair Value Adjustments Payments and Other Balance as of December 31, 2015 Medicines 360 acquisition $ 126.6 $ - $ 93.6 $ (76.1 ) $ 144.1 Furiex Acquisition 88.4 - 30.2 (118.6 ) - Forest Acquisition 52.4 - (29.8 ) (2.2 ) 20.4 Durata Acquisition 49.0 - 6.4 (30.9 ) 24.5 Metrogel acquisition 31.2 - (0.4 ) 0.1 30.9 Uteron acquisition 10.4 - (2.1 ) (0.1 ) 8.2 Allergan Acquisition - 383.7 3.1 (57.1 ) 329.7 Oculeve Acquisition - 90.0 - - 90.0 AqueSys Acquisition - 193.5 - - 193.5 Other 15.8 15.8 (4.8 ) (0.1 ) 26.7 Total $ 373.8 $ 683.0 $ 96.2 $ (285.0 ) $ 868.0

Warner Chilcott Limited ("WCL60

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information (Tables) - Warner Chilcott Acquisition [Member]	12 Months Ended
	Dec. 31, 2015
Consolidating Balance Sheets	Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2015 ($ in millions) Current assets: Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash and cash equivalents $ - $ 13.5 $ - $ 2.0 $ 1,020.7 $ - $ 1,036.2 Marketable securities - - - - 9.3 - 9.3 Accounts receivable, net - - - - 2,401.6 - 2,401.6 Receivable from Parents - - - - 457.3 - 457.3 Inventories, net - - - - 1,009.7 - 1,009.7 Intercompany receivables - 94,999.2 25,225.6 302.4 101,864.8 (222,392.0 ) - Prepaid expenses and other current assets - 12.6 24.5 6.1 512.8 - 556.0 Current assets held for sale - - - - 3,540.3 - 3,540.3 Deferred tax assets - - - - - - - Total current assets - 95,025.3 25,250.1 310.5 110,816.5 (222,392.0 ) 9,010.4 Property, plant and equipment, net - - - 34.3 1,539.6 - 1,573.9 Investments and other assets - 14.1 124.6 37.7 401.0 - 577.4 Investment in subsidiaries 75,571.6 79,597.3 - 6,742.7 - (161,911.6 ) - Non current assets held for sale - - - 45.8 10,495.5 - 10,541.3 Deferred tax assets - - - - 49.5 - 49.5 Product rights and other intangibles - - - - 67,931.7 - 67,931.7 Goodwill - - - - 46,551.5 - 46,551.5 Total assets $ 75,571.6 $ 174,636.7 $ 25,374.7 $ 7,171.0 $ 237,785.3 $ (384,303.6 ) $ 136,235.7 Current liabilities: Accounts payable and accrued expenses - 3.9 210.5 171.5 3,909.5 - 4,295.4 Intercompany payables - 92,093.5 526.3 9,245.0 120,527.2 (222,392.0 ) - Payable to Parents - - - - 1,466.8 - 1,466.8 Income taxes payable - - - 44.1 10.1 - 54.2 Current portion of long-term debt and capital leases - 756.7 - - 1,676.1 - 2,432.8 Current liabilities held for sale - - - 23.3 1,468.5 - 1,491.8 Deferred tax liabilities - - - - - - - Total current liabilities - 92,854.1 736.8 9,483.9 129,058.2 (222,392.0 ) 9,741.0 Long-term debt and capital leases - 7,009.1 24,637.6 4,273.5 4,373.2 - 40,293.4 Other long-term liabilities - - - - 1,262.0 - 1,262.0 Non current liabilities held for sale - - - - 580.1 - 580.1 Other taxes payable - - - 72.1 729.8 - 801.9 Deferred tax liabilities - - - - 7,985.7 - 7,985.7 Total liabilities - 99,863.2 25,374.4 13,829.5 143,989.0 (222,392.0 ) 60,664.1 Total equity 75,571.6 74,773.5 0.3 (6,658.5 ) 93,796.3 (161,911.6 ) 75,571.6 Total liabilities and equity $ 75,571.6 $ 174,636.7 $ 25,374.7 $ 7,171.0 $ 237,785.3 $ (384,303.6 ) $ 136,235.7 Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2014 ($ in millions) Current assets: Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash and cash equivalents $ 0.1 $ 5.5 $ - $ 1.5 $ 237.2 $ - $ 244.3 Marketable securities - - - - 1.0 - 1.0 Accounts receivable, net - - - - 1,111.6 - 1,111.6 Receivable from Parents - - - - 269.8 - 269.8 Inventories - - - - 984.6 - 984.6 Intercompany receivables - 22,987.9 3,659.0 18,720.9 52,730.5 (98,098.3 ) - Prepaid expenses and other current assets - 123.1 2.7 - 350.1 - 475.9 Current assets held for sale - - - - 3,806.9 - 3,806.9 Deferred tax assets - - - - 477.0 - 477.0 Total current assets 0.1 23,116.5 3,661.7 18,722.4 59,968.7 (98,098.3 ) 7,371.1 Property, plant and equipment, net - - - 8.2 274.3 - 282.5 Investments and other assets - 9.0 23.6 82.0 38.7 - 153.3 Investment in subsidiaries 28,076.9 31,549.0 - 4,761.1 - (64,387.0 ) - Non current assets held for sale - - - 43.4 8,144.3 - 8,187.7 Deferred tax assets - - - - 34.7 - 34.7 Product rights and other intangibles - - - - 16,090.7 - 16,090.7 Goodwill - - - - 20,897.6 - 20,897.6 Total assets $ 28,077.0 $ 54,674.5 $ 3,685.3 $ 23,617.1 $ 105,449.0 $ (162,485.3 ) $ 53,017.6 Current liabilities: Accounts payable and accrued expenses - 2.8 6.1 112.7 2,905.4 - 3,027.0 Intercompany payables - 25,953.8 2.0 26,774.7 45,367.8 (98,098.3 ) - Payable to Parents - - - - 521.1 - 521.1 Income taxes payable - - - 33.9 - - 33.9 Current portion of long-term debt and capital leases - 571.6 - - 121.8 - 693.4 Current liabilities held for sale - - - 62.8 1,386.3 - 1,449.1 Deferred tax liabilities - - - - 41.0 - 41.0 Total current liabilities - 26,528.2 8.1 26,984.1 50,343.4 (98,098.3 ) 5,765.5 Long-term debt and capital leases - 2,516.0 3,677.2 4,270.7 4,373.8 - 14,837.7 Other long-term liabilities - - - - 253.4 - 253.4 Non current liabilities for sale 102.7 438.0 540.7 Other taxes payable - - - 789.5 - - 789.5 Deferred tax liabilities - - - - 2,753.8 - 2,753.8 Total liabilities - 29,044.2 3,685.3 32,147.0 58,162.4 (98,098.3 ) 24,940.6 Total equity 28,077.0 25,630.3 - (8,529.9 ) 47,286.6 (64,387.0 ) 28,077.0 Total liabilities and equity $ 28,077.0 $ 54,674.5 $ 3,685.3 $ 23,617.1 $ 105,449.0 $ (162,485.3 ) $ 53,017.6
Consolidating Statements of Operations	Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2015 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 15,071.0 $ - $ 15,071.0 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 4,810.4 - 4,810.4 Research and development - - - - 2,358.5 - 2,358.5 Selling and marketing - - - - 2,914.0 - 2,914.0 General and administrative - 212.1 16.1 - 1,402.0 - 1,630.2 Amortization - - - - 5,453.4 - 5,453.4 In-process research and development impairments - - - - 511.6 - 511.6 Asset sales and impairments, net - - - - 272.0 - 272.0 Total operating expenses - 212.1 16.1 - 17,721.9 - 17,950.1 Operating income / (loss) - (212.1 ) (16.1 ) - (2,650.9 ) - (2,879.1 ) Non-operating income (expense): Interest income / (expense), net - 1,572.4 (14.6 ) (168.5 ) (2,571.2 ) - (1,181.9 ) Other income (expense), net - (265.4 ) 31.0 - 0.6 - (233.8 ) Total other income (expense), net - 1,307.0 16.4 (168.5 ) (2,570.6 ) - (1,415.7 ) Income / (loss) before income taxes and noncontrolling interest - 1,094.9 0.3 (168.5 ) (5,221.5 ) - (4,294.8 ) Provision for income taxes - - - (58.3 ) (1,503.6 ) - (1,561.9 ) (Earnings) / losses of equity interest subsidiaries (4,050.6 ) (4,336.5 ) - (1,981.6 ) - 10,368.7 - Net income / (loss) from continuing operations, net of tax $ 4,050.6 $ 5,431.4 $ 0.3 $ 1,871.4 $ (3,717.9 ) $ (10,368.7 ) $ (2,732.9 ) Income from discontinued operations - - - - 6,787.7 - 6,787.7 Net income / (loss) $ 4,050.6 $ 5,431.4 $ 0.3 $ 1,871.4 $ 3,069.8 $ (10,368.7 ) $ 4,054.8 (Income) attributable to noncontrolling interest - - - - (4.2 ) - (4.2 ) Net income / (loss) attributable to ordinary shareholders $ 4,050.6 $ 5,431.4 $ 0.3 $ 1,871.4 $ 3,065.6 $ (10,368.7 ) $ 4,050.6 Other comprehensive (loss) / income (28.7 ) 24.5 - - (28.7 ) 4.2 (28.7 ) Comprehensive income / (loss) $ 4,021.9 $ 5,455.9 $ 0.3 $ 1,871.4 $ 3,036.9 $ (10,364.5 ) $ 4,021.9 Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2014 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues - - - - 6,738.9 - 6,738.9 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 3,453.6 - 3,453.6 Research and development - - - - 605.7 - 605.7 Selling and marketing - - - - 1,201.0 - 1,201.0 General and administrative - - - 9.9 1,167.1 - 1,177.0 Amortization - - - - 1,945.5 - 1,945.5 In process research and development impairments - - - - 424.3 - 424.3 Asset sales and impairments, net - - - (0.1 ) 305.8 - 305.7 Total operating expenses - - - 9.8 9,103.0 - 9,112.8 Operating income / (loss) - - - (9.8 ) (2,364.1 ) - (2,373.9 ) Non-operating income (expense): Interest income / (expense), net - (740.0 ) - (182.0 ) 519.1 - (402.9 ) Other income (expense), net - (74.5 ) - - 47.2 - (27.3 ) Total other income (expense), net - (814.5 ) - (182.0 ) 566.3 - (430.2 ) Income / (loss) before income taxes and noncontrolling interest - (814.5 ) - (191.8 ) (1,797.8 ) - (2,804.1 ) Provision for income taxes - - - (108.6 ) (358.4 ) - (467.0 ) Losses / (earnings) of equity interest subsidiaries 1,560.5 539.7 - (886.2 ) - (1,214.0 ) - Net (loss) / income from continuing operations, net of tax $ (1,560.5 ) $ (1,354.2 ) $ - $ 803.0 $ (1,439.4 ) $ 1,214.0 $ (2,337.1 ) (Loss) / income from discontinued operations - - - (70.0 ) 846.6 - 776.6 Net (loss) / income $ (1,560.5 ) $ (1,354.2 ) $ - $ 733.0 $ (592.8 ) $ 1,214.0 $ (1,560.5 ) (Income) / loss attributable to noncontrolling interest - - - - - - - Net (loss) / income attributable to ordinary shareholders $ (1,560.5 ) $ (1,354.2 ) $ - $ 733.0 $ (592.8 ) $ 1,214.0 $ (1,560.5 ) Other comprehensive (loss) / income (555.9 ) (505.9 ) - - (555.9 ) 1,061.8 (555.9 ) Comprehensive (loss) / income $ (2,116.4 ) $ (1,860.1 ) $ - $ 733.0 $ (1,148.7 ) $ 2,275.8 $ (2,116.4 ) Warner Chilcott Limited Consolidating Statements of Operations and Comprehensive Income / (Loss) For the Year Ended December 31, 2013 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 2,602.5 $ - $ 2,602.5 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 1,644.7 - 1,644.7 Research and development - - - - 191.3 - 191.3 Selling and marketing - - - - 374.8 - 374.8 General and administrative - 0.3 - 75.0 356.4 - 431.7 Amortization - - - - 303.8 - 303.8 In process research and development impairments - - - - - - - Asset sales and impairments, net - - - (0.3 ) 1.3 - 1.0 Total operating expenses - 0.3 - 74.7 2,872.3 - 2,947.3 Operating income / (loss) - (0.3 ) - (74.7 ) (269.8 ) - (344.8 ) Non-operating income (expense): Interest income / (expense), net - 87.5 - 264.5 (587.0 ) - (235.0 ) Other income (expense), net - (1.1 ) - (6.4 ) (11.1 ) - (18.6 ) Total other income (expense), net - 86.4 - 258.1 (598.1 ) - (253.6 ) Income / (loss) before income taxes and noncontrolling interest - 86.1 - 183.4 (867.9 ) - (598.4 ) Provision for income taxes - - - 19.1 (175.3 ) - (156.2 ) (Earnings) / losses of equity interest subsidiaries 724.5 162.2 - 498.8 - (1,385.5 ) - Net (loss) / income from continuing operations, net of tax $ (724.5 ) $ (76.1 ) $ - $ (334.5 ) $ (692.6 ) $ 1,385.5 $ (442.2 ) Income / (loss) from discontinued operations - - - - (282.3 ) - (282.3 ) Net (loss) /income $ (724.5 ) $ (76.1 ) $ - $ (334.5 ) $ (974.9 ) $ 1,385.5 $ (724.5 ) (Income) / loss attributable to noncontrolling interest - - - - - - - Net income / (loss) attributable to ordinary shareholders $ (724.5 ) $ (76.1 ) $ - $ (334.5 ) $ (974.9 ) $ 1,385.5 $ (724.5 ) Other comprehensive income / (loss) 53.7 48.2 - 6.7 53.7 (108.6 ) 53.7 Comprehensive (loss) / income $ (670.8 ) $ (27.9 ) $ - $ (327.8 ) $ (921.2 ) $ 1,276.9 $ (670.8 )
Consolidating Statement of Cash Flows	Warner Chilcott Limited Consolidating Statement of Cash Flows For the Year Ended December 31, 2015 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net income / (loss) $ 4,050.6 $ 5,431.4 $ 0.3 $ 1,871.4 $ 3,069.8 $ (10,368.7 ) $ 4,054.8 Reconciliation to net cash provided by operating activities: (Earnings) / losses of equity interest subsidiaries (4,050.6 ) (4,336.5 ) - (1,981.6 ) - 10,368.7 - Depreciation - - - 0.2 218.1 - 218.3 Amortization - - - - 5,777.0 - 5,777.0 Provision for inventory reserve - - - - 140.9 - 140.9 Share-based compensation - - - 51.6 638.8 - 690.4 Deferred income tax benefit - - - - (7,380.1 ) - (7,380.1 ) In-process research and development impairments - - - - 511.6 - 511.6 Loss / (gain) on asset sales and impairments, net - - - - 334.4 - 334.4 Amortization of inventory step-up - - - - 1,192.9 - 1,192.9 Amortization of deferred financing costs - 272.5 20.9 4.1 0.8 - 298.3 Accretion and contingent consideration - - - - 108.8 - 108.8 Dividends from subsidiaries 208.1 208.1 - - - (416.2 ) - Other, net - - - - 66.4 - 66.4 Changes in assets and liabilities (net of effects of acquisitions) (0.1 ) (370.6 ) 122.5 97.7 (1,199.2 ) - (1,349.7 ) Net cash provided by / (used in) operating activities 208.0 1,204.9 143.7 43.4 3,480.2 (416.2 ) 4,664.0 Cash Flows From Investing Activities: Additions to property plant and equipment - - - (42.9 ) (412.0 ) - (454.9 ) Additions to product rights and other intangibles - - - - (154.7 ) - (154.7 ) Additions to investments (9,000.8 ) (9,000.8 ) - - (24.3 ) 18,001.6 (24.3 ) Proceeds from sale of investments and other assets - - - - 883.0 - 883.0 Proceeds from sales of property, plant and equipment - - - - 140.1 - 140.1 Acquisitions of business, net of cash acquired - - - - (37,510.1 ) - (37,510.1 ) Net cash (used in) investing activities (9,000.8 ) (9,000.8 ) - (42.9 ) (37,078.0 ) 18,001.6 (37,120.9 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness - 5,500.0 20,955.6 - 0.1 - 26,455.7 Financing structure and other activity with affiliates - (5,500.0 ) (20,955.6 ) - 26,455.6 - - Proceeds from borrowings on credit facility and other - 3,610.0 - - 72.0 - 3,682.0 Debt issuance and other financing costs - (167.1 ) (143.7 ) - - - (310.8 ) Payments on debt, including capital lease obligations - (4,431.7 ) - - (702.5 ) - (5,134.2 ) Payments of contingent consideration - - - - (230.1 ) - (230.1 ) Dividends to Parent (208.1 ) (208.1 ) - - (208.1 ) 416.2 (208.1 ) Contribution from Parent 9,000.8 9,000.8 - - 9,000.8 (18,001.6 ) 9,000.8 Net cash provided by / (used in) financing activities 8,792.7 7,803.9 (143.7 ) - 34,387.8 (17,585.4 ) 33,255.3 Effect of currency exchange rate changes on cash and cash equivalents - - - - (6.5 ) - (6.5 ) Movement in cash held for sale - - - - - - - Net increase / (decrease) in cash and cash equivalents (0.1 ) 8.0 - 0.5 783.5 - 791.9 Cash and cash equivalents at beginning of period 0.1 5.5 - 1.5 237.2 - 244.3 Cash and cash equivalents at end of period $ - $ 13.5 $ - $ 2.0 $ 1,020.7 $ - $ 1,036.2 Warner Chilcott Limited Consolidating Statement of Cash Flows For the Year Ended December 31, 2014 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (1,560.5 ) $ (1,354.2 ) $ - $ 733.0 $ (592.8 ) $ 1,214.0 $ (1,560.5 ) Reconciliation to net cash provided by operating activities: Losses / (earnings) of equity interest subsidiaries 1,560.5 539.7 - (886.2 ) - (1,214.0 ) - Depreciation - - - 0.2 230.7 - 230.9 Amortization - - - - 2,597.5 - 2,597.5 Provision for inventory reserve - - - - 156.1 - 156.1 Share-based compensation - - - 1.4 366.6 - 368.0 Deferred income tax benefit - - - - (690.1 ) - (690.1 ) In-process research and development impairments - - - - 424.3 - 424.3 Goodwill Impairment - - - - 17.3 - 17.3 Loss / (gain) on asset sales and impairments, net - - - - 143.1 - 143.1 Amortization of inventory step-up - - - - 985.8 - 985.8 Amortization of deferred financing costs - 1.0 22.9 2.4 60.9 - 87.2 Accretion and contingent consideration - - - - (71.2 ) - (71.2 ) Non-cash impact of debt extinguishment - - - - (91.7 ) - (91.7 ) Impact of assets held for sale - - - - 190.8 - 190.8 Other, net - - - - 8.5 - 8.5 Changes in assets and liabilities (net of effects of acquisitions) - 1,156.5 (3,647.2 ) 159.2 1,805.2 - (526.3 ) Net cash provided by / (used in) operating activities - 343.0 (3,624.3 ) 10.0 5,541.0 - 2,269.7 Cash Flows From Investing Activities: Additions to property plant and equipment - - - (9.9 ) (228.7 ) - (238.6 ) Additions to product rights and other intangibles - - - - (36.1 ) - (36.1 ) Additions to investments - - - - (1.0 ) - (1.0 ) Proceeds from sale of investments and other assets - - - - 453.7 - 453.7 Proceeds from sales of property, plant and equipment - - - - 13.7 - 13.7 Acquisitions of business, net of cash acquired - - - - (5,562.3 ) - (5,562.3 ) Net cash (used in) investing activities - - - (9.9 ) (5,360.7 ) - (5,370.6 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness - - 6,076.2 - 2,000.0 - 8,076.2 Proceeds from borrowings on credit facility and other - 80.0 - - 1,200.0 - 1,280.0 Debt issuance and other financing costs - - (51.9 ) - (172.4 ) - (224.3 ) Payments on debt, including capital lease obligations - (417.8 ) (2,400.0 ) - (3,309.2 ) - (6,127.0 ) Payments of contingent consideration - - - - (14.3 ) - (14.3 ) Dividends to Parent - - - - - - - Contribution from Parent - - - - - - - Net cash provided by / (used in) financing activities - (337.8 ) 3,624.3 - (295.9 ) - 2,990.6 Effect of currency exchange rate changes on cash and cash equivalents - - - - (5.9 ) - (5.9 ) Movement in cash held for sale - - - - 37.0 - 37.0 Net increase / (decrease) in cash and cash equivalents - 5.2 - 0.1 (84.5 ) - (79.2 ) Cash and cash equivalents at beginning of period 0.1 0.3 - 1.4 321.7 - 323.5 Cash and cash equivalents at end of period $ 0.1 $ 5.5 $ - $ 1.5 $ 237.2 $ - $ 244.3 Warner Chilcott Limited Consolidating Statement of Cash Flows For the Year Ended December 31, 2013 ($ in millions) Warner Chilcott Limited (Parent Guarantor) Actavis Capital S.a.r.l. (Guarantor) Actavis Funding SCS (Issuer) Actavis Inc. (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (724.5 ) $ (76.1 ) $ - $ (334.5 ) $ (974.9 ) $ 1,385.5 $ (724.5 ) Reconciliation to net cash provided by operating activities: Losses / (earnings) of equity interest subsidiaries 724.5 162.2 - 498.8 - (1,385.5 ) - Depreciation - - - 1.0 201.0 - 202.0 Amortization - - - - 842.7 - 842.7 Provision for inventory reserve - - - - 113.8 - 113.8 Share-based compensation - - - 48.2 85.4 - 133.6 Deferred income tax benefit - - - - (275.0 ) - (275.0 ) In-process research and development impairments - - - - 4.9 - 4.9 Goodwill Impairment - - - - 647.5 - 647.5 Loss / (gain) on asset sales and impairments, net - - - - 55.9 - 55.9 Amortization of inventory step-up - - - - 267.0 - 267.0 Amortization of deferred financing costs - - - - 10.3 - 10.3 Accretion and contingent consideration - - - - 160.0 - 160.0 Excess tax benefit from stock-based compensation - - - (69.2 ) 0.1 - (69.1 ) Non-cash impact of debt extinguishment - - - - - - - Impact of assets held for sale - - - - 42.7 - 42.7 Other, net - - - - (9.0 ) - (9.0 ) Changes in assets and liabilities (net of effects of acquisitions) 0.1 (86.1 ) - 503.8 (613.4 ) - (195.6 ) Net cash provided by operating activities 0.1 - - 648.1 559.0 - 1,207.2 Cash Flows From Investing Activities: Additions to property plant and equipment - - - (17.6 ) (160.3 ) - (177.9 ) Additions to product rights and other intangibles - - - - (130.0 ) - (130.0 ) Additions to investments - - - - - - - Proceeds from sale of investments and other assets - - - - 40.6 - 40.6 Proceeds from sales of property, plant and equipment - - - - 7.1 - 7.1 Acquisitions of business, net of cash acquired - - - - (15.1 ) - (15.1 ) Net cash (used in) investing activities - - - (17.6 ) (257.7 ) - (275.3 ) Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness - - - - 1,882.3 - 1,882.3 Proceeds from borrowings on credit facility and other - 430.0 - 125.0 - - 555.0 Debt issuance and other financing costs - (2.2 ) - (0.5 ) (4.7 ) - (7.4 ) Payments on debt, including capital lease obligations - (427.5 ) - (702.5 ) (2,099.5 ) - (3,229.5 ) Proceeds from stock plans - - - 44.0 - - 44.0 Payments of contingent consideration - - - - (4.3 ) - (4.3 ) Repurchase of ordinary shares - - - (165.4 ) - - (165.4 ) Acquisition of noncontrolling interest - - - - (10.4 ) - (10.4 ) Excess tax benefit from stock-based compensation - - - 69.2 - - 69.2 Net cash provided by / (used in) financing activities - 0.3 - (630.2 ) (236.6 ) - (866.5 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - (23.9 ) - (23.9 ) Movement in cash held for sale - - - - (37.0 ) - (37.0 ) Net increase / (decrease) in cash and cash equivalents 0.1 0.3 - 0.3 3.8 - 4.5 Cash and cash equivalents at beginning of period - - - 1.1 317.9 - 319.0 Cash and cash equivalents at end of period $ 0.1 $ 0.3 $ - $ 1.4 $ 321.7 $ - $ 323.5

Compensation (Tables)

Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Compensation Related Costs [Abstract]
Schedule of Compensation Charges	The following table represents compensation costs for the years ended December 31, 2015, 2014 and 2013 ($ in millions): Year Ended December 31, 2015 2014 2013 Wages and salaries $ 2,252.3 $ 1,557.9 $ 887.2 Stock-based compensation 925.7 401.2 133.6 Pensions 99.9 89.0 53.9 Social welfare 185.1 97.1 62.4 Other benefits 271.6 231.8 287.7 Total $ 3,734.6 $ 2,377.0 $ 1,424.8 Amount included in continuing operations $ 2,681.0 $ 1,332.9 $ 558.2 Amount included in discontinued operations $ 1,053.6 $ 1,044.1 $ 866.6

Concentration (Tables)

Concentration (Tables)	12 Months Ended
	Dec. 31, 2015
Risks And Uncertainties [Abstract]
Schedule of Concentration on Revenues	The following table illustrates any customer, on a global basis, which accounted for 10% or more of our annual revenues in any of the past three fiscal years and the respective percentage of our revenues for which they account for each of the last three years: Customer 2015 2014 2013 McKesson Corporation 24 % 22 % 11 % Cardinal Health, Inc. 18 % 16 % 10 % AmerisourceBergen Corporation 17 % 17 % 6 %

Supplementary Data (Tables)

Supplementary Data (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Consolidated Financial Data and Market Price Information	Selected unaudited quarterly consolidated financial data and market price information are shown below ($ in millions except per share data): For Three Month Periods Ended Year Ended 12/31/2015 Dec. 31, 2015 Sept. 30, 2015 June 30, 2015 Mar. 31, 2015 Net revenues $ 15,071.0 $ 4,197.5 $ 4,088.9 $ 4,222.0 $ 2,562.6 Net income/(loss) $ 3,919.4 $ (629.3 ) $ 5,302.6 $ (241.6 ) $ (512.3 ) Basic earnings per share 10.01 (1.78 ) 13.29 (0.80 ) (1.85 ) Diluted earnings per share 10.01 (1.78 ) 13.29 (0.80 ) (1.85 ) Market price per share: High $ 322.68 $ 340.34 $ 315.00 $ 317.72 Low $ 237.50 $ 245.32 $ 279.74 $ 253.00 For Three Month Periods Ended Year Ended 12/31/2014 Dec. 31, 2014 Sept. 30, 2014 June 30, 2014 Mar. 31, 2014 Net revenues $ 6,738.9 $ 2,415.6 $ 2,150.8 $ 1,087.2 $ 1,085.3 Net income/(loss) $ (1,630.5 ) $ (733.2 ) $ (1,042.8 ) $ 48.8 $ 96.7 Basic earnings per share (7.42 ) (3.34 ) (3.95 ) 0.28 0.56 Diluted earnings per share (7.42 ) (3.34 ) (3.95 ) 0.28 0.55 Market price per share: High $ 272.75 $ 249.94 $ 226.23 $ 230.77 Low $ 208.64 $ 201.91 $ 184.71 $ 166.38

Description of Business - Addit

Description of Business - Additional Information (Detail) shares in Millions, $ in Millions	Jul. 26, 2015USD ($)shares	Mar. 17, 2015USD ($)	Dec. 31, 2015USD ($)Country
Segment Reporting Information [Line Items]
Number of operating countries | Country			100
Agreement date of the transaction			May 19, 2013
Allergan Global Generic Pharmaceuticals Business and Certain Other Assets | Teva Pharmaceutical Industries Ltd [Member]
Segment Reporting Information [Line Items]
Proceeds Expected To Be Received From Divestiture of Businesses	$ 33,750
Ordinary shares expected to be received from divestiture of businesses | shares	100.3
Stock Expected To Be Received In Divestiture of Businesses	$ 6,750
Business divestiture expected effective period description			The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2016; however, it is possible that closing could slip beyond the end of the first quarter.
Pfizer Inc
Segment Reporting Information [Line Items]
Agreement date of the transaction			Nov. 23, 2015
Stock transaction valuation			$ 160,000
Shares issued in connection with acquisition, ratio			100.00%
Allergan, Inc. [Member]
Segment Reporting Information [Line Items]
Stock transaction valuation		$ 34,700
Shares issued in connection with acquisition, ratio			1130.00%

Formation of the Company - Addi

Formation of the Company - Additional Information (Detail) $ / shares in Units, shares in Millions, $ in Millions	Mar. 17, 2015USD ($)shares	Oct. 01, 2013USD ($)Ratio	Dec. 31, 2015$ / shares	Dec. 31, 2014$ / shares
Business Acquisition [Line Items]
Date of incorporation as a private limited company			May 16, 2013
Effective date of re-registration as a public limited company			Sep. 20, 2013
Agreement date of the transaction			May 19, 2013
Ordinary shares, par value | $ / shares			$ 0.0001	$ 0.0001
Class A [Member]
Business Acquisition [Line Items]
Ordinary shares, par value | $ / shares			$ 0.0033
Warner Chilcott and Actavis Inc. [Member]
Business Acquisition [Line Items]
Ordinary share, conversion ratio | Ratio		0.160
Stock transaction valuation		$ 5,833.9
Actavis Group [Member]
Business Acquisition [Line Items]
Ordinary share, conversion ratio | Ratio		1
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Stock transaction valuation	$ 34,700
Business acquisition, purchase consideration cash paid	77,000
Outstanding indebtedness	2,200
Payments to acquire business, cash	$ 40,100
Business acquisition date			Mar. 17, 2015
Shares issued to acquire entity | shares	111.2
Allergan, Inc. [Member] | Non-qualified Options [Member]
Business Acquisition [Line Items]
Shares issued to acquire entity | shares	7
Allergan, Inc. [Member] | Restricted Stock Units (RSUs) [Member]
Business Acquisition [Line Items]
Shares issued to acquire entity | shares	0.5

Reconciliation of Warner Chil66

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Summary of Assets Reconciliation Results of Warner Chilcott Limited to Allergan Plc (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	$ 1,096	$ 250	$ 329	$ 319
Prepaid expenses and other current assets	558.5	478.8
Property, plant and equipment, net	1,573.9	283.4
Accounts payable and accrued liabilities	4,349.5	3,030.1
Material Reconciling Items [Member] | Allergan plc [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	1,096	250
Accounts receivable, net	2,401.6	1,112.3
Prepaid expenses and other current assets	558.5	478.8
Property, plant and equipment, net	1,573.9	283.4
Accounts payable and accrued liabilities	4,349.5	3,030.1
Material Reconciling Items [Member] | Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	1,036.2	244.3
Accounts receivable, net	2,401.6	1,111.6
Prepaid expenses and other current assets	556	475.9
Property, plant and equipment, net	1,573.9	282.5
Accounts payable and accrued liabilities	4,295.4	3,027
Material Reconciling Items [Member] | Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	59.8	5.7
Accounts receivable, net		0.7
Prepaid expenses and other current assets	2.5	2.9
Property, plant and equipment, net		0.9
Accounts payable and accrued liabilities	$ 54.1	$ 3.1

Reconciliation of Warner Chil67

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Summary of Operating Profit Loss Reconciliation Results of Warner Chilcott Limited to Allergan Plc (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									$ 1,765.6	$ 1,247	$ 456.1
Operating (loss)									(3,014.5)	(2,443.9)	(369.2)
(Loss) before income taxes and noncontrolling interest									(4,430.2)	(2,874.1)	(622.8)
(Benefit)/provision for income taxes									(1,561.9)	(467)	(155.3)
Net (loss) from continuing operations, net of tax									(2,868.3)	(2,407.1)	(467.5)
Net income / (loss)	$ (629.3)	$ 5,302.6	$ (241.6)	$ (512.3)	$ (733.2)	$ (1,042.8)	$ 48.8	$ 96.7	3,919.4	(1,630.5)	(750.4)
Net income / (loss) attributable to ordinary shareholders/members		$ 5,086.6							3,683.2	(1,630.5)	(750.4)
Dividends on preferred stock									232
Material Reconciling Items [Member] | Allergan plc [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									1,765.6	1,247	456.1
Operating (loss)									(3,014.5)	(2,443.9)	(369.2)
(Loss) before income taxes and noncontrolling interest									(4,430.2)	(2,874.1)	(622.8)
(Benefit)/provision for income taxes									(1,561.9)	(467)	(155.3)
Net (loss) from continuing operations, net of tax									(2,868.3)	(2,407.1)	(467.5)
Net income / (loss)									3,919.4	(1,630.5)	(750.4)
Net income / (loss) attributable to ordinary shareholders/members									3,683.2	(1,630.5)	(750.4)
Dividends on preferred stock									232
Material Reconciling Items [Member] | Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									1,630.2	1,177	431.7
Operating (loss)									(2,879.1)	(2,373.9)	(344.8)
(Loss) before income taxes and noncontrolling interest									(4,294.8)	(2,804.1)	(598.4)
(Benefit)/provision for income taxes									(1,561.9)	(467)	(156.2)
Net (loss) from continuing operations, net of tax									(2,732.9)	(2,337.1)	(442.2)
Net income / (loss)									4,054.8	(1,560.5)	(724.5)
Net income / (loss) attributable to ordinary shareholders/members									4,050.6	(1,560.5)	(724.5)
Material Reconciling Items [Member] | Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses									135.4	70	24.4
Operating (loss)									(135.4)	(70)	(24.4)
(Loss) before income taxes and noncontrolling interest									(135.4)	(70)	(24.4)
(Benefit)/provision for income taxes											0.9
Net (loss) from continuing operations, net of tax									(135.4)	(70)	(25.3)
Net income / (loss)									(135.4)	(70)	(25.9)
Net income / (loss) attributable to ordinary shareholders/members									(367.4)	$ (70)	$ (25.9)
Dividends on preferred stock									$ 232

Summary of Significant Accoun68

Summary of Significant Accounting Policies - Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2015
Computer Software / Hardware (Including Internally Developed) [Member] | Minimum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	3 years
Computer Software / Hardware (Including Internally Developed) [Member] | Maximum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	10 years
Machinery and Equipment [Member] | Minimum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	15 years
Research and Laboratory Equipment [Member] | Minimum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	3 years
Research and Laboratory Equipment [Member] | Maximum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	10 years
Buildings, Improvements, Leasehold Improvements and Other [Member] | Minimum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	4 years
Buildings, Improvements, Leasehold Improvements and Other [Member] | Maximum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	50 years
Transportation [Member] | Minimum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	3 years
Transportation [Member] | Maximum [Member]
Depreciation Amortization Impairment [Line Items]
Estimated useful life	20 years

Summary of Significant Accoun69

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies [Line Items]
Maximum percentage of ownership for equity method accounting		50.00%
Gains or losses on marketable securities		$ 0
Provision for warranty expense		4,500,000
Liability of expected future obligations included in current liabilities		7,600,000
Liability of expected future obligations included in long-term liabilities		$ 28,400,000
Period of implants for surgical procedures		10 years
Adjusted goodwill		$ 83,600,000
Maximum percentage of actuarial gain or loss in excess of greater of projected benefit obligation or market related value of plan assets		10.00%
Current deferred tax assets		$ 500,300,000	$ 477,000,000
Current deferred tax liabilities		47,300,000	$ 41,000,000
New Accounting Pronouncement, Early Adoption, Effect [Member]
Summary Of Significant Accounting Policies [Line Items]
Decrease prepaid expenses and other currents assets and current portion of long-term debt and capital leases		36,300,000
Investments and other assets and long-term debt and capital leases		$ 159,500,000
Ordinary Shares [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted EPS		13.6
Stock Awards [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted EPS		5.2	3	2.1
Branded Prescription Drug Fee [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional expense recognized for drug fee	$ 105,100,000
Forest Acquisition [Member]
Summary Of Significant Accounting Policies [Line Items]
Decrease in SRA related to valuation of assets and liabilities acquired		$ 53,200,000
Adjusted goodwill		33,200,000
Recognition of deferred tax asset from the change of goodwill		20,000,000
Saline Breast Implants [Member]
Summary Of Significant Accounting Policies [Line Items]
Financial assistance		2,400
Silicone Gel Breast Implants [Member]
Summary Of Significant Accounting Policies [Line Items]
Financial assistance		$ 3,500
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Ownership percentage in cost method investments		20.00%

Summary of Significant Accoun70

Summary of Significant Accounting Policies - Provisions for Sales Returns and Allowances from Continuing Operations Activity (Detail) - Continuing Operations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	$ 1,317.3	$ 524	$ 300.2
Provision related to sales	5,766.9	2,315.8	674.1
Credits and payments	(5,679.9)	(2,079.5)	(838.2)
Balance at end of period	1,833.8	1,317.3	524
Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	28	21.8	81.2
Provision related to sales	649.9	442.9	214.5
Credits and payments	(613.8)	(464.6)	(279.5)
Balance at end of period	78.2	28	21.8
Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	1,008.8	289.9	30.8
Provision related to sales	4,082.9	1,562.8	330.2
Credits and payments	(4,044.1)	(1,268.9)	(326.6)
Balance at end of period	1,354	1,008.8	289.9
Returns and Other Allowances [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	260.8	203.1	178.9
Provision related to sales	732.2	154.4	86.5
Credits and payments	(720.3)	(191)	(183.6)
Balance at end of period	373.1	260.8	203.1
Cash Discounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	19.7	9.2	9.3
Provision related to sales	301.9	155.7	42.9
Credits and payments	(301.7)	(155)	(48.5)
Balance at end of period	28.5	19.7	9.2
Warner Chilcott [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition			387.9
Warner Chilcott [Member] | Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition			5.6
Warner Chilcott [Member] | Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition			255.5
Warner Chilcott [Member] | Returns and Other Allowances [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition			121.3
Warner Chilcott [Member] | Cash Discounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition			$ 5.5
Forest Acquisition [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition		557
Forest Acquisition [Member] | Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition		27.9
Forest Acquisition [Member] | Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition		425
Forest Acquisition [Member] | Returns and Other Allowances [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition		94.3
Forest Acquisition [Member] | Cash Discounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition		$ 9.8
Allergan Acquisition [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition	429.5
Allergan Acquisition [Member] | Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition	14.1
Allergan Acquisition [Member] | Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition	306.4
Allergan Acquisition [Member] | Returns and Other Allowances [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition	100.4
Allergan Acquisition [Member] | Cash Discounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Add: Acquisition	$ 8.6

Summary of Significant Accoun71

Summary of Significant Accounting Policies - Provisions for Sales Returns and Allowances from Discontinued Operations Activity (Detail) - Discontinued Operations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	$ 1,667	$ 1,449.8	$ 1,148.5
Provision related to sales	8,759.9	6,809.9	5,110.8
Credits and payments	(8,706.8)	(6,592.7)	(4,809.5)
Balance at end of period	1,720.1	1,667	1,449.8
Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	536.9	224.6	130.3
Provision related to sales	5,907.2	4,148.8	2,125.5
Credits and payments	(5,825.1)	(3,836.5)	(2,031.2)
Balance at end of period	619	536.9	224.6
Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	737.8	771.9	820
Provision related to sales	1,944.7	1,761.1	2,008.9
Credits and payments	(1,961.1)	(1,795.2)	(2,057)
Balance at end of period	721.4	737.8	771.9
Returns and Other Allowances [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	351.3	414.8	170.6
Provision related to sales	657	705	817.6
Credits and payments	(685.2)	(768.5)	(573.4)
Balance at end of period	323.1	351.3	414.8
Cash Discounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	41	38.5	27.6
Provision related to sales	251	195	158.8
Credits and payments	(235.4)	(192.5)	(147.9)
Balance at end of period	$ 56.6	$ 41	$ 38.5

Summary of Significant Accoun72

Summary of Significant Accounting Policies - Summarizes The Balance Sheet Classification of Our SRA Reserves (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Sales Return Allowance Reserve [Line Items]
Accounts receivable	$ 2,401.6	$ 1,112.3
Accounts payable and accrued expenses	4,349.5	3,030.1
Current liabilities held for sale	1,491.8	1,449.1
Sales Return and Allowances [Member]
Sales Return Allowance Reserve [Line Items]
Accounts receivable	263.8	162.4
Accounts payable and accrued expenses	1,570	1,154.9
Net of accounts receivable and payables	1,833.8	1,317.3
Sales Return and Allowances [Member] | Teva Pharmaceutical Industries Ltd [Member]
Sales Return Allowance Reserve [Line Items]
Current assets held for sale	1,306.6	1,269.6
Current liabilities held for sale	413.5	397.4
Net of current assets and current liabilities held for sale	$ 1,720.1	$ 1,667

Summary of Significant Accoun73

Summary of Significant Accounting Policies - Summary of Activity in Gross-to-Net Revenue (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation and Qualifying Accounts Disclosure [Line Items]
Gross Product Sales	$ 20,653.9	$ 8,987.3	$ 3,212.2
Chargebacks	649.9	442.9	214.5
Rebates	4,082.9	1,562.8	330.2
Return and Other Allowances	732.2	154.4	86.5
Cash Discounts	301.9	155.7	42.9
Net Product Sales	$ 14,887	$ 6,671.5	$ 2,538.1
Product Concentration Risk [Member] | Sales Revenue, Net [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Gross-to-net Percentages	72.10%	74.20%	79.00%

Summary of Significant Accoun74

Summary of Significant Accounting Policies - Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net income:
Net income/(loss) attributable to ordinary shareholders excluding income/(loss) from discontinued operations, net of tax									$ (3,104.5)	$ (2,407.1)	$ (467.5)
Income / (loss) from discontinued operations, net of tax									6,787.7	776.6	(282.9)
Net income / (loss) attributable to ordinary shareholders		$ 5,086.6							$ 3,683.2	$ (1,630.5)	$ (750.4)
Basic weighted average ordinary shares outstanding									367.8	219.7	142.3
Basic EPS:
Continuing operations									$ (8.44)	$ (10.96)	$ (3.29)
Discontinued operations									18.45	3.54	(1.98)
Net income / (loss) per share - basic	$ (1.78)	$ 13.29	$ (0.80)	$ (1.85)	$ (3.34)	$ (3.95)	$ 0.28	$ 0.56	$ 10.01	$ (7.42)	$ (5.27)
Diluted weighted average ordinary shares outstanding									367.8	219.7	142.3
Diluted EPS:
Continuing operations									$ (8.44)	$ (10.96)	$ (3.29)
Discontinued operations									18.45	3.54	(1.98)
Net income / (loss) per share - diluted	$ (1.78)	$ 13.29	$ (0.80)	$ (1.85)	$ (3.34)	$ (3.95)	$ 0.28	$ 0.55	$ 10.01	$ (7.42)	$ (5.27)

Business Development - Unaudite

Business Development - Unaudited Pro Forma Results of Businesses Acquired (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Net revenues	$ 4,197.5	$ 4,088.9	$ 4,222	$ 2,562.6	$ 2,415.6	$ 2,150.8	$ 1,087.2	$ 1,085.3	$ 15,071	$ 6,738.9	$ 2,602.5
Net income / (loss) attributable to ordinary shareholders/members		$ 5,086.6							$ 3,683.2	$ (1,630.5)	$ (750.4)
Net income (loss) per share
Basic	$ (1.78)	$ 13.29	$ (0.80)	$ (1.85)	$ (3.34)	$ (3.95)	$ 0.28	$ 0.56	$ 10.01	$ (7.42)	$ (5.27)
Diluted	$ (1.78)	$ 13.29	$ (0.80)	$ (1.85)	$ (3.34)	$ (3.95)	$ 0.28	$ 0.55	$ 10.01	$ (7.42)	$ (5.27)
Pro Forma [Member]
Business Acquisition [Line Items]
Net revenues									$ 16,594	$ 16,204.1	$ 8,125.9
Net income / (loss) attributable to ordinary shareholders/members									$ 4,060.9	$ (4,552.2)	$ (2,493.6)
Net income (loss) per share
Basic									$ 10.32	$ (11.66)	$ (9.51)
Diluted									$ 10.32	$ (11.66)	$ (9.51)
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Net revenues									$ 1,523	$ 7,225.4
Net income / (loss) attributable to ordinary shareholders/members									$ 377.7	(3,067.8)
Forest Laboratories Inc. [Member]
Business Acquisition [Line Items]
Net revenues										2,239.8	$ 3,876.8
Net income / (loss) attributable to ordinary shareholders/members										$ 146.1	(2,261.4)
Warner Chilcott Acquisition [Member]
Business Acquisition [Line Items]
Net revenues											1,646.6
Net income / (loss) attributable to ordinary shareholders/members											$ 518.2

Business Development - Addition

Business Development - Additional Information (Detail) $ / shares in Units, € in Millions, £ in Millions, shares in Millions, Patient in Millions, $ in Millions

Nov. 23, 2015

Nov. 04, 2015USD ($)

Oct. 27, 2015EUR (€)

Oct. 16, 2015USD ($)

Oct. 01, 2015USD ($)$ / shares

Aug. 28, 2015USD ($)

Aug. 10, 2015USD ($)

May. 29, 2015USD ($)

May. 29, 2015GBP (£)

Mar. 17, 2015USD ($)shares

Nov. 17, 2014USD ($)Contingent_Value_Right$ / shares

Jul. 02, 2014USD ($)PatientProduct

Jul. 01, 2014USD ($)

Jun. 30, 2014USD ($)shares

Apr. 01, 2014USD ($)

Oct. 01, 2013USD ($)

Jun. 10, 2013USD ($)

Jan. 23, 2013USD ($)

Jun. 30, 2014USD ($)

Dec. 31, 2015USD ($)$ / shares

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)

Mar. 02, 2015USD ($)

Dec. 17, 2014USD ($)

Business Acquisition [Line Items]

Goodwill

$ 46,551.5

$ 20,897.6

Inventory, finished goods

46.1

262.9

Defined benefit pension obligation

1,188.5

111.6

$ 96.5

Payments to acquire intangible assets

154.7

36.1

130

Asset held for sale

3,540.3

3,806.9

Goodwill

309.1

Impairment on assets held for disposal

189.6

Payment of contingent consideration

230.1

14.3

4.3

Number of patients | Patient

28

Product rights and other intangibles

12,877.5

Research and development

2,358.5

605.7

191.3

Increase (decrease) in acquired intangible assets

(135)

Increase (decrease) in Deferred Liabilities

(51.4)

Increase (decrease) in acquired goodwill

83.6

Income (Loss) from Discontinued Operations

6,787.7

776.6

(282.9)

Number of divested products | Product

2

Divestiture of business

38.8

Gain on sale of assets

$ 5.4

Written off contingent liability

96.2

(78.8)

10.1

Operating Segments [Member]

Business Acquisition [Line Items]

Research and development

2,358.5

605.7

191.3

IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

9.90%

Product rights and other intangibles

1,362

Eluxadoline | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

1,003

Actavis Products [Member]

Business Acquisition [Line Items]

Divestiture of business

$ 8

Forest Products [Member]

Business Acquisition [Line Items]

Divestiture of business

13.5

AstraZeneca [Member]

Business Acquisition [Line Items]

Consideration amount on sale of business

$ 600

Additional consideration amount on sale of business

$ 100

Royalty Pharm, Inc. [Member] | Alogliptin and Priligy [Member]

Business Acquisition [Line Items]

Sale of royalties

408.6

Royalty Pharm, Inc. [Member] | Alogliptin and Priligy [Member] | Product Rights Intangible Assets

Business Acquisition [Line Items]

Product rights and other intangibles

408.6

Respiratory Therapeutic Area [Member]

Business Acquisition [Line Items]

Asset held for sale

734

Goodwill

309.1

Incremental charge in cost of sales relating to inventory

35.3

Corona Facility [Member]

Business Acquisition [Line Items]

Impairment on assets held for disposal

20

Corona Facility [Member] | Property, Plant and Equipment [Member]

Business Acquisition [Line Items]

Write-off of property, plant and equipment, net

5.8

Other (Expense) Income [Member] | AstraZeneca [Member]

Business Acquisition [Line Items]

Recognized loss on disposal of assets

5.3

Western European [Member]

Business Acquisition [Line Items]

Recognized loss on disposal of assets

20.9

Fair value of sale of assets

$ 65

$ 65

Income / (loss) on net assets held for sale

3.4

(34.3)

Deferred revenue

10.1

Maximum [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

9.00%

Minimum [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

8.00%

US Brands [Member]

Business Acquisition [Line Items]

Goodwill

36,107.5

20,603.7

International Brands [Member]

Business Acquisition [Line Items]

Goodwill

6,351

207.6

US Medical Aesthetics [Member]

Business Acquisition [Line Items]

Goodwill

$ 4,006.7

CMP [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

8.00%

AqueSys [Member]

Business Acquisition [Line Items]

Business acquisition date

Oct. 16, 2015

Acquisition purchase price

$ 298.9

Contingent consideration liability

$ 193.5

Intangible assets amortizable period

12 years 2 months 12 days

Goodwill

$ 138.5

Product rights and other intangibles

221

AqueSys [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

302

AqueSys [Member] | US Brands [Member]

Business Acquisition [Line Items]

Goodwill

50.5

AqueSys [Member] | International Brands [Member]

Business Acquisition [Line Items]

Goodwill

$ 88

AqueSys [Member] | CMP and IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

21.00%

Northwood Medical Innovation Ltd [Member]

Business Acquisition [Line Items]

Business acquisition date

Oct. 1, 2015

Acquisition purchase price

$ 25.5

Contingent consideration liability

15

Goodwill

13.6

Product rights and other intangibles

19.5

Northwood Medical Innovation Ltd [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

13.6

Northwood Medical Innovation Ltd [Member] | International Brands [Member]

Business Acquisition [Line Items]

Goodwill

$ 13.6

Northwood Medical Innovation Ltd [Member] | CMP and IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

15.00%

Kythera [Member]

Business Acquisition [Line Items]

Business acquisition date

Oct. 1, 2015

Acquisition purchase price

$ 2,089.5

Intangible assets amortizable period

17 years 3 months 18 days

Goodwill

$ 328.7

Business combination cash consideration for each share | $ / shares

$ 75

Product rights and other intangibles

$ 2,120

Kythera [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

320

$ 320

Kythera [Member] | International Brands [Member]

Business Acquisition [Line Items]

Goodwill

120

Kythera [Member] | US Medical Aesthetics [Member]

Business Acquisition [Line Items]

Goodwill

$ 208.7

Kythera [Member] | CMP [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

8.50%

Indefinite lived assets, Amount recognized as of the acquisition date

$ 2,120

Kythera [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

9.50%

Oculeve, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Aug. 10, 2015

Acquisition purchase price

$ 134.5

Contingent consideration liability

90

$ 90

Goodwill

33.3

Oculeve, Inc. [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

286

286

Oculeve, Inc. [Member] | Maximum [Member]

Business Acquisition [Line Items]

Future contingent payments

$ 300

Oculeve, Inc. [Member] | US Brands [Member]

Business Acquisition [Line Items]

Goodwill

$ 33.3

Oculeve, Inc. [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

11.00%

Auden Mckenzie [Member]

Business Acquisition [Line Items]

Business acquisition date

May 29, 2015

Contingent consideration liability

$ 17.3

$ 17.3

Goodwill

123.3

123.3

Payments to acquire business, cash

495.9

£ 323.7

Product rights and other intangibles

342.4

Auden Mckenzie [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

$ 38.6

Auden Mckenzie [Member] | International Brands [Member] | North American Generics [Member]

Business Acquisition [Line Items]

Goodwill

$ 123.3

Auden Mckenzie [Member] | CMP [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

15.00%

Auden Mckenzie [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

16.00%

Allergan, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Mar. 17, 2015

Acquisition purchase price

$ 77,000

Contingent consideration liability

383.7

$ 383.7

Goodwill

27,088.9

Payments to acquire business, cash

40,100

Cash and equity consideration

74,800

Value of equity shares outstanding

33,900

Portion of equity awards deemed to have been earned

800

Portion of equity awards deemed not to have been earned

843.1

Portion of equity awards deemed expense

516.2

Step-up in the value of inventories

923.9

Amortization of inventory step-up to cost of sales

902.3

Inventory, finished goods

21.6

Defined benefit plans, net liability

302.6

Defined benefit pension obligation

60.2

Indefinite lived assets, Amount recognized as of the acquisition date

$ 54,750.5

Product rights and other intangibles

45,050.5

45,050.5

Outstanding indebtedness

2,200

Stock transaction valuation

$ 34,700

Shares issued to acquire entity | shares

111.2

Allergan, Inc. [Member] | Non-qualified Options [Member]

Business Acquisition [Line Items]

Shares issued to acquire entity | shares

7

Allergan, Inc. [Member] | Restricted Stock Units (RSUs) [Member]

Business Acquisition [Line Items]

Shares issued to acquire entity | shares

0.5

Allergan, Inc. [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

$ 9,700

9,700

$ 9,700

Allergan, Inc. [Member] | Pension Plans [Member]

Business Acquisition [Line Items]

Fair value of assets

1,042

Allergan, Inc. [Member] | Other Benefit Obligation [Member]

Business Acquisition [Line Items]

Fair value of assets

117.1

Fair value of liabilities

120

Allergan, Inc. [Member] | Cash and Cash Equivalents [Member] | Pension Plans [Member]

Business Acquisition [Line Items]

Fair value of assets

13.6

Allergan, Inc. [Member] | Equity Securities [Member] | Pension Plans [Member]

Business Acquisition [Line Items]

Fair value of assets

480.1

Allergan, Inc. [Member] | Fixed Income Securities [Member] | Pension Plans [Member]

Business Acquisition [Line Items]

Fair value of assets

548.3

Allergan, Inc. [Member] | US Brands [Member]

Business Acquisition [Line Items]

Goodwill

15,352

Allergan, Inc. [Member] | International Brands [Member]

Business Acquisition [Line Items]

Goodwill

7,938.9

Allergan, Inc. [Member] | US Medical Aesthetics [Member]

Business Acquisition [Line Items]

Goodwill

$ 3,798

Allergan, Inc. [Member] | CMP [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

10.00%

Product rights and other intangibles

$ 43,310

Allergan, Inc. [Member] | IPR&D [Member] | Maximum [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

11.00%

Allergan, Inc. [Member] | IPR&D [Member] | Minimum [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

10.00%

Mimetogen Pharmaceuticals [Member]

Business Acquisition [Line Items]

Payment for license upfront fees

$ 50

Almirall [Member]

Business Acquisition [Line Items]

Payments to acquire intangible assets | €

€ 60

Naurex [Member]

Business Acquisition [Line Items]

Business acquisition date

Aug. 28, 2015

Upfront charge of acquired rights recognized as research and development expenses

$ 571.7

Naurex [Member] | Maximum [Member]

Business Acquisition [Line Items]

Future contingent payments

$ 1,150

Merck And Company [Member]

Business Acquisition [Line Items]

Upfront charge of acquired rights recognized as research and development expenses

$ 250

Partial payment of acquired rights

125

Amount of acquired rights payable in April 2016

125

Merck And Company [Member] | Maximum [Member]

Business Acquisition [Line Items]

Future contingent payments

965

Pharmatech Transaction [Member]

Business Acquisition [Line Items]

Impairment on assets held for disposal

189.9

Durata Therapeutics Inc [Member]

Business Acquisition [Line Items]

Contingent consideration liability

$ 49

Goodwill

75.8

Payments to acquire business, cash

$ 724.5

Additional consideration for contingent value rights | $ / shares

$ 5

Number of contingent value right per share | Contingent_Value_Right

1

Product rights and other intangibles

$ 480

Durata Therapeutics Inc [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

$ 249

Durata Therapeutics Inc [Member] | Contingent Value Right [Member]

Business Acquisition [Line Items]

Contingent consideration liability

49

Payment of contingent consideration

30.9

Fair value of contingent consideration paid

24.5

Difference between fair value and payment made recorded as operating expense

$ 6.4

Durata Therapeutics Inc [Member] | CMP [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

9.50%

Durata Therapeutics Inc [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

10.50%

Furiex Pharmaceuticals, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Jul. 2, 2014

Research and development

$ 29.8

Furiex Pharmaceuticals, Inc. [Member] | Contingent Value Right [Member]

Business Acquisition [Line Items]

Payments to acquire business, cash

1,156.2

Additional consideration for contingent value rights | $ / shares

$ 10

Payment of contingent consideration

$ 118.5

Furiex Pharmaceuticals, Inc. [Member] | Contingent Value Right [Member] | Eluxadoline

Business Acquisition [Line Items]

Contingent consideration liability

88

Furiex Pharmaceuticals, Inc. [Member] | Maximum [Member] | Contingent Value Right [Member]

Business Acquisition [Line Items]

Contingent consideration liability

$ 360

Forest Laboratories Inc. [Member]

Business Acquisition [Line Items]

Business acquisition date

Jul. 1, 2014

Acquisition purchase price

30,900

Goodwill

$ 16,403.6

Payments to acquire business, cash

7,100

Value of equity shares outstanding

20,000

Portion of equity awards deemed to have been earned

568.1

568.1

Portion of equity awards deemed not to have been earned

570.4

570.4

Portion of equity awards deemed expense

$ 142.8

287.5

Step-up in the value of inventories

1,036.3

Amortization of inventory step-up to cost of sales

224.7

751

Inventory, finished goods

20.1

244.7

Indefinite lived assets, Amount recognized as of the acquisition date

12,256.5

Product rights and other intangibles

11,515.5

Outstanding indebtedness

3,300

Stock transaction valuation

$ 20,600

Shares issued to acquire entity | shares

89.8

Equity consideration

$ 27,700

Income (Loss) from Discontinued Operations

0.6

40.6

Forest Laboratories Inc. [Member] | Non-qualified Options [Member]

Business Acquisition [Line Items]

Shares issued to acquire entity | shares

6.1

Forest Laboratories Inc. [Member] | Restricted Stock Units (RSUs) [Member]

Business Acquisition [Line Items]

Shares issued to acquire entity | shares

1.1

Forest Laboratories Inc. [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

1,362

Forest Laboratories Inc. [Member] | Forest Products [Member]

Business Acquisition [Line Items]

Divestiture of business

$ 13.5

Silom Medical Company [Member]

Business Acquisition [Line Items]

Goodwill

$ 20

Payments to acquire business, cash

103

Product rights and other intangibles

$ 64

Warner Chilcott [Member]

Business Acquisition [Line Items]

Business acquisition date

Oct. 1, 2013

Goodwill

$ 3,956.1

Value of equity shares outstanding

5,761.3

Portion of equity awards deemed to have been earned

72.6

Portion of equity awards deemed not to have been earned

77.4

Portion of equity awards deemed expense

5.8

45.4

Amortization of inventory step-up to cost of sales

1.9

232.9

$ 173.5

Product rights and other intangibles

4,729

Stock transaction valuation

5,833.9

Fair value including assumption of debt

9,200

Step-up in the value of inventories

408.3

Warner Chilcott [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

1,708

Warner Chilcott [Member] | US Brands [Member] | Operating Segments [Member]

Business Acquisition [Line Items]

Goodwill

3,795.5

Warner Chilcott [Member] | International Brands [Member] | Operating Segments [Member]

Business Acquisition [Line Items]

Goodwill

$ 160.6

Warner Chilcott [Member] | CMP [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

800.00%

Warner Chilcott [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Product rights and other intangibles

$ 1,708

Warner Chilcott [Member] | IPR&D [Member] | Maximum [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

900.00%

Warner Chilcott [Member] | IPR&D [Member] | Minimum [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

800.00%

Medicines 360 [Member]

Business Acquisition [Line Items]

Acquisition purchase price

$ 52.3

Potential milestone payments

$ 125

Uteron Pharma, SA [Member]

Business Acquisition [Line Items]

Business acquisition date

Jan. 23, 2013

Acquisition purchase price

$ 142

Contingent consideration liability

43.4

Goodwill

26.4

Potential milestone payments

155

Assumption of debt and other liabilities

7.7

Uteron Pharma, SA [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

$ 250

Uteron Pharma, SA [Member] | Estelle [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

$ 13.1

13.1

Written off contingent liability

22.8

22.8

22.8

Gain (loss) on written off of contingent liability

9.7

9.7

Uteron Pharma, SA [Member] | Colvir [Member]

Business Acquisition [Line Items]

Indefinite lived assets, Amount recognized as of the acquisition date

2

2

Written off contingent liability

1.5

1.5

Gain (loss) on written off of contingent liability

$ (0.5)

$ 1.5

$ (0.5)

Uteron Pharma, SA [Member] | IPR&D [Member]

Business Acquisition [Line Items]

Discount rate to arrive present value

22.00%

Business Development - Summary

Business Development - Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Oct. 16, 2015	Oct. 01, 2015	Aug. 10, 2015	May. 29, 2015	Mar. 31, 2015	Mar. 17, 2015	Dec. 31, 2014	Dec. 17, 2014	Nov. 17, 2014	Jul. 02, 2014	Jul. 01, 2014	Apr. 01, 2014	Oct. 01, 2013	Jan. 23, 2013
Business Acquisition [Line Items]
Product rights and other intangibles								$ 12,877.5
Goodwill	$ 46,551.5							20,897.6
CMP [Member]
Business Acquisition [Line Items]
Product rights and other intangibles								11,275
AqueSys [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		$ 6.2
Current assets		1.2
Product rights and other intangibles		221
Goodwill		138.5
Current liabilities		(6.9)
Contingent consideration		(193.5)
Deferred tax liabilities, net		(169.6)
Net assets acquired		298.9
Northwood Medical Innovation Ltd [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			$ 0.5
Product rights and other intangibles			19.5
Goodwill			13.6
Other assets and liabilities			(0.1)
Contingent consideration			(15)
Deferred tax liabilities, net			(6.6)
Net assets acquired			25.5
Kythera [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			78.1
Marketable securities			79.9
Inventories			18.2
Other current assets			14.5
Product rights and other intangibles			2,120
Goodwill			328.7
Other current liabilities			(48.6)
Deferred tax liabilities, net			(766.7)
Outstanding indebtedness			(54.6)
Net assets acquired			2,089.5
Oculeve, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents				$ 1.6
Goodwill				33.3
Other assets and liabilities				(1.9)
Contingent consideration	(90)			(90)
Deferred tax liabilities, net				(94.5)
Net assets acquired				134.5
Auden Mckenzie [Member]
Business Acquisition [Line Items]
Cash and cash equivalents					$ 32.2
Inventories					49.1
Product rights and other intangibles					342.4
Goodwill	123.3				123.3
Other assets and liabilities					7.2
Contingent consideration	(17.3)				(17.3)
Deferred tax liabilities, net					(79.6)
Net assets acquired					495.9
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	5,424.5
Accounts receivable	948.7
Inventories	1,218.6
Other current assets	318.8
Property, plant and equipment, net	1,214.5
Product rights and other intangibles	45,050.5						$ 45,050.5
Other long-term assets	196.1
IPR&D intangible assets									$ 54,750.5
Goodwill	27,088.9
Current liabilities	(1,222.1)
Contingent consideration	(383.7)						(383.7)
Deferred tax liabilities, net	(11,880.1)
Other taxes payable	(111.3)
Other long-term liabilities	(622)
Outstanding indebtedness	(2,183.5)
Net assets acquired	74,757.9
Allergan, Inc. [Member] | Preliminary Values [Member]
Business Acquisition [Line Items]
Cash and cash equivalents						$ 5,424.5
Accounts receivable						962.7
Inventories						1,223.2
Other current assets						318.8
Property, plant and equipment, net						1,202.5
Product rights and other intangibles						45,050.5
Other long-term assets						189.3
Goodwill						26,368.5
Current liabilities						(1,212.2)
Contingent consideration						(379.1)
Deferred tax liabilities, net						(12,512.9)
Other taxes payable						(82.4)
Other long-term liabilities						(622)
Outstanding indebtedness						(2,183.5)
Net assets acquired						74,757.9
Allergan, Inc. [Member] | Measurement Period Adjustment [Member]
Business Acquisition [Line Items]
Accounts receivable	(14)
Inventories	(4.6)
Property, plant and equipment, net	12
Other long-term assets	6.8
Goodwill	720.4
Current liabilities	(9.9)
Contingent consideration	(4.6)
Deferred tax liabilities, net	632.8
Other taxes payable	(28.9)
Durata Therapeutics Inc [Member]
Business Acquisition [Line Items]
Cash and cash equivalents										$ 17.8
Inventories										21
Product rights and other intangibles										480
Goodwill										75.8
Other assets and liabilities										(30.2)
Contingent consideration										(49)
Deferred tax liabilities, net										(39.9)
Outstanding indebtedness										(67)
Net assets acquired										657.5
Furiex Acquisition [Member]
Business Acquisition [Line Items]
Cash and cash equivalents											$ 14.9
Product rights and other intangibles											408.6
IPR&D intangible assets											1,411.6
Goodwill											251.9
Other assets and liabilities											(30.1)
Contingent consideration											(88)
Deferred tax liabilities, net											(404.1)
Outstanding indebtedness											(55.3)
Net assets acquired											1,100.9
Forest Laboratories Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents												$ 3,424.2
Accounts receivable												496.2
Inventories												1,455.8
Other current assets												261.2
Current assets held for sale												87.1
Property, plant and equipment, net												221.1
Product rights and other intangibles												11,515.5
Other long-term assets												84.1
IPR&D intangible assets												12,256.5
Goodwill												16,403.6
Current liabilities												(1,372.1)
Deferred tax liabilities, net												(2,277.3)
Other taxes payable												(618.4)
Other long-term liabilities												(120)
Outstanding indebtedness												(3,261.9)
Net assets acquired												27,661.1
Silom Medical Company [Member]
Business Acquisition [Line Items]
Cash and cash equivalents													$ 3
Inventories													4
Property, plant and equipment, net													16
Product rights and other intangibles													64
Goodwill													20
Other assets and liabilities													(4)
Net assets acquired													$ 103
Warner Chilcott [Member]
Business Acquisition [Line Items]
Cash and cash equivalents														$ 179.5
Accounts receivable														306.1
Inventories														532.5
Other current assets														83.4
Property, plant and equipment, net														220
Product rights and other intangibles														4,729
Other long-term assets														1.2
Goodwill														3,956.1
Current liabilities														(613.5)
Deferred tax liabilities, net														(60.4)
Other long-term liabilities														(99.6)
Outstanding indebtedness														(3,400.4)
Net assets acquired														5,833.9
Warner Chilcott [Member] | CMP [Member]
Business Acquisition [Line Items]
Product rights and other intangibles														3,021
Uteron Pharma, SA [Member]
Business Acquisition [Line Items]
Accounts receivable															$ 1.6
Other current assets															1.2
Property, plant and equipment, net															5.7
Other long-term assets															0.5
Goodwill															26.4
Current liabilities															(8)
Long-term deferred tax and other tax liabilities															(82.5)
Contingent consideration															(43.4)
Debt															(5.2)
Other long-term liabilities															(4.3)
Net assets acquired															142
IPR&D [Member]
Business Acquisition [Line Items]
Product rights and other intangibles								$ 1,362
IPR&D [Member] | AqueSys [Member]
Business Acquisition [Line Items]
IPR&D intangible assets		$ 302
IPR&D [Member] | Northwood Medical Innovation Ltd [Member]
Business Acquisition [Line Items]
IPR&D intangible assets			13.6
IPR&D [Member] | Kythera [Member]
Business Acquisition [Line Items]
IPR&D intangible assets	320		$ 320
IPR&D [Member] | Oculeve, Inc. [Member]
Business Acquisition [Line Items]
IPR&D intangible assets	286			$ 286
IPR&D [Member] | Auden Mckenzie [Member]
Business Acquisition [Line Items]
IPR&D intangible assets					$ 38.6
IPR&D [Member] | Allergan, Inc. [Member]
Business Acquisition [Line Items]
IPR&D intangible assets	9,700						$ 9,700		$ 9,700
IPR&D [Member] | Allergan, Inc. [Member] | Preliminary Values [Member]
Business Acquisition [Line Items]
IPR&D intangible assets						$ 11,010
IPR&D [Member] | Allergan, Inc. [Member] | Measurement Period Adjustment [Member]
Business Acquisition [Line Items]
IPR&D intangible assets	$ (1,310)
IPR&D [Member] | Durata Therapeutics Inc [Member]
Business Acquisition [Line Items]
IPR&D intangible assets										$ 249
IPR&D [Member] | Furiex Acquisition [Member]
Business Acquisition [Line Items]
IPR&D intangible assets											$ 1,003
IPR&D [Member] | Forest Laboratories Inc. [Member]
Business Acquisition [Line Items]
IPR&D intangible assets												$ 1,362
IPR&D [Member] | Warner Chilcott [Member]
Business Acquisition [Line Items]
IPR&D intangible assets														$ 1,708
IPR&D [Member] | Uteron Pharma, SA [Member]
Business Acquisition [Line Items]
IPR&D intangible assets															$ 250

Business Development - Summar78

Business Development - Summary of Amounts Recognized and Weighted Average Useful Lives Using Economic Benefit of Intangible Assets (Detail) - USD ($) $ in Millions	Oct. 01, 2013	Dec. 31, 2015	Dec. 31, 2014	Mar. 17, 2015	Dec. 17, 2014
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 12,877.5
IPR&D [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			1,362
IPR&D [Member] | Other Products [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			74
IPR&D [Member] | Gastroenterology [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			791
IPR&D [Member] | Central Nervous System [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			304
IPR&D [Member] | Cardiovascular [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			193
Customer Relationships [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 67
Weighted average useful lives (years)			4 years 6 months
CMP [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 11,275
Weighted average useful lives (years)			4 years 3 months 18 days
CMP [Member] | Other Products [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 1,904
Weighted average useful lives (years)			5 years 8 months 12 days
CMP [Member] | Namenda Franchise [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 2,125
Weighted average useful lives (years)			1 year 8 months 12 days
CMP [Member] | Bystolic Franchise [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 1,810
Weighted average useful lives (years)			3 years 3 months 18 days
CMP [Member] | Linzess [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 1,052
Weighted average useful lives (years)			5 years
CMP [Member] | Zenpep [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 978
Weighted average useful lives (years)			6 years 9 months 18 days
CMP [Member] | Carafate [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 915
Weighted average useful lives (years)			6 years 2 months 12 days
CMP [Member] | Armour Thyroid [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 747
Weighted average useful lives (years)			5 years 10 months 24 days
CMP [Member] | Viibryd [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 413
Weighted average useful lives (years)			4 years 6 months
CMP [Member] | Fetzima [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 392
Weighted average useful lives (years)			5 years
CMP [Member] | Teflaro [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 343
Weighted average useful lives (years)			3 years
CMP [Member] | Canasa [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 327
Weighted average useful lives (years)			2 years 7 months 6 days
CMP [Member] | Daliresp [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 269
Weighted average useful lives (years)			3 years 6 months
Other [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date			$ 173.5
Weighted average useful lives (years)			4 years 2 months 12 days
Allergan, Inc. [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date		$ 45,050.5		$ 45,050.5
Indefinite lived assets, Amount recognized as of the acquisition date					$ 54,750.5
Intangible Assets, Amount recognized as of the acquisition date				54,750.5
Weighted average useful lives (years)		6 years 7 months 6 days
Allergan, Inc. [Member] | IPR&D [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date		$ 9,700		9,700	$ 9,700
Allergan, Inc. [Member] | IPR&D [Member] | Botox [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date				810
Allergan, Inc. [Member] | IPR&D [Member] | Eye Care [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date				5,500
Allergan, Inc. [Member] | IPR&D [Member] | Aesthetics [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date				2,270
Allergan, Inc. [Member] | IPR&D [Member] | Other Products [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date				1,120
Allergan, Inc. [Member] | CMP [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date				43,310
Weighted average useful lives (years)		6 years 8 months 12 days
Allergan, Inc. [Member] | CMP [Member] | Restasis [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date				3,970
Weighted average useful lives (years)		4 years
Allergan, Inc. [Member] | CMP [Member] | Refresh Optive [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date				2,720
Weighted average useful lives (years)		7 years 7 months 6 days
Allergan, Inc. [Member] | CMP [Member] | Other Eye Care Products [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date				6,690
Weighted average useful lives (years)		4 years 2 months 12 days
Allergan, Inc. [Member] | CMP [Member] | Botox [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date				22,600
Weighted average useful lives (years)		8 years
Allergan, Inc. [Member] | CMP [Member] | Aczone [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date				160
Weighted average useful lives (years)		1 year 3 months 18 days
Allergan, Inc. [Member] | CMP [Member] | Other Skin Products [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date				820
Weighted average useful lives (years)		5 years
Allergan, Inc. [Member] | CMP [Member] | Other Aesthetics [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date				6,350
Weighted average useful lives (years)		6 years
Allergan, Inc. [Member] | Trade Name [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date				690
Weighted average useful lives (years)		4 years 6 months
Allergan, Inc. [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date				$ 1,050.5
Weighted average useful lives (years)		3 years 4 months 24 days
Warner Chilcott [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 4,729
Warner Chilcott [Member] | IPR&D [Member]
Business Acquisition [Line Items]
Indefinite lived assets, Amount recognized as of the acquisition date	1,708
Warner Chilcott [Member] | CMP [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 3,021
Weighted average useful lives (years)	2 years 8 months 12 days
Warner Chilcott [Member] | CMP [Member] | Oral Contraceptive Franchise [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 1,181
Weighted average useful lives (years)	3 years 2 months 12 days
Warner Chilcott [Member] | CMP [Member] | Mesalamine Franchise [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 589
Weighted average useful lives (years)	1 year 9 months 18 days
Warner Chilcott [Member] | CMP [Member] | Estrace Cream [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 397
Weighted average useful lives (years)	2 years 1 month 6 days
Warner Chilcott [Member] | CMP [Member] | Risedronate Franchise [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 311
Weighted average useful lives (years)	3 years 7 months 6 days
Warner Chilcott [Member] | CMP [Member] | Doryx [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 237
Weighted average useful lives (years)	2 years 4 months 24 days
Warner Chilcott [Member] | CMP [Member] | Enablex [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 107
Weighted average useful lives (years)	2 years 1 month 6 days
Warner Chilcott [Member] | CMP [Member] | Other Products [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 199
Weighted average useful lives (years)	3 years 10 months 24 days
Warner Chilcott [Member] | IPR&D [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 1,708
Warner Chilcott [Member] | IPR&D [Member] | Oral Contraceptive Franchise [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	321
Warner Chilcott [Member] | IPR&D [Member] | Mesalamine Franchise [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	809
Warner Chilcott [Member] | IPR&D [Member] | Other Products [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	135
Warner Chilcott [Member] | IPR&D [Member] | Estradiol [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	278
Warner Chilcott [Member] | IPR&D [Member] | Urology [Member]
Business Acquisition [Line Items]
Definite lived assets, Amount recognized as of the acquisition date	$ 165

Business Development - Summar79

Business Development - Summary of Transaction and Integration Costs (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Legacy Allergan [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	$ 1,288.4
Legacy Allergan [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | Cost of Sales
Business Acquisition [Line Items]
Total transaction and integration costs	14.9
Legacy Allergan [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | Research and Development Expense
Business Acquisition [Line Items]
Total transaction and integration costs	83.5
Legacy Allergan [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | Selling and Marketing Expense
Business Acquisition [Line Items]
Total transaction and integration costs	75.7
Legacy Allergan [Member] | Acquisition, Integration and Restructuring Related Charges [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	298.6
Legacy Allergan [Member] | Acquisition-Related Expenses [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	65.5
Legacy Allergan [Member] | Bridge Loan Facilities Expense [Member] | Other (Expense) Income [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	(264.9)
Legacy Allergan [Member] | Interest Rate Lock [Member] | Other (Expense) Income [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	30.9
Forest Laboratories Inc. [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	246	$ 571.9
Forest Laboratories Inc. [Member] | Bridge Loan Facilities Expense [Member] | Other (Expense) Income [Member]
Business Acquisition [Line Items]
Total transaction and integration costs		(25.8)
Forest Laboratories Inc. [Member] | Severance Related Charges [Member] | Cost of Sales
Business Acquisition [Line Items]
Total transaction and integration costs	1.1	11.3
Forest Laboratories Inc. [Member] | Severance Related Charges [Member] | Research and Development Expense
Business Acquisition [Line Items]
Total transaction and integration costs	9.2	24.5
Forest Laboratories Inc. [Member] | Severance Related Charges [Member] | Selling and Marketing Expense
Business Acquisition [Line Items]
Total transaction and integration costs	17.4	45.3
Forest Laboratories Inc. [Member] | Severance Related Charges [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	17.1	71.5
Forest Laboratories Inc. [Member] | Other Integration Costs [Member] | Selling and Marketing Expense
Business Acquisition [Line Items]
Total transaction and integration costs		3.8
Forest Laboratories Inc. [Member] | Other Integration Costs [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	58.4	92.9
Forest Laboratories Inc. [Member] | Financing Related Charges [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs		9.3
Stock Compensation Plan [Member] | Legacy Allergan [Member] | Cost of Sales
Business Acquisition [Line Items]
Total transaction and integration costs	22.5
Stock Compensation Plan [Member] | Legacy Allergan [Member] | Research and Development Expense
Business Acquisition [Line Items]
Total transaction and integration costs	124.8
Stock Compensation Plan [Member] | Legacy Allergan [Member] | Selling and Marketing Expense
Business Acquisition [Line Items]
Total transaction and integration costs	110
Stock Compensation Plan [Member] | Legacy Allergan [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	258.9
Stock Compensation Plan [Member] | Forest Laboratories Inc. [Member] | Cost of Sales
Business Acquisition [Line Items]
Total transaction and integration costs	4.7	9.5
Stock Compensation Plan [Member] | Forest Laboratories Inc. [Member] | Research and Development Expense
Business Acquisition [Line Items]
Total transaction and integration costs	36.3	66.7
Stock Compensation Plan [Member] | Forest Laboratories Inc. [Member] | Selling and Marketing Expense
Business Acquisition [Line Items]
Total transaction and integration costs	47.9	58.7
Stock Compensation Plan [Member] | Forest Laboratories Inc. [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Total transaction and integration costs	$ 53.9	$ 152.6

Collaborations - Additional Inf

Collaborations - Additional Information (Detail) - USD ($) $ in Millions	Aug. 13, 2014	Dec. 02, 2013	May. 09, 2013	Oct. 22, 2012	Sep. 30, 2007	Dec. 31, 2015	Dec. 31, 2013	Dec. 31, 2014
Collaborations And License Agreements [Line Items]
Fair Value of contingent consideration						$ 683
Sanofi Aventis [Member] | Collaborative Arrangement [Member]
Collaborations And License Agreements [Line Items]
Payment by wholly-owned subsidiary							$ 125
Intangible asset acquired							$ 125
Amgen, Inc. [Member] | Collaborative Arrangement [Member]
Collaborations And License Agreements [Line Items]
Co-development costs						209.4
Apollo Endosurgery, Inc [Member]
Collaborations And License Agreements [Line Items]
Payments to acquire business, cash		$ 75
Stock transaction valuation						$ 15
Business acquisition date						Dec. 2, 2013
LiRIS Biomedical, Inc. [Member]
Collaborations And License Agreements [Line Items]
Business acquisition upfront payment	$ 67.5
Fair Value of contingent consideration	169.6
LiRIS Biomedical, Inc. [Member] | Maximum [Member]
Collaborations And License Agreements [Line Items]
Aggregate payments contingent upon achieving certain future development milestones	295
Aggregate payments contingent upon achieving certain future commercial milestones	$ 225
Trevena [Member]
Collaborations And License Agreements [Line Items]
Purchases of preferred stock			$ 30
Purchases of common stock			$ 3
Fair Value of acquired common stock						$ 35.6		$ 20.3
Ironwood Collaboration Agreement [Member]
Collaborations And License Agreements [Line Items]
Acquisition related contingent milestone payments					$ 100
Collaborative arrangement, fair value						24.1		31.9
Moksha8 Pharmaceuticals, Inc. [Member]
Collaborations And License Agreements [Line Items]
Debt finance costs				$ 101.9
Debt financing, term				7 years
Loan receivable related to investments and other assets						$ 33.4		$ 31.1

Discontinued Operations - Summa

Discontinued Operations - Summary of Key Financial Results of Global Generics Business Income from Discontinued Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Discontinued Operations And Disposal Groups [Abstract]
Third party revenues	$ 6,116.1	$ 6,323.4	$ 6,075.1
Related party sales	259.2	255.4	273.1
Net revenues	6,375.3	6,578.8	6,348.2
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	3,048.1	3,105.6	3,319.1
Research and development	422.2	480.2	425.6
Selling and marketing	557.7	649	645.5
General and administrative	653	496.2	571.4
Amortization	323.6	652	538.9
In-process research and development impairments			4.9
Asset sales and impairments, net	62.4	19.6	896.8
Total operating expenses	5,067	5,402.6	6,402.2
Operating income	1,308.3	1,176.2	(54)
Other (expense) income, net	(7.9)	(14.5)	39.1
(Benefit) / provision for income taxes	(5,487.3)	385.1	268
Net income / (loss) from discontinued operations	$ 6,787.7	$ 776.6	$ (282.9)

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015
Discontinued Operations And Disposal Groups [Abstract]
Deferred tax benefit related to investment	$ 5,985.4	$ 5,738.8

Discontinued Operations - Sched

Discontinued Operations - Schedule of Aggregate Carrying Amounts of Major Classes of Assets and Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Assets:
Accounts receivable, net	$ 2,089.7	$ 1,488.9
Inventories	1,138.5	1,090.9
Prepaid expenses and other current assets	302.8	254.6
Current deferred tax assets		23.3
Property, plant and equipment, net	1,355.6	1,347.5
Investments and other assets	33	82.1
Non-current deferred tax assets	223.7	72.7
Product rights and other intangibles	2,919.3	3,097.7
Goodwill	6,009.7	3,623.9
Total assets	14,072.3	11,081.6
Liabilities:
Accounts payable and accrued expenses	1,455.8	1,396.4
Income taxes payable	33.9	16.5
Current deferred tax liabilities		6.3
Debt and capital leases	5.8	12.6
Other long-term liabilities	92	121.3
Other taxes payable	69	102.7
Long-term deferred tax liabilities	415.4	308.1
Total liabilities	$ 2,071.9	$ 1,963.9

Discontinued Operations - Sch84

Discontinued Operations - Schedule of Depreciation Amortization and Significant Operating and Investing Noncash Items of Discontinued Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Discontinued Operations And Disposal Groups [Abstract]
Depreciation from discontinued operations	$ 89.7	$ 159.6	$ 166.9
Amortization from discontinued operations	323.6	652	538.9
Capital expenditures	234.5	184.5	168
Deferred taxes	$ (5,568.8)	$ (259.5)	$ (242.4)

Assets Held For Sale - Global N

Assets Held For Sale - Global Net Assets Held for Sale (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015
Long Lived Assets Held-for-sale [Line Items]
Accounts receivable, net	$ 17.7
Inventories	161.5
Prepaid expenses and other assets	161.3	$ 9.3
Intangible assets	453
Goodwill	309.1
Impairment on assets held for sale	(189.6)
Total assets held for sale	913	9.3
Accounts payable and accrued expenses	25.9
Total liabilities held for sale	25.9
Net assets held for sale	10,004.8	12,009.7
Teva Pharmaceutical Industries Ltd [Member]
Long Lived Assets Held-for-sale [Line Items]
Net assets held for sale	11,081.6	14,072.3
Net liabilities held for sale	$ 1,963.9	$ 2,071.9

Assets Held For Sale - Addition

Assets Held For Sale - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015
Long Lived Assets Held-for-sale [Line Items]
Net assets held for sale	$ 10,004.8	$ 12,009.7
Asset held for sale	3,806.9	3,540.3
Goodwill	309.1
Commack, Long Island [Member]
Long Lived Assets Held-for-sale [Line Items]
Properties acquired, assets held for sale	46.4
St. Louis, Missouri [Member]
Long Lived Assets Held-for-sale [Line Items]
Properties acquired, assets held for sale	20.4
Hauppauge, New York [Member]
Long Lived Assets Held-for-sale [Line Items]
Properties acquired, assets held for sale		14.8
Respiratory Therapeutic Area [Member]
Long Lived Assets Held-for-sale [Line Items]
Asset held for sale	734
Goodwill	309.1
Teva Pharmaceutical Industries Ltd [Member]
Long Lived Assets Held-for-sale [Line Items]
Net assets held for sale	11,081.6	14,072.3
Net liabilities held for sale	1,963.9	$ 2,071.9
Pharmatech Transaction [Member]
Long Lived Assets Held-for-sale [Line Items]
Increase in assets held for sale	97.2
Increase in liabilities held for sale	$ 25.9

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period	10 years
Share-based compensation expense included as discontinued operations	$ 31.5	$ 18.8	$ 22.1
Stock-based compensation and related tax benefits	285.9	145.7	44.4
Stock-based compensation	925.7	401.2	133.6
Share-based compensation	690.4	368	133.6
Unrecognized future stock-based compensation expense	$ 672
Remaining weighted average period (years)	1 year 8 months 12 days
Allergan, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	$ 314.8
Unrecognized future stock-based compensation expense	319.8
Kythera Acquisition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	64.4
Forest Laboratories Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense relating to acquisition accounting treatment of outstanding awards acquired	109.7	287.5
Stock-based compensation		$ 249.1
Unrecognized future stock-based compensation expense	$ 115.4
Warner Chilcott [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation			41.3
Share-based compensation			$ 45.4
Minimum [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option exercisable period	3 years
Minimum [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period	1 year
Maximum [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option exercisable period	5 years
Maximum [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period	4 years

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Fair Value Assumptions of Options based on Black-Scholes Valuation Model (Detail)	12 Months Ended
	Dec. 31, 2015
2015 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
Expected volatility, Minimum	26.00%
Expected volatility, Maximum	29.00%
Risk-free interest rate, Minimum	1.90%
Risk-free interest rate, Maximum	2.10%
2015 Acquired Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
Expected volatility, Minimum	26.00%
Expected volatility, Maximum	27.00%
Risk-free interest rate, Minimum	0.10%
Risk-free interest rate, Maximum	2.10%
2014 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
Expected volatility	29.00%
Risk-free interest rate, Minimum	1.90%
Risk-free interest rate, Maximum	2.20%
2014 Acquired Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
Expected volatility	28.00%
Risk-free interest rate, Minimum	0.00%
Risk-free interest rate, Maximum	2.10%
Maximum [Member] | 2015 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	7 years 6 months
Maximum [Member] | 2015 Acquired Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years 10 months 24 days
Maximum [Member] | 2014 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	7 years 6 months
Maximum [Member] | 2014 Acquired Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years 4 months 24 days
Minimum [Member] | 2015 Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	7 years

Share-Based Compensation - Shar

Share-Based Compensation - Share-Based Compensation Expense Recognized in Company's Results of Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 925.7	$ 401.2	$ 133.6
Equity Based Compensation Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	690.4	368	132.1
Cash-Settled Equity Awards [Member] | Allergan, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	127.1
Cash-Settled Equity Awards [Member] | Kythera Acquisition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	9.6
Cash-Settled Equity Awards [Member] | Durata Acquisition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		16.6
Cash-Settled Equity Awards [Member] | Furiex Pharmaceuticals, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		$ 16.6
Non Equity-Settled Awards Other [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 98.6		$ 1.5

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Equity Award Activity for Unvested Restricted Stock and Stock Units (Detail) - Restricted Stock [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares / units outstanding, beginning balance	2.1
Shares, Granted	0.5
Shares, Vested	(1)
Shares, Assumed as part of the Allergan Acquisition	0.5
Shares, Forfeited	(0.1)
Restricted shares / units outstanding, ending balance	2	2.1
Weighted Average Grant Date Fair Value, outstanding, beginning balance	$ 148.79
Weighted Average Grant Date Fair Value, Granted	304.94
Weighted Average Grant Date Fair Value, Vested	(127.15)
Weighted Average Grant Date Fair Value, Assumed as part of the Allergan Acquisition	218.47
Weighted Average Grant Date Fair Value, Forfeited	(152.63)
Weighted Average Grant Date Fair Value, outstanding, ending balance	$ 209.90	$ 148.79
Weighted Average Remaining Contractual Term (Years)	1 year 8 months 12 days	1 year 3 months 18 days
Aggregate Grant Date Fair Value, outstanding, beginning balance	$ 312.5
Aggregate Grant Date Fair Value, Granted	152.5
Aggregate Grant Date Fair Value, Vested	(128.1)
Aggregate Grant Date Fair Value, Assumed as part of the Allergan Acquisition	102.8
Aggregate Grant Date Fair Value, Forfeited	(19.9)
Aggregate Grant Date Fair Value, outstanding, ending balance	$ 419.8	$ 312.5

Share-Based Compensation - Su91

Share-Based Compensation - Summary of Equity Award Activity for Non-Qualified Options to Purchase Ordinary Shares (Detail) - Non-qualified Options [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Outstanding, Beginning Balance	5.4
Options, Granted	0.2
Options, Exercised	(2.4)
Options, Cancelled	(0.4)
Options, Outstanding, Ending Balance	10.5	5.4
Options, Vested and expected to vest	9.9
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 93.96
Weighted Average Exercise Price, Granted	300.29
Weighted Average Exercise Price, Exercised	(134.54)
Weighted Average Exercise Price, Cancelled	(135.92)
Weighted Average Exercise Price, Outstanding, Ending Balance	149.11	$ 93.96
Weighted Average Exercise Price, Vested and expected to vest	$ 148.14
Weighted Average Remaining Contractual Term (Years), Outstanding	6 years 8 months 12 days	7 years 3 months 18 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest	6 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 1,707.8	$ 858.9
Aggregate Intrinsic Value, Vested and expected to vest	$ 1,620.5
Allergan Acquisition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Assumed as part of the acquisition	7
Weighted Average Exercise Price, Assumed as part of the acquisition - aggregate	$ 103.63
Kythera Acquisition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Assumed as part of the acquisition	0.7
Weighted Average Exercise Price, Assumed as part of the acquisition - aggregate	$ 127.02

Pension and Other Postretirem92

Pension and Other Postretirement Benefit Plans - Summary of Net Periodic Benefit Cost of Defined Benefit Plans for Continuing Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Service cost	$ 5	$ 2
Interest cost	35	3.3
Expected Return on plan assets	(46.4)	(3.5)
Settlement	(4.3)
Net periodic benefit (income) cost	$ (10.7)	$ 1.8

Pension and Other Postretirem93

Pension and Other Postretirement Benefit Plans - Schedule of Benefit Obligation and Asset Data for Defined Benefit Plans for Continuing Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Change in Plan Assets
Fair value of plan assets at beginning of year	$ 83.6	$ 79.9
Employer contribution	107.6	3.2
Return on plan assets	(60.3)	13.9
Benefits paid	(21.5)	(2.9)
Settlements	(100)
Effects of exchange rate changes	(0.3)	(10.5)
Fair value of plan assets at end of year	1,051.1	83.6
Change in Benefit Obligation
Benefit obligation at beginning of the year	111.6	96.5
Service cost	5	2
Interest cost	35	3.3
Actuarial loss/(gain)	(191.2)	27
Curtailments		(0.7)
Settlements and other	(101.1)
Benefits paid	(21.5)	(2.8)
Effects of exchange rate changes	6.1	(13.7)
Fair value of plan assets at end of year	1,051.1	83.6
Benefit obligation at end of year	1,188.5	111.6
Funded status at end of year	(137.4)	$ (28)
Allergan, Inc. [Member]
Change in Plan Assets
Fair value of plan assets assumed in the Acquisition	1,042
Change in Benefit Obligation
Benefit obligation assumed in the Acquisition	$ 1,344.6

Pension and Other Postretirem94

Pension and Other Postretirement Benefit Plans - Schedule of Funded Status Amount Recognized in Consolidated Balance Sheet (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Amounts Recognized In Balance Sheet [Abstract]
Current liabilities	$ (29.3)	$ (2.7)
Noncurrent liabilities	(108.1)	(25.3)
Funded status at end of year	$ (137.4)	$ (28)

Pension and Other Postretirem95

Pension and Other Postretirement Benefit Plans - Schedule of Plan Assets and Liabilities Held for Sale (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at end of year	$ 1,051.1	$ 83.6	$ 79.9
Benefit obligation at end of year	1,188.5	111.6	$ 96.5
Funded status at end of year	(137.4)	(28)
Teva Pharmaceutical Industries Ltd [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at end of year	111.9	112.5
Benefit obligation at end of year	161.8	174.5
Funded status at end of year	$ (49.9)	$ (62)

Pension and Other Postretirem96

Pension and Other Postretirement Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Income from discontinued operations	$ 6.8	$ 4.7	$ 7.1
Continuing Operations [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions to pension plans in next fiscal year	29.3
Continuing Operations [Member] | Savings Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions	26.6	35	24.9
Discontinued Operations [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions to pension plans in next fiscal year	6
Discontinued Operations [Member] | Savings Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions	$ 23.6	$ 31	$ 22

Pension and Other Postretirem97

Pension and Other Postretirement Benefit Plans - Schedule of Fair Values of Pension Plan Assets by Asset Category for Continuing Operations (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	$ 1,051.1	$ 83.6	$ 79.9
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	365	24.9
Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	686.1	58.7
Investment Funds [Member] | Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	365	24.9
Investment Funds [Member] | Equity Securities [Member] | U.S. Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	114.6
Investment Funds [Member] | Equity Securities [Member] | International Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	151.3
Investment Funds [Member] | Equity Securities [Member] | Other Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	99.1
Investment Funds [Member] | Debt Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	671.3	56.5
Investment Funds [Member] | Debt Securities [Member] | U.S. Treasury Bonds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	120.6
Investment Funds [Member] | Debt Securities [Member] | Bonds and Bond Funds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	490.7
Investment Funds [Member] | Debt Securities [Member] | Other Debt Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	60
Investment Funds [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	365	24.9
Investment Funds [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Equity Securities [Member] | U.S. Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	114.6
Investment Funds [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Equity Securities [Member] | International Equities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	151.3
Investment Funds [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Equity Securities [Member] | Other Equity Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	99.1
Investment Funds [Member] | Significant Other Observable Inputs (Level 2) [Member] | Debt Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	671.3	56.5
Investment Funds [Member] | Significant Other Observable Inputs (Level 2) [Member] | Debt Securities [Member] | U.S. Treasury Bonds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	120.6
Investment Funds [Member] | Significant Other Observable Inputs (Level 2) [Member] | Debt Securities [Member] | Bonds and Bond Funds [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	490.7
Investment Funds [Member] | Significant Other Observable Inputs (Level 2) [Member] | Debt Securities [Member] | Other Debt Securities [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	60
Other Investments [Member] | Other [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	14.8	2.2
Other Investments [Member] | Significant Other Observable Inputs (Level 2) [Member] | Other [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets at end of year	$ 14.8	$ 2.2

Pension and Other Postretirem98

Pension and Other Postretirement Benefit Plans - Schedule of Allocated Target Investment Portfolio of Pension Plans for Continuing Operations (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	35.00%	30.00%
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	62.50%	67.50%
Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	2.50%	2.50%

Pension and Other Postretirem99

Pension and Other Postretirement Benefit Plans - Schedule of Expected Benefit Payments of Pension Plans for Continuing Operations (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Estimated Future Benefit Payments [Abstract]
2,016	$ 29.3
2,017	31.7
2,018	34.6
2,019	37.6
2,020	40.5
Thereafter	1,014.8
Total liability	$ 1,188.5	$ 111.6	$ 96.5

Pension and Other Postretire100

Pension and Other Postretirement Benefit Plans - Schedule of Defined Benefit Plans with Accumulated Benefit Obligation in Excess of Plan Assets for Continuing Operations (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets [Abstract]
Projected benefit obligations	$ 1,188.5	$ 111.6
Accumulated benefit obligations	1,054.6	100.8
Plan assets	$ 904.3	$ 83.6

Pension and Other Postretire101

Pension and Other Postretirement Benefit Plans - Schedule of Balances Recognized within Accumulated Other Comprehensive Income / (Loss) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Amounts Recognized In Other Comprehensive Income [Abstract]
Beginning balance	$ (30.8)	$ 5.6
Net actuarial gain (loss)	101.2	(36.4)
Ending Balance	$ 70.4	$ (30.8)

Pension and Other Postretire102

Pension and Other Postretirement Benefit Plans - Weighted Average Assumptions Used to Calculate Projected Benefit Obligations and Net Periodic Benefit Cost (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Weighted Average Assumptions Used In Calculating Benefit Obligation [Abstract]
Projected benefit obligations, Discount rate	3.80%	2.90%
Projected benefit obligations, Salary growth rate	3.70%	3.70%
Net periodic benefit cost, Discount Rate	3.50%	3.90%
Net periodic benefit cost, Expected rate of return on plan assets	4.60%	4.90%
Net periodic benefit cost, Salary growth rate	3.50%	3.70%

Pension and Other Postretire103

Pension and Other Postretirement Benefit Plans - Schedule of Accumulated Benefit Obligation and Asset Data for Defined Benefit Plans (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Pension Plan With Accumulated Benefit Obligation In Excess Of Fair Value Of Plan Assets [Line Items]
Interest cost	$ 35	$ 3.3
Actuarial loss/(gain)	(191.2)	27
Benefits paid	(21.5)	(2.8)
Forest Laboratories Inc. [Member] | Other Benefit Obligation [Member]
Defined Benefit Pension Plan With Accumulated Benefit Obligation In Excess Of Fair Value Of Plan Assets [Line Items]
Accumulated benefit obligation, Beginning balance	20.5	14
Interest cost		0.4
Actuarial loss/(gain)		6.4
Benefits paid		(0.3)
Accumulated benefit obligation, Ending balance		20.5
Allergan, Inc. [Member] | Other Benefit Obligation [Member]
Defined Benefit Pension Plan With Accumulated Benefit Obligation In Excess Of Fair Value Of Plan Assets [Line Items]
Accumulated benefit obligation, Beginning balance	60.2
Interest cost	(2.3)
Actuarial loss/(gain)	(26.3)
Benefits paid	(2)
Accumulated benefit obligation, Ending balance	$ 50.1	$ 60.2

Other Income (Expense) - Compon

Other Income (Expense) - Components of Other Income (Expense) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Other Income And Expenses [Abstract]
Bridge loan commitment fee	$ (264.9)	$ (73.6)
Interest rate lock	31
Extinguishment of debt		29.9	$ (18.5)
Other (expense) income	0.1	16.4	(0.1)
Other (expense) income, net	$ (233.8)	$ (27.3)	$ (18.6)

Other Income (Expense) - Additi

Other Income (Expense) - Additional Information (Detail) - USD ($) $ in Millions	Jul. 21, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Other Non operating Income Expense [Line Items]
Bridge loan financing and commitment costs		$ 264.9	$ 73.6
Interest rate lock income		31
Senior notes, gross		34,050	11,000
Gain (loss) on extinguishment of debt			29.9	$ (18.5)
5.00% Senior Notes Due August 15, 2014 [Member]
Other Non operating Income Expense [Line Items]
Gain (loss) on extinguishment of debt				(17.1)
Debt extinguishment, carrying amount				$ 450
Senior notes, interest rate				5.00%
Non-cash write-off of deferred loan costs				$ 1.4
Interest Rate Lock [Member]
Other Non operating Income Expense [Line Items]
Interest rate lock income		31
Allergan Acquisition [Member]
Other Non operating Income Expense [Line Items]
Bridge loan expenses			$ 47.8
Allergan Acquisition [Member] | Interest Rate Lock [Member]
Other Non operating Income Expense [Line Items]
Debt issued on business combination		21,000
Forest Acquisition [Member]
Other Non operating Income Expense [Line Items]
Bridge loan financing and commitment costs		25.8
Forest Acquisition [Member] | Maximum [Member]
Other Non operating Income Expense [Line Items]
Bridge loan commitment		$ 7,000
Warner Chilcott [Member]
Other Non operating Income Expense [Line Items]
Debt instrument, maturity date		Jul. 21, 2014
Repayment of debt	$ 1,311.8
Redeemable premium interest	61.8
Senior notes, gross	1,250
Gain (loss) on extinguishment of debt	$ 29.9

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 242.3	$ 203.5
Work-in-process	149.7	80.9
Finished goods	706.3	763.6
Inventories, gross	1,098.3	1,048
Less: inventory reserves	88.6	63.4
Total Inventories	$ 1,009.7	$ 984.6

Inventories - Schedule of Amoun

Inventories - Schedule of Amounts Related to Fair Value Step-up of Acquired Inventory (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Inventory, finished goods	$ 46.1	$ 262.9
Allergan, Inc. [Member]
Inventory [Line Items]
Inventory, finished goods	21.6
Forest Laboratories Inc. [Member]
Inventory [Line Items]
Inventory, finished goods	20.1	244.7
Durata Acquisition [Member]
Inventory [Line Items]
Inventory, finished goods	$ 4.4	16.3
Warner Chilcott Acquisition [Member]
Inventory [Line Items]
Inventory, finished goods		$ 1.9

Accounts Payable and Accrued108

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Accrued expenses:
Accrued third-party rebates	$ 1,281.6	$ 904.6
Accrued payroll and related benefits	409.7	198.7
Accrued R&D expenditures	384.1	169.9
Interest payable	312	82.7
Accrued returns	288.4	250.3
Litigation-related reserves and legal fees	213.5	300.9
Accrued non-provision taxes	100.3	3.3
Accrued pharmaceutical fees	162.2	118.7
Accrued selling and marketing expenditures	127.2	9.6
Royalties payable	126.9	128.9
Accrued severance, retention and other shutdown costs	110.4	107.2
Current portion of contingent consideration obligations	79.9	233.9
Accrued professional fees	25.4	39.3
Dividends payable	23.9
Manufacturing related	14.9	11.2
Accrued warranties	7.6
Other accrued expenses	312.1	147.6
Total accrued expenses	3,980.1	2,706.8
Accounts payable	369.4	323.3
Total accounts payable and accrued expenses	$ 4,349.5	$ 3,030.1

Property, Plant and Equipmen109

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Line Items]
Beginning balance	$ 2,614.7
Additions	448.4
Additions due to acquisitions	1,214.5
Disposals/transfers/impairments	(157.5)
Transfer to assets held for sale	(4.5)
Currency translation	(97.7)
Ending balance	4,017.9	$ 2,614.7
Accumulated depreciation
Accumulated depreciation, beginning balance	1,020
Additions	218.3	230.9	$ 202
Disposals/transfers/impairments	(120.7)
Currency translation	(29.2)
Accumulated depreciation, ending balance	1,088.4	1,020
Balance	2,929.5	1,594.7
Property, plant and equipment, net	1,573.9	283.4
Discontinued Operations	1,355.6	1,311.3
Machinery and Equipment [Member]
Property Plant And Equipment [Line Items]
Beginning balance	950.3
Additions	79.8
Additions due to acquisitions	224.4
Disposals/transfers/impairments	19.9
Currency translation	(42.7)
Ending balance	1,231.7	950.3
Accumulated depreciation
Accumulated depreciation, beginning balance	415.3
Additions	65.7
Disposals/transfers/impairments	(22.6)
Currency translation	(16.2)
Accumulated depreciation, ending balance	442.2	415.3
Balance	789.5	535
Property, plant and equipment, net	269.2	30.9
Discontinued Operations	520.3	504.1
Research and Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Beginning balance	155.5
Additions	4.1
Additions due to acquisitions	19.1
Disposals/transfers/impairments	(6.3)
Currency translation	(0.5)
Ending balance	171.9	155.5
Accumulated depreciation
Accumulated depreciation, beginning balance	130.8
Additions	8.3
Disposals/transfers/impairments	(8.3)
Currency translation	(0.7)
Accumulated depreciation, ending balance	130.1	130.8
Balance	41.8	24.7
Property, plant and equipment, net	17.8	2.4
Discontinued Operations	24	22.3
Other [Member]
Property Plant And Equipment [Line Items]
Beginning balance	365.4
Additions	40
Additions due to acquisitions	72.3
Disposals/transfers/impairments	(23.3)
Currency translation	(8.9)
Ending balance	445.5	365.4
Accumulated depreciation
Accumulated depreciation, beginning balance	249.4
Additions	78.7
Disposals/transfers/impairments	(23.3)
Currency translation	(4.6)
Accumulated depreciation, ending balance	300.2	249.4
Balance	145.3	116
Property, plant and equipment, net	90.9	51
Discontinued Operations	54.4	65
Transportation [Member]
Property Plant And Equipment [Line Items]
Beginning balance	85.7
Additions	77.5
Additions due to acquisitions	1
Disposals/transfers/impairments	(9.4)
Currency translation	(4.3)
Ending balance	150.5	85.7
Accumulated depreciation
Accumulated depreciation, beginning balance	11.4
Additions	12.3
Disposals/transfers/impairments	(6)
Currency translation	(1.4)
Accumulated depreciation, ending balance	16.3	11.4
Balance	134.2	74.3
Property, plant and equipment, net	117.5	53.4
Discontinued Operations	16.7	20.9
Land, Buildings and Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Beginning balance	907.1
Additions	10.8
Additions due to acquisitions	585.2
Disposals/transfers/impairments	(20.3)
Transfer to assets held for sale	(4.5)
Currency translation	(38.4)
Ending balance	1,439.9	907.1
Accumulated depreciation
Accumulated depreciation, beginning balance	213.1
Additions	53.3
Disposals/transfers/impairments	(60.5)
Currency translation	(6.3)
Accumulated depreciation, ending balance	199.6	213.1
Balance	1,240.3	694
Property, plant and equipment, net	654.6	109.1
Discontinued Operations	585.7	584.9
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Beginning balance	150.7
Additions	236.2
Additions due to acquisitions	312.5
Disposals/transfers/impairments	(118.1)
Currency translation	(2.9)
Ending balance	578.4	150.7
Accumulated depreciation
Balance	578.4	150.7
Property, plant and equipment, net	423.9	36.6
Discontinued Operations	$ 154.5	$ 114.1

Property, Plant and Equipmen110

Property, Plant and Equipment, Net - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Line Items]
Depreciation expense	$ 218.3	$ 230.9	$ 202
Continuing Operations [Member]
Property Plant And Equipment [Line Items]
Depreciation expense	$ 128.6	$ 71.3	$ 35.1

Other Assets - Prepaid Expenses

Other Assets - Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Prepaid Expense And Other Assets Current [Abstract]
Prepaid taxes	$ 240.5	$ 207.7
Current portion of deferred loan costs	36.3	124.9
Prepaid insurance	24.1	14
Other	257.6	132.2
Total prepaid expenses and other current assets	$ 558.5	$ 478.8

Other Assets - Marketable Secur

Other Assets - Marketable Securities and Other Investments (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Marketable securities:
Total marketable securities	$ 9.3	$ 1
Investments and other assets:
Deferred loan costs	159.5	58.9
Legacy Allergan Deferred executive compensation investments	118.1
Equity method investments	17.3	0.1
Cost method investments	16.7	0.3
Other long-term investments	78.2	53.9
Taxes receivable	39.6
Other assets	148	40.1
Total investments and other assets	577.4	153.3
U.S. Treasury and Agency Securities - Maturing Within One Year [Member]
Marketable securities:
U.S. Treasury and agency securities	$ 9.3	$ 1

Other Assets - Summary of Fair

Other Assets - Summary of Fair Value and Unrealized Gains (Losses) Related to Available-for-Sale Securities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 29.9	$ 1
Fair Value	29.9	1
U.S. Treasury and Agency Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	29.9	1
Fair Value	$ 29.9	$ 1

Other Assets - Additional Infor

Other Assets - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015
Maximum [Member]
Schedule Of Available For Sale Securities [Line Items]
Ownership percentage in cost method investments	20.00%

Other Assets - Summary of Long-

Other Assets - Summary of Long-term Investments (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Long Term Investments [Abstract]
Equity Method investments, beginning balance	$ 0.1
Equity Method investments, Acquired from the Allergan Acquisition	17.3
Equity Method investments, Other	(0.1)
Equity Method investments, ending balance	17.3
Cost Method and Other Long-term Investments, beginning balance	54.2
Cost Method and Other Long-term Investments, Additions	20
Cost Method and Other Long-term Investments, Acquired from the Allergan Acquisition	15
Cost Method and Other Long-term Investments, Other	5.7
Cost Method and Other Long-term Investments, ending balance	$ 94.9

Goodwill, Product Rights and116

Goodwill, Product Rights and Other Intangible Assets - Schedule of Goodwill (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Goodwill [Line Items]
Balance as of December 31, 2014	$ 20,897.6
Additions through acquisitions	27,726.3
Measurement period adjustments and other	68
Held for sale	(2,385.8)
Foreign exchange and other adjustments	245.4
Balance as of December 31, 2015	46,551.5
US Brands [Member]
Goodwill [Line Items]
Balance as of December 31, 2014	20,603.7
Additions through acquisitions	15,435.8
Measurement period adjustments and other	68
Balance as of December 31, 2015	36,107.5
US Medical Aesthetics [Member]
Goodwill [Line Items]
Additions through acquisitions	4,006.7
Balance as of December 31, 2015	4,006.7
International Brands [Member]
Goodwill [Line Items]
Balance as of December 31, 2014	207.6
Additions through acquisitions	8,283.8
Held for sale	(2,385.8)
Foreign exchange and other adjustments	245.4
Balance as of December 31, 2015	6,351
Anda Distribution Segment
Goodwill [Line Items]
Balance as of December 31, 2014	86.3
Balance as of December 31, 2015	$ 86.3

Goodwill, Product Rights and117

Goodwill, Product Rights and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions

Jul. 02, 2014

Jul. 01, 2014

Dec. 31, 2014

Sep. 30, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Oct. 01, 2015

Aug. 10, 2015

May. 29, 2015

Mar. 17, 2015

Dec. 17, 2014

Nov. 17, 2014

Oct. 01, 2013

Goodwill [Line Items]

Gross balance of goodwill

$ 20,914.9

$ 46,568.8

$ 20,914.9

Addition to goodwill

27,726.3

Goodwill held for sale

3,623.9

3,623.9

Goodwill

20,897.6

46,551.5

20,897.6

Adjusted goodwill

83.6

Goodwill impairment

17.3

$ 647.5

In-process research and development impairments

511.6

$ 424.3

$ 4.9

Divestiture of business

38.8

Forest Products [Member]

Goodwill [Line Items]

Divestiture of business

$ 13.5

Bystolic [Member]

Goodwill [Line Items]

In-process research and development impairments

$ 140

Doryx [Member]

Goodwill [Line Items]

In-process research and development impairments

89

Doryx Litigation Indirect Purchasers [Member]

Goodwill [Line Items]

Intangible assets reduction arising from divestiture of businesses

46.6

Abandoned IPR&D [Member]

Goodwill [Line Items]

In-process research and development impairments

300

CMP [Member]

Goodwill [Line Items]

Intangibles with definite lives, Impairments

206.1

IPR&D [Member] | FDA Correspondence [Member]

Goodwill [Line Items]

Impairment charge

$ 53

Teva Pharmaceutical Industries Ltd [Member]

Goodwill [Line Items]

Goodwill held for sale

2,385.8

Allergan, Inc. [Member]

Goodwill [Line Items]

Addition to goodwill

27,088.9

Goodwill

27,088.9

IPR&D intangible assets

$ 54,750.5

Allergan, Inc. [Member] | Expected Delay In Launch Of Product [Member]

Goodwill [Line Items]

In-process research and development impairments

14

Allergan, Inc. [Member] | Product Rights and Other Related Intangibles [Member]

Goodwill [Line Items]

IPR&D intangible assets

44,360.5

Allergan, Inc. [Member] | Trade Name [Member]

Goodwill [Line Items]

IPR&D intangible assets

690

Allergan, Inc. [Member] | IPR&D [Member]

Goodwill [Line Items]

IPR&D intangible assets

9,700

$ 9,700

$ 9,700

Auden Mckenzie [Member]

Goodwill [Line Items]

Goodwill

123.3

$ 123.3

Auden Mckenzie [Member] | IPR&D [Member]

Goodwill [Line Items]

IPR&D intangible assets

$ 38.6

Oculeve, Inc. [Member]

Goodwill [Line Items]

Addition to goodwill

33.3

Goodwill

$ 33.3

Oculeve, Inc. [Member] | IPR&D [Member]

Goodwill [Line Items]

IPR&D intangible assets

286

$ 286

Kythera [Member]

Goodwill [Line Items]

Addition to goodwill

328.7

Goodwill

$ 328.7

Kythera [Member] | CMP [Member]

Goodwill [Line Items]

IPR&D intangible assets

2,120

Kythera [Member] | IPR&D [Member]

Goodwill [Line Items]

IPR&D intangible assets

320

$ 320

AqueSys, Inc. [Member]

Goodwill [Line Items]

Addition to goodwill

138.5

AqueSys, Inc. [Member] | CMP [Member]

Goodwill [Line Items]

IPR&D intangible assets

221

AqueSys, Inc. [Member] | IPR&D [Member]

Goodwill [Line Items]

IPR&D intangible assets

302

Northwood [Member]

Goodwill [Line Items]

Addition to goodwill

13.6

Northwood [Member] | CMP [Member]

Goodwill [Line Items]

IPR&D intangible assets

19.5

Northwood [Member] | IPR&D [Member]

Goodwill [Line Items]

IPR&D intangible assets

13.6

Forest Laboratories Inc. and Durata Acquisition [Member]

Goodwill [Line Items]

Adjusted goodwill

(21.3)

Forest Laboratories Inc. [Member]

Goodwill [Line Items]

Goodwill

$ 16,403.6

Out-of-period adjustment in goodwill

83.6

IPR&D intangible assets

12,256.5

Out-of-period adjustment in intangible assets

135

Forest Laboratories Inc. [Member] | Forest Products [Member]

Goodwill [Line Items]

Divestiture of business

13.5

Forest Laboratories Inc. [Member] | IPR&D [Member]

Goodwill [Line Items]

IPR&D intangible assets

$ 1,362

Impairment charge

165

Warner Chilcott [Member]

Goodwill [Line Items]

Goodwill

$ 3,956.1

Warner Chilcott [Member] | Women’s Healthcare Portfolio Products [Member]

Goodwill [Line Items]

In-process research and development impairments

$ 192.1

Warner Chilcott [Member] | IPR&D [Member]

Goodwill [Line Items]

IPR&D intangible assets

$ 1,708

Furiex Acquisition [Member]

Goodwill [Line Items]

Goodwill

251.9

IPR&D intangible assets

1,411.6

Furiex Acquisition [Member] | Product Rights and Other Related Intangibles [Member]

Goodwill [Line Items]

IPR&D intangible assets

408.6

Furiex Acquisition [Member] | IPR&D [Member]

Goodwill [Line Items]

IPR&D intangible assets

$ 1,003

Durata Acquisition [Member]

Goodwill [Line Items]

IPR&D intangible assets

$ 729

Durata Acquisition [Member] | Product Rights and Other Related Intangibles [Member]

Goodwill [Line Items]

IPR&D intangible assets

480

Durata Acquisition [Member] | IPR&D [Member]

Goodwill [Line Items]

IPR&D intangible assets

$ 249

Goodwill, Product Rights and118

Goodwill, Product Rights and Other Intangible Assets - Schedule of Cost Basis on Product Rights and Other Intangible Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with indefinite lives, Impairments	$ (511.6)	$ (424.3)	$ (4.9)
Intangible assets, gross, Amortization	(5,777)	(2,597.5)	(842.7)
Intangible assets net, beginning balance	16,090.7	5,038
Intangible assets net, ending balance	67,931.7	16,090.7	5,038
Cost Basis [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	15,305.7	4,006.6
Intangibles with definite lives, Acquisitions	47,853.8	11,850.8
Intangibles with definite lives, Impairments	(242.2)
Intangibles with definite lives, IPR&D to CMP Transfers	3,128.5	140
Intangibles with definite lives Disposals/Held for Sale/Other	(975.5)	(685.5)
Intangibles with definite lives, Foreign Currency Translation	163.9	(6.2)
Intangibles with definite lives, Ending balance	65,234.2	15,305.7	4,006.6
Intangibles with indefinite lives, Beginning balance	4,192.6	2,192.2
Intangibles with indefinite lives, Acquisitions	10,714.4	2,675.8
Intangibles with indefinite lives, Impairments	(511.6)	(424.3)
Intangibles with indefinite lives, IPR&D to CMP Transfers	(3,128.5)	(140)
Intangibles with indefinite lives, Held For Sale/Disposals/Other	(38.8)	(36.3)
Intangibles with indefinite lives, Foreign Currency Translation	(23.7)	(74.8)
Intangibles with indefinite lives, Ending balance	11,204.4	4,192.6	2,192.2
Intangible assets, gross, Beginning balance	19,498.3	6,198.8
Intangible assets, gross, Acquisitions	58,568.2	14,526.6
Intangible assets, gross, Impairments	(753.8)	(424.3)
Intangibles assets, Held For Sale/Disposals/Other	(1,014.3)	(721.8)
Intangibles assets, gross, Foreign Currency Translation	140.2	(81)
Intangible assets, gross, Ending balance	76,438.6	19,498.3	6,198.8
Cost Basis [Member] | Product Rights and Other Related Intangibles [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance	15,305.7	4,006.6
Intangibles with definite lives, Acquisitions	47,163.8	11,850.8
Intangibles with definite lives, Impairments	(242.2)
Intangibles with definite lives, IPR&D to CMP Transfers	3,128.5	140
Intangibles with definite lives Disposals/Held for Sale/Other	(975.5)	(685.5)
Intangibles with definite lives, Foreign Currency Translation	163.9	(6.2)
Intangibles with definite lives, Ending balance	64,544.2	15,305.7	4,006.6
Cost Basis [Member] | Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Acquisitions	690
Intangibles with definite lives, Ending balance	690
Intangibles with indefinite lives, Beginning balance	76.2	76.2
Intangibles with indefinite lives, Ending balance	76.2	76.2	76.2
Cost Basis [Member] | IPR&D [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with indefinite lives, Beginning balance	4,116.4	2,116
Intangibles with indefinite lives, Acquisitions	10,714.4	2,675.8
Intangibles with indefinite lives, Impairments	(511.6)	(424.3)
Intangibles with indefinite lives, IPR&D to CMP Transfers	(3,128.5)	(140)
Intangibles with indefinite lives, Held For Sale/Disposals/Other	(38.8)	(36.3)
Intangibles with indefinite lives, Foreign Currency Translation	(23.7)	(74.8)
Intangibles with indefinite lives, Ending balance	11,128.2	4,116.4	2,116
Accumulated Amortization [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(3,407.6)	(1,160.8)
Intangibles with definite lives, Impairments	(7.5)	(289.7)
Intangibles with definite lives, Foreign Currency Translation	(0.1)	(20.1)
Intangible assets, gross, Impairments	(7.5)	(289.7)
Intangibles assets, gross, Foreign Currency Translation	(0.1)	(20.1)
Intangible assets, gross, Amortization	(5,453.4)	(1,945.5)
Intangible assets gross, Disposals/Other	361.7	8.5
Intangibles with definite lives, Disposals/Other	361.7	8.5
Intangible assets, Accumulated Amortization, Ending balance	(8,506.9)	(3,407.6)	(1,160.8)
Accumulated Amortization [Member] | Product Rights and Other Related Intangibles [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance	(3,407.6)	(1,160.8)
Intangibles with definite lives, Impairments	(7.5)	(289.7)
Intangibles with definite lives, Foreign Currency Translation	(0.1)	(20.1)
Intangible assets, gross, Amortization	(5,393.9)	(1,945.5)
Intangibles with definite lives, Disposals/Other	361.7	8.5
Intangible assets, Accumulated Amortization, Ending balance	(8,447.4)	$ (3,407.6)	$ (1,160.8)
Accumulated Amortization [Member] | Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, gross, Amortization	(59.5)
Intangible assets, Accumulated Amortization, Ending balance	$ (59.5)

Goodwill, Product Rights and119

Goodwill, Product Rights and Other Intangible Assets - Schedule of Annual Amortization Expense on Product Rights and Other Related Intangibles (Detail) - Product Rights and Other Related Intangibles [Member] $ in Millions	Dec. 31, 2015USD ($)
Finite Lived Intangible Assets [Line Items]
2,016	$ 6,349
2,017	6,286.8
2,018	5,799.1
2,019	5,717.3
2,020	$ 5,470.8

Long-Term Debt and Capital Leas

Long-Term Debt and Capital Leases - Schedule of Long-Term Debt and Capital Leases (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Mar. 17, 2015	Dec. 31, 2014	Jun. 10, 2014	Oct. 01, 2013
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 34,050		$ 11,000
Unamortized premium	225.9		239.9
Unamortized discount	(107.4)		(52.1)
Total Senior Notes Net	34,168.5		11,187.8
Senior Notes, Fair Market Value	34,100.5		11,236.7
Total Term Loan Indebtedness	8,256.2		4,084.2
Revolver Borrowings	200		255
Total Other Borrowings	297.4		255
Total Indebtedness	42,726.2		15,531.1
Capital Leases [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	4.1		4.1
Floating Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,500
Senior Notes, Fair Market Value	1,496.3
Floating Rate Notes [Member] | Notes Due September 1, 2016 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500
Senior Notes, Fair Market Value	500.5
Floating Rate Notes [Member] | Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500
Senior Notes, Fair Market Value	499.6
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500
Senior Notes, Fair Market Value	496.2
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	32,550		11,000
Senior Notes, Fair Market Value	32,604.2		11,236.7
Fixed Rate Notes [Member] | 5.750% Notes Due April 1, 2016 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	800	$ 800
Senior Notes, Fair Market Value	808.4
Fixed Rate Notes [Member] | 1.850% Notes Due March 1, 2017 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,000
Senior Notes, Fair Market Value	1,001.5
Fixed Rate Notes [Member] | 1.300% Notes Due June 15, 2017 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500		500	$ 500
Senior Notes, Fair Market Value	496.3		489
Fixed Rate Notes [Member] | 1.875% Notes Due October 1, 2017 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,200		1,200		$ 1,200
Senior Notes, Fair Market Value	1,196		1,187.3
Fixed Rate Notes [Member] | 2.350% Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	3,000
Senior Notes, Fair Market Value	3,004.6
Fixed Rate Notes [Member] | 1.350% Notes Due March 15, 2018 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	250	250
Senior Notes, Fair Market Value	244.9
Fixed Rate Notes [Member] | 4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,050		1,050
Senior Notes, Fair Market Value	1,099.5		1,111.4
Fixed Rate Notes [Member] | 2.450% Notes Due June 15, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500		500	500
Senior Notes, Fair Market Value	494.4		498.2
Fixed Rate Notes [Member] | 6.125% Senior Notes Due August 15, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	400		400		400
Senior Notes, Fair Market Value	444.2		457.9
Fixed Rate Notes [Member] | 3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	3,500
Senior Notes, Fair Market Value	3,505.1
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	650	650
Senior Notes, Fair Market Value	656.6
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	750		750
Senior Notes, Fair Market Value	807.4		808.9
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,200		1,200
Senior Notes, Fair Market Value	1,299.4		1,301
Fixed Rate Notes [Member] | 3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	3,000
Senior Notes, Fair Market Value	3,006.8
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,700		1,700		1,700
Senior Notes, Fair Market Value	1,669.6		1,647.5
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	350	$ 350
Senior Notes, Fair Market Value	327.7
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,200		1,200	1,200
Senior Notes, Fair Market Value	1,202.6		1,215.5
Fixed Rate Notes [Member] | 3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	4,000
Senior Notes, Fair Market Value	3,984.6
Fixed Rate Notes [Member] | 4.550% notes due March 15, 2035 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	2,500
Senior Notes, Fair Market Value	2,462.2
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,000		1,000		$ 1,000
Senior Notes, Fair Market Value	956.1		980.1
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	1,500		1,500	$ 1,500
Senior Notes, Fair Market Value	1,483.6		1,539.9
Fixed Rate Notes [Member] | 4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	2,500
Senior Notes, Fair Market Value	2,452.7
Variable Rate Debt [Member] | WC Three Year Tranche Maturing October 1, 2016 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	191.5		506.9
Variable Rate Debt [Member] | WC Five Year Trance Maturing October 1, 2018 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	498.8		744.7
Variable Rate Debt [Member] | WC Term Loan [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	690.3		1,251.6
Variable Rate Debt [Member] | Act Term Loan Agreement Maturing October 31, 2017 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	572.1		932.6
Variable Rate Debt [Member] | Act Term Loan Amendment Maturing July 1, 2019 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	1,700		1,900
Variable Rate Debt [Member] | ACT Term Loan [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	2,272.1		$ 2,832.6
Variable Rate Debt [Member] | Agn Tranche Three Maturing March 17, 2018 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	2,750
Variable Rate Debt [Member] | Agn Tranche Five Maturing March 17, 2020 [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	2,543.8
Variable Rate Debt [Member] | AGN Term Loan [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness	5,293.8
Other [Member]
Debt Instrument [Line Items]
Total Other Borrowings	$ 97.4

Long-Term Debt and Capital L121

Long-Term Debt and Capital Leases - Schedule of Long-Term Debt and Capital Leases (Parenthetical) (Detail)	Dec. 17, 2014	Dec. 31, 2015	Dec. 31, 2014	Mar. 17, 2015	Jun. 10, 2014	Oct. 01, 2013
Debt Instrument [Line Items]
Quarterly Required Payments		2.50%
Floating Rate Notes [Member] | Notes Due September 1, 2016 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Sep. 1, 2016	Sep. 1, 2016
Floating Rate Notes [Member] | Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 12, 2018	Mar. 12, 2018
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 12, 2020	Mar. 12, 2020
Fixed Rate Notes [Member] | 5.750% Notes Due April 1, 2016 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Apr. 1, 2016	Apr. 1, 2016
Senior notes, interest rate		5.75%	5.75%	5.75%
Fixed Rate Notes [Member] | 1.850% Notes Due March 1, 2017 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 1, 2017	Mar. 1, 2017
Senior notes, interest rate		1.85%	1.85%
Fixed Rate Notes [Member] | 1.300% Notes Due June 15, 2017 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Jun. 15, 2017	Jun. 15, 2017
Senior notes, interest rate		1.30%	1.30%		1.30%
Fixed Rate Notes [Member] | 1.875% Notes Due October 1, 2017 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Oct. 1, 2017	Oct. 1, 2017
Senior notes, interest rate		1.875%	1.875%			1.875%
Fixed Rate Notes [Member] | 2.350% Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 12, 2018	Mar. 12, 2018
Senior notes, interest rate		2.35%	2.35%
Fixed Rate Notes [Member] | 1.350% Notes Due March 15, 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 15, 2018	Mar. 15, 2018
Senior notes, interest rate		1.35%	1.35%	1.35%
Fixed Rate Notes [Member] | 4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Feb. 1, 2019	Feb. 1, 2019
Senior notes, interest rate		4.375%	4.375%
Fixed Rate Notes [Member] | 2.450% Notes Due June 15, 2019 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Jun. 15, 2019	Jun. 15, 2019
Senior notes, interest rate		2.45%	2.45%		2.45%
Fixed Rate Notes [Member] | 6.125% Senior Notes Due August 15, 2019 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Aug. 15, 2019	Aug. 15, 2019
Senior notes, interest rate		6.125%	6.125%			6.125%
Fixed Rate Notes [Member] | 3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 12, 2020	Mar. 12, 2020
Senior notes, interest rate		3.00%	3.00%
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Sep. 15, 2020	Sep. 15, 2020
Senior notes, interest rate		3.375%	3.375%	3.375%
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Feb. 15, 2021	Feb. 15, 2021
Senior notes, interest rate		4.875%	4.875%
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Dec. 15, 2021	Dec. 15, 2021
Senior notes, interest rate		5.00%	5.00%
Fixed Rate Notes [Member] | 3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 15, 2022	Mar. 15, 2022
Senior notes, interest rate		3.45%	3.45%
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Oct. 1, 2022	Oct. 1, 2022
Senior notes, interest rate		3.25%	3.25%			3.25%
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 15, 2023	Mar. 15, 2023
Senior notes, interest rate		2.80%	2.80%	2.80%
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Jun. 15, 2024	Jun. 15, 2024
Senior notes, interest rate		3.85%	3.85%		3.85%
Fixed Rate Notes [Member] | 3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 15, 2025	Mar. 15, 2025
Senior notes, interest rate		3.80%	3.80%
Fixed Rate Notes [Member] | 4.550% notes due March 15, 2035 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 15, 2035	Mar. 15, 2035
Senior notes, interest rate		4.55%	4.55%
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Oct. 1, 2042	Oct. 1, 2042
Senior notes, interest rate		4.625%	4.625%			4.625%
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Jun. 15, 2044	Jun. 15, 2044
Senior notes, interest rate		4.85%	4.85%		4.85%
Fixed Rate Notes [Member] | 4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Mar. 15, 2045	Mar. 15, 2045
Senior notes, interest rate		4.75%	4.75%
Variable Rate Debt [Member] | WC Three Year Tranche Maturing October 1, 2016 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Oct. 1, 2016	Oct. 1, 2016
Variable Rate Debt [Member] | WC Five Year Trance Maturing October 1, 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Oct. 1, 2018	Oct. 1, 2018
Variable Rate Debt [Member] | Act Term Loan Agreement Maturing October 31, 2017 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Oct. 31, 2017	Oct. 31, 2017
Variable Rate Debt [Member] | Act Term Loan Amendment Maturing July 1, 2019 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Jul. 1, 2019	Jul. 1, 2019
Variable Rate Debt [Member] | Agn Tranche Three Maturing March 17, 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Mar. 17, 2018	Mar. 17, 2018	Mar. 17, 2018
Variable Rate Debt [Member] | Agn Tranche Five Maturing March 17, 2020 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Mar. 17, 2020	Mar. 17, 2020	Mar. 17, 2020
Quarterly Required Payments	2.50%

Long-Term Debt and Leases - Flo

Long-Term Debt and Leases - Floating Rate Notes - Additional Information (Detail) - Floating Rate Notes [Member]	12 Months Ended
	Dec. 31, 2015
Debt Instrument [Line Items]
Debt instrument variable rate basis	Three-month LIBOR
Interest payment terms	Interest on the 2016 Floating Rate Notes is payable quarterly on March 1, June 1, September 1 and December 1 of each year, and began on June 1, 2015. Interest on the 2018 Floating Rate Notes and the 2020 Floating Rate Notes is payable quarterly on March 12, June 12, September 12 and December 12 of each year, and began on June 12, 2015.
Notes Due September 1, 2016 [Member]
Debt Instrument [Line Items]
Percentage of margin	0.875%
Notes Due March 12, 2018 [Member]
Debt Instrument [Line Items]
Percentage of margin	1.08%
Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Percentage of margin	1.255%

Long-Term Debt and Leases - Acq

Long-Term Debt and Leases - Acquired Allergan Notes - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 17, 2015
Debt Instrument [Line Items]
Senior notes, gross	$ 34,050	$ 11,000
Senior Notes, Fair Market Value	34,100.5	11,236.7
Unamortized premium	225.9	239.9
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Senior notes, gross	32,550	11,000
Senior Notes, Fair Market Value	$ 32,604.2	$ 11,236.7
Fixed Rate Notes [Member] | Allergan Acquisition [Member]
Debt Instrument [Line Items]
Senior Notes, Fair Market Value			$ 2,087.5
Unamortized premium			$ 37.5
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Mar. 15, 2023	Mar. 15, 2023
Interest payment terms	semi-annually
Senior notes, interest rate	2.80%	2.80%	2.80%
Senior notes, gross	$ 350		$ 350
Senior Notes, Fair Market Value	$ 327.7
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Sep. 15, 2020	Sep. 15, 2020
Interest payment terms	semi-annually
Senior notes, interest rate	3.375%	3.375%	3.375%
Senior notes, gross	$ 650		$ 650
Senior Notes, Fair Market Value	$ 656.6
Fixed Rate Notes [Member] | 1.350% Notes Due March 15, 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Mar. 15, 2018	Mar. 15, 2018
Interest payment terms	semi-annually
Senior notes, interest rate	1.35%	1.35%	1.35%
Senior notes, gross	$ 250		$ 250
Senior Notes, Fair Market Value	$ 244.9
Fixed Rate Notes [Member] | 5.750% Notes Due April 1, 2016 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date	Apr. 1, 2016	Apr. 1, 2016
Interest payment terms	semi-annually
Senior notes, interest rate	5.75%	5.75%	5.75%
Senior notes, gross	$ 800		$ 800
Senior Notes, Fair Market Value	$ 808.4

Long-Term Debt and Leases - 124

Long-Term Debt and Leases - Acquired Forest Notes - Additional Information (Detail) - USD ($) $ in Millions	Jul. 01, 2014	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Senior notes, gross		$ 34,050	$ 11,000
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Senior notes, gross		$ 32,550	$ 11,000
Fixed Rate Notes [Member] | 4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Feb. 1, 2019	Feb. 1, 2019
Senior notes, interest rate		4.375%	4.375%
Senior notes, gross		$ 1,050	$ 1,050
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Dec. 15, 2021	Dec. 15, 2021
Senior notes, interest rate		5.00%	5.00%
Senior notes, gross		$ 1,200	$ 1,200
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Feb. 15, 2021	Feb. 15, 2021
Senior notes, interest rate		4.875%	4.875%
Senior notes, gross		$ 750	$ 750
Fixed Rate Notes [Member] | Forest Laboratories Inc. [Member]
Debt Instrument [Line Items]
Acquisition premium on indebtedness	$ 260.3
Fixed Rate Notes [Member] | Forest Laboratories Inc. [Member] | 4.375% Notes Due February 1, 2019 [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Jul. 1, 2014
Interest payment terms		Interest payments are due on the $1,050.0 million senior notes semi-annually in arrears on February 1 and August 1 beginning August 1, 2014.
Senior notes, interest rate	4.375%
Senior notes, gross	$ 1,050
Fixed Rate Notes [Member] | Forest Laboratories Inc. [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Interest payment terms		Interest payments are due on the $1,200.0 million senior note due 2021 semi-annually in arrears on June 15 and December 15, beginning December 15, 2014.
Senior notes, interest rate	5.00%
Senior notes, gross	$ 1,200
Fixed Rate Notes [Member] | Forest Laboratories Inc. [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Interest payment terms		Interest payments are due on the $750.0 million senior notes due 2021 semi-annually in arrears on February 15 and August 15 beginning August 15, 2014.
Senior notes, interest rate	4.875%
Senior notes, gross	$ 750

Long-Term Debt and Leases - 201

Long-Term Debt and Leases - 2014 Notes Issuance - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Jun. 10, 2014
Debt Instrument [Line Items]
Senior notes, gross	$ 34,050	$ 11,000
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Senior notes, gross	$ 32,550	$ 11,000
Fixed Rate Notes [Member] | 1.300% Notes Due June 15, 2017 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	1.30%	1.30%	1.30%
Senior notes, gross	$ 500	$ 500	$ 500
Debt instrument, maturity date	Jun. 15, 2017	Jun. 15, 2017
Fixed Rate Notes [Member] | 2.450% Notes Due June 15, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	2.45%	2.45%	2.45%
Senior notes, gross	$ 500	$ 500	$ 500
Debt instrument, maturity date	Jun. 15, 2019	Jun. 15, 2019
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	3.85%	3.85%	3.85%
Senior notes, gross	$ 1,200	$ 1,200	$ 1,200
Debt instrument, maturity date	Jun. 15, 2024	Jun. 15, 2024
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	4.85%	4.85%	4.85%
Senior notes, gross	$ 1,500	$ 1,500	$ 1,500
Debt instrument, maturity date	Jun. 15, 2044	Jun. 15, 2044
Fixed Rate Notes [Member] | 2014 Senior Notes [Member]
Debt Instrument [Line Items]
Interest payment terms	Interest payments are due on the 2014 New Notes on June 15 and December 15 semi-annually, beginning on December 15, 2014.

Long-Term Debt and Leases - Act

Long-Term Debt and Leases - Actavis Inc Supplemental Indenture - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 01, 2013
Debt Instrument [Line Items]
Senior notes, gross	$ 34,050	$ 11,000
5.00% Senior Notes Due August 15, 2014 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate			5.00%
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Senior notes, gross	$ 32,550	11,000
Fixed Rate Notes [Member] | 5.00% Senior Notes Due August 15, 2014 [Member]
Debt Instrument [Line Items]
Senior notes, gross				$ 450
Senior notes, interest rate				5.00%
Debt instrument, maturity date	Aug. 15, 2014
Fixed Rate Notes [Member] | 6.125% Senior Notes Due August 15, 2019 [Member]
Debt Instrument [Line Items]
Senior notes, gross	$ 400	$ 400		$ 400
Senior notes, interest rate	6.125%	6.125%		6.125%
Debt instrument, maturity date	Aug. 15, 2019	Aug. 15, 2019
Fixed Rate Notes [Member] | 1.875% Notes Due October 1, 2017 [Member]
Debt Instrument [Line Items]
Senior notes, gross	$ 1,200	$ 1,200		$ 1,200
Senior notes, interest rate	1.875%	1.875%		1.875%
Debt instrument, maturity date	Oct. 1, 2017	Oct. 1, 2017
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, gross	$ 1,700	$ 1,700		$ 1,700
Senior notes, interest rate	3.25%	3.25%		3.25%
Debt instrument, maturity date	Oct. 1, 2022	Oct. 1, 2022
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Senior notes, gross	$ 1,000	$ 1,000		$ 1,000
Senior notes, interest rate	4.625%	4.625%		4.625%
Debt instrument, maturity date	Oct. 1, 2042	Oct. 1, 2042

Long-Term Debt and Leases - WC

Long-Term Debt and Leases - WC Supplemental Indenture - Additional Information (Detail) - USD ($) $ in Millions	Jul. 21, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015
Debt Instrument [Line Items]
Senior notes, gross		$ 11,000		$ 34,050
Extinguishment of debt		$ 29.9	$ (18.5)
Warner Chilcott [Member]
Debt Instrument [Line Items]
Senior notes, gross	$ 1,250
Repayment of debt	1,311.8
Redeemable premium interest	61.8
Extinguishment of debt	$ 29.9

Long-Term Debt and Leases - 128

Long-Term Debt and Leases - 2012 Notes Issuance - Additional Information (Detail)	Oct. 02, 2012	Dec. 31, 2015
2017 Notes [Member]
Debt Instrument [Line Items]
Maturity of senior notes	2,017
2022 Notes [Member]
Debt Instrument [Line Items]
Maturity of senior notes	2,022
2042 Notes [Member]
Debt Instrument [Line Items]
Maturity of senior notes	2,042
2012 Senior Notes [Member]
Debt Instrument [Line Items]
Interest payment terms		Interest payments are due on the 2012 Senior Notes semi-annually in arrears on April 1 and October 1 beginning April 1, 2013.

Long-Term Debt and Leases - 200

Long-Term Debt and Leases - 2009 Notes Issuance and Lease Commitments - Additional Information (Detail) - USD ($) $ in Millions	Nov. 05, 2013	Aug. 24, 2009	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Senior notes, gross			$ 34,050	$ 11,000
Rent expenses for operating leases			$ 49.9	$ 69.7	$ 12.3
2014 Notes [Member]
Debt Instrument [Line Items]
Maturity of senior notes		2,014
Senior notes, gross	$ 450
2019 Notes [Member]
Debt Instrument [Line Items]
Maturity of senior notes		2,019
2009 Senior Notes [Member]
Debt Instrument [Line Items]
Interest payment terms			Interest payments are due on the 2009 Senior Notes semi-annually in arrears on February 15 and August 15, respectively, beginning February 15, 2010.
Redemption price	465.6
Interest penalty expense	$ 15.6

Long-Term Debt and Leases - 130

Long-Term Debt and Leases - WC Term Loan Agreement - Additional Information (Detail) - USD ($) $ in Millions	Oct. 01, 2013	Feb. 23, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Quarterly Required Payments			2.50%
WC Term Loan Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 2,000
Cash on hand	41
Term loan credit agreement payment terms			The outstanding principal amount of loans under the WC Three Year Tranche is not subject to quarterly amortization and shall be payable in full on the three year anniversary of the WC Closing Date. The outstanding principal amount of loans under the WC Five Year Tranche is payable in equal quarterly amounts of 2.50% per quarter prior to the fifth anniversary of the WC Closing Date, with the remaining balance payable on the fifth year anniversary of the WC Closing Date.
Three Year Tranche [Member] | WC Term Loan Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	1,000
Debt instrument, maturity date			Oct. 1, 2016
Three Year Tranche [Member] | WC Term Loan Agreement [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin			0.00%
Three Year Tranche [Member] | WC Term Loan Agreement [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin			0.75%
Three Year Tranche [Member] | WC Term Loan Agreement [Member] | Eurodollar [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin			1.00%
Three Year Tranche [Member] | WC Term Loan Agreement [Member] | Eurodollar [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin			1.75%
Five Year Tranche [Member] | WC Term Loan Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000
Debt instrument, maturity date			Oct. 1, 2018
Quarterly Required Payments			2.50%
Five Year Tranche [Member] | WC Term Loan Agreement [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Prepayments of outstanding indebtedness		$ 310
Five Year Tranche [Member] | WC Term Loan Agreement [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin			0.125%
Five Year Tranche [Member] | WC Term Loan Agreement [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin			0.875%
Five Year Tranche [Member] | WC Term Loan Agreement [Member] | Eurodollar [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin			1.125%
Five Year Tranche [Member] | WC Term Loan Agreement [Member] | Eurodollar [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin			1.875%

Long-Term Debt and Leases - 131

Long-Term Debt and Leases - ACT Term Loan - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 23, 2016	Dec. 31, 2015	Dec. 31, 2014	Jul. 01, 2014	Oct. 01, 2013	Jun. 22, 2012
Debt Instrument [Line Items]
Borrowings outstanding		$ 200,000,000	$ 255,000,000
Quarterly Required Payments		2.50%
ACT Term Loan Agreement (2017 Term-Loan) [Member]
Debt Instrument [Line Items]
Loan agreement effective date		Mar. 31, 2014
Maximum borrowing capacity						$ 1,800,000,000
Borrowings outstanding					$ 1,572,500,000
Debt instrument, maturity date		Oct. 31, 2017
Quarterly Required Payments		2.50%
ACT Term Loan Agreement (2017 Term-Loan) [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Prepayments of outstanding indebtedness	$ 200,000,000
ACT Term Loan Agreement (2017 Term-Loan) [Member] | Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin		0.00%
ACT Term Loan Agreement (2017 Term-Loan) [Member] | Minimum [Member] | Eurodollar Rate [Member]
Debt Instrument [Line Items]
Percentage of margin		1.00%
ACT Term Loan Agreement (2017 Term-Loan) [Member] | Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin		1.00%
ACT Term Loan Agreement (2017 Term-Loan) [Member] | Maximum [Member] | Eurodollar Rate [Member]
Debt Instrument [Line Items]
Percentage of margin		2.00%
ACT Term Loan Amendment (2019 Term-Loan) [Member] | Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin		0.125%
ACT Term Loan Amendment (2019 Term-Loan) [Member] | Minimum [Member] | Eurodollar Rate [Member]
Debt Instrument [Line Items]
Percentage of margin		1.125%
ACT Term Loan Amendment (2019 Term-Loan) [Member] | Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin		0.875%
ACT Term Loan Amendment (2019 Term-Loan) [Member] | Maximum [Member] | Eurodollar Rate [Member]
Debt Instrument [Line Items]
Percentage of margin		1.875%
ACT Term Loan Amendment (2019 Term-Loan) [Member] | Forest Laboratories Inc. [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 2,000,000,000
Debt instrument, maturity date		Jul. 1, 2019
Quarterly Required Payments		2.50%

Long-Term Debt and Leases - AGN

Long-Term Debt and Leases - AGN Term Loan - Additional Information (Detail) - USD ($)	Dec. 17, 2014	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Quarterly Required Payments		2.50%
Minimum [Member]
Debt Instrument [Line Items]
Aggregate indebtedness		$ 350,000,000
AGN Term Loan [Member] | Minimum [Member]
Debt Instrument [Line Items]
Aggregate indebtedness		$ 350,000,000
Variable Rate Debt [Member] | Agn Tranche Three Maturing March 17, 2018 [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 2,750,000,000
Debt instrument, maturity date	Mar. 17, 2018	Mar. 17, 2018	Mar. 17, 2018
Debt instrument, maturity term	3 years
Variable Rate Debt [Member] | Agn Tranche Three Maturing March 17, 2018 [Member] | Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	0.00%
Variable Rate Debt [Member] | Agn Tranche Three Maturing March 17, 2018 [Member] | Minimum [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Percentage of margin	1.00%
Variable Rate Debt [Member] | Agn Tranche Three Maturing March 17, 2018 [Member] | Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	1.00%
Variable Rate Debt [Member] | Agn Tranche Three Maturing March 17, 2018 [Member] | Maximum [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Percentage of margin	2.00%
Variable Rate Debt [Member] | Agn Tranche Five Maturing March 17, 2020 [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 2,750,000,000
Debt instrument, maturity date	Mar. 17, 2020	Mar. 17, 2020	Mar. 17, 2020
Debt instrument, maturity term	5 years
Quarterly Required Payments	2.50%
Variable Rate Debt [Member] | Agn Tranche Five Maturing March 17, 2020 [Member] | Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	0.125%
Variable Rate Debt [Member] | Agn Tranche Five Maturing March 17, 2020 [Member] | Minimum [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Percentage of margin	1.125%
Variable Rate Debt [Member] | Agn Tranche Five Maturing March 17, 2020 [Member] | Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	1.25%
Variable Rate Debt [Member] | Agn Tranche Five Maturing March 17, 2020 [Member] | Maximum [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Percentage of margin	2.25%
Variable Rate Debt [Member] | AGN Term Loan [Member]
Debt Instrument [Line Items]
Term loan credit agreement payment terms		The outstanding principal amount of loans under the AGN Three Year Tranche is not subject to quarterly amortization and shall be payable in full on the maturity date. The outstanding principal amount of loans under the AGN Five Year Tranche is payable in equal quarterly amounts of 2.50% per quarter prior to March 17, 2020, with the remaining balance payable on March 17, 2020.

Long-Term Debt and Leases - Bri

Long-Term Debt and Leases - Bridge Loan Facility - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Nov. 17, 2014
Debt Instrument [Line Items]
Borrowings outstanding	$ 200,000,000	$ 255,000,000
Bridge Loan Facility [Member]
Debt Instrument [Line Items]
Borrowings outstanding			$ 0
Debt instrument, maturity date	Mar. 17, 2015

Long-Term Debt and Leases - Cas

Long-Term Debt and Leases - Cash Bridge Loan Facility - Additional Information (Detail) - USD ($)	Apr. 09, 2015	Mar. 11, 2015	Dec. 31, 2015	Mar. 17, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Borrowings outstanding			$ 200,000,000		$ 255,000,000
Cash Bridge Loan Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 2,800,000,000
Borrowings outstanding				$ 2,800,000,000
Facility repayment	$ 2,800,000,000
Cash Bridge Loan Facility [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin		0.00%
Cash Bridge Loan Facility [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin		1.00%
Cash Bridge Loan Facility [Member] | Eurodollar [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of margin		1.00%
Cash Bridge Loan Facility [Member] | Eurodollar [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of margin		2.00%

Long-Term Debt and Leases - Rev

Long-Term Debt and Leases - Revolving Credit Facility - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 17, 2014	Jun. 30, 2014
Debt Instrument [Line Items]
Borrowings outstanding	$ 200,000,000	$ 255,000,000
Minimum [Member]
Debt Instrument [Line Items]
Aggregate indebtedness	$ 350,000,000
Unsecured Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 1,000,000,000
Second Amended and Restated Revolving Credit and Guaranty Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 750,000,000
Revolver Agreement [Member]
Debt Instrument [Line Items]
Borrowings outstanding			$ 600,000,000
Debt instrument, maturity date	Dec. 17, 2019
Line of credit facility interest rate description	The Revolver Agreement provides that loans thereunder will bear interest, at Actavis Capital’s choice, of a per annum rate equal to either (a) a base rate, plus an applicable margin per annum varying from 0.00% per annum to 1.00% per annum depending on the Debt Rating or (b) a Eurodollar rate, plus an applicable margin varying from 0.875% per annum to 2.00% per annum depending on the Debt Rating.
Revolver Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Commitment fee to maintain availability of funds	0.075%
Revolver Agreement [Member] | Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	0.00%
Revolver Agreement [Member] | Minimum [Member] | Eurodollar Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	0.875%
Revolver Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Commitment fee to maintain availability of funds	0.25%
Revolver Agreement [Member] | Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	1.00%
Revolver Agreement [Member] | Maximum [Member] | Eurodollar Rate [Member]
Debt Instrument [Line Items]
Percentage of margin	2.00%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Borrowings outstanding	$ 200,000,000
Net availability under the Revolver Agreement	28,800,000
Letter of credit outstanding	771,200,000
Revolving Credit Facility [Member] | Kythera [Member]
Debt Instrument [Line Items]
Borrowings outstanding	$ 800,000,000

Long-Term Debt and Leases - Sch

Long-Term Debt and Leases - Schedule of Annual Debt Maturities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
2,016	$ 2,175.5
2,017	3,999.8
2,018	7,095.1
2,019	3,325
2,020	6,093.8
2021 and after	19,617
Long Term Debt, Gross	42,306.2
Capital leases	4.1
Other borrowings	297.4	$ 255
Unamortized premium	225.9	239.9
Unamortized discount	(107.4)	(52.1)
Total Indebtedness	$ 42,726.2	$ 15,531.1

Long-Term Debt and Leases - 137

Long-Term Debt and Leases - Schedule of Future Minimum Lease Payments under Capital and Operating Leases (Detail) $ in Millions	Dec. 31, 2015USD ($)
Debt Disclosure [Abstract]
2,016	$ 0.3
2,017	0.3
2,018	0.3
2,019	0.3
2,020	0.3
Thereafter	2.6
Total minimum lease payments	4.1
Present value of net minimum lease payments	4.1
2,016	29.9
2,017	27.7
2,018	23.6
2,019	21.6
2,020	17
Thereafter	70.8
Total minimum lease payments	$ 190.6

Other Long-Term Liabilities - S

Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Acquisition related contingent consideration liabilities	$ 788.1	$ 139.9
Long-term pension and post retirement liability	222.1	48.1
Legacy Allergan deferred executive compensation	117.9
Long-term severance and restructuring liabilities	34.9	3.9
Liability of expected future obligations included in long-term liabilities	28.4
Long-term contractual obligations	26.4	29.7
Litigation-related reserves		4.9
Deferred Revenue	18.2	26.3
Other long-term liabilities	26	0.5
Total other long-term liabilities	$ 1,262	$ 253.3

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2009	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2015
Income Tax [Line Items]
Foreign losses before taxes		$ 4,174.4	$ 2,841.8	$ 604.7
Tax benefit from exercise of equity based awards		76.1	51.1	69
Reduction in income tax rate related to tax ruling	2.00%
Tax benefit from income tax ruling		97.5
Deferred tax liabilities related to acquired entities		12,900	2,600
Net operating loss carryforward		1,305.8	709.9
Net operating loss carryforwards		1,931.7
Tax credit carryforwards		191.7
Income tax benefit due to reversal of valuation allowance		296.2
Valuation allowance		196.2	474
Net operating income (losses)		(3,014.5)	(2,443.9)	(369.2)
Other deferred tax assets		15.7	41.9
Deferred tax assets related to investments					$ 5,700
Undistributed earnings of foreign subsidiaries		2,087.6
Accrued income taxes, including withholding taxes		2,165.6
Unrecognized amount that would favorably affect Company's effective tax rate		749.1
Interest and penalties related to uncertain tax positions recognized in tax expense		(0.5)	5.1	0.2
Interest and penalties related to tax positions accrued		63.3	65.6	5.2
Tax benefit on penalties and interest accrued		34.2	$ 25.3	$ 2.2
Reasonably possible change in unrecognized tax benefits		200
Tax Valuation Allowance [Member]
Income Tax [Line Items]
Capital loss carryforwards		5.8
Net operating income (losses)		88.2
Tax credits		101.8
Other deferred tax assets		0.4
U.S. [Member]
Income Tax [Line Items]
Capital loss carryforwards		866.6
Net operating loss carryforward		1,961.6
Tax credits, expire in 2018		289.2
Tax net operating losses, expire in 2016		367.7
Non-U.S. [Member]
Income Tax [Line Items]
Tax net operating losses, expire in 2016		46.7
Tax net operating losses, not subject to expiration		$ 354.2

Income Taxes - Schedule of (Ben

Income Taxes - Schedule of (Benefit)/Provision for Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current (benefit) provision:
Current (benefit) provision, U.S. federal	$ 14.4	$ (62)	$ (105.1)
Current (benefit) provision, U.S. state	9.7	12.9	(3.6)
Current (benefit) provision, Non-U.S.	225.6	17.2	(14.1)
Total current (benefit) provision	249.7	(31.9)	(122.8)
Deferred (benefit) provision:
Deferred (benefit) provision, U.S. federal	(1,326.2)	(304.3)	(2)
Deferred (benefit) provision, U.S. state	(58.7)	(5.1)	0.8
Deferred (benefit) provision, Non-U.S.	(426.7)	(125.7)	(31.3)
Total deferred (benefit) provision	(1,811.6)	(435.1)	(32.5)
Total provision for income taxes	$ (1,561.9)	$ (467)	$ (155.3)

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliations between Statutory Income Tax Rate and Company's Effective Income Tax Rate (Detail) - Irish And Bermuda [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Statutory rate	(12.50%)	(12.50%)	(12.50%)
Earnings subject to the U.S. federal and state tax rates	(18.50%)	(11.30%)	(13.90%)
Earnings subject to rates different than the statutory rate	(2.30%)	1.10%	(2.50%)
Tax reserves and audit outcomes	0.30%	1.30%	4.80%
Non-deductible expenses	5.40%	5.00%	0.10%
R&D credits and U.S. manufacturing deduction	(0.50%)	(1.20%)	(0.40%)
Rate changes	0.00%	1.50%	(0.10%)
Valuation allowances	(6.70%)	0.00%	(0.80%)
Other	(0.50%)	(0.10%)	0.40%
Effective income tax rate	(35.30%)	(16.20%)	(24.90%)
Warner Chilcott Limited [Member]
Real Estate Acquired Through Foreclosure Under Forward Purchase Agreements [Line Items]
Statutory rate	0.00%	0.00%	0.00%
Earnings subject to the U.S. federal and state tax rates	(29.60%)	(18.10%)	(22.30%)
Earnings subject to rates different than the statutory rate	(4.80%)	(5.10%)	(7.70%)
Tax reserves and audit outcomes	0.30%	1.30%	5.00%
Non-deductible expenses	5.60%	5.20%	0.10%
R&D credits and U.S. manufacturing deduction	(0.60%)	(1.20%)	(0.50%)
Rate changes	0.00%	1.50%	(0.10%)
Valuation allowances	(6.90%)	0.00%	(0.80%)
Other	(0.40%)	(0.30%)	0.20%
Effective income tax rate	(36.40%)	(16.70%)	(26.10%)

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components Company's Net Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Benefits from net operating and capital losses and tax credit carryforwards	$ 1,305.8	$ 709.9
Differences in financial statement and tax accounting for:
Inventories, receivables and accruals	1,023.8	404.5
Outside basis differences	5,738.8
Share-based compensation	596.6	235.9
Basis difference in debt	82.2	89.9
Other	15.7	41.9
Total deferred tax asset, gross	8,762.9	1,482.1
Less: Valuation allowance	(196.2)	(474)
Total deferred tax asset, net	8,566.7	1,008.1
Property, equipment and intangible assets	(14,080.7)	(2,346.7)
Outside basis differences	(2,422.2)	(944.5)
Total deferred tax liabilities	(16,502.9)	(3,291.2)
Total deferred taxes	$ (7,936.2)	$ (2,283.1)

Income Taxes - Schedule of R143

Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 712.2	$ 119.3	$ 5.7
Increases for current year tax positions	41.2	51.3	29.4
Increases for prior year tax positions	19.7	4.2	0.1
Increases due to acquisitions	115.5	567	83.7
Decreases for prior year tax positions	(41.4)	(26.6)	0.1
Settlements	(60.6)	(0.4)	(0.6)
Lapse of applicable statute of limitations	(3.2)	(0.5)	0
Foreign exchange	(1.7)	(2.1)
Foreign exchange			0.9
Balance at the end of the year	$ 781.7	$ 712.2	$ 119.3

Income Taxes - Summary of Acqui

Income Taxes - Summary of Acquired U.S. Entities and Taxable Years that are Currently under Audit by IRS (Detail) - U.S. Federal Income Tax Authority [Member]	12 Months Ended
	Dec. 31, 2015
Actavis, Inc. (f/k/a Watson Pharmaceuticals, Inc.) [Member] | Tax Year 2008 [Member]
Income Tax Examination [Line Items]
Tax Years	2,008
Actavis, Inc. (f/k/a Watson Pharmaceuticals, Inc.) [Member] | Tax Year 2009 [Member]
Income Tax Examination [Line Items]
Tax Years	2,009
Actavis, Inc. (f/k/a Watson Pharmaceuticals, Inc.) [Member] | Tax Year 2010 [Member]
Income Tax Examination [Line Items]
Tax Years	2,010
Actavis, Inc. (f/k/a Watson Pharmaceuticals, Inc.) [Member] | Tax Year 2011 [Member]
Income Tax Examination [Line Items]
Tax Years	2,011
Actavis Inc [Member] | Tax Year 2009 [Member]
Income Tax Examination [Line Items]
Tax Years	2,009
Actavis Inc [Member] | Tax Year 2010 [Member]
Income Tax Examination [Line Items]
Tax Years	2,010
Actavis Inc [Member] | Tax Year 2011 [Member]
Income Tax Examination [Line Items]
Tax Years	2,011
Actavis Inc [Member] | Tax Year 2012 [Member]
Income Tax Examination [Line Items]
Tax Years	2,012
Warner Chilcott Corporation [Member] | Tax Year 2010 [Member]
Income Tax Examination [Line Items]
Tax Years	2,010
Warner Chilcott Corporation [Member] | Tax Year 2011 [Member]
Income Tax Examination [Line Items]
Tax Years	2,011
Warner Chilcott Corporation [Member] | Tax Year 2012 [Member]
Income Tax Examination [Line Items]
Tax Years	2,012
Forest Laboratories Inc. [Member] | Tax Year 2008 [Member]
Income Tax Examination [Line Items]
Tax Years	2,008
Forest Laboratories Inc. [Member] | Tax Year 2009 [Member]
Income Tax Examination [Line Items]
Tax Years	2,009
Forest Laboratories Inc. [Member] | Tax Year 2007 [Member]
Income Tax Examination [Line Items]
Tax Years	2,007
Aptalis Holdings, Inc. [Member] | Tax Year 2013 [Member]
Income Tax Examination [Line Items]
Tax Years	2,013
Durata Therapeutics Inc [Member] | Tax Year 2012 [Member]
Income Tax Examination [Line Items]
Tax Years	2,012
Allergan, Inc. [Member] | Tax Year 2009 [Member]
Income Tax Examination [Line Items]
Tax Years	2,009
Allergan, Inc. [Member] | Tax Year 2010 [Member]
Income Tax Examination [Line Items]
Tax Years	2,010

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Mar. 02, 2015	Feb. 24, 2015	Dec. 31, 2015	Dec. 31, 2014
Shareholders Equity [Line Items]
Preferred shares, shares issued			5,100,000	0
Preferred shares, par value			$ 0.0001	$ 0.0001
Proceeds from the issuance of Mandatory Convertible Preferred Shares			$ 4,929.7
Dividends on preferred shares			208.1
Ordinary shares, per share	$ 288
Proceeds from issuance of ordinary shares			$ 4,071.1
Ordinary Shares [Member]
Shareholders Equity [Line Items]
Ordinary shares, shares issued	14,513,889
Allergan, Inc. [Member]
Shareholders Equity [Line Items]
Proceeds from issuance of ordinary shares	$ 4,071.1
Mandatory Convertible Preferred Stock [Member]
Shareholders Equity [Line Items]
Preferred shares, shares issued		5,060,000
Preferred shares, dividend rate percentage		5.50%
Preferred shares, par value		$ 0.0001
Preferred shares, liquidation preference per share		$ 1,000
Preferred stock, dividend payment terms			The Company may pay declared dividends in cash, by delivery of our ordinary shares or by delivery of any combination of cash and our ordinary shares, as determined by us in our sole discretion, subject to certain limitations, on March 1, June 1, September 1 and December 1 of each year commencing June 1, 2015, to and including March 1, 2018.
Convertible Preferred Share, conversion date			Mar. 1, 2018
Convertible Preferred Share, terms of conversion			The number of our ordinary shares issuable on conversion of the Mandatory Convertible Preferred Shares will be determined based on the volume weighted average price per ordinary share over the 20 consecutive trading day period beginning on and including the 22nd scheduled trading day immediately preceding March 1, 2018, the mandatory conversion date.
Mandatory Convertible Preferred Stock [Member] | Minimum [Member]
Shareholders Equity [Line Items]
Convertible Preferred Share issued upon conversion subject to anti-dilution adjustments		2.8345
Mandatory Convertible Preferred Stock [Member] | Maximum [Member]
Shareholders Equity [Line Items]
Convertible Preferred Share issued upon conversion subject to anti-dilution adjustments		3.4722
Mandatory Convertible Preferred Stock [Member] | Allergan, Inc. [Member]
Shareholders Equity [Line Items]
Proceeds from the issuance of Mandatory Convertible Preferred Shares		$ 4,929.7

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Movements in Accumulated Other Comprehensive (Loss) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ (465.4)	$ 90.5
Other comprehensive gain / (loss) before reclassifications into general and administrative	(28.7)	(555.9)
Total other comprehensive (loss) / income, net of tax	(28.7)	(555.9)	$ 53.7
Ending balance	(494.1)	(465.4)	90.5
Foreign Currency Translation Items [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(434.4)	85.1
Other comprehensive gain / (loss) before reclassifications into general and administrative	(129.9)	(519.5)
Total other comprehensive (loss) / income, net of tax	(129.9)	(519.5)
Ending balance	(564.3)	(434.4)	85.1
Unrealized Gains/(Loss) Net of Tax [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(31)	5.4
Other comprehensive gain / (loss) before reclassifications into general and administrative	101.2	(36.4)
Total other comprehensive (loss) / income, net of tax	101.2	(36.4)
Ending balance	$ 70.2	$ (31)	$ 5.4

Segments - Additional Informati

Segments - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015Segment
Segment Reporting [Abstract]
Number of operating segments	4

Segments - Schedule of Net Reve

Segments - Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net revenues	$ 4,197.5	$ 4,088.9	$ 4,222	$ 2,562.6	$ 2,415.6	$ 2,150.8	$ 1,087.2	$ 1,085.3	$ 15,071	$ 6,738.9	$ 2,602.5
Operating expenses:
Cost of sales									4,810.4	3,453.6	1,644.7
Selling and marketing									2,914	1,201	374.8
General and administrative									1,765.6	1,247	456.1
Research and development									2,358.5	605.7	191.3
Amortization									5,777	2,597.5	842.7
In-process research and development impairments									511.6	424.3	4.9
Asset sales and impairments, net									272	305.7	1
Operating (loss)									(3,014.5)	(2,443.9)	(369.2)
US Brands [Member]
Segment Reporting Information [Line Items]
Net revenues									9,134.3	4,511.2	1,001.2
US Medical Aesthetics [Member]
Segment Reporting Information [Line Items]
Net revenues									1,513.9
International Brands [Member]
Segment Reporting Information [Line Items]
Net revenues									2,187.3	203.5	40.2
Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues									15,060.9	6,738.9	2,602.5
Operating expenses:
Cost of sales									3,512.6	2,496.5	1,467.2
Selling and marketing									2,683.6	990.2	374.8
General and administrative									343.3	167.9	73.5
Segment Contribution									$ 8,521.4	$ 3,084.3	$ 687
Contribution margin									56.60%	45.80%	26.40%
Corporate									$ 2,940.4	$ 2,247	$ 560.1
Research and development									2,358.5	605.7	191.3
Amortization									5,453.4	1,945.5	303.8
In-process research and development impairments									511.6	424.3
Asset sales and impairments, net									272	305.7	1
Operating (loss)									$ (3,014.5)	$ (2,443.9)	$ (369.2)
Operating margin									(20.00%)	(36.30%)	(14.20%)
Operating Segments [Member] | US Brands [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 9,134.3	$ 4,511.2	$ 1,001.2
Operating expenses:
Cost of sales									1,131.9	736.7	153.8
Selling and marketing									1,664.6	806.4	240.7
General and administrative									139.6	119.5	39.4
Segment Contribution									$ 6,198.2	$ 2,848.6	$ 567.3
Contribution margin									67.90%	63.10%	56.70%
Operating Segments [Member] | US Medical Aesthetics [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 1,513.9
Operating expenses:
Cost of sales									99
Selling and marketing									302.9
General and administrative									34
Segment Contribution									$ 1,078
Contribution margin									71.20%
Operating Segments [Member] | International Brands [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 2,187.3	$ 203.5	$ 40.2
Operating expenses:
Cost of sales									376.4	48.2	15.8
Selling and marketing									569.2	48.2	21.6
General and administrative									125.5	12	1.4
Segment Contribution									$ 1,116.2	$ 95.1	$ 1.4
Contribution margin									51.00%	46.70%	3.50%
Operating Segments [Member] | Anda Distribution Segment [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 2,225.4	$ 2,024.2	$ 1,561.1
Operating expenses:
Cost of sales									1,905.3	1,711.6	1,297.6
Selling and marketing									146.9	135.6	112.5
General and administrative									44.2	36.4	32.7
Segment Contribution									$ 129	$ 140.6	$ 118.3
Contribution margin									5.80%	6.90%	7.60%

Segments - Reconciliation of Ne

Segments - Reconciliation of Net Revenues for Operating Segments (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net revenues	$ 4,197.5	$ 4,088.9	$ 4,222	$ 2,562.6	$ 2,415.6	$ 2,150.8	$ 1,087.2	$ 1,085.3	$ 15,071	$ 6,738.9	$ 2,602.5
Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues									15,060.9	$ 6,738.9	$ 2,602.5
Corporate Revenues [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 10.1

Segments - Presents of Global N

Segments - Presents of Global Net Revenues by Segment (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	$ 4,197.5	$ 4,088.9	$ 4,222	$ 2,562.6	$ 2,415.6	$ 2,150.8	$ 1,087.2	$ 1,085.3	$ 15,071	$ 6,738.9	$ 2,602.5
Global [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									15,071	6,738.9	2,602.5
Global [Member] | Products [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									12,845.6	4,714.7	1,041.4
Global [Member] | Anda Distribution [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2,225.4	2,024.2	1,561.1
Global [Member] | Botox [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,975.7
Global [Member] | Restasis [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,047.8
Global [Member] | Namenda XR [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									759.3	269.5
Global [Member] | Bystolic [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									646.1	292.6
Global [Member] | Asacol/Delzicol [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									618.5	614.1	164.2
Global [Member] | Fillers [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									573.9
Global [Member] | Namenda IR [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									556.3	629.7
Global [Member] | Lumigan And Ganfort [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									547.3
Global [Member] | Linzess/Constella [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									459.3	174.4
Global [Member] | Alphagan And Combigan [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									411.1
Global [Member] | Lo Loestrin [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									349.6	277.1	63.3
Global [Member] | Viibryd/Fetzima [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									327.6	140.3
Global [Member] | Estrace Cream [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									326.2	258.2	60.7
Global [Member] | Minastrin 24 [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									273	217.9	53.7
Global [Member] | Silicone Implants [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									229.7
Global [Member] | Carafate And Sulcrate [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									213.1	90.9
Global [Member] | Aczone [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									170.8
Global [Member] | Other Products [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3,360.3	1,750	699.5
U.S. [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									12,883.7	6,535.4	2,562.3
U.S. [Member] | Products [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									10,658.3	4,511.2	1,001.2
U.S. [Member] | Anda Distribution [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2,225.4	2,024.2	1,561.1
U.S. [Member] | Botox [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1,386.6
U.S. [Member] | Restasis [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									999.6
U.S. [Member] | Namenda XR [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									759.3	269.5
U.S. [Member] | Bystolic [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									644.8	291.6
U.S. [Member] | Asacol/Delzicol [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									552.9	541	145.2
U.S. [Member] | Fillers [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									304.3
U.S. [Member] | Namenda IR [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									556.3	629.7
U.S. [Member] | Lumigan And Ganfort [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									260.7
U.S. [Member] | Linzess/Constella [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									454.8	173.2
U.S. [Member] | Alphagan And Combigan [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									285
U.S. [Member] | Lo Loestrin [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									346.5	275.7	63.3
U.S. [Member] | Viibryd/Fetzima [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									327.6	140.3
U.S. [Member] | Estrace Cream [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									326.2	258.2	60.7
U.S. [Member] | Minastrin 24 [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									272.4	217.9	53.7
U.S. [Member] | Silicone Implants [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									113.3
U.S. [Member] | Carafate And Sulcrate [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									213.1	90.9
U.S. [Member] | Aczone [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									170.8
U.S. [Member] | Other Products [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2,684.1	1,623.2	678.3
International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2,187.3	203.5	40.2
International [Member] | Products [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									2,187.3	203.5	40.2
International [Member] | Botox [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									589.1
International [Member] | Restasis [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									48.2
International [Member] | Bystolic [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									1.3	1
International [Member] | Asacol/Delzicol [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									65.6	73.1	19
International [Member] | Fillers [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									269.6
International [Member] | Lumigan And Ganfort [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									286.6
International [Member] | Linzess/Constella [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									4.5	1.2
International [Member] | Alphagan And Combigan [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									126.1
International [Member] | Lo Loestrin [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									3.1	1.4
International [Member] | Minastrin 24 [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									0.6
International [Member] | Silicone Implants [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									116.4
International [Member] | Other Products [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues									$ 676.2	$ 126.8	$ 21.2

Segments - Schedule of Revenue,

Segments - Schedule of Revenue, by Segment (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net revenues	$ 4,197.5	$ 4,088.9	$ 4,222	$ 2,562.6	$ 2,415.6	$ 2,150.8	$ 1,087.2	$ 1,085.3	$ 15,071	$ 6,738.9	$ 2,602.5
US Brands [Member]
Segment Reporting Information [Line Items]
Net revenues									9,134.3	4,511.2	1,001.2
US Brands [Member] | Central Nervous System (CNS) [Member]
Segment Reporting Information [Line Items]
Net revenues									2,541.2	1,109.4
US Brands [Member] | Eye Care [Member]
Segment Reporting Information [Line Items]
Net revenues									1,831.3
US Brands [Member] | Gastroenterology [Member]
Segment Reporting Information [Line Items]
Net revenues									1,575.3	966.8	145.2
US Brands [Member] | Women's Health [Member]
Segment Reporting Information [Line Items]
Net revenues									998	791.7	290.8
US Brands [Member] | Cardiovascular [Member]
Segment Reporting Information [Line Items]
Net revenues									644.8	291.6
US Brands [Member] | Urology [Member]
Segment Reporting Information [Line Items]
Net revenues									238.8	111.9
US Brands [Member] | Infectious Disease [Member]
Segment Reporting Information [Line Items]
Net revenues									188.8	62.7
US Brands [Member] | Other [Member]
Segment Reporting Information [Line Items]
Net revenues									1,116.1	1,177.1	565.2
US Medical Aesthetics [Member]
Segment Reporting Information [Line Items]
Net revenues									1,513.9
US Medical Aesthetics [Member] | Facial Anesthetics [Member]
Segment Reporting Information [Line Items]
Net revenues									817.8
US Medical Aesthetics [Member] | Medical Dermatology [Member]
Segment Reporting Information [Line Items]
Net revenues									493.5
US Medical Aesthetics [Member] | Plastic Surgery [Member]
Segment Reporting Information [Line Items]
Net revenues									202.6
International Brands [Member]
Segment Reporting Information [Line Items]
Net revenues									2,187.3	203.5	40.2
International Brands [Member] | Eye Care [Member]
Segment Reporting Information [Line Items]
Net revenues									924
International Brands [Member] | Facial Anesthetics [Member]
Segment Reporting Information [Line Items]
Net revenues									620
International Brands [Member] | Plastic Surgery [Member]
Segment Reporting Information [Line Items]
Net revenues									125.5
International Brands [Member] | Other Therapeutics [Member]
Segment Reporting Information [Line Items]
Net revenues									$ 517.8	$ 203.5	$ 40.2

Business Restructuring Charg152

Business Restructuring Charges - Schedule of Activity Related to Business Restructuring and Facility Rationalization Activities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance	$ 111.1	$ 67.5
Acquired liability	57.1	12.2
Charged to expense:	819.5	330.9	$ 147.8
Cash payments	(498.5)	(111.1)
Other reserve impact	(343.9)	(188.4)
Reserve ending balance	145.3	111.1	67.5
Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance	111.1	67.5
Acquired liability	27.9	12.2
Charged to expense:	289	142.5
Cash payments	(312.3)	(111.1)
Other reserve impact	(19)
Reserve ending balance	96.7	111.1	$ 67.5
Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	464.7	186.6
Cash payments	(127.1)
Other reserve impact	(337.6)	(186.6)
Other [Member]
Restructuring Cost And Reserve [Line Items]
Acquired liability	29.2
Charged to expense:	65.8	1.8
Cash payments	(59.1)
Other reserve impact	12.7	(1.8)
Reserve ending balance	48.6
Cost of Sales
Restructuring Cost And Reserve [Line Items]
Charged to expense:	52.5	10.4
Cost of Sales | Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	9.3	7
Cost of Sales | Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	19.8	3.4
Cost of Sales | Other [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	23.4
Research and Development Expense
Restructuring Cost And Reserve [Line Items]
Charged to expense:	182.3	22.8
Research and Development Expense | Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	77.7	22.8
Research and Development Expense | Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	104.6
Selling and Marketing Expense
Restructuring Cost And Reserve [Line Items]
Charged to expense:	118.5	40.9
Selling and Marketing Expense | Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	71.5	40.9
Selling and Marketing Expense | Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	47
General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	466.2	256.8
General and Administrative Expense [Member] | Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	130.5	71.8
General and Administrative Expense [Member] | Share-Based Compensation [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	293.3	183.2
General and Administrative Expense [Member] | Other [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense:	$ 42.4	$ 1.8

Business Restructuring Charg153

Business Restructuring Charges - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Restructuring And Related Activities [Abstract]
Restructuring charges recognized	$ 819.5	$ 330.9	$ 147.8

Derivative Instruments and H154

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Foreign Currency Forward Contracts [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Gains (losses) recognized on foreign currency forward contracts	$ (1.4)	$ (2.3)	$ 0.3
Foreign Exchange Option Contracts [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Foreign currency derivative assets	73.5	$ 2.3
Foreign Exchange Option Contracts [Member] | Accounts Payable and Accrued Expenses [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Foreign currency derivative liabilities	$ (0.3)

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
ASSETS
Marketable securities	$ 29.9	$ 1
Deferred executive compensation investments	118.1
Foreign currency derivatives	73.5	2.3
Marketable equity securities	32.3
Total assets	253.8	3.3
Liabilities:
Deferred executive compensation liabilities	117.9
Contingent consideration	868	373.8
Total liabilities	985.9	373.8
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
ASSETS
Marketable securities	29.9	1
Deferred executive compensation investments	102.3
Marketable equity securities	32.3
Total assets	164.5	1
Liabilities:
Deferred executive compensation liabilities	102.1
Total liabilities	102.1
Significant Other Observable Inputs (Level 2) [Member]
ASSETS
Deferred executive compensation investments	15.8
Foreign currency derivatives	73.5	2.3
Total assets	89.3	2.3
Liabilities:
Deferred executive compensation liabilities	15.8
Total liabilities	15.8
Significant Unobservable Inputs (Level 3) [Member]
Liabilities:
Contingent consideration	868	373.8
Total liabilities	$ 868	$ 373.8

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Notional Principal and Fair Value of Company's Outstanding Foreign Currency Derivative Financial Instruments (Detail)	Dec. 31, 2015USD ($)$ / ForeignCurrency	Dec. 31, 2014USD ($)$ / ForeignCurrency
Foreign Currency Forward Contracts [Member]
Derivatives Fair Value [Line Items]
Notional Principal	$ 18,800,000	$ 10,300,000
Estimated fair value	(300,000)	2,300,000
Foreign Currency Forward Contracts [Member] | Russian Ruble [Member]
Derivatives Fair Value [Line Items]
Notional Principal	$ 18,800,000	$ 10,300,000
Average Contract Rate or Strike Amount | $ / ForeignCurrency	1.41	1.05
Foreign Currency Sold - Put Options [Member]
Derivatives Fair Value [Line Items]
Notional Principal	$ 340,500,000
Estimated fair value	73,500,000
Foreign Currency Sold - Put Options [Member] | Euro [Member]
Derivatives Fair Value [Line Items]
Notional Principal	$ 340,500,000
Average Contract Rate or Strike Amount | $ / ForeignCurrency	1.41

Fair Value Measurement - Change

Fair Value Measurement - Change in Fair Value of Contingent Consideration Obligations (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value Assets Measured On Recurring and Nonrecurring Basis [Line Items]
Written off contingent liability	$ 96.2	$ (78.8)	$ 10.1
Cost of Sales
Fair Value Assets Measured On Recurring and Nonrecurring Basis [Line Items]
Written off contingent liability	58.5	(9.9)	5.8
Research and Development Expense
Fair Value Assets Measured On Recurring and Nonrecurring Basis [Line Items]
Written off contingent liability	$ 37.7	(69.3)	1.1
General And Administrative Expense
Fair Value Assets Measured On Recurring and Nonrecurring Basis [Line Items]
Written off contingent liability		$ 0.4	$ 3.2

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 17, 2014	Jul. 01, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration			$ 868	$ 373.8
Written off contingent liability			96.2	(78.8)	$ 10.1
Furiex Pharmaceuticals, Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration			29.8
Medicines 360 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration			81.4
Durata Therapeutics Inc [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration			6.4
Forest Laboratories Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain on contingent consideration fair value adjustment			32.3
IPR&D intangible assets							$ 12,256.5
Allergan plc [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain on contingent consideration fair value adjustment			$ 8.2
IPR&D intangible assets						$ 54,750.5
Uteron Pharma, SA [Member] | Estelle [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain (loss) on written off of contingent liability	$ 9.7			9.7
Written off contingent liability	22.8	$ 22.8		22.8
IPR&D intangible assets	13.1	13.1
Uteron Pharma, SA [Member] | Colvir [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain (loss) on written off of contingent liability	(0.5)	1.5		(0.5)
Written off contingent liability	1.5	1.5
IPR&D intangible assets	$ 2	$ 2
Aeroquin [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Written off contingent liability				16
Aeroquin [Member] | IPR&D [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain (loss) on written off of contingent liability				2
Written off contingent liability				18
Metronidazole 1.3% Vaginal Gel [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration				50.3
Gain (loss) on written off of contingent liability				4
Written off contingent liability				21
Impairment charge				$ 25

Fair Value Measurement - Sum159

Fair Value Measurement - Summary of Changes in Fair Value of all Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 373.8
Contingent obligations, ending balance	868	$ 373.8
Contingent Consideration Obligations [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	373.8	203.8
Purchases and settlements, net	405.1	251.9
Net accretion and fair value adjustments	96.2	(78.8)
Foreign currency translation	(7.1)	(3.1)
Contingent obligations, ending balance	$ 868	$ 373.8

Fair Value Measurement - Sch160

Fair Value Measurement - Schedule of Contingent Consideration Obligations (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Business Acquisition [Line Items]
Beginning balance	$ 373.8
Acquisitions	683
Fair Value Adjustments and Accretion	96.2
Payments and Other	(285)
Contingent obligations, ending balance	868
Medicines 360 Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	126.6
Fair Value Adjustments and Accretion	93.6
Payments and Other	(76.1)
Contingent obligations, ending balance	144.1
Furiex Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Beginning balance	88.4
Fair Value Adjustments and Accretion	30.2
Payments and Other	(118.6)
Forest Laboratories Inc. [Member]
Business Acquisition [Line Items]
Beginning balance	52.4
Fair Value Adjustments and Accretion	(29.8)
Payments and Other	(2.2)
Contingent obligations, ending balance	20.4
Durata Therapeutics Inc [Member]
Business Acquisition [Line Items]
Beginning balance	49
Fair Value Adjustments and Accretion	6.4
Payments and Other	(30.9)
Contingent obligations, ending balance	24.5
Metrogel Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	31.2
Fair Value Adjustments and Accretion	(0.4)
Payments and Other	0.1
Contingent obligations, ending balance	30.9
Uteron Pharma, SA [Member]
Business Acquisition [Line Items]
Beginning balance	10.4
Fair Value Adjustments and Accretion	(2.1)
Payments and Other	(0.1)
Contingent obligations, ending balance	8.2
Allergan plc [Member]
Business Acquisition [Line Items]
Acquisitions	383.7
Fair Value Adjustments and Accretion	3.1
Payments and Other	(57.1)
Contingent obligations, ending balance	329.7
Oculeve Acquisition [Member]
Business Acquisition [Line Items]
Acquisitions	90
Contingent obligations, ending balance	90
AqueSys Acquisition [Member]
Business Acquisition [Line Items]
Acquisitions	193.5
Contingent obligations, ending balance	193.5
Other Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	15.8
Acquisitions	15.8
Fair Value Adjustments and Accretion	(4.8)
Payments and Other	(0.1)
Contingent obligations, ending balance	$ 26.7

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands

Feb. 16, 2016

Feb. 11, 2016

Feb. 05, 2016Cases

Jan. 31, 2016

Jan. 05, 2016

Sep. 21, 2015Litigation

Jun. 24, 2015

Jun. 22, 2015Litigation

Jun. 08, 2015Litigation

May. 29, 2015Litigation

Apr. 29, 2015

Feb. 24, 2015Litigation

Dec. 31, 2013Litigation

Nov. 08, 2013Litigation

Apr. 05, 2013LitigationCases

Jul. 31, 2012LitigationCases

May. 31, 2015Litigation

Dec. 31, 2015USD ($)ClaimDefendantPlaintiff

Mar. 05, 2015Claim

Feb. 03, 2009Cases

Feb. 02, 2009Cases

Loss Contingencies [Line Items]

Accrued loss contingencies | $

$ 340,000

Canasa [Member]

Loss Contingencies [Line Items]

Settlement agreement date

November 11, 2015

Delzicol [Member]

Loss Contingencies [Line Items]

Trial date

2017-10

Minastrin 24 Fe [Member]

Loss Contingencies [Line Items]

Dismissal date

Jan. 31, 2016

Minastrin 24 Fe [Member] | Warner Chilcott Limited [Member]

Loss Contingencies [Line Items]

Dismissal date

May 18, 2015

Subsequent Event [Member] | Namzaric [Member]

Loss Contingencies [Line Items]

Trial date

2017-10

Androgel Antitrust Litigation [Member]

Loss Contingencies [Line Items]

Approximate number of cases pending | Cases

3

3

Loestrin 24 Fe [Member]

Loss Contingencies [Line Items]

Approximate number of cases pending | Cases

2

Ranbaxy [Member]

Loss Contingencies [Line Items]

Settlement agreement date

June 13, 2014

Amneal [Member]

Loss Contingencies [Line Items]

Settlement agreement date

June 30, 2014

Impax [Member]

Loss Contingencies [Line Items]

Settlement agreement date

July 15, 2014

Anchen and Par [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 13, 2015

Settlement agreement terms

Under the terms of the settlement agreement, and subject to review of the settlement terms by the U.S. Federal Trade Commission, Plaintiffs will provide a license to Wockhardt that will permit it to launch its generic version of Namenda XR as of the date that is the later of (a) two (2) calendar months prior to the expiration date of the last to expire of the ‘703 patent, the ‘209 patent, the ‘708 patent, the ‘379 patent, the ‘752 patent, the ‘085 patent, and the ‘233 patent, including any extensions and/or pediatric exclusivities; or (b) the date that Wockhardt obtains final FDA approval of its ANDA, or earlier in certain circumstances.

Amerigen [Member]

Loss Contingencies [Line Items]

Settlement agreement date

October 20, 2015

Mylan [Member]

Loss Contingencies [Line Items]

Settlement agreement date

November 16, 2015

Lupin [Member]

Loss Contingencies [Line Items]

Settlement agreement date

December 22, 2015

Apotex [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 19, 2016

Apotex [Member] | Restasis IPR [Member]

Loss Contingencies [Line Items]

Settlement agreement date

December 15, 2015

Apotex [Member] | Subsequent Event [Member]

Loss Contingencies [Line Items]

Settlement agreement date

February 11, 2016

Apotex [Member] | Subsequent Event [Member] | Restasis [Member]

Loss Contingencies [Line Items]

Trial date

2017-08

Teva [Member] | Subsequent Event [Member]

Loss Contingencies [Line Items]

Trial commencement date

Feb. 16, 2016

First Time US Generics [Member]

Loss Contingencies [Line Items]

Settlement agreement date

May 12, 2014

Hetero and Glenmark [Member]

Loss Contingencies [Line Items]

Settlement agreement date

December 11, 2015

Actos [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

2

2

Asacol Litigation [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

2

Number of additional putative class actions filed

3

Botox [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Doryx Litigation Direct Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

3

Doryx Litigation Indirect Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Doryx Antitrust Complaints [Member]

Loss Contingencies [Line Items]

Number of defendant cases | Cases

4

Lidoderm [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Lidoderm Antitrust Complaints [Member]

Loss Contingencies [Line Items]

Approximate number of cases pending | Claim

5

Loestrin 24 [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

2

Namenda Litigation Direct Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Namenda Litigation Indirect Purchasers [Member]

Loss Contingencies [Line Items]

Number of putative class actions filed

1

Zymar/Zymaxid Litigation [Member]

Loss Contingencies [Line Items]

Dismissal date

May 2, 2015

Commercial Litigation [Member]

Loss Contingencies [Line Items]

Number of defendant cases | Defendant

3

Payment of legal settlement costs | $

$ 7,650

Agreement in principle to settle claims, amount | $

$ 10,350

Prescription Drug Abuse Litigation [Member]

Loss Contingencies [Line Items]

Dismissal date

May 8, 2015

Xaleron Pharmaceuticals, Inc [Member] | Subsequent Event [Member]

Loss Contingencies [Line Items]

Number of lawsuit filed | Cases

1

Forest Laboratories Inc. [Member] | Savella [Member]

Loss Contingencies [Line Items]

Settlement agreement date

April 29, 2015

Forest Laboratories Inc. [Member] | Ranbaxy [Member]

Loss Contingencies [Line Items]

Settlement agreement date

May 1, 2015

Forest Laboratories Inc. [Member] | Amneal [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 8, 2016

Forest Laboratories Inc. [Member] | Accord [Member]

Loss Contingencies [Line Items]

Settlement agreement date

January 14, 2016

Forest [Member]

Loss Contingencies [Line Items]

Trial date

2017-06

Endo [Member]

Loss Contingencies [Line Items]

Trial commencement date

Feb. 21, 2017

Actonel Litigation [Member]

Loss Contingencies [Line Items]

Approximate number of cases pending | Claim

386

Number of defendant cases | Defendant

194

Number of plaintiffs | Plaintiff

588

Commitments and Contingencie162

Commitments and Contingencies - Additional Information 1 (Detail) $ in Thousands	Dec. 28, 2015Claim	Mar. 20, 2014USD ($)	Aug. 28, 2013USD ($)	Dec. 31, 2015USD ($)CasesPlaintiff
Loss Contingencies [Line Items]
Civil penalties for each alleged false claim and attorneys' fees and costs | $				$ 11
Compensatory damages and civil penalties | $			$ 12,400
Putative Class of Private Payers [Member]
Loss Contingencies [Line Items]
Number of putative class actions filed | Claim	1
Alendronate Litigation [Member]
Loss Contingencies [Line Items]
Approximate number of cases pending				130
Number of plaintiffs | Plaintiff				175
Cases that are part of consolidated litigation in the California Superior Court (Orange County)				9
Celexa/Lexapro Litigation [Member]
Loss Contingencies [Line Items]
Approximate number of cases pending				187
Metoclopramide Litigation [Member] | Watson Pharmaceuticals, Inc. [Member]
Loss Contingencies [Line Items]
Approximate number of cases pending				1,500
Propoxyphene Litigation [Member]
Loss Contingencies [Line Items]
Approximate number of proceeding cases				35
Approximate number of case filed (Oklahoma)				8
Propoxyphene Litigation [Member] | Watson Pharmaceuticals, Inc. [Member]
Loss Contingencies [Line Items]
Number of plaintiffs | Plaintiff				1,400
Testosterone Litigation [Member]
Loss Contingencies [Line Items]
Approximate number of cases pending				287
Punitive Damages [Member]
Loss Contingencies [Line Items]
Compensatory damages and civil penalties | $		$ 17,900

Warner Chilcott Limited ("WC163

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Balance Sheets (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 1,096	$ 250	$ 329	$ 319
Marketable securities	9.3	1
Accounts receivable, net	2,401.6	1,112.3
Inventories	1,009.7	984.6
Prepaid expenses and other current assets	558.5	478.8
Current assets held for sale	3,540.3	3,806.9
Deferred tax assets	500.3	477
Total current assets	8,615.4	7,110.6
Property, plant and equipment, net	1,573.9	283.4
Investments and other assets	577.4	153.3
Non current assets held for sale	10,541.3	8,187.7
Deferred tax assets	49.5	34.7
Product rights and other intangibles	67,931.7	16,090.7	5,038
Goodwill	46,551.5	20,897.6
Total assets	135,840.7	52,758
Current liabilities:
Accounts payable and accrued expenses	4,349.5	3,030.1
Income taxes payable	54.2	33.9
Current portion of long-term debt and capital leases	2,432.8	693.4
Current liabilities held for sale	1,491.8	1,449.1
Deferred tax liabilities	47.3	41
Total current liabilities	8,328.3	5,247.5
Long-term debt and capital leases	40,293.4	14,837.7
Other long-term liabilities	1,262	253.3
Long-term liabilities held for sale	580.1	540.7
Other taxes payable	801.9	789.5
Deferred tax liabilities	7,985.7	2,753.8
Total liabilities	59,251.4	24,422.5
Total equity	76,589.3	28,335.5
Total liabilities and equity	135,840.7	52,758
Warner Chilcott Limited Parent Guarantor [Member]
Current assets:
Cash and cash equivalents		0.1	0.1
Total current assets		0.1
Investment in subsidiaries	75,571.6	28,076.9
Total assets	75,571.6	28,077
Current liabilities:
Total equity	75,571.6	28,077
Total liabilities and equity	75,571.6	28,077
Actavis Capital S.a.r.l. (Guarantor) [Member]
Current assets:
Cash and cash equivalents	13.5	5.5	0.3
Intercompany receivables	94,999.2	22,987.9
Prepaid expenses and other current assets	12.6	123.1
Total current assets	95,025.3	23,116.5
Investments and other assets	14.1	9
Investment in subsidiaries	79,597.3	31,549
Total assets	174,636.7	54,674.5
Current liabilities:
Accounts payable and accrued expenses	3.9	2.8
Intercompany payables	92,093.5	25,953.8
Current portion of long-term debt and capital leases	756.7	571.6
Total current liabilities	92,854.1	26,528.2
Long-term debt and capital leases	7,009.1	2,516
Total liabilities	99,863.2	29,044.2
Total equity	74,773.5	25,630.3
Total liabilities and equity	174,636.7	54,674.5
Actavis Funding SCS (Issuer) [Member]
Current assets:
Intercompany receivables	25,225.6	3,659
Prepaid expenses and other current assets	24.5	2.7
Total current assets	25,250.1	3,661.7
Investments and other assets	124.6	23.6
Total assets	25,374.7	3,685.3
Current liabilities:
Accounts payable and accrued expenses	210.5	6.1
Intercompany payables	526.3	2
Total current liabilities	736.8	8.1
Long-term debt and capital leases	24,637.6	3,677.2
Total liabilities	25,374.4	3,685.3
Total equity	0.3
Total liabilities and equity	25,374.7	3,685.3
Actavis Inc [Member]
Current assets:
Cash and cash equivalents	2	1.5	1.4	1.1
Intercompany receivables	302.4	18,720.9
Prepaid expenses and other current assets	6.1
Total current assets	310.5	18,722.4
Property, plant and equipment, net	34.3	8.2
Investments and other assets	37.7	82
Investment in subsidiaries	6,742.7	4,761.1
Non current assets held for sale	45.8	43.4
Total assets	7,171	23,617.1
Current liabilities:
Accounts payable and accrued expenses	171.5	112.7
Intercompany payables	9,245	26,774.7
Income taxes payable	44.1	33.9
Current liabilities held for sale	23.3	62.8
Total current liabilities	9,483.9	26,984.1
Long-term debt and capital leases	4,273.5	4,270.7
Long-term liabilities held for sale		102.7
Other taxes payable	72.1	789.5
Total liabilities	13,829.5	32,147
Total equity	(6,658.5)	(8,529.9)
Total liabilities and equity	7,171	23,617.1
Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	1,020.7	237.2	321.7	317.9
Marketable securities	9.3	1
Accounts receivable, net	2,401.6	1,111.6
Receivable from Parents	457.3	269.8
Inventories	1,009.7	984.6
Intercompany receivables	101,864.8	52,730.5
Prepaid expenses and other current assets	512.8	350.1
Current assets held for sale	3,540.3	3,806.9
Deferred tax assets		477
Total current assets	110,816.5	59,968.7
Property, plant and equipment, net	1,539.6	274.3
Investments and other assets	401	38.7
Non current assets held for sale	10,495.5	8,144.3
Deferred tax assets	49.5	34.7
Product rights and other intangibles	67,931.7	16,090.7
Goodwill	46,551.5	20,897.6
Total assets	237,785.3	105,449
Current liabilities:
Accounts payable and accrued expenses	3,909.5	2,905.4
Intercompany payables	120,527.2	45,367.8
Payable to Parents	1,466.8	521.1
Income taxes payable	10.1
Current portion of long-term debt and capital leases	1,676.1	121.8
Current liabilities held for sale	1,468.5	1,386.3
Deferred tax liabilities		41
Total current liabilities	129,058.2	50,343.4
Long-term debt and capital leases	4,373.2	4,373.8
Other long-term liabilities	1,262	253.4
Long-term liabilities held for sale	580.1	438
Other taxes payable	729.8
Deferred tax liabilities	7,985.7	2,753.8
Total liabilities	143,989	58,162.4
Total equity	93,796.3	47,286.6
Total liabilities and equity	237,785.3	105,449
Warner Chilcott Limited [Member]
Current assets:
Cash and cash equivalents	1,036.2	244.3	$ 323.5	$ 319
Marketable securities	9.3	1
Accounts receivable, net	2,401.6	1,111.6
Receivable from Parents	457.3	269.8
Inventories	1,009.7	984.6
Prepaid expenses and other current assets	556	475.9
Current assets held for sale	3,540.3	3,806.9
Deferred tax assets		477
Total current assets	9,010.4	7,371.1
Property, plant and equipment, net	1,573.9	282.5
Investments and other assets	577.4	153.3
Non current assets held for sale	10,541.3	8,187.7
Deferred tax assets	49.5	34.7
Product rights and other intangibles	67,931.7	16,090.7
Goodwill	46,551.5	20,897.6
Total assets	136,235.7	53,017.6
Current liabilities:
Accounts payable and accrued expenses	4,295.4	3,027
Payable to Parents	1,466.8	521.1
Income taxes payable	54.2	33.9
Current portion of long-term debt and capital leases	2,432.8	693.4
Current liabilities held for sale	1,491.8	1,449.1
Deferred tax liabilities		41
Total current liabilities	9,741	5,765.5
Long-term debt and capital leases	40,293.4	14,837.7
Other long-term liabilities	1,262	253.4
Long-term liabilities held for sale	580.1	540.7
Other taxes payable	801.9	789.5
Deferred tax liabilities	7,985.7	2,753.8
Total liabilities	60,664.1	24,940.6
Total equity	75,571.6	28,077
Total liabilities and equity	136,235.7	53,017.6
Eliminations [Member]
Current assets:
Intercompany receivables	(222,392)	(98,098.3)
Total current assets	(222,392)	(98,098.3)
Investment in subsidiaries	(161,911.6)	(64,387)
Total assets	(384,303.6)	(162,485.3)
Current liabilities:
Intercompany payables	(222,392)	(98,098.3)
Total current liabilities	(222,392)	(98,098.3)
Total liabilities	(222,392)	(98,098.3)
Total equity	(161,911.6)	(64,387)
Total liabilities and equity	$ (384,303.6)	$ (162,485.3)

Warner Chilcott Limited ("WC164

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Statements of Operations and Comprehensive Income / (Loss) (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Condensed Income Statements Captions [Line Items]
Net revenues	$ 4,197.5	$ 4,088.9	$ 4,222	$ 2,562.6	$ 2,415.6	$ 2,150.8	$ 1,087.2	$ 1,085.3	$ 15,071	$ 6,738.9	$ 2,602.5
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)									4,810.4	3,453.6	1,644.7
Research and development									2,358.5	605.7	191.3
Selling and marketing									2,914	1,201	374.8
General and administrative									1,765.6	1,247	456.1
Amortization									5,453.4	1,945.5	303.8
In-process research and development impairments									511.6	424.3
Asset sales and impairments, net									272	305.7	1
Total operating expenses									18,085.5	9,182.8	2,971.7
Operating (loss)									(3,014.5)	(2,443.9)	(369.2)
Non-operating income (expense):
Other income (expense), net									(233.8)	(27.3)	(18.6)
Total other income (expense), net									(1,415.7)	(430.2)	(253.6)
Other income (expense), net									(233.8)	(27.3)	(18.6)
Total other income (expense), net									(1,415.7)	(430.2)	(253.6)
(Loss) before income taxes and noncontrolling interest									(4,430.2)	(2,874.1)	(622.8)
(Benefit)/provision for income taxes									(1,561.9)	(467)	(155.3)
Net (loss) from continuing operations, net of tax									(2,868.3)	(2,407.1)	(467.5)
Income from discontinued operations									6,787.7	776.6	(282.9)
(Income) attributable to noncontrolling interest									(4.2)
Net income / (loss) attributable to shareholders									3,915.2	(1,630.5)	(750.4)
Other comprehensive (loss) / income									(28.7)	(555.9)	53.7
Comprehensive income / (loss) attributable to ordinary shareholders / members									3,886.5	(2,186.4)	(696.7)
Warner Chilcott Limited Parent Guarantor [Member]
Non-operating income (expense):
(Earnings) / losses of equity interest subsidiaries									(4,050.6)	1,560.5	724.5
Net (loss) from continuing operations, net of tax									4,050.6	(1,560.5)	(724.5)
Net income / (loss)									4,050.6	(1,560.5)	(724.5)
Net income / (loss) attributable to shareholders									4,050.6	(1,560.5)	(724.5)
Other comprehensive (loss) / income									(28.7)	(555.9)	53.7
Comprehensive income / (loss) attributable to ordinary shareholders / members									4,021.9	(2,116.4)	(670.8)
Actavis Capital S.a.r.l. (Guarantor) [Member]
Operating expenses:
General and administrative									212.1		0.3
Total operating expenses									212.1		0.3
Operating (loss)									(212.1)		(0.3)
Non-operating income (expense):
Interest income / (expense), net									1,572.4	(740)	87.5
Other income (expense), net									(265.4)	(74.5)	(1.1)
Total other income (expense), net									1,307	(814.5)	86.4
Interest income / (expense), net									1,572.4	(740)	87.5
Other income (expense), net									(265.4)	(74.5)	(1.1)
Total other income (expense), net									1,307	(814.5)	86.4
(Loss) before income taxes and noncontrolling interest									1,094.9	(814.5)	86.1
(Earnings) / losses of equity interest subsidiaries									(4,336.5)	539.7	162.2
Net (loss) from continuing operations, net of tax									5,431.4	(1,354.2)	(76.1)
Net income / (loss)									5,431.4	(1,354.2)	(76.1)
Net income / (loss) attributable to shareholders									5,431.4	(1,354.2)	(76.1)
Other comprehensive (loss) / income									24.5	(505.9)	48.2
Comprehensive income / (loss) attributable to ordinary shareholders / members									5,455.9	(1,860.1)	(27.9)
Actavis Funding SCS (Issuer) [Member]
Operating expenses:
General and administrative									16.1
Total operating expenses									16.1
Operating (loss)									(16.1)
Non-operating income (expense):
Interest income / (expense), net									(14.6)
Other income (expense), net									31
Total other income (expense), net									16.4
Interest income / (expense), net									(14.6)
Other income (expense), net									31
Total other income (expense), net									16.4
(Loss) before income taxes and noncontrolling interest									0.3
Net (loss) from continuing operations, net of tax									0.3
Net income / (loss)									0.3
Net income / (loss) attributable to shareholders									0.3
Comprehensive income / (loss) attributable to ordinary shareholders / members									0.3
Actavis Inc [Member]
Operating expenses:
General and administrative										9.9	75
Asset sales and impairments, net										(0.1)	(0.3)
Total operating expenses										9.8	74.7
Operating (loss)										(9.8)	(74.7)
Non-operating income (expense):
Interest income / (expense), net									(168.5)	(182)	264.5
Other income (expense), net											(6.4)
Total other income (expense), net									(168.5)	(182)	258.1
Interest income / (expense), net									(168.5)	(182)	264.5
Other income (expense), net											(6.4)
Total other income (expense), net									(168.5)	(182)	258.1
(Loss) before income taxes and noncontrolling interest									(168.5)	(191.8)	183.4
(Benefit)/provision for income taxes									(58.3)	(108.6)	19.1
(Earnings) / losses of equity interest subsidiaries									(1,981.6)	(886.2)	498.8
Net (loss) from continuing operations, net of tax									1,871.4	803	(334.5)
Income from discontinued operations										(70)
Net income / (loss)									1,871.4	733	(334.5)
Net income / (loss) attributable to shareholders									1,871.4	733	(334.5)
Other comprehensive (loss) / income											6.7
Comprehensive income / (loss) attributable to ordinary shareholders / members									1,871.4	733	(327.8)
Non-Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Net revenues									15,071	6,738.9	2,602.5
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)									4,810.4	3,453.6	1,644.7
Research and development									2,358.5	605.7	191.3
Selling and marketing									2,914	1,201	374.8
General and administrative									1,402	1,167.1	356.4
Amortization									5,453.4	1,945.5	303.8
In-process research and development impairments									511.6	424.3
Asset sales and impairments, net									272	305.8	1.3
Total operating expenses									17,721.9	9,103	2,872.3
Operating (loss)									(2,650.9)	(2,364.1)	(269.8)
Non-operating income (expense):
Interest income / (expense), net									(2,571.2)	519.1	(587)
Other income (expense), net									0.6	47.2	(11.1)
Total other income (expense), net									(2,570.6)	566.3	(598.1)
Interest income / (expense), net									(2,571.2)	519.1	(587)
Other income (expense), net									0.6	47.2	(11.1)
Total other income (expense), net									(2,570.6)	566.3	(598.1)
(Loss) before income taxes and noncontrolling interest									(5,221.5)	(1,797.8)	(867.9)
(Benefit)/provision for income taxes									(1,503.6)	(358.4)	(175.3)
Net (loss) from continuing operations, net of tax									(3,717.9)	(1,439.4)	(692.6)
Income from discontinued operations									6,787.7	846.6	(282.3)
Net income / (loss)									3,069.8	(592.8)	(974.9)
(Income) attributable to noncontrolling interest									(4.2)
Net income / (loss) attributable to shareholders									3,065.6	(592.8)	(974.9)
Other comprehensive (loss) / income									(28.7)	(555.9)	53.7
Comprehensive income / (loss) attributable to ordinary shareholders / members									3,036.9	(1,148.7)	(921.2)
Warner Chilcott Limited [Member]
Condensed Income Statements Captions [Line Items]
Net revenues									15,071	6,738.9	2,602.5
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)									4,810.4	3,453.6	1,644.7
Research and development									2,358.5	605.7	191.3
Selling and marketing									2,914	1,201	374.8
General and administrative									1,630.2	1,177	431.7
Amortization									5,453.4	1,945.5	303.8
In-process research and development impairments									511.6	424.3
Asset sales and impairments, net									272	305.7	1
Total operating expenses									17,950.1	9,112.8	2,947.3
Operating (loss)									(2,879.1)	(2,373.9)	(344.8)
Non-operating income (expense):
Interest income / (expense), net									(1,181.9)	(402.9)	(235)
Other income (expense), net									(233.8)	(27.3)	(18.6)
Total other income (expense), net									(1,415.7)	(430.2)	(253.6)
Interest income / (expense), net									(1,181.9)	(402.9)	(235)
Other income (expense), net									(233.8)	(27.3)	(18.6)
Total other income (expense), net									(1,415.7)	(430.2)	(253.6)
(Loss) before income taxes and noncontrolling interest									(4,294.8)	(2,804.1)	(598.4)
(Benefit)/provision for income taxes									(1,561.9)	(467)	(156.2)
Net (loss) from continuing operations, net of tax									(2,732.9)	(2,337.1)	(442.2)
Income from discontinued operations									6,787.7	776.6	(282.3)
Net income / (loss)									4,054.8	(1,560.5)	(724.5)
(Income) attributable to noncontrolling interest									(4.2)
Net income / (loss) attributable to shareholders									4,050.6	(1,560.5)	(724.5)
Other comprehensive (loss) / income									(28.7)	(555.9)	53.7
Comprehensive income / (loss) attributable to ordinary shareholders / members									4,021.9	(2,116.4)	(670.8)
Eliminations [Member]
Non-operating income (expense):
(Earnings) / losses of equity interest subsidiaries									10,368.7	(1,214)	(1,385.5)
Net (loss) from continuing operations, net of tax									(10,368.7)	1,214	1,385.5
Net income / (loss)									(10,368.7)	1,214	1,385.5
Net income / (loss) attributable to shareholders									(10,368.7)	1,214	1,385.5
Other comprehensive (loss) / income									4.2	1,061.8	(108.6)
Comprehensive income / (loss) attributable to ordinary shareholders / members									$ (10,364.5)	$ 2,275.8	$ 1,276.9

Warner Chilcott Limited ("WC165

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities:
Net income / (loss)	$ (629.3)	$ 5,302.6	$ (241.6)	$ (512.3)	$ (733.2)	$ (1,042.8)	$ 48.8	$ 96.7	$ 3,919.4	$ (1,630.5)	$ (750.4)
Reconciliation to net cash provided by operating activities:
Depreciation									218.3	230.9	202
Amortization									5,777	2,597.5	842.7
Provision for inventory reserve									140.9	156.1	113.8
Share-based compensation									690.4	368	133.6
Deferred income tax benefit									(7,380.1)	(690.1)	(275)
In-process research and development impairments									511.6	424.3	4.9
Goodwill impairment										17.3	647.5
Loss / (gain) on asset sales and impairments, net									334.4	143.1	55.9
Amortization of inventory step-up									1,192.9	985.8	267
Amortization of deferred financing costs									298.3	87.2	10.3
Accretion and contingent consideration									108.8	(71.2)	160
Excess tax benefit from stock-based compensation									(76.1)	(51.1)	(69)
Non-cash impact of debt extinguishment										(91.7)
Impact of assets held for sale										190.8	42.7
Other, net									66.4	8.5	(8.9)
Cash Flows From Investing Activities:
Additions to property, plant and equipment									(454.9)	(238.6)	(177.9)
Additions to product rights and other intangibles									(154.7)	(36.1)	(130)
Additions to investments									(24.3)	(1)	2.9
Proceeds from the sale of investments and other assets									883	453.7	37.7
Proceeds from sales of property, plant and equipment									140.1	13.7	7.1
Acquisitions of businesses, net of cash acquired									(37,510.1)	(5,562.3)	(15.1)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness									26,455.7	8,076.2	1,882.3
Proceeds from borrowings on credit facility and other									3,682	1,280	555
Debt issuance and other financing costs									(310.8)	(224.3)	(7.4)
Payments on debt, including capital lease obligations									(5,134.2)	(6,127)	(3,229.5)
Proceeds from stock plans									230	105.9	37.6
Payments of contingent consideration									(230.1)	(14.3)	(4.3)
Repurchase of ordinary shares									(118)	(130.1)	(170)
Excess tax benefit from stock-based compensation									76.1	51.1	69
Effect of currency exchange rate changes on cash and cash equivalents									(6.5)	(5.9)	(23.9)
Movement in cash held for sale										37	(37)
Net increase in cash and cash equivalents									846	(79)	10
Cash and cash equivalents at beginning of period				250				329	250	329	319
Cash and cash equivalents at end of period	1,096				250				1,096	250	329
Warner Chilcott Limited Parent Guarantor [Member]
Cash Flows From Operating Activities:
Net income / (loss)									4,050.6	(1,560.5)	(724.5)
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries									(4,050.6)	1,560.5	724.5
Dividends from subsidiaries									208.1
Changes in assets and liabilities (net of effects of acquisitions)									(0.1)		0.1
Net cash provided by / (used in) operating activities									208		0.1
Cash Flows From Investing Activities:
Additions to investments									(9,000.8)
Net cash (used in) investing activities									(9,000.8)
Cash Flows From Financing Activities:
Dividend to Parent									(208.1)
Contribution from Parent									9,000.8
Net cash provided by / (used in) financing activities									8,792.7
Net increase in cash and cash equivalents									(0.1)		0.1
Cash and cash equivalents at beginning of period				0.1				0.1	0.1	0.1
Cash and cash equivalents at end of period					0.1					0.1	0.1
Actavis Capital S.a.r.l. (Guarantor) [Member]
Cash Flows From Operating Activities:
Net income / (loss)									5,431.4	(1,354.2)	(76.1)
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries									(4,336.5)	539.7	162.2
Amortization of deferred financing costs									272.5	1
Dividends from subsidiaries									208.1
Changes in assets and liabilities (net of effects of acquisitions)									(370.6)	1,156.5	(86.1)
Net cash provided by / (used in) operating activities									1,204.9	343
Cash Flows From Investing Activities:
Additions to investments									(9,000.8)
Net cash (used in) investing activities									(9,000.8)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness									5,500
Financing structure and other activity with affiliates									(5,500)
Proceeds from borrowings on credit facility and other									3,610	80	430
Debt issuance and other financing costs									(167.1)		(2.2)
Payments on debt, including capital lease obligations									(4,431.7)	(417.8)	(427.5)
Dividend to Parent									(208.1)
Contribution from Parent									9,000.8
Net cash provided by / (used in) financing activities									7,803.9	(337.8)	0.3
Net increase in cash and cash equivalents									8	5.2	0.3
Cash and cash equivalents at beginning of period				5.5				0.3	5.5	0.3
Cash and cash equivalents at end of period	13.5				5.5				13.5	5.5	0.3
Actavis Funding SCS (Issuer) [Member]
Cash Flows From Operating Activities:
Net income / (loss)									0.3
Reconciliation to net cash provided by operating activities:
Amortization of deferred financing costs									20.9	22.9
Changes in assets and liabilities (net of effects of acquisitions)									122.5	(3,647.2)
Net cash provided by / (used in) operating activities									143.7	(3,624.3)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness									20,955.6	6,076.2
Financing structure and other activity with affiliates									(20,955.6)
Debt issuance and other financing costs									(143.7)	(51.9)
Payments on debt, including capital lease obligations										(2,400)
Net cash provided by / (used in) financing activities									(143.7)	3,624.3
Actavis Inc [Member]
Cash Flows From Operating Activities:
Net income / (loss)									1,871.4	733	(334.5)
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries									(1,981.6)	(886.2)	498.8
Depreciation									0.2	0.2	1
Share-based compensation									51.6	1.4	48.2
Amortization of deferred financing costs									4.1	2.4
Excess tax benefit from stock-based compensation											(69.2)
Changes in assets and liabilities (net of effects of acquisitions)									97.7	159.2	503.8
Net cash provided by / (used in) operating activities									43.4	10	648.1
Cash Flows From Investing Activities:
Additions to property, plant and equipment									(42.9)	(9.9)	(17.6)
Net cash (used in) investing activities									(42.9)	(9.9)	(17.6)
Cash Flows From Financing Activities:
Proceeds from borrowings on credit facility and other											125
Debt issuance and other financing costs											(0.5)
Payments on debt, including capital lease obligations											(702.5)
Proceeds from stock plans											44
Repurchase of ordinary shares											(165.4)
Excess tax benefit from stock-based compensation											69.2
Net cash provided by / (used in) financing activities											(630.2)
Net increase in cash and cash equivalents									0.5	0.1	0.3
Cash and cash equivalents at beginning of period				1.5				1.4	1.5	1.4	1.1
Cash and cash equivalents at end of period	2				1.5				2	1.5	1.4
Non-Guarantors [Member]
Cash Flows From Operating Activities:
Net income / (loss)									3,069.8	(592.8)	(974.9)
Reconciliation to net cash provided by operating activities:
Depreciation									218.1	230.7	201
Amortization									5,777	2,597.5	842.7
Provision for inventory reserve									140.9	156.1	113.8
Share-based compensation									638.8	366.6	85.4
Deferred income tax benefit									(7,380.1)	(690.1)	(275)
In-process research and development impairments									511.6	424.3	4.9
Goodwill impairment										17.3	647.5
Loss / (gain) on asset sales and impairments, net									334.4	143.1	55.9
Amortization of inventory step-up									1,192.9	985.8	267
Amortization of deferred financing costs									0.8	60.9	10.3
Accretion and contingent consideration									108.8	(71.2)	160
Excess tax benefit from stock-based compensation											0.1
Non-cash impact of debt extinguishment										(91.7)
Impact of assets held for sale										190.8	42.7
Other, net									66.4	8.5	(9)
Changes in assets and liabilities (net of effects of acquisitions)									(1,199.2)	1,805.2	(613.4)
Net cash provided by / (used in) operating activities									3,480.2	5,541	559
Cash Flows From Investing Activities:
Additions to property, plant and equipment									(412)	(228.7)	(160.3)
Additions to product rights and other intangibles									(154.7)	(36.1)	(130)
Additions to investments									(24.3)	(1)
Proceeds from the sale of investments and other assets									883	453.7	40.6
Proceeds from sales of property, plant and equipment									140.1	13.7	7.1
Acquisitions of businesses, net of cash acquired									(37,510.1)	(5,562.3)	(15.1)
Net cash (used in) investing activities									(37,078)	(5,360.7)	(257.7)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness									0.1	2,000	1,882.3
Financing structure and other activity with affiliates									26,455.6
Proceeds from borrowings on credit facility and other									72	1,200
Debt issuance and other financing costs										(172.4)	(4.7)
Payments on debt, including capital lease obligations									(702.5)	(3,309.2)	(2,099.5)
Payments of contingent consideration									(230.1)	(14.3)	(4.3)
Dividend to Parent									(208.1)
Contribution from Parent									9,000.8
Acquisition of noncontrolling interest											(10.4)
Net cash provided by / (used in) financing activities									34,387.8	(295.9)	(236.6)
Effect of currency exchange rate changes on cash and cash equivalents									(6.5)	(5.9)	(23.9)
Movement in cash held for sale										37	(37)
Net increase in cash and cash equivalents									783.5	(84.5)	3.8
Cash and cash equivalents at beginning of period				237.2				321.7	237.2	321.7	317.9
Cash and cash equivalents at end of period	1,020.7				237.2				1,020.7	237.2	321.7
Warner Chilcott Limited [Member]
Cash Flows From Operating Activities:
Net income / (loss)									4,054.8	(1,560.5)	(724.5)
Reconciliation to net cash provided by operating activities:
Depreciation									218.3	230.9	202
Amortization									5,777	2,597.5	842.7
Provision for inventory reserve									140.9	156.1	113.8
Share-based compensation									690.4	368	133.6
Deferred income tax benefit									(7,380.1)	(690.1)	(275)
In-process research and development impairments									511.6	424.3	4.9
Goodwill impairment										17.3	647.5
Loss / (gain) on asset sales and impairments, net									334.4	143.1	55.9
Amortization of inventory step-up									1,192.9	985.8	267
Amortization of deferred financing costs									298.3	87.2	10.3
Accretion and contingent consideration									108.8	(71.2)	160
Excess tax benefit from stock-based compensation											(69.1)
Non-cash impact of debt extinguishment										(91.7)
Impact of assets held for sale										190.8	42.7
Other, net									66.4	8.5	(9)
Changes in assets and liabilities (net of effects of acquisitions)									(1,349.7)	(526.3)	(195.6)
Net cash provided by / (used in) operating activities									4,664	2,269.7	1,207.2
Cash Flows From Investing Activities:
Additions to property, plant and equipment									(454.9)	(238.6)	(177.9)
Additions to product rights and other intangibles									(154.7)	(36.1)	(130)
Additions to investments									(24.3)	(1)
Proceeds from the sale of investments and other assets									883	453.7	40.6
Proceeds from sales of property, plant and equipment									140.1	13.7	7.1
Acquisitions of businesses, net of cash acquired									(37,510.1)	(5,562.3)	(15.1)
Net cash (used in) investing activities									(37,120.9)	(5,370.6)	(275.3)
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness									26,455.7	8,076.2	1,882.3
Proceeds from borrowings on credit facility and other									3,682	1,280	555
Debt issuance and other financing costs									(310.8)	(224.3)	(7.4)
Payments on debt, including capital lease obligations									(5,134.2)	(6,127)	(3,229.5)
Proceeds from stock plans											44
Payments of contingent consideration									(230.1)	(14.3)	(4.3)
Dividend to Parent									(208.1)
Contribution from Parent									9,000.8
Repurchase of ordinary shares											(165.4)
Acquisition of noncontrolling interest											(10.4)
Excess tax benefit from stock-based compensation											69.2
Net cash provided by / (used in) financing activities									33,255.3	2,990.6	(866.5)
Effect of currency exchange rate changes on cash and cash equivalents									(6.5)	(5.9)	(23.9)
Movement in cash held for sale										37	(37)
Net increase in cash and cash equivalents									791.9	(79.2)	4.5
Cash and cash equivalents at beginning of period				$ 244.3				$ 323.5	244.3	323.5	319
Cash and cash equivalents at end of period	$ 1,036.2				$ 244.3				1,036.2	244.3	323.5
Eliminations [Member]
Cash Flows From Operating Activities:
Net income / (loss)									(10,368.7)	1,214	1,385.5
Reconciliation to net cash provided by operating activities:
(Earnings) / losses of equity interest subsidiaries									10,368.7	$ (1,214)	$ (1,385.5)
Dividends from subsidiaries									(416.2)
Net cash provided by / (used in) operating activities									(416.2)
Cash Flows From Investing Activities:
Additions to investments									18,001.6
Net cash (used in) investing activities									18,001.6
Cash Flows From Financing Activities:
Dividend to Parent									416.2
Contribution from Parent									(18,001.6)
Net cash provided by / (used in) financing activities									$ (17,585.4)

Compensation - Schedule of Comp

Compensation - Schedule of Compensation Charges (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation Related Costs [Line Items]
Wages and salaries	$ 2,252.3	$ 1,557.9	$ 887.2
Stock-based compensation	925.7	401.2	133.6
Pensions	99.9	89	53.9
Social welfare	185.1	97.1	62.4
Other benefits	271.6	231.8	287.7
Total compensation charges	3,734.6	2,377	1,424.8
Continuing Operations [Member]
Compensation Related Costs [Line Items]
Total compensation charges	2,681	1,332.9	558.2
Discontinued Operations [Member]
Compensation Related Costs [Line Items]
Total compensation charges	$ 1,053.6	$ 1,044.1	$ 866.6

Concentration - Additional Info

Concentration - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015CustomerManufacturer	Dec. 31, 2014Customer
Concentration Risk [Line Items]
Percentage of other individual customers in relation to net revenues	10.00%
Percentage of gross accounts receivable due from largest customers	65.00%	70.00%
Number of largest customers | Customer	3	3
Concentration risk, supplier	No third party manufacturer accounted for 10% or more of the Company’s products sold based on third-party revenues for the year ended December 31, 2015.
Number of manufacturers accounted more than 10% of company's product sold | Manufacturer	0
Customer Concentration Risk [Member] | Revenues [Member] | Minimum [Member]
Concentration Risk [Line Items]
Concentration risk percentage	10.00%

Concentration - Schedule of Con

Concentration - Schedule of Concentration on Revenues (Detail) - Revenues [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
McKesson Corporation [Member]
Concentration Risk [Line Items]
Concentration risk percentage	24.00%	22.00%	11.00%
Cardinal Health, Inc. [Member]
Concentration Risk [Line Items]
Concentration risk percentage	18.00%	16.00%	10.00%
AmerisourceBergen Corporation [Member]
Concentration Risk [Line Items]
Concentration risk percentage	17.00%	17.00%	6.00%

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Millions	Jan. 07, 2016USD ($)
Anterios Inc [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Payment for license upfront fees	$ 90

Schedule II - Valuation and 170

Schedule II - Valuation and Qualifying Accounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation And Qualifying Accounts [Abstract]
Allowance for doubtful accounts, Balance at beginning of period	$ 4.8	$ 2.7	$ 5.2
Allowance for doubtful accounts, Charged to costs and expenses	8.4	3.9	1.6
Allowance for doubtful accounts, Deductions/ Write-offs	(7.3)	(4.2)	(4.9)
Allowance for doubtful accounts, Other	74.7	2.4	0.8
Allowance for doubtful accounts, Balance at end of period	80.6	4.8	2.7
Tax valuation allowance, Balance at beginning of period	474	319.1	7.2
Tax valuation allowance, Charged to costs and expenses	(335.6)	112.7	310.6
Tax valuation allowance, Other	57.8	42.2	1.3
Tax valuation allowance, Balance at end of period	$ 196.2	$ 474	$ 319.1

Supplementary Data - Quarterly

Supplementary Data - Quarterly Consolidated Financial Data and Market Price Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Selected Quarterly Financial Information [Abstract]
Net revenues	$ 4,197.5	$ 4,088.9	$ 4,222	$ 2,562.6	$ 2,415.6	$ 2,150.8	$ 1,087.2	$ 1,085.3	$ 15,071	$ 6,738.9	$ 2,602.5
Net income/(loss)	$ (629.3)	$ 5,302.6	$ (241.6)	$ (512.3)	$ (733.2)	$ (1,042.8)	$ 48.8	$ 96.7	$ 3,919.4	$ (1,630.5)	$ (750.4)
Basic earnings per share	$ (1.78)	$ 13.29	$ (0.80)	$ (1.85)	$ (3.34)	$ (3.95)	$ 0.28	$ 0.56	$ 10.01	$ (7.42)	$ (5.27)
Diluted earnings per share	(1.78)	13.29	(0.80)	(1.85)	(3.34)	(3.95)	0.28	0.55	$ 10.01	$ (7.42)	$ (5.27)
Market price per share:
High	322.68	340.34	315	317.72	272.75	249.94	226.23	230.77
Low	$ 237.50	$ 245.32	$ 279.74	$ 253	$ 208.64	$ 201.91	$ 184.71	$ 166.38

Supplementary Data - Quarter172

Supplementary Data - Quarterly Consolidated Financial Data and Market Price Information (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Condensed Financial Statements Captions [Line Items]
Deferred tax benefit related to the outside basis difference	$ 5,985.4	$ 5,738.8
Overstated tax benefit recognized	145
Net income loss	5,086.6	$ 3,683.2	$ (1,630.5)	$ (750.4)
Previously Reported [Member]
Condensed Financial Statements Captions [Line Items]
Net income loss	$ 5,231.6